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Abstract
Colorectal cancer is the 4th most common and 2nd deadliest cancer. Problems exist with
predicting which patients will respond best to certain therapy regimens. Diffuse reflectance
spectroscopy has been suggested as a candidate to optically monitor a patient’s early response to
therapy and has been received favorably in experimentally managing other cancers such as breast
and skin. In this dissertation, two diffuse reflectance spectroscopy probes were designed: one
with a combined high-resolution microendoscopy modality, and one that was optimized for
acquiring data from subcutaneous murine tumors. For both probes, percent errors for estimating
tissue optical properties (reduced scattering coefficient and absorption coefficient) were less than
5% and 10%, respectively. Then, studies on tissue-simulating phantoms were performed to test
probe sensitivity and to serve as testing platforms for investigators in biomedical optics. Next,
the diffuse reflectance spectroscopy probe was applied to subcutaneous murine colon tumors
(n=61) undergoing either antibody immunotherapy or standard 5-fluorouracil chemotherapy.
Mice treated with a combination of these therapies showed reduced tumor growth compared to
saline control, isotype control, immunotherapy, and chemotherapy groups (p<0.001, <0.001,
<0.001, and 0.046, respectively) 7 days post-treatment. Additionally, at 7 days post-treatment,
oxyhemoglobin, a marker currently being explored as a functional prognostic cancer marker,
trended to increase in immunotherapy, chemotherapy, and combination therapy groups compared
to controls (p=0.315, 0.149, and 0.190). Also of interest, an oxyhemoglobin flare (average
increase of 1.44x from baseline, p=0.03 compared to controls) was shown in tumors treated with
chemotherapy, indicating that diffuse reflectance spectroscopy may be useful as a complimentary
tool to monitor early tumor therapeutic response in colon cancer. However, subject-to-subject
variability was high and studies correlating survival to early oxyhemoglobin flares are suggested.
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Chapter 1: Introduction
1. Background
The overall health focus of this dissertation is colorectal cancer (CRC). Murine
subcutaneous allografts were used as a model for CRC. No clinical human work was performed
in CRC. Mice with subcutaneous CRC were treated with chemotherapy and immunotherapy, and
the tumor therapeutic response was measured using a non-invasive optical technique, diffuse
reflectance spectroscopy (DRS).
Figure 1 shows the general dissertation workflow. Before DRS was implemented in the
scientific investigation of therapy response in murine subcutaneous CRC allografts, an
engineering approach was taken to design a DRS probe, design tissue-simulating phantoms with
tunable optical properties, and perform calibration and validation of DRS hardware to ensure
robust results.
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Figure 1. DRS was used as a non-invasive optical tool to monitor tumor
therapeutic response to chemotherapy and immunotherapy in a subcutaneous
mouse model of CRC. Aims 1 and 2 primarily focus on engineering design and
testing of a DRS probe and the calibration and validation of DRS hardware using
tissue-simulating phantoms. Aim 3 primarily focuses scientific results from
treating murine subcutaneous CRC allografts with chemotherapy and
immunotherapy. Photo of DRS probe and mouse taken by author. Image of colon
and colon cancer sourced from the Smart Servier Medical Art, which are free to
share, copy, and redistribute under Create Commons License CC BY 3.0. Image
of antibodies sourced from the Library of Science Medical Figures by
somersault1824, which are free to share, copy, and redistribute under Create
Commons License CC BY-NC-SA 4.0.
Therefore, this introduction opens with a discussion on the overall clinical health
problem: CRC. This discussion introduces basic CRC epidemiological statistics, the
biology of tumorigenesis, hypoxia, and angiogenesis, the current diagnostic and treatment
standards for CRC, the emerging role of immunotherapy in CRC, and the current
methods to assess CRC tumor response to therapy, and how DRS can offer additional
clinically relevant information to better assess CRC tumor response to therapy. The
2

introduction next turns to describing DRS in detail, including the exact DRS platforms
used for various studies in this dissertation. We discuss the optical physics of DRS, and
how information gathered from light that has scattered and absorbed in body tissues
relates to both structural and functional biological characteristics. Finally, the
introduction closes with a brief summary of all three specific aims. Chapters 2 and 3
represent specific aims 1 and 2, respectively. Aim 3, on the other hand, is longer, and
consists of chapters 4, 5, and 6.
1.1 Clinical health focus: colorectal cancer
In the United States, CRC is the 4th most common cancer with 140,000 new cases and
50,000 deaths in the United States annually. CRC has the 7th worst 5-year survival rate (~65%)
of all cancers (Siegel et al., 2018). CRC makes up 8.1% of all cancers cases and 8.3% of all
cancer-related death (Siegel et al., 2018). It has been estimated that individuals have a 2% and
0.9% cumulative lifetime risk of developing and dying from CRC, respectively (Stigliano et al.,
2014), and the disease is more prevalent in

Summary of acronyms
5-FU
5-fluorouracil
CCL2
Monocyte chemoattractant protein-1
CSF2
Colony-stimulating factor 2
DRS
Diffuse reflectance spectroscopy
Hb
Hemoglobin
LACC Locally advanced colorectal cancer
LCC
Left-sided colorectal cancer
pCR
Pathological complete response
RCC
Right-sided colorectal cancer
RTE
Radiative transport equation
StO2
Tissue oxygen saturation
SDS
Source-detector separation
TAM
Tumor-associated macrophage
THC
Total hemoglobin concentration
TME
Tumor microenvironment
TNM
Tumor, node, and metastasis
μa
Absorption coefficient
μs’
Reduced scattering coefficient

males (54% of cases) compared to females
(46% of cases) (Siegel et al., 2018). Although
the incidence of CRC in the U.S. has been
decreasing over the past several decades, there
are still nearly 1.25 million U.S. residents
(~0.4% of the population) living with CRC
(Marley et al., 2016), costing the U.S. $14
billion annually (Yabroff et al., 2007; Yabroff
et al., 2011). Furthermore, per person costs
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associated with CRC treatment are $30 thousand within a year of diagnosis (Luo et al., 2009). In
developing countries, on the other hand, CRC incidence is expected to increase over the next
decade as population and life expectancy increase (Stigliano et al., 2014). Although there has
been a steady reduction in CRC incidence and mortality since the 1970’s, primarily attributed to
reduction in preventable risk factors, advances in early detection, and nationwide screening
initiatives (Siegel et al., 2018; Levin, 2016), research into monitoring tumor therapeutic response
to better personalize patient treatment is still needed and an active area of research in the field of
CRC (Park et al., 2014).
CRC (Figure 2) is classified in multiple ways. CRCs can either be sporadic (70-85% of
cases) (Yamagishi et al., 2016; Mundade et al., 2014) or familial (15-30% of cases) (Stigliano et
al., 2014; Jasperson et al., 2010). Sporadic cases arise as a result of multiple rare variants, which
are genetic variants occurring in < 1% of the population. Familial cases arise when individuals
have a genetic disposition or family history of CRC, although family history is often unreported
which contributes to the large percent range of cases (Stigliano et al., 2014). Treatment of
sporadic vs. familial CRC currently does not differ significantly as chemotherapy and surgical
resection remain the curative standard, although patients with certain subtypes of familial CRC
may be screened and treated earlier (Esplin et al., 2014). Alternatively, CRC can be classified on
where the disease occurs. CRC can arise in the rectum (31% of cases), left colon (30% of cases),
or right colon (39% of cases) (Mik et al., 2017; Siegel et al., 2018). The left and right colon have
different embryological origins (hindgut vs. midgut, respectively) (Baek, 2017) and many
believe that left-sided (LCC) and right-sided CRC (RCC) should be considered separate diseases
because they have different characteristics and oncological outcomes (Lim et al., 2017; Qin et
al., 2017; Hussain et al., 2016). Although LCC and RCC are currently treated identically, these
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diseases may be screened and treated differently in the future (Mik et al., 2017). Next, CRC can
be histologically classified into adenocarcinomas (>90% of cases) or other types (<10% of
cases), such as neuroendocrine, squamous cell, adenosquamous, spindle cell, and
undifferentiated carcinoma (Fleming et al., 2012). Finally, a recent 2015 collaborative gene
expression-based subtyping initiative has classified CRC into four distinct subtypes: CMS1
(14%), CMS2 (37%), CMS3 (13%), CMS4 (23%), as well as 13% of cases with mixed features.
It is anticipated that the CMS subtype classification will have the biggest impact on future
targeted therapies (Guinney et al., 2015).

Figure 2. The primary health focus of this dissertation is CRC. Images sourced
from the Smart Servier Medical Art, which are free to share, copy, and
redistribute under Create Commons License CC BY 3.0.
1.1.1 Hypoxia in colorectal cancer
Hypoxia is a condition of insufficient tissue oxygen saturation and arises due to
uncontrolled and rapid proliferation of cancer cells in the absence of efficient vasculature (Eales
et al., 2016). Initial tumor growth occurs without angiogenesis (Tafani et al., 2016). When
intercapillary distances exceed the diffusion limit of oxygen (200 μm), average oxygen partial
pressure (pO2) drops from ~35 mmHg to ~10 mmHg (Tafani et al., 2016). Intratumoral hypoxia
5

is spatially heterogenous, with between 50-60% of a solid tumor’s mass being hypoxic on
average (Vadde et al., 2017). While much is known about how hypoxia affects the tumor
microenvironment, the exact biological mechanism by which cells first detect low oxygen levels
is under active investigation (Hamanaka et al., 2009). Despite this knowledge gap, hypoxia has
several broad effects on tumors which will be briefly described here, including maintaining
cancer cell stemness (Vadde et al., 2017), inducing release of damage-associated molecular
patterns (DAMPs) (Tafani et al., 2016), increasing production of reactive oxygen species (ROS)
(Tafani et al., 2016), and triggering angiogenesis and vascularization of the tumor mass (Eales et
al., 2016).
In the colon and rectum, superficial glandular epithelial cells (of which > 95% of CRC
cases arise)(Marley et al., 2016; Hinck et al., 2014; Xue et al., 2012) ubiquitously express a
family of transcription factors, known as hypoxia inducible factors (HIF) (Ulivi et al., 2016), of
which HIF-1 is the best studied (Vadde et al., 2017). HIF-1 consists of two subunits: HIF-1α and
HIF-1β (Ulivi et al., 2016). HIF-1β is constitutively active whereas the activity of HIF-1α is
oxygen-regulated (Ulivi et al., 2016). HIF-1α gene expression has been shown to significantly
increase with increased CRC stage (Mansour et al., 2016). In normoxic conditions, HIF-1α
undergoes hydroxylation of two proline residues (P402 and P564) via prolyl hydroxylase 2
(PHD-2) (Ulivi et al., 2016; Vadde et al., 2017; Cejudo-Martin et al., 2005). Hydroxylated HIF1α then binds to the Hippel-Lindau tumor suppression protein (pVHL) located on the E3
ubiquitin ligase complex, which mediates ubiquitination and proteasomal degradation of HIF-1α
(Maxwell et al., 2001; Vadde et al., 2017). Alternatively, in hypoxic conditions, HIF-1α
circumvents ubiquitination. From here, HIF-1α, or the structurally related HIF-2α, can act alone
to regulate the tumor microenvironment or move inside the cell to the nucleus where it
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dimerizes with HIF-1β to form a complex which serves as a transcription factor for a variety of
genes that support CRC progression (Ulivi et al., 2016). An extensive list of HIF-1 or HIF-1α
target genes that support cancer progression has been previously published (Semenza, 2010).
In the stem cell theory of cancer, stemness is defined as the property of self-renewal and
proliferative and differentiation potential of a subpopulation of cancer cells (Lathia et al., 2017).
With regards to maintaining stemness of CRC in hypoxic conditions, activated HIF-1α interacts
with the intracellular domain of the transmembrane protein, Notch1. In the presence of HIF-1α,
the half-life of Notch1 increases which stimulates the Notch signaling cascade (Vadde et al.,
2017; Cejudo-Martin et al., 2005). The Notch signaling cascade, described in detail elsewhere
(Wang et al., 2012), maintains cancer cell stemness by increasing proliferation and
differentiation potential (Vadde et al., 2017). Additionally, HIF-2α (also known as EPAS 1,
HLF, or HRF), which is also expressed in CRC, acts as a transcription factor for the Octamerbinding transcription factor 4 gene (Oct-4) and thus upregulates Oct-4 expression (Covello et al.,
2006; Santoyo-Ramos et al., 2014). Oct-4 expression has been shown to increase going from
normal tissue to benign polyps to CRC tissue with expression ratios of 4.4%, 12.7%, and 42,4%,
respectively (Zhou et al., 2015). Specifically, Oct-4 maintains cell stemness within the CRC
tumor microenvironment and is also a useful biomarker and potential therapeutic target (Vadde
et al., 2017; Lathia et al., 2017), Therefore, hypoxic conditions contribute to stemness,
progression, and malignancy of CRC.
Next, hypoxia induces necrosis and the subsequent release of DAMPs (Hernandez et al.,
2016). DAMPs are a broad array of intracellularly sequestered molecules, which, upon necrosis
or other cellular injury or stress, are actively secreted or passively released extracellularly (Land,
2015; Eppensteiner et al., 2018). In CRC, DAMPs include adenosine, ATP, calreticulin,
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HMGB1, S100A4, S100A8, S100A9, and IL-33 (Hernandez et al., 2016). These DAMPs act as
ligands for receptors on nearby tumor cells, dendritic cells, myofibroblasts, or mast cells. Broad
downstream pro-tumor effects include tumor growth and progression, tumor regrowth in woundhealing sites such as tumor margins, and metastasis (Hernandez et al., 2016). Additionally,
DAMPs such as HMGB1 has been shown to be highly expressed in solid CRC tumors (Sims et
al., 2010). However, ATP has been shown to induce an anti-tumor immune response
(Ghiringhelli et al., 2009) and calreticulin has been shown to improve chemotherapy-induced
tumor regression (Obeid et al., 2007), and thus DAMPs are considered “double-edged” in that
they can have both pro-tumor and anti-tumor effects (Hernandez et al., 2016). However, data
regarding hypoxia-necrosis-DAMP pathways in CRC is relatively sparse, yielding an intriguing
research gap (Hernandez et al., 2016).
Cancer cells require high ROS levels to proliferate (Sosa et al., 2013). In both normal and
cancerous cells, mitochondria are the main producers of ROS, which include hydroxyl radicals,
superoxides, and hydroperoxides (Tafani et al., 2016). Under normoxic conditions, complexes I,
II, and III of the mitochondrial electron transport chain (ETC) produce low concentrations of
ROS during oxidative phosphorylation (Kondoh et al., 2013; Görlach et al., 2015; Hamanaka et
al., 2009). Alternatively, under hypoxic conditions in solid tumors, ROS levels increase,
although the exact biological mechanism is currently under investigation (Tafani et al., 2016).
ROS levels also increase early in the tumorigenesis, such as during carcinogen exposure or
chronic inflammation (Tafani et al., 2016). Increases in ROS can cause mitochondrial DNA
damage and mutation (Lievre et al., 2005), as well as inactivation of PHD-2, which would
otherwise inactivate HIF-1α. Thus, ROS increase activation of HIF-1α, which, as described
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previously, drives gene expression that contribute to CRC progression and malignancy
(Semenza, 2010).
In summary, hypoxic conditions promote non-angiogenic CRC tumor progression by
maintaining cancer cell stemness (Vadde et al., 2017), inducing release of damage-associated
molecular patterns (DAMPs)(Tafani et al., 2016), and increasing production of reactive oxygen
species (ROS) (Tafani et al., 2016). However, the most prominent effect of CRC tumor hypoxia
is angiogenesis, which will be described in the following section.
1.1.2 Angiogenesis in colorectal cancer
The most well-known and studied effect of hypoxia is angiogenesis. As previously stated,
HIF-1α is activated during hypoxia and translocates to the nucleus where it dimerizes with HIF1β. This dimerized complex, also known as HIF-α/Arnt, undergoes posttranslational
modification and binds to hypoxia response elements (HREs) of target gene promoters and
enhancers with the sequence G/ACGTG (Krock et al., 2011). HIF upregulates a variety of proangiogenic proteins including fibroblast growth factor (FGF)(Korc et al., 2009), vascular
endothelial growth factor (VEGF) (Duff et al., 2006), angiopoietin-1 and 2(Ellis et al., 2002),
platelet-derived growth factor (PDGF) (Manzat Saplacan et al., 2017), as well as the angiogenic
chemokine, monocyte chemoattractant protein-1 (CCL2 aka MCP-1)(Yoshidome et al., 2009),
and a variety of interleukins (Krock et al., 2011). The angiogenic effects of FGF, VEGF, PDGF,
angiopoietins, and interleukins are well-understood.
The less well-known effects of CCL2, and its receptor, CCR2, are briefly described here.
After CCL2 is transcribed and translated by CRC cells and monocytes/macrophages, in part due
to HIF-1, it binds to CCR2 on target cells which include monocytes, macrophages, memory T
lymphocytes, natural killer (NK) cells, and arterial endothelial cells (Deshmane et al., 2009). The
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CCL2-CCR2 binding on endothelial cells causes upregulation of MCP-1-induced protein
(MCPIP), which is a transcription factor for cadherins 12 (cdh12) and cadherin 19 (cdh19). It has
been shown that in vitro knockdown of cdh12 and cdh19 reduced capillary formation (Niu et al.,
2008), although the exact biological mechanism is not fully elucidated (Roy et al., 2012).
Finally, CCL2 induces gene expression of HIF-1α, creating a pro-angiogenic feedback loop
(Hong et al., 2005). Thus, HIF-1 mediates CRC tumor angiogenesis by up-regulation of myriad
pro-angiogenic growth factors, cytokines, and chemokines.
1.1.3 Clinical background: diagnostic standard for colorectal cancer
Colonoscopy is the gold standard for CRC diagnosis because of its ability to quickly
examine the entire colon while simultaneously performing biopsies and polypectomies (Geiger et
al., 2009) (Figure 3). Colonoscopies are recommended every 10 years beginning at age 50 for
average-risk individuals, although screening prevalence is only 63% for this group (Burt et al.,
2010; Society, 2017).

Figure 3. Colonoscopy is the gold standard for CRC diagnosis because of its
ability to quickly examine the entire colon while simultaneously performing
biopsies and polypectomies. Images sourced from the Smart Servier Medical Art,
which are free to share, copy, and redistribute under Create Commons License
CC BY 3.0.
Other diagnostic tests do exist, such as the fecal occult blood test (FOBT), fecal
immunochemical based stool test (FIT), double-contrast barium enema (DCBE), and computed
10

tomography colonography (CTC), but colonoscopy is still used to confirm abnormal results in
most cases (Geiger et al., 2009; Society, 2017; Navarro et al., 2017). Treatment for CRC is based
on the Tumor, Node and Metastasis (TNM) staging system. The TNM system stages tumors I-IV
(Figure 4) based on how deep the tumor has spread, how many lymph nodes contain tumor cells,
and number of distant metastases (Dienstmann et al., 2017). Stages I, II, III, and IV account for
28%, 27%, 26%, and 19% of cases at diagnosis, respectively, according to a 2013 meta-analysis
of 132,696 patients based on data from the Surveillance, Epidemiology, and End Results
Program (SEER) database (Lee et al., 2013).

Figure 4. The TNM system stages tumors I-IV based on how deep the tumor has
spread, how many lymph nodes contain tumor cells, and the number of distant
metastases. Image sourced from the Smart Servier Medical Art, which are free to
share, copy, and redistribute under Create Commons License CC BY 3.0.
However, in locally advanced CRC (stages II and III), which account for over half of
patients at diagnosis, TNM staging less clearly predicts patient prognosis, so standard treatment
for both stages includes colectomy with postoperative adjuvant chemotherapy (Dienstmann et
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al., 2017; Lee et al., 2013). Currently, the most clinically valuable method to classify tumors is
the tumor, node, and metastasis (TNM) staging system, which is used to guide treatment.
1.1.4 Clinical background: treatment standard for colorectal cancer
In recent years, growing evidence has supported using preoperative neoadjuvant
chemotherapy prior to surgical resection to achieve a complete eradication of cancer cells before
surgery, or, at least, a reduction in intraoperative tumor cell shedding (Zhou et al., 2013; Boland
et al., 2014). Such preoperative therapy typically uses a fluorouracil-based regimen, such as
FOLFOX (Jeon et al., 2011). A patient’s response to neoadjuvant chemotherapy is a critical
prognostic indicator; patients who exhibit a significant reduction in tumor burden during
neoadjuvant chemotherapy are more likely to experience complete resection of the tumor during
colectomy, have fewer local and distal recurrences (Zhou et al., 2013), and have greater 5-year
disease-free survival (Martin et al., 2012). However, in patients treated with neoadjuvant
chemotherapy, pathologic complete response (pCR), a complete eradication of tumor cells, and
surgical downstaging still remain low (both ~20-25%) (Zhou et al., 2013). Predicting which
patients will respond to neoadjuvant chemotherapy, and which drugs are most appropriate,
remains challenging (Wang et al., 2017). Ideally, CRC preoperative treatment would be tailored
to each patient based on initial therapeutic response, with the end goal of avoiding surgery if
possible (Walker et al., 2014). At present, in locally advanced CRC, fluorouracil-based
FOLFOX chemotherapy is generally given to patients in 3-4 cycles over 6-8 weeks in the
neoadjuvant setting, following by surgery and by 9-12 cycles of adjuvant chemotherapy over 1824 weeks (Zhou et al., 2013; Cheeseman et al., 2008; Habr-Gama et al., 2010). The current
FOLFOX treatment regimen consists of 2,400 mg/m2 of 5-FU, 400 mg/m2 of leucovorin, and 85
mg/m2 of oxaliplatin per cycle. Occasionally, irinotecan is given instead of oxaliplatin at a dose
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of 180 mg/m2 in the FOLFIRI treatment regimen (de Gramont et al., 2000; Cheeseman et al.,
2008; Maindrault-Goebel et al., 2000; Fuchs et al., 2007; Goldberg et al., 2004). Tumor
therapeutic response to neoadjuvant chemotherapy is assessed using radiological techniques (CT,
PET-CT, or MRI) following conclusion of neoadjuvant chemotherapy (after 1.5-2 months) and
before surgery (Habr-Gama et al., 2010) (Figure 5).

Figure 5. Tumor therapeutic response is not assessed until nearly 2 months
following chemotherapy initiation
However, several studies have shown that therapeutic response can, in fact, be assessed
on a scale of days, rather than months, using a variety of methods. However, most methods lack
practicality as routine clinical applications (Park et al., 2014). Therefore, one branch of CRC
research is devoted to developing clinically-translatable methods to rapidly assess (within 72
hours following therapy initiation) whether a therapy regimen is effective on a per patient basis
(Berger et al., 2017; Roblyer et al., 2011). A second branch is devoted to exploring
immunotherapy, a broad term for any treatment that modulates the host immune system to fight
cancer, to compliment neoadjuvant chemotherapy and increase rates of pCR and decrease rates
of distal recurrence (Boland et al., 2017; Walker et al., 2014; Bouvier et al., 2015; Xiang et al.,
2014). The research in this proposal exists at the interface between these two branches.
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1.1.5 Effects of chemotherapy on colorectal cancer tumors
Fluorouracil-based chemotherapy, especially 5-fluorouracil (5-FU) used in the FOLFOX
regimen (combined 5-FU, leucovorin, and oxaliplatin), has been a staple in CRC treatment for
nearly 60 years (Noordhuis et al., 2004; Monteil et al., 2009), with leucovorin and oxaliplatin
becoming standard in first-line chemotherapy in the early-to-mid 2000’s after successful Phase
III clinical trials (Jeon et al., 2011; Wolmark et al., 1999; de Gramont et al., 2000; Andre et al.,
2003; Goldberg et al., 2004). In the body, 5-FU is converted to fluorodeoxyuridine
monophosphate (FdUMP). FdUMP forms a complex with thymidylate synthase (TS), an enzyme
that catalyzes deoxyuridine monophosphate (dUMP) to deoxythymidine
monophosphate (dTMP), which is a DNA monomer and key for DNA replication. Thus, 5-FUmediated depletion of dTMP results in cytotoxicity and apoptosis in the rapidly growing cells in
CRC (Zhang et al., 2008).
1.1.6 Immunotherapy in colorectal cancer
Immunotherapy is an emerging approach to treat a variety of cancers by modulating the
immune system. Although the pathogenesis of CRC is well understood, the effects of
immunotherapy on the TME is less understood (Boland et al., 2017). Immunotherapy, in general,
can fall into one of several categories: 1) adoptive cell transfer therapy (ACT) (Rosenberg et al.,
2008), 2) monoclonal antibody (mAb) therapy (Weiner et al., 2009), 3) immune checkpoint
inhibitors (Dine et al., 2017; Jacobs et al., 2015), 4) cancer vaccines (Guo et al., 2014), and 5)
cytokine-targeted immunotherapy (Lee et al., 2011; Waldmann, 2017). The immunotherapy
focus of this proposal is on cytokine-targeted immunotherapy; for brevity and focus, other
categories of immunotherapy are not discussed. Several mAb immunotherapy drugs are FDA
approved for CRC, including nivolumab (Mehrvarz Sarshekeh et al., 2018) and pembrolizumab
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(Birendra et al., 2017), as well as ipilimumab, which is currently under FDA priority review.
Other drugs such as durvalumab and tremelimumab, also mAbs, are undergoing clinical trials
(Grierson et al., 2017). The mAb immunotherapy drugs have been a breakthrough for treating
MSI-high metastatic CRC (Grierson et al., 2017), one of several subtypes of CRC (Guinney et
al., 2015). However, this subtype is estimated to represent less than 20% of all CRC cases
(Guinney et al., 2015; Boland et al., 2011). Thus, there has been renewed research interest in
cytokine-targeted immunotherapy to compliment neoadjuvant chemotherapy regimens to capture
a wider variety of patients (Lynch et al., 2016). Whereas most cancers have, in general,
benefitted from immunotherapeutics, CRC, aside from MSI-high metastatic CRC, has not
(Boland et al., 2017). One overarching hypothesis as to why CRC has benefitted less from
immunotherapy compared to other cancers is the controversial role of tumor-associated
macrophages (TAMs) in the TME (Erreni et al., 2011).
1.1.7 Tumor-associated macrophage controversy in colorectal cancer
TAMs, the most abundant immune cell in the TME, also have the most substantial and
pervasive effect of any immune cell in the TME (Allavena et al., 2008; Chen et al., 2005; Erreni
et al., 2011; Marech et al., 2016). In CRC, TAMs have been shown to have both anti-tumor and
pro-tumor functions, depending on whether they are polarized more towards an M1 (classical) or
M2 (alternative) phenotype and their physical location within the tumor (Marech et al., 2016).
CRC cells, independent of sub-type (Lim et al., 2016; Becht et al., 2016), recruit circulating
monocytes via chemotaxis to the TME through monocyte chemoattractant protein-1 (CCL2), a
highly elevated chemokine in CRC (Marech et al., 2016; Chun et al., 2015; Becht et al., 2016;
Lim et al., 2016). Monocytes differentiate into M2-polarized TAMs through a variety of
cytokines and chemokines including IL-4, IL-10, IL-13, CSF-1, CSF2 (primary cytokine
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responsible for monocyte-TAM differentiation), CCL2, CXCL12, TGFα, MFG-E8, and MIF
produced by CRC cells, helper T-cells, regulatory T-cells, mesenchymal stem cells, and
previously differentiated TAMs (Liu et al., 2015). CCL2 is primarily responsible for monocyte
recruitment, which leads to TAM infiltration into the TME. Broad anti-tumor functions of
classically activated M1-polarized TAMs include inflammation and immune response (Funada et
al., 2003; Sugita et al., 2002; Zhou et al., 2010). On the other hand, pro-tumor functions of
alternatively activated M2-polarized TAMs include tumor growth, angiogenesis,
immunosuppression, and matrix remodeling (Liu et al., 2015) (Figure 6).

Figure 6. TAMs in CRC generally have pro-tumor functions. Image of
macrophage sourced from the Library of Science Medical Figures by
somersault1824, which are free to share, copy, and redistribute under Create
Commons License CC BY-NC-SA 4.0.
For tumor growth and angiogenesis, TAMs release a variety of pro-angiogenic growth
factors (GFs) including VEGF, PDGF, EGF, FGF, TGF-β, MMP9, CXCL8, IL-1, IL-6, and IL-8
(Liu et al., 2015). Additionally, TAMs suppress the activity of cytotoxic (CD8+) T-cells, whose
otherwise elevated expression is associated with increased 5-year survival in CRC patients (Ziai
et al., 2018), by releasing immunosuppressive factors including IL-10, TGF-β, CCL17, CCL18,
CCL22, and PGE2 (Liu et al., 2015). For matrix remodeling, TAMs release a variety of
proteolytic enzymes called matrix metalloproteases (MMPs) which allow for tumor expansion
and release of ECM-sequestered pro-angiogenic GFs. Finally, TAMs release a variety of
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cytokines such as IL-10, CXCL12, and MIF that help differentiate monocytes into TAMs
(Marech et al., 2016; Erreni et al., 2011; Barbera-Guillem et al., 2002; Burmeister et al., 2017;
Ucuzian et al., 2011). It has recently been shown that macrophages induce resistance to 5-FU
chemotherapy, and that this TAM-induced resistance may contribute to the heterogenous patient
response to chemotherapy (Zhang et al., 2016; Zhang et al., 2008). Currently, a gap in CRC
research is how cytokine-targeted immunotherapy affects tumor-associated macrophages in the
colon TME. Furthermore, does altering TAM population impact tumor response to
chemotherapy? If so, can this impact be quantified by clinically translatable tools on a scale of
days rather than months after treatment initiation?
1.1.8 Current methods to assess tumor response to therapy
This study proposes using DRS as a tool to monitor early tumor therapeutic response to
chemotherapy and CCL2-targeted immunotherapy. However, other methods to quantify
therapeutic response do exist. Clinically, after initiation of neoadjuvant chemotherapy, tumor
response is not assessed for nearly 2 months using radiological imaging methods (Kim et al.,
2015; Habr-Gama et al., 2010). There are several solutions to this problem, all with advantages
and disadvantages. One clinical assessment tool is quantifying carcinoembryonic antigen (CEA),
a cell adhesion glycoprotein elevated in the blood of CRC patients that correlates with tumor
stage. However, this test, although widely used and inexpensive, is non-specific does not
sufficiently predict positive responders to therapy (Dreyer et al., 2017). Many biomarkers, such
as p53, Ki67, and VEGF, are under investigation to correlate with initial tumor response, but the
literature shows conflicting results (Kim et al., 2015). Both cancer stem cell markers (CD133,
CD44, and CD24) and gene expression profiling show promising results for predicting tumor
response, although it is generally agreed that these methods have several practical limitations in
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clinical practice despite high potential for elucidating the complex genetic response of CRC
(Kim et al., 2015). On the other hand, several optical and spectroscopic methods have shown
promise in assessing tumor response after neoadjuvant chemotherapy. Several diffuse
spectroscopy-based studies have shown a significant increase in oxyhemoglobin, or
concentration of oxygen-bound heme in blood (Stadler et al., 2008), within one day after starting
neoadjuvant chemotherapy (Figure 7).

Figure 7. DRS is a clinically translatable & complimentary tool that can quantify
oxy-hemoglobin flare (tumor response) to guide clinicians in modifying or ceasing
treatment.
This increase, referred to as the “oxyhemoglobin flare,” was shown in patients with
partially or pathologically complete responding tumors but not in nonresponding patients
(Roblyer et al., 2011). The oxyhemoglobin flare has been extensively shown by the Tromberg
group in clinical trials of locally advanced breast cancer patients receiving neoadjuvant
chemotherapy (Falou et al., 2012; Ueda et al., 2013; Tromberg et al., 2017). However, a gap in
research is that the oxyhemoglobin flare has not been quantified after combinatorial
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chemotherapy and immunotherapy, and furthermore, has not been quantified in CRC tumors.
DRS is a probe-based spectroscopy tool, operating under the same principals as described in the
above studies, with the ability to accurately assess oxyhemoglobin in vivo (Chin et al., 2017;
Rajaram, Gopal, et al., 2010; Rajaram et al., 2016; Jayanthi et al., 2011; Greening, Rajaram, et
al., "Multimodal Imaging and Spectroscopy Fiber-Bundle Microendoscopy Platform for NonInvasive, in Vivo Tissue Analysis," 2016; Greening, James, et al., 2016; Greening, Rajaram, et
al., "In Vivo Measurement of Non-Keratinized Squamous Epithelium Using a Spectroscopic
Microendoscope with Multiple Source-Detector Separations," 2016; Hennessy et al., 2015;
Glennie et al., 2015; Yu et al., 2014; Glennie et al., 2014; Karsten et al., 2013; Spliethoff et al.,
2014). In the past decade, there have been 6 clinical trials using DRS in CRC (Jermyn et al.,
2017; Tanis, Evers, et al., 2016; Spliethoff et al., 2016; Tanis, Spliethoff, et al., 2016; Wang et
al., 2009; Douplik et al., 2010). However, all trials focus on early cancer diagnostics and
intraoperative surgical guidance, rather than tracking tissue response to therapy. Thus, our group
believes that non-invasively quantifying the oxyhemoglobin flare following initiation of
chemotherapy and cytokine-targeted immunotherapy via DRS is worth exploring.
1.1.9 Significance of clinical health problem
At present, there have been no studies correlating tumor perfusion response (via clinically
translatable DRS) with biological correlates, such as TAMs and associated cytokines, in the
TME following combinatorial cytokine-targeted immunotherapy and chemotherapy in a mouse
model of CRC. We expect that DRS can potentially be used in the clinic to monitor the
oxyhemoglobin flare in colon tumors of patients in response to neoadjuvant therapy initiation
(Fig. X). We have built and validated a DRS platform that can monitor the oxyhemoglobin flare
in response to therapy initiation in a mouse model of CRC. We note that, although we have

19

claimed DRS is potentially clinically translatable (i.e. fits through the biopsy port of a standard
colonoscope with minimal interference with established clinical workflow), the specific DRS
platform used in this study is not translatable since we hope to quantify daily perfusion metrics in
mouse subcutaneous tumor allografts, which necessarily require a larger probe size.
1.1.10 Research perspectives of diffuse reflectance spectroscopy
DRS has been received favorably in the clinical management of certain cancers such as
breast and skin cancer, pioneered in part by the Tromberg and Tunnell groups, respectively
(Tromberg et al., 2017; Ueda et al., 2013; Roblyer et al., 2011; Shah et al., 2004; Hennessy et
al., 2015; Bish et al., 2014; Sharma et al., 2014; Bish et al., 2011; Rajaram, Reichenberg, et al.,
2010; Rajaram, Aramil, et al., 2010). Adoptability in CRC has been milder, although the
Richards-Kortum group has done a lot of work with microendoscopy imaging systems
compatible with the biopsy port of standard colonoscopes (Parikh et al., 2014; Chang et al.,
2013) or upper GI endoscopes (Muldoon et al., 2011; Muldoon et al., 2010; Muldoon et al.,
2008; Muldoon et al., 2007; Pierce, Schwarz, et al., 2012; Pavlova et al., 2009; Schwarz et al.,
2008). DRS systems, which can be of comparable physical size to microendoscopes, have also
been integrated with colonoscopes in clinical research studies (Schols et al., 2015). In fact, future
studies in the Translational Biophotonics and Imaging Laboratory at the University of Arkansas
will explore DRS in a colonoscope in an orthotopic mouse model of CRC. Although physically
feasible, clinical adoptability of DRS (i.e. integration of DRS within standard colonoscopy
workflow) is not yet scientifically justified. Therefore, one goal of my PhD work was to lay the
foundation for our laboratory to be a pioneer in compiling evidence to justify using DRS in the
clinical management of CRC. In addition to DRS, long-term clinical prospects of cytokinetargeted immunotherapy are promising. Neutralizing antibodies for specific cytokines involved
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in pro-tumor pathways have shown therapeutic activity in both murine models and in several
human cancers. Several research groups are engineering innovative targeted cytokine delivery
approaches to reduce systemic toxicity. Overall, cytokine-targeted immunotherapy will continue
to be an active cancer research field (Lee et al., 2011; Waldmann, 2017). This research
capitalizes on this prospect and will help clarify how blocking of several key intercellular
communication pathways affects certain aspects of the colon TME and tumor therapeutic
response.
1.1.11 Murine subcutaneous allograft model of colorectal cancer
In the studies reported in this dissertation, Balb/c mice were subcutaneously injected with
CT26 cells in sterile saline (Figure 8). CT26 cells are colon carcinoma cells derived from the
Balb/c mouse strain. CT26 cells were originally induced in 1975 via N-nitroso-Nmethylurethane-(NNMU) and are an undifferentiated cell line (Ojo-Amaize et al., 2007). The
CT26 cell line is currently one of the most common models of murine CRC. As such, Balb/c
mice were chosen as the host organism since CT26 cells were originally derived from this mouse
strain (Castle et al., 2014). A 2014 genomic report verified that subcutaneous CT26 tumor
allografts in Balb/c mice have gene expression profiles similar to sporadic, undifferentiated, and
metastatic human CRC (Castle et al., 2014) and are a valid model for an in vivo CRC test
system.
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Figure 8. Balb/c mice were the model organization for the studies presented here.
CT26 cells were injected subcutaneously into the left flank to form colon tumor
allografts. Image of mouse and syringe sourced from the Library of Science
Medical Figures by somersault1824, which are free to share, copy, and
redistribute under Create Commons License BY-NC-SA 4.0.
1.2 Engineering focus: diffuse reflectance spectroscopy
1.2.1 Introduction to diffuse reflectance spectroscopy platforms
In this dissertation, we have engineered three DRS systems (Figure 9); however, only two
systems were used for data collection in this dissertation. The first system, described in detail in
Chapter 2 and briefly in Chapter 3, combines DRS with fiber-based high-resolution
microendoscopy (HRME) (Figure 9, acf). This system was used for initial feasibility testing to
investigate a combined DRS-HRME system and was tested on various in vitro and human in vivo
platforms. Additionally, a novel third modality was included, diffuse reflectance intensity
mapping (DRIM), although this modality was only briefly explored in Chapter 2. The second
system, described in detail in Chapters 4-6, is a uni-modal DRS system that was optimized to
quantify tissue optical parameters in subcutaneous colon tumors in mice (Figure 9, abe). This
system was designed to test the feasibility of using DRS as a method to quantify tumor
therapeutic response to chemotherapy and immunotherapy. A third DRS system, described
briefly in the overall discussion (Chapter 7), is a combined DRS-HRME system optimized to fit
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within the biopsy port of a small animal colonoscope to test the feasibility of using combined
DRS-HRME as a method to monitor tumor therapeutic response in orthotopic murine colorectal
tumors (Figure 9, adg). The engineering of this third system was pioneered by Ariel Mundo of
the Translational Biophotonics and Imaging Laboratory (Muldoon Lab), while I served as a
technical advisor based on my previous DRS experience.

Figure 9. In this dissertation, we have engineered three DRS systems (a). The
first system (c, f) was used for initial feasibility testing to investigate a combined
DRS-HRME system and was tested on various in vitro and human in vivo
platforms. The second system (b, e) was designed to test the feasibility of using
DRS as a method to quantify tumor therapeutic response to chemotherapy and
immunotherapy in the Balb/c-CT26 subcutaneous model of CRC. The third
system (d, g) is a combined DRS-HRME system optimized to fit within the
biopsy port of a small animal colonoscope to test the feasibility of using
combined DRS-HRME as a method to monitor tumor therapeutic response in
orthotopic murine colorectal tumors. Photo and 3D renderings of probe taken and
created by the author.
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1.2.2 High-resolution microendoscopy
HRME will be briefly described here since it is used as an imaging modality for two of
the three DRS systems. HRME is a non-invasive diagnostic imaging technique that provides subcellular resolution images of tissue in vivo. Tissue samples are topically stained with a
fluorescent contrast agent like proflavine, an acridine-derive fluorescent dye that intercalates
DNA. Proflavine highlights cell nuclei with appropriate excitation light to allow visualization of
morphological features (Muldoon et al., 2007; Pierce, Guan, et al., 2012; Pierce et al., 2011;
Quinn et al., 2012; Chang et al., 2013; Keahey et al., 2015; Parikh et al., 2014; Prieto et al.,
2015). Other contrast agents, such as benzoporphyrin-derivative monoacid ring A (BPD-MA)
and fluorescein, have also been investigated for similar purposes (Pierce et al., 2011). Generally,
excitation light is delivered to the specimen though a coherent image fiber consisting of tens of
thousands of individual fibers. The image fiber is placed in direct contact with tissue to excite
fluorescent contrast agent and resultant fluorescence is collected by the same image fiber. Lateral
and axial resolution are approximately 4 and 20 µm, respectively, with variable fields-of-view
depending on the diameter of the image fiber and any distal optics. The primary advantages of
HRME are low cost and portability, making this technique clinically translatable (Muldoon et al.,
2007; Muldoon et al., 2011; Parikh et al., 2014; Chang et al., 2013; Quinn et al., 2012; Pierce,
Guan, et al., 2012; Keahey et al., 2015; Pierce et al., 2011). Development of these systems has
led to clinical studies in the upper and lower gastrointestinal tracts (Muldoon et al., 2007;
Muldoon et al., 2011; Parikh et al., 2014; Chang et al., 2013) and cervix (Quinn et al., 2012;
Pierce, Guan, et al., 2012; Keahey et al., 2015). However, a limitation of HRME is insufficient
depth resolution, minimizing effectiveness in detecting dysplastic changes in the sub-epithelial
microenvironment. Only cells on the topmost 20 µm can be visualized and thus some
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information is lost that would normally be apparent with histopathological analysis (Keahey et
al., 2015; Muldoon et al., 2007; Muldoon et al., 2011). While other microendoscopy methods,
such as laser scanning confocal systems, are able to perform axial optical sectioning to resolve
cellular structures below the surface, these systems require the use of complex galvanometer or
microelectromechanical (MEMS)-based approaches to raster scan the excitation source across
the surface of the tissue (Rivera et al., 2011; Piyawattanametha et al., 2010; Chen et al., 2015).
Fiber bundle microendoscopy, as described in this manuscript, does not include these features in
favor of increased robustness and decreased cost. An additional limitation of HRME is its
inability to quantify changes in tissue scattering and absorption (Muldoon et al., 2007; Pierce,
Guan, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; Chang et al., 2013; Keahey et al.,
2015; Parikh et al., 2014). Thus, HRME techniques could benefit from additional quantitative
and depth sensitive modalities.
1.2.3 Diffuse reflectance spectroscopy
Recent work has described DRS, which uses short source-detector separations (SDS)
(less than 1 mm) to non-invasively interrogate deeper within epithelia and quantify optical
properties (Kanick et al., 2014; Kanick et al., 2009; Hennessy et al., 2014; Jayanthi et al., 2011;
Zonios et al., 1999; Marin et al., 2005; Rajaram, Reichenberg, et al., 2010). Optical properties
depend on tissue morphology and can provide a means to quantify dysplastic changes (Jayanthi
et al., 2011). More specifically, broadband DRS has been used in multiple clinical studies
including quantifying hemoglobin absorption to distinguish between different grades of oral
cancer (Jayanthi et al., 2011), distinguishing between adenomatous colon polyps and normal
tissue (Zonios et al., 1999), diagnosing cervical dysplasia in vivo (Marin et al., 2005), and
quantifying changes associated with non-melanoma skin cancer (Rajaram, Reichenberg, et al.,
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2010). These studies have shown that DRS can be a useful, non-invasive method to quantify the
health of small volumes of tissue although the ability to resolve fine cellular detail with
spectroscopy is non-existent (Rajaram, Reichenberg, et al., 2010; Marin et al., 2005; Zonios et
al., 1999; Jayanthi et al., 2011). DRS is used in this study because it can indicate tumor
perfusion, which is affected by treatment with chemotherapy and immunotherapy. Alteration of
the monocyte and TAM population in the colon TME via cytokine-targeted immunotherapy is
hypothesized to alter downstream pro-angiogenic signals (Liu et al., 2015). As tumors grow,
they require an adequate oxygen supply, nutrients, and the ability to remove waste such as CO2,
catabolites, and other toxins (Cuenod et al., 2013). Angiogenesis is a normal process of new
blood vessel formation from already existing nearby blood vessels, and is utilized by tumors to
meet their growing metabolic demands (Nishida et al., 2006; Dighe et al., 2012). Angiogenesis is
known to increase tumor perfusion, defined as blood flow through the tumor’s circulatory
network (Cuenod et al., 2013). Functional changes in angiogenesis-induced perfusion occur prior
to structural/morphological changes, such as tumor growth (Cuenod et al., 2013; Hu et al.,
2007). It is well known that tumor perfusion is a strong predictor of therapeutic response to
chemotherapy. Delivery of cytotoxic drugs, such as 5-FU, and availability of oxygen are critical
factors in inducing apoptosis of colon tumor cells (Turley et al., 2012). DRS is a probe-based
technique that can measure bulk tumor perfusion. DRS has several advantages including ability
to quantify the functional oxyhemoglobin flare (as a quantifier of early perfusion) and tissue
optical properties, non-invasiveness, depth-sensitivity, potential for clinical translation, ease-ofimplementation in the laboratory, and scalability (physical size) for different tissue types in
question. Because of the inherent scalability and adaptability of DRS, each DRS system and
probe must be extensively calibrated to extract accurate perfusion metrics. This aim focuses on

26

validating a DRS platform for in vivo assessment of tissue perfusion and quantification of tissue
optical properties, all of which may be affected by chemo- and/or immunotherapy-induced
changes to the TME. Fundamental tissue optical properties are the reduced scattering coefficient
(μs’), which depends on light scattering from cell nuclei, lipid membranes of cells and organelles,
keratin (in skin), and collagenous, elastic, and reticular fibers (Lister et al., 2012; Arifler et al.,
2007; Kumka et al., 2012; Sandell et al., 2011), and absorption coefficient (μa), which depends
on hemoglobin concentration ([Hb]) and oxygen saturation (SaO2) (Prahl, 2015; Greening,
James, et al., 2016; Rajaram, Reichenberg, et al., 2010; Rajaram, Aramil, et al., 2010; Rajaram,
Gopal, et al., 2010; Rajaram et al., 2008). The μa also relies on melanin, fat, and water, although
these physiological parameters are not quantified in this study (Spliethoff et al., 2014; Prahl,
2015). A mobile, all-inclusive spectroscopy suite, which integrates with all three custom DRS
probes, was created to monitor in vivo tissue properties (Figure 10).

Figure 10. DRS setup for in vivo measurements on tissue or tissue-simulating
phantoms. Photo taken by the author.
Bulk, volume-averaged tumor perfusion was optically quantified by DRS-derived
oxyhemoglobin (product of total hemoglobin concentration and tissue oxygen saturation). The
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post-processing DRS software to quantify µs’ and µa is based on the damped least-squares fitting
method, in which a curve is iterated to “best-fit” the raw spectra. Based on the best-fit curve, µs’
and µa experimental values are extracted. Once µa is accurately quantified, THC and StO2 of in
vivo tissue can be derived (process described in detail in Chapters 2 and 4).
1.3 Diffuse reflectance physics
1.3.1 Turbid media
DRS is one a simple and widely used technique for non-invasively studying biological
tissues. All biological tissues, including colorectal and CRC tissue, are considered turbid media
(Zonios et al., 2011). But what is exactly meant by the term, turbid media? Turbid media is any
medium which has significant scattering due to randomly distributed optical nonuniformities. A
light wave/photon contacting or passing through the turbid media will change direction based on
the index of refraction throughout the medium (Figure 11). A photon will continue scattering
throughout the turbid media until it is absorbed by an absorber or is transmitted or diffusely
reflected from the media. Light propagation through biological tissues can indicate the structural
and functional makeup of the tissue due to scattering, absorption, and fluorescence events;
however, light propagation through turbid media is a challenging problem (Romanov et al.,
2012).
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Figure 11. An oversimplification of the movement of photons through turbid
media. Photons can be scattered by scattering agents (white circles) or absorbed
by absorbing agents (red circles). Image created by the author.
Light propagation in tissue can be fully described by the radiative transport equation
(RTE). The RTE states that the total radiance for photons traveling in a specific direction through
time and space is equal to the sum of all sources that affect (increase or decrease) radiance.
Radiance is defined as the quantity of photons per unit volume. A more detailed description of
the RTE can be found in numerous sources (Liemert et al., 2012; Liemert et al., 2014; Wilson et
al., 2011). The RTE has been successfully used to model photon transport in turbid media.
However, the RTE is mathematically and computationally intensive, and because of this,
research has sought to create simpler models that approximate the RTE (Liemert et al., 2014;
Liemert et al., 2012; Wilson et al., 2011; Kim et al., 2006; Kim, 2004; Kim et al., 2003).
One such simplification used in biological tissues is the diffuse approximation. The
diffusion approximation is a method that has been used to determine μs’ and μa in tissue (Wilson
et al., 2011; Reif et al., 2007; Gibson et al., 2005; Kim, 2004; Kim et al., 2003). However, the
diffusion approximation is only valid in turbid media if the following requirements are met: 1)
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the μs’ must be much greater than the μa, and 2) large source-detector separations must exist
(Reif et al., 2007). Some sources have also claimed that the diffusion approximation is not valid
in media that exhibit anisotropic scattering (Gibson et al., 2005). These requirements ensure that
any collected photons have traveled through large volumes of tissue. In turn, this ensures that
extracted optical properties represent an accurate average of the real optical properties. However,
in many cases, investigators used small endoscopy devices, to sample thin tissues with a small
sampling depth. This is the case for dysplasia or cancers that are confined to the epithelium,
which is only between 100-500 µm thick (Rajaram et al., 2008).
Therefore, a distinction must be made between what is meant by the diffuse
regime, in which the diffusion approximation is valid, and the sub-diffuse regime, in
which the diffusion approximation is not valid (Reif et al., 2007; Subramanian et al.,
2007; Turzhitsky, Rogers, et al., 2010; Turzhitsky, Radosevich, et al., 2010; Bosschaart
et al., 2011; Kanick et al., 2014). For many of the cases listed here, the validity of the
diffusion approximation begins to fail for one of two reasons. The first reason is that μs’
is not much greater than μa (Reif et al., 2007; Turzhitsky, Radosevich, et al., 2010;
Turzhitsky, Rogers, et al., 2010; Subramanian et al., 2007; Bosschaart et al., 2011). The
μs’ is considered “not much greater” than the μa when albedo is less than 0.9 (Rajaram et
al., 2008). The second reason the diffusion approximation begins to fail is the use of
small source-detector separations common to small endoscopic probes. A source-detector
separation is considered “small” if it is less than approximately one reduced mean free
path (Rajaram et al., 2008; Subramanian et al., 2007; Bosschaart et al., 2011; Kanick et
al., 2014). Therefore, although most “diffuse reflectance spectroscopy” is really “subdiffuse reflectance spectroscopy”, the term “sub-diffuse” will not be used for clarity.
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1.3.2 Light scattering in turbid media
There are two primary types of scattering: Rayleigh scattering and Mie scattering (Figure
12). Simply, Rayleigh scattering refers to scattering by particles much smaller than the
wavelength of light. Mie scattering refers to scattering by particles larger or of comparable size
to the wavelength of light. However, it is more correct to say that all scattering is Mie scattering,
and Rayleigh scattering is the Rayleigh limit of Mie scattering (Jacques, 2013). Biological tissue
typically exhibits Mie scattering. In biological tissue, organelles such as mitochondria and cell
nuclei are the primary scattering agents (Mourant et al., 1998). Striations in collagen fibrils are
also responsible for scattering (Arifler et al., 2007). The magnitude of scattering is typically
quantified with μs’, which can be measured with DRS.

Figure 12. Rayleigh and Mie scattering in biological tissue (a turbid media). Mie
scattering is the name for scattering by a sphere of any size, whereas Rayleigh
scattering is a type of Mie scattering in which the scattering agents are much
smaller than the wavelength of light (Jacques, 2013). Image created by the author.
1.3.3 Light absorption in turbid media
In addition to μs’, DRS can also measure μa. The μa depends on the concentration of
absorbing agents in the biological tissue. In living systems, there are 5 primary absorbers
spanning the ultraviolet to near-infrared spectrum (approximately between 300-2000 nm):
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melanin, oxygenated hemoglobin, deoxygenated hemoglobin, fat, and water. The normalized μa
of these 5 absorbers are shown in Figure 13 (Prahl, 2015).

Figure 13. Normalized absorption coefficients of melanin, oxygenated
hemoglobin, deoxygenated hemoglobin, fat, and water in biological tissues.
Graph created by the author using data by Scott Prahl (Prahl, 2015).
Our studies report absorption in the visible and very near-infrared spectrum (~450
to 800 nm). Therefore, in the following studies for this dissertation, water is not looked at
because absorption is negligible below 1400 nm. Melanin is not analyzed since albino
mice (Balb/c) were used as the test subjects. Additionally, some studies were done in the
oral mucosa of health human volunteers – oral mucosa does not contain melanin. Finally,
fat was not analyzed because, although fat does contribute slightly to absorption in the
visible to near-infrared spectrum, it is negligible compared to the two primary absorbers,
oxygenated and deoxygenated hemoglobin. Figure 14 shows the absolute μa of
oxygenated and deoxygenated hemoglobin in whole blood compared to the μa of fat
(Prahl, 2015; Greening, James, et al., 2016; Greening, James, et al., 2015; Greening et
al., 2018; Greening, Powless, et al., 2015).
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Figure 14. Absorption coefficients of melanin, oxygenated hemoglobin, and
deoxygenated hemoglobin below 1000 nm. Graph created by the author using
data by Scott Prahl (Prahl, 2015).
1.4 Concluding remarks to introduction
Chapters 2 and 3 represent specific aims 1 and 2, respectively. Aim 3, on the other hand,
is longer, and consists of chapters 4, 5, and 6. The following aims were designed to address the
investigation and optimization of using DRS as a technique to monitor in vivo tissue health and
tumor therapeutic response, specifically in murine colon cancer.
1.5 Specific Aims
The overall health focus of this dissertation is CRC. Murine subcutaneous allografts were
used as a model for CRC. Specifically, for my dissertation work, I looked at murine
subcutaneous CRC allografts as a model for CRC from two angles. First, can DRS be used as a
platform to monitor tumor therapeutic response in this CRC tumor model? Second, does
treatment with standard chemotherapy and macrophage-targeted immunotherapy alter the TME?
Combining these two angles (Figure 1), do these TME alterations correlate with DRS data?
Before DRS was implemented in the scientific investigation of therapy response in
murine subcutaneous CRC allografts, the first step (Aim 1) was to engineer and characterize a
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DRS probe for in vivo tissue analysis. The second step (Aim 2) was to design tissue-simulating
phantoms with tunable optical properties to test the sensitivity of our probe to phantom-based,
sub-surface optical heterogeneities. Additionally, this phantom design sparked a non-DRS-based
collaboration with Boston University who used these phantoms to improve longitudinal
preclinical tumor imaging in the spatial frequency domain (Tabassum et al., 2018). The third
step (Aim 3) was to develop the murine subcutaneous CRC allografts, optimize probe design for
subcutaneous tumor allografts, test isoflurane anesthesia as a potential confounding variable, and
implement DRS in a longitudinal study on treating mice with chemotherapy and macrophagetargeted immunotherapy to see how this therapy would affect DRS results.
Specific Aim 1: Design and characterization of broadband diffuse reflectance spectroscopy
probes for in vivo tissue analysis
Publications:
▪

Greening GJ, Powless AJ, Hutcheson JA, James HM, Dierks MK, Rajaram N, Muldoon
TJ, “Fiber-bundle microendoscopy with sub-diffuse reflectance spectroscopy and
intensity mapping for multimodal optical biopsy of stratified epithelium,” Biomedical
Optics Express, 6(12), (2015).

▪

Greening GJ, James HM, Dierks MK, Vongkittiargorn N, Osterholm SM, Rajaram N,
Muldoon TJ. “Towards monitoring dysplastic progression in the oral cavity using a
hybrid fiber-bundle imaging and spectroscopy probe,” Scientific Reports, 6(26734),
(2016).

▪

Greening GJ, Rajaram N, Muldoon TJ. “Multimodal imaging and spectroscopy fiberbundle microendoscopy platform for non-invasive in vivo tissue analysis,” Journal of
Visualized Experiments, 116, (2016).
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Background: Early detection of structural or functional changes in dysplastic epithelia is crucial
for improving long-term patient care. Recent work has explored non-invasive or minimally
invasive optical biopsy techniques for diagnosing early dysplasia, such as HRME, a method to
resolve sub-cellular features of apical epithelia, as well as DRS, a method that evaluates bulk
health of a small volume of tissue. It is possible that the high-resolution imaging modality may
be beneficial in providing image data of later stage moderate and severe dysplasia while the DRS
modality may be sensitive to tissue optical changes associated with early dysplasia.
Objective: Develop and validate a quantitative hybrid imaging and spectroscopy microendoscope
to monitor dysplastic progression within epithelial tissues. Co-registration of both techniques is
important because this technique can be potentially used to not only detect dysplasia using two
different modalities, but also to monitor personalized response of sub-surface dysplastic lesions to
anti-tumor therapy at multiple source-detector separations.
Central Hypothesis: High-resolution microendoscopy and DRS can be combined within a single
optical probe to co-register image and spectral data of in vivo epithelia.
Significance: With this multimodal system, epithelial morphological data can be correlated with
quantitative spectroscopy data of the subsurface microenvironment, including associated optical
properties. This multimodal microendoscopy approach encompasses both structural and
spectroscopic reporters of perfusion within the tissue microenvironment and can potentially be
used to monitor tumor response to therapy. This hybrid imaging and spectroscopy platform may
be capable of collecting a wealth of information about the structural and functional properties of
tissue at various imaging sites in ex vivo and in vivo models. The potential of this technique to be
coupled to the biopsy port of a conventional endoscope makes further clinical translation and
complimentary optical biopsy in the oral cavity and other epithelial tissues feasible.
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Specific Aim 2: Characterization of poly(dimethylsiloxane)-based tissue-simulating
phantoms with tunable reduced scattering and absorption coefficients with applications for
diffuse reflectance spectroscopy
Publications:
▪

Greening GJ, Istfan R, Higgins LM, Balachandran K, Roblyer D, Pierce MC, Muldoon
TJ, “Characterization of thin poly (dimethylsiloxane)-based tissue simulating phantoms
with tunablereduced scattering and absorption coefficients at visible and near infrared
wavelength,” Journal of Biomedical Optics, 19(11), (2014).

▪

Greening GJ, James HM, Muldoon TJ. “Optical Phantoms: Diffuse and sub-diffuse
imaging and spectroscopy validation,” SPIE Spotlights, (2015).

▪

Tabassum S, Pera V, Greening GJ, Muldoon TJ, Roblyer D. “Two-layer inverse model
for improved longitudinal preclinical tumor imaging in the spatial frequency domain,”
Journal of Biomedical Optics, 23(7), (2018).

Background: Optical phantoms are used in the development of various imaging systems. For
certain applications, the development of thin phantoms that simulate physical size and optical
properties of tissue is important.
Objective: Here, we demonstrate a method for producing thin phantom layers with tunable
optical properties using poly(dimethylsiloxane) (PDMS) as a substrate material at six discrete
wavelengths (591, 631, 659, 691, 731, and 851 nm) at varying concentrations of titanium dioxide
and nigrosin.
Central Hypothesis: Thin, PDMS-based optical phantoms can accurately simulate the geometry
and optical properties of target epithelia, and can be used to tst the sensitivity of various imaging
and spectroscopy equipment to heterogeneities.

36

Significance: From the presented data, we provide lookup tables to determine appropriate
concentrations of scattering and absorbing agents to be used in the design of PDMS-based
phantoms with specific optical coefficients. In addition, heterogeneous phantoms, mimicking the
layered features of certain tissue types, may be fabricated from multiple stacked layers, each with
custom optical properties. These thin, tunable PDMS optical phantoms can simulate many tissue
types and have broad imaging calibration applications in endoscopy, diffuse optical spectroscopic
imaging (DOSI), or optical coherence tomography (OCT), among others.
Specific Aim 3: Optical property quantification of subcutaneous murine colon carcinoma
tumors in response to chemotherapy and macrophage-targeted immunotherapy measured
using diffuse reflectance spectroscopy
Publications:
▪

Greening GJ, Mundo AI, Rajaram N, Muldoon TJ. “Sampling depth of a diffuse
reflectance spectroscopy probe for in vivo physiologic quantification of murine
subcutaneous tumor allografts,” Journal of Biomedical Optics, 23(8), (2018).

▪

Greening GJ, Miller KP, Spainhour CR, Cato MD, Muldoon TJ. “Effects of isoflurane
anesthesia on physiological parameters in murine subcutaneous tumor allografts
measured via diffuse reflectance spectroscopy,” Biomedical Optics Express, 9(6), (2018).

▪

Greening GJ, Bess SN, Muldoon TJ. “Immunohistochemistry staining for tumorassociated macrophage polarization in murine subcutaneous colon tumor allografts,” Bio101, 3106, (2018).

Background: (1) DRS is a probe-based spectral biopsy technique used in cancer studies to
quantify tissue reduced scattering (μs’) and absorption (μa) coefficients and vary in sourcedetector separation (SDS) to fine tune sampling depth. In subcutaneous murine tumor allografts
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or xenografts, a key design requirement is ensuring the source light interrogates past the skin
layer into the tumor without significantly sacrificing signal-to-noise ratio (target of ≥ 15 dB).
Once this has been verified, DRS can be used in cancer allograft or xenograft studies, such as
those subject to chemotherapy and/or immunotherapy regimens. (2) Immunotherapy in colorectal
cancer (CRC) describes therapy that regulates specific immune checkpoints, and when used in
combination with chemotherapy, can improve prognosis. One specific immune checkpoint is
recruitment of circulating monocytes, which differentiate into tumor-associated macrophages
(TAMs) and promote angiogenesis and tumor progression. Thus, immunotherapeutic strategies
blocking monocyte recruitment may play an anti-tumor role. Vascularization can be noninvasively assessed via DRS, which quantifies metrics such as hemoglobin concentration and
oxygenation in a localized tumor volume. However, there have been no studies investigating the
efficacy of DRS in evaluating therapeutic response of combined immunotherapy and
chemotherapy.
Objecive: (1) Design a DRS probe with four SDSs (0.75, 2.00, 3.00, and 4.00 mm) to interrogate
increasing tissue volumes between 450-900 nm. The goal was to quantify percent errors in
extracting μa and μs’, and to quantify sampling depth into subcutaneous Balb/c-CT26 colon
tumor allografts. Using an optical phantom-based experimental method, lookup-tables were
constructed relating μa, μs’, diffuse reflectance, and sampling depth. (2) Examine whether
blockade of monocyte recruitment via anti-CCL2 (macrophage chemoattractant protein-1) leads
to enhanced sensitivity of 5-FU (5-fluorouracil) therapy in a CT26-Balb/c mouse model of CRC,
and whether this effect can be quantified via DRS.
Central Hypothesis: The oxyhemoglobin flare has not been quantified after combinatorial
chemotherapy and immunotherapy, and furthermore, has not been quantified in colon cancer
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tumors. Can DRS be used to quantify the therapy-induced oxyhemoglobin flare in a mouse
model of colon cancer? The central hypothesis is that tumors treated with immunotherapy will
have increased tumor therapeutic response to chemotherapy, as measured via tumor size and
DRS-derived metrics.
Significance: This work shows that the DRS probe can accurately extract optical properties, and
the resultant physiological parameters such as total hemoglobin concentration and tissue oxygen
saturation, from sufficient depth within subcutaneous Balb/c-CT26 colon tumor allografts.
Methods described here can be generalized for other murine tumor models.
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Chapter 2 (Specific Aim 1): Design and characterization of broadband diffuse reflectance
spectroscopy probes for in vivo tissue analysis

2.1 Introduction
Several recent non-invasive translational endoscopy-based techniques have aimed at
improving cancer detection and monitoring tumor therapeutic response in both oral
intraepithelial dysplasia and colon carcinoma.
Intraepithelial dysplastic progression within the oral mucosa is a dynamic process that
typically arises at the basement membrane and is classified into stages based on how far it has
spread towards the upper epithelial layers (Zhu and Liu, 2011; Speight, 2007; Warnakulasuriya
et al., 2008; Bouquot et al., 2006). For example, mild dysplasia occurs in the basal epithelial
layers, directly above the basement membrane. As dysplasia progresses upwards towards the
apical epithelial surface, the stages are characterized as moderate and severe (or carcinoma insitu), respectively (Speight, 2007; Warnakulasuriya et al., 2008; Bouquot et al., 2006). These
stages are not considered invasive cancer since they have not yet penetrated the basement
membrane and metastasized, although the severity of dysplasia increases this risk (Speight, 2007;
Bouquot et al., 2006). It has been found that <5%, 3-15%, and >15% of patients with mild,
moderate, and severe dysplasia, respectively, progressed to carcinoma (Speight, 2007; Bouquot
et al., 2006). Oral squamous cell carcinoma (OSCC) is the most common form of this carcinoma
in the oral cavity and patients diagnosed with OSCC have a 5-year survival rate of less than 6070% and this number decreases in developing countries (Speight, 2007; Davies et al., 2015;
Cheng et al., 2015; Muldoon et al., 2011). This is because primary detection of dysplastic
malignancies typically occurs upon visual inspection by non-specialized dentists, who then refer
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patients to specialists (Davies et al., 2015; Brailo, 2015; Brocklehurst et al., 2015). Diagnoses at
this point are often late-stage (Brailo, 2015). Therefore, detection of oral dysplasia at its various
stages via affordable, available, and non-invasive techniques is crucial in limiting the number of
cases that progress to OSCC.
Gastrointestinal dysplasia is an abnormal but non-invasive proliferation of cells in the
gastrointestinal epithelium that, when diagnosed, is assumed to progress to carcinoma (Sharma,
2013; Speight, 2007). In the oral cavity and esophagus, dysplasia can potentially become
squamous cell carcinoma (SCC) or adenocarcinoma, cancer of the stratified squamous
epithelium or columnar glandular cells, respectively (Speight, 2007). Most adenocarcinomas
arise from dysplastic changes associated with Barrett’s esophagus, although SCC is more
prevalent in the upper digestive tract worldwide (Zhang, 2013). In the colorectal region,
dysplasia can form adenomatous polyps which become invasive upon penetration into the
submucosa (Harpaz and Polydorides, 2010; Ponz de Leon and Di Gregorio, 2001). Dysplasia can
also arise in the epithelia of other organs. For example, cervical dysplasia, which can be either
squamous or columnar in origin, leads to increased risk of cervical cancer (Arends et al., 1998).
Conventional practice for diagnosing dysplasia in the lumen of the gastrointestinal tract is
endoscopy-guided biopsy with wide-field, broadband illumination followed by histological
examination by a pathologist using hematoxylin and eosin (H&E) staining (Hwang and Shroyer,
2012; Dacosta et al., 2002; Muldoon et al., 2011). However, diagnosis in this way may be
subject to sampling errors and is subjective to the experience of the pathologist, potentially
limiting reproducibility (Appelman, 2005; Dacosta et al., 2002; Muldoon et al., 2011).
One such technique aimed at improving cancer detection and monitoring tumor
therapeutic response is high-resolution microendoscopy, which can provide clinicians rapid,
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high-resolution visualization of tissue architecture and histology when compared to that of the
naked eye alone. These techniques provide a step towards point-of-care “optical biopsy,”
potentially reducing the number of biopsies performed each year (Muldoon et al., 2011; Shukla
et al., 2011). Preclinical and clinical studies using high-resolution microendoscopy techniques
have been demonstrated in various body organs including the oral cavity (Muldoon et al., 2011;
Pierce, Schwarz, et al., 2012), esophagus (Hur et al., 2015; Muldoon et al., 2008; Muldoon et al.,
2010; Shin et al., 2015), lower gastrointestinal tract (Carns et al., 2013; Chang et al., 2013; Elahi
et al., 2011; Louie et al., 2014; Parikh et al., 2014; Prieto, Powless, Lai, et al., 2015), cervix
(Pierce, Guan, et al., 2012; Quinn et al., 2012), ear (Campbell et al., 2010; Levy et al., 2013;
Monfared et al., 2006), and liver and pancreas (Regunathan et al., 2012). Furthermore, several
studies have developed high-resolution imaging techniques compatible with the biopsy port of
conventional white-light endoscopes, making it more attractive for clinicians to adopt these new
techniques (Muldoon et al., 2008; Shukla et al., 2011; Louie et al., 2014). Work has also been
performed in quantifying high-resolution microendoscopy image data, but for the most part this
remains a qualitative screening technique (Muldoon et al., 2010; Shin et al., 2015; Prieto,
Powless, Lai, et al., 2015; Ishijimi et al., 2015). The advantages of high-resolution
microendoscopy are low cost, portability, and instantaneous imaging of tissue architecture.
However, a drawback of high-resolution microendoscopy is lack of depth sectioning, meaning it
can only resolve tissue architecture at the apical epithelial surface. More complex
instrumentation does exist to overcome this drawback, including laser scanning confocal
systems, but this instrumentation requires galvanometers or microelectromechanical (MEMS)based technology to do so. Additionally, information gathered by these more complex depthsensitive technologies are primarily qualitative (Greening, James, Powless, et al., 2015; Rivera et
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al., 2011; Chen et al., 2015; Piyawattanametha and Wang, 2010). High-resolution
microendoscopy can thus benefit from additional depth sensitive modalities since mild and
moderate dysplasia are often sub-epithelial surface phenomena, but relatively simple and
quantitative techniques are desirable.
One depth sensitive technique that has demonstrated diagnostic efficacy is diffuse
reflectance spectroscopy (DRS), a well-established method capable of non-invasively
quantifying volume-averaged tissue optical parameters using simple probe designs (Glennie et
al., 2014; Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Rajaram, Reichenberg, et
al., 2010; Bish et al., 2014; Karsten et al., "Diffuse Reflectance Spectroscopy as a Tool to
Measure the Absorption Coefficient in Skin: South African Skin Phototypes," 2013; Hennessy et
al., 2013), Raw DRS data is given in terms of reflectance, that is, the percentage of light
recovered from a detection fiber to light delivered by a source fiber. Studies have shown that
volume-averaged optical properties, such as reduced scattering coefficient (µs’) and absorption
coefficient (µa) can be determined from in vivo samples (Rajaram, Aramil, et al., 2010; Karsten
et al., "Diffuse Reflectance Spectroscopy as a Tool to Measure the Absorption Coefficient in
Skin: South African Skin Phototypes," 2013; Rajaram et al., 2008; Karsten et al., "Diffuse
Reflectance Spectroscopy as a Tool to Measure the Absorption Coefficient in Skin: System
Calibration," 2013; Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011;
Pimenta et al., 2012; Nichols et al., 2015). It should be noted that these extracted values are
based on the delivery and collection of light throughout an often inhomogeneous layered media,
such as tissue, and extracted optical properties thus represent volume averaged, rather than
axially resolved, values. Several in vivo DRS studies have extracted other clinically relevant
optical parameters including blood volume fraction, hemoglobin concentration, oxygen
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saturation, mean blood vessel diameter, nicotinamide adenine dinucleotide (NADH)
concentration, and tissue thickness (Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010;
Rajaram, Reichenberg, et al., 2010; Bish et al., 2014; Lim et al., 2011; Nichols et al., 2012;
Sharma et al., 2014; Sharma et al., 2013; Hennessy et al., 2015). Furthermore, DRS is an
appealing non-invasive screening technique because it is sensitive to optical changes beneath the
apical tissue layer (Glennie et al., 2014; Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al.,
2010; Rajaram, Reichenberg, et al., 2010; Bish et al., 2014; Karsten et al., "Diffuse Reflectance
Spectroscopy as a Tool to Measure the Absorption Coefficient in Skin: South African Skin
Phototypes," 2013; Hennessy et al., 2013; Rajaram et al., 2008; Karsten et al., "Diffuse
Reflectance Spectroscopy as a Tool to Measure the Absorption Coefficient in Skin: System
Calibration," 2013; Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011;
Pimenta et al., 2012; Nichols et al., 2015; Lim et al., 2011; Nichols et al., 2012; Sharma et al.,
2013; Sharma et al., 2014; Hennessy et al., 2015). However, a drawback of DRS is inability to
spatially resolve tissue architecture.
We have recently reported on a probe-based technique that combines high-resolution
microendoscopy imaging, and DRS (Rajaram et al., 2008; Durduran et al., 2010; Dehghani et
al., 2009; Subramanian et al., 2007; Turzhitsky, Radosevich, et al., 2010; Turzhitsky, Rogers, et
al., 2010). This hybrid fiber-bundle spectroscopy and imaging probe is capable of co-registering
qualitative high-resolution images of tissue surface microarchitecture with complimentary
quantitative and depth-sensitive spectral data (Greening, James, Powless, et al., 2015; Greening,
Powless, et al., 2015). Furthermore, our design uses two SDSs (shallow and deep channels) to
collect data at two different sampling depths with the goal of sampling different tissue volumes.
Therefore, the high-resolution imaging modality may be beneficial in providing image data of
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later stage moderate and severe dysplasia while the DRS modality may be sensitive to tissue
optical changes associated with early dysplasia arising at the basement membrane (Greening,
James, Powless, et al., 2015).
In this manuscript, we validate the DRS portion of the quantitative hybrid imaging and
spectroscopy microendoscope and present a pilot phantom and pre-clinical study to extract in
vivo optical parameters of the human oral mucosa. First, a set of calibration phantoms was used
to generate reflectance lookup tables (LUT) describing the relationship between reflectance and
optical properties (µs’ and µa) for the DRS modality (Rajaram et al., 2008). Then, to validate the
LUT, the probe and LUT-based inverse model was used to extract µs’ and µa from a set of
hemoglobin-based validation phantoms with known µs’ and µa (Rajaram et al., 2008). Extracted
optical properties were compared to theoretical values and reported as percent errors. Next, we
quantify sampling depth for the shallow and deep SDSs of the DRS modality and validate results
using the same calibration and validation phantoms (Hennessy et al., 2014). Following this, we
present a simple phantom study simulating the physical layered progression from healthy tissue
to severe dysplasia to show how reflectance changes with an optically scattering heterogeneity
buried at various depths (Zhu and Liu, 2011; Bouquot et al., 2006; Speight, 2007). Finally, the
LUT-based inverse model was demonstrated on in vivo human oral mucosa from thirteen healthy
volunteers in a laboratory setting to determine volume-averaged scattering exponent, hemoglobin
concentration, oxygen saturation, and sampling depth. The extracted in vivo quantitative optical
parameters were compared to an in vivo high-resolution image of healthy, non-keratinized oral
tissue. These studies validate our hybrid fiber-bundle imaging and spectroscopy technique and
demonstrate the translational potential to a clinical setting. This technique can potentially be used
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to for diagnostic purposes as well as dynamically monitoring personalized tumor response to
therapy.
2.2 Rationale
This multimodal instrumentation and associated technique is the first combination of
these modalities within a single probe, although other combined structural/functional techniques
do exist that combine different modalities. For example, hyperspectral imaging combines widefield imaging with quantitative hemoglobin and melanin properties (Ghassemi et al., 2014;
Vasefi et al., 2014), and other techniques have been developed that combine optical coherence
tomography (OCT) with analysis of tissue protein expression (Winkler et al., 2010), to name a
few. This article reports on a compact and easy-to-implement instrumentation setup that uses a
general fiber-optic probe which can be optimized for various purposes including endoscopic use
in the lower gastrointestinal tract and esophagus or as a handheld probe for use in the oral cavity
and external skin placement (Greening, James, Powless, et al., 2015; Bish et al., 2014).
The hardware for this instrumentation requires both custom data acquisition and postprocessing code to acquire diffuse reflectance spectra and then extract the resulting volumeaveraged tissue physiological parameters including THC, [Mel], and StO2. The custom data
acquisition code was built to allow the simultaneous acquisition from a camera (for highresolution fluorescence microscopy) and a spectrometer (for diffuse reflectance spectroscopy).
Drivers are often available from the manufacturers’ websites to allow integration with a variety
of programming languages. The custom post-processing code imports a priori absorption values
of in vivo THC and [Mel](Prahl, 1999) and then utilizes a previously developed nonlinear
optimization fitting process that creates a fitted curve of the spectra (Rajaram, Aramil, et al.,
2010). The fitted curve is built by minimizing the χ2 value between itself and the raw spectra and
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determining the tissue physiological parameters (THC, [Mel], and StO2) from the fitted curve
and with the lowest χ2 value (Rajaram, Aramil, et al., 2010). The code can be modified to include
absorption from other chromophores as well, such as the exogenous pyranine ink used here, so
that target physiological parameters are unaffected.
Physiological indicators of tissue health, such as THC, [Mel], and StO2, can be used as
reports of tumor response to therapy or as indicators of local vascularization and angiogenesis
(Hennessy et al., 2015; Chang et al., 2009). Including a high-resolution fluorescence
microendoscopy modality helps guide probe placement and provides investigators with a more
complete picture of the relationship between epithelial tissue structure and function. In this
article, construction and application of the multimodal microendoscope is described (Greening,
James, Powless, et al., 2015).
2.3 Materials and Methods
2.3.1 Fiber-Optic Probe Design
The custom fiber-optic probe (Myriad Fiber Imaging, USA) used for this trimodal
microendoscopy technique uses five 200/220 µm core/cladding, 0.22 NA multimode fibers
(Molex Inc., USA) surrounding a 1 mm Fujikura image fiber (Myriad Fiber Imaging, USA) for a
total of six fibers. The central 1 mm image fiber contains approximately 50,000 individual fiber
elements 4.5 µm in diameter with center-to-center spacing of approximately 4.5 µm. The centerto-center separation between any one of the 200 µm fibers and the image fiber is 864 µm.
Therefore, the closest edge of the image fiber to the center of any 200 µm fiber is approximately
350 µm. Similarly, the farthest edge of the image fiber to the center of any 200 µm fiber is
approximately 1,350 µm. The centers of each of the 200 µm fibers are separated by 25°. Based
on this geometry, center-to-center SDS between adjacent 200 µm fibers with respect to the
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leftmost fiber are 374, 730, 1,051, and 1,323 µm. For the purposes of this paper, only the first
two SDSs (374 and 730 µm) were used for DRS measurements. The total length of the fiberoptic probe is 4 ft. in which the distal 2 ft. of the fiber-optic probe consists of a single probe tip 3
mm in diameter and the proximal 2 ft. of the fiber-optic probe, nearest the optical
instrumentation, splits into six individual fibers corresponding to each fiber within the bundle.
Each of the six fibers ends in an SMA905 connector and can be readily coupled to the
microendoscopy instrumentation. Figure 1 shows the details of the fiber-optic probe (Greening,
Powless, et al., 2015). Figure 2 shows the details of the hybrid fiber-bundle imaging and
spectroscopy system including the proximal instrumentation such as the imaging hardware,
spectroscopy hardware, and the optical fiber switch.

Figure 1. Fiber-optic probe showing (a) the full length (4 ft.) of the probe with
the single bundle at the distal end and splitting into six individual bundles at the
proximal end, (b) a schematic of the probe tip with the central 1 mm image fiber
(#6) surrounded by five 200 µm multimode fibers (#1-5) separated by 25º. SDS
between fiber #1 and the four adjacent fibers (#2-5) are 374, 730, 1051, and 1323
µm, respectively, and (c) close-up of the distal end of the fiber-optic probe (scale
bar = 2 mm).
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Figure 2. Representation of the hybrid fiber-bundle imaging and spectroscopy
system showing (a) the major instrumentation components including (from left to
right) fiber switch, imaging portion, and spectroscopy portion, (b) a SolidWorks
representation of the distal probe (scale bar = 1 cm) showing the (c) en face view
of the central 1 mm-diameter image fiber and 5 surrounding 200 μm multimode
fibers (scale bar = 2.5 mm), (d) distal probe (scale bar = 1 cm), and (e) en face
view of the distal probe tip (scale bar = 2.5 mm).
2.3.2 Instrumentation Design
Three light sources, corresponding to the three optical modes of the instrumentation, are
delivered to the sample via the custom fiber-optic probe: an LED light source (Philips, USA)
centered at 455 nm (20 nm FWHM), a broadband tungsten-halogen white light source (Ocean
Optics, USA), and a 635 nm laser (Thorlabs, USA).
For the first mode (high-resolution, image fiber-based fluorescence imaging), light from
the 455 nm LED passes through a 460 nm short pass excitation filter (Chroma Technology
Corp., USA) and is directed into the back aperture of a 10X/0.30 NA infinity-corrected objective
lens (Olympus Corp., Japan) using a 475 nm cut-off dichroic mirror (Chroma Technology Corp.,
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USA). 455 nm excitation light passes through the 1 mm image fiber to the distal end of the
probe, illuminating the sample with 1 mW of power. Samples fluorescently stained with
proflavine excite in this wavelength range and emit light centered at approximately 515 nm
which is collected by the image fiber (Prieto, Powless, Boice, et al., 2015). Emission light passes
through the 475 nm dichroic mirror and is reflected by a second dichroic mirror with a cut-off
wavelength of 590 nm (Chroma Technology Corp., USA). This reflected emission light
(centered at 515 nm) then passes through a 525/40 nm emission bandpass filter (Chroma
Technology Corp., USA), a 50 mm tube lens (Thorlabs), and into an 8-bit, Flea3 USB 3.0
monochrome CMOS camera (Point Grey, Canada) (Greening, Powless, et al., 2015; Muldoon et
al., 2007; Muldoon et al., 2011; Pierce, Guan, et al., 2012; Pierce et al., 2011; Quinn et al., 2012;
Chang et al., 2013; Keahey et al., 2015; Parikh et al., 2014). The CMOS camera thus provides
magnified apical cell morphological data from the 1 mm-diameter field-of-view (FOV).
For the second mode (broadband DRS), broadband light (450-750 nm) from the tungstenhalogen lamp is coupled into one 200 µm fiber (fiber #1 from Figure 1) of the fiber-optic probe
to deliver white light to the sample. The wavelength range is limited by the output of the
tungsten-halogen source lamp. Sub-diffusely reflected light is collected by two adjacent 200 µm
fibers (fiber #2 and #3 from Figure 1) with corresponding center-to-center SDS of 374 and 730
µm and delivered to a single visible-to-near infrared spectrometer (Ocean Optics, USA) with a
spectral resolution of 0.36 nm. A custom designed motorized optical fiber switch allows the
spectrometer to sequentially acquire from each collection fiber (Greening, Powless, et al., 2015).
For the third mode (DRIM), the 635 nm laser is coupled into one 200 µm fiber (fiber #5
from Figure 1) of the fiber-optic probe to deliver light to the sample. Within the sample, laser
light undergoes multiple scattering events and emitted light is collected by the central 1 mm
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image fiber (Kanick et al., 2014; Turzhitsky, Radosevich, et al., 2010). This emitted 635 nm
light passes through both the 475 and 590 nm cut-off dichroic mirrors before being reflected by a
1-inch aluminum mirror (Thorlabs, USA). The collected 635 nm light then passes through a 610
nm long pass emission filter (Chroma Technology Corp., USA), a 50 mm tube lens (Thorlabs,
USA), and into a second 8-bit, Flea3 USB 3.0 monochrome CMOS camera (Point Grey,
Canada). A second camera is necessary so the resultant 2D sub-diffuse reflectance image maps
have the same FOV and image area as the apical cell morphological data and thus can be directly
compared. Both CMOS cameras presented here have a sensor array of 2080 x 1552 pixels 2.5
µm wide, a corresponding sensor size of 5.2 x 3.9 mm, and a dynamic range of 62.9 dB
(Greening, Powless, et al., 2015).
All modalities of the instrumentation are controlled with custom LabVIEW software
(National Instruments, USA). Figure 3 shows a schematic of the fiber-bundle microendoscopy
system along with images of the physical bench-top instrumentation.
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Figure 3. The trimodal microendoscope showing (a) a schematic illustrating
major components. 455 nm light passes through a 460 nm short pass excitation
filter (Ex). Emitted signal passes through a 10X objective, 475 nm dichroic mirror
(DCM1), 525/40 nm emission filter (Em1), and into a camera (Cam 1). 635 nm
DRIM signal passes through the objective lens, 475 (DCM1) and 590 nm dichroic
mirrors (DCM2), 610 long pass filter (Em2), and into a camera (Cam 2). An
optical fiber switch delivers reflected broadband light from the tungsten halogen
lamp to a spectrometer. Finally, (b) shows a close-up of the optical components
and (c) shows the optical components and custom LabVIEW software acquiring
data from a hybrid cell phantom.
2.3.3 Assembly of the High-Resolution Fluorescence Microendoscopy Modality
Note: The outlined steps for assembly of the high-resolution fluorescence
microendoscopy modality can be visualized in Figure 4.
1.1)

Place a 470 nm dichroic mirror inside a 30 mm cage cube.

1.1.1) Obtain a 30 mm cage cube and remove the dichroic filter mount.
1.1.2) Place a 470 nm dichroic mirror in the dichroic filter mount.
1.1.3) Re-insert and secure the dichroic filter mount back inside the cage cube.
1.2)

Attach cage assembly rods to the 30 mm cage cube.
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1.2.1) Secure four 1.5 in. cage assembly rods to the front of the cage cube.
1.2.2) Secure four 3.0 in. cage assembly rods to the right side of the cage cube.
1.2.3) Secure two 2.0 in. cage assembly rods diagonally on the left side of the cage cube.
1.3)

Build a cage plate/lens tube assembly.

1.3.1) Obtain a 1.0 in. threaded 30 mm cage plate and attach a stress free retaining ring to the
inside of the cage plate using the provided threading.
1.3.2) Screw in a 1.0 in. lens tube to the stress-free retaining ring.
1.3.3) Attach a second 1.0 in. threaded 30 mm cage plate to the 1.0 in. lens tube and adjust the
standard retaining rings so that the two cage plates are flush.
1.4)

Slide the 1.0 in. cage plate/lens tube assembly onto the left side of the 30 mm cage cube.

1.5)

Build the right-angle mirror mount assembly.

1.5.1) Obtain a right-angle mirror mount and a 1.0 in. UV-enhanced aluminum mirror.
1.5.2) Place the 1.0 in. UV-enhanced aluminum mirror into the mirror mount and tighten.
1.5.3) Secure four 2.0 in. cage assembly rods to the front of mirror mount
1.5.4) Secure two 2.0 in. cage assembly rods diagonally on the right side of the cage cube.
1.6)

Connect the right-angle mirror mount assembly onto the left side of the 1.0 in. cage

plate/lens tube assembly by placing the opposing cage assembly rods through the respective
openings of the 30 mm cage plate.
1.7)

Thread a z-axis translation mount through the 3.0 in. cage assembly rods on the right side

of the assembly.
1.8)

Attach a 10X achromatic objective lens to the z-axis translation mount.

1.9)

Build a 1.0 in. fiber adaptor plate/xy-axis translation lens mount assembly.

1.9.1) Obtain an xy-axis translation mount and an 1.0 in. fiber adaptor plate.
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1.9.2) Secure the 1.0 in. fiber adaptor plate into the xy-axis translation lens mount.
1.10) Slide the 1.0 in. fiber adaptor/xy-axis translation lens mount assembly in front of the
objective lens.
1.11) Obtain two 0.5 in. long, 1.0 in. diameter lens tubes, one 440/40 nm bandpass filter
(excitation filter) and one 525/36 nm bandpass filter (emission filter).
1.12) Place each filter inside a 0.5 in. long, 1.0 in. diameter lens tube, such that the arrow on
the outside of the filter is facing the side of the lens tube with the external threads.
1.13) Attach the filters to the assembly.
1.13.1) Obtain two standard retaining rings.
1.13.2) Secure the filters inside the 0.5 in. long, 1.0 in. diameter lens tubes with the standard
retaining rings.
1.13.3) Screw in the lens tube with the excitation filter to the front of the 30 mm cage cube and
screw in the lens tube with the emission filter to the right-angle mirror mount.
1.13.4) Screw in the 0.5 in. lens tube with the emission filter to the front of the right-angle mirror
mount.
1.14) Obtain two 1.0 in. threaded 30 mm cage plates and place them in front of the 0.5 in. long,
1.0 in. diameter lens tubes containing the filters.
1.15) Using epoxy or strong adhesive, attach a 455 nm LED to the cage plate connected to the
excitation filter.
1.16) Obtain one 0.5 in. long, 1.0 in. diameter lens tube and a 1.0 in. achromatic doublet tube
lens with focal length of 50 mm.
1.17) Place the tube lens inside the lens tube such that the arrow on the outside of lens is facing
the side of the lens tube with the external threads.
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1.18) Screw in the tube lens to the assembly.
1.18.1) Obtain one standard retaining ring.
1.18.2) Secure the lens inside the 0.5 in. long, 1.0 in. diameter lens tube with the standard
retaining ring.
1.18.3) Attach the lens tube with the tube lens to the left-most cage plate.
1.19) Place a 30 mm cage plate in front of the 0.5 in. long, 1.0 in. diameter lens tube containing
the tube lens.
1.20) Attach a stress-free retaining ring to the inside of the 30 mm cage plate.
1.21) Attach a USB monochrome camera to the cage plate with the stress-free retaining ring.
1.22) Construct the optical post mounting devices.
1.22.1) Obtain four 0.5 in. post holders, four 0.5 in. optical posts, and four mounting
bases.
1.22.2) Secure the 0.5 in. optical posts inside the 0.5 in. post holders.
1.23.3) Secure the 0.5 in. post holders onto the mounting bases.
1.23) Screw in the four optical post mounting devices to the screw holes located under the 30
mm cage cube, the right-angle mirror mount, the cage plate connected to the LED, and the cage
plate connected to the camera.
1.24) Screw in the four the optical post mounting devices to either an optical breadboard or
optical table to finish construction of the high-resolution fluorescence microendoscopy modality.
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Figure 4. Assembly of the high-resolution fluorescence microendoscopy
modality. The high-resolution fluorescence microendoscopy modality can be
constructed by building a shell of 1.0 in. diameter-sized components, with special
care taken in handling the dichroic mirror, objective lens, excitation/emission
filters, and tube lens. Glass surfaces of these components must be carefully
handled using lens paper.

71

2.3.4 Assembly of the Diffuse Reflectance Spectroscopy Modality
Note: The outlined steps for assembly of the sub-diffuse reflectance spectroscopy
modality can be visualized in Figure 5.
2.1)

Obtain a tungsten-halogen light source and, using epoxy or a strong adhesive, secure a
1.0 in. threaded 30 mm cage plate onto the front.

2.2)

Secure four 3.0 in. cage assembly rods to the cage plate.

2.3)

Attach a z-axis translation mount to the cage assembly rods.

2.4)

Screw in a 20X achromatic objective lens to the z-axis translation mount.

2.5)

Build a fiber adaptor plate/xy-axis translation lens mount assembly.
2.5.1) Obtain an xy-axis translation mount and an 1.0 in. fiber adaptor plate.
2.5.2) Secure the fiber adaptor plate into the xy-axis translation lens mount.

2.6)

Slide the 1.0 in. fiber adaptor/xy-translation mount assembly in front of the objective

lens.
2.7)

Build the motor arm assembly.
2.7.1) Obtain the custom-built aluminum motor arm and one SMA fiber adaptor plate.
2.7.2) Screw in the fiber adaptor plate (with external threading) into the aluminum motor

arm (with internal threading).
2.7.3) Attach the custom-built aluminum motor arm adaptor to the motor arm with four
#4-40 0.5 in. screws.
2.8)

Build the motor/motor arm/motor housing assembly.
2.8.1) Obtain the custom-built aluminum motor housing and the 400-step stepper motor.
2.8.2) Line up the screw holes on the stepper motor and motor housing and then secure

with four #4-40 0.5 in. screws.
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2.8.3) Feed the rotating motor rod of the stepper motor through the opening of the motor
arm assembly and tighten the locking screw on the aluminum motor arm adaptor.
2.9)

Build the optical switch assembly.
2.9.1) Obtain the custom-built aluminum optical switch and three 1.0 in. fiber adaptor

plates.
2.9.2) Thread the adaptor plates into the threaded holes in the optical switch.
2.9.3) Attach the custom-built aluminum optical switch face-plate onto the optical switch
with four #4-40 0.5 in. screws.
2.10) Attach the motor/motor arm/motor housing assembly to the optical switch by feeding the
rotating motor rod of the stepper motor through the central hole of the optical switch.
2.11) Obtain an electric circuit board and stepper motor driver, and then place the stepper
motor driver across the central groove of the breadboard.
2.12) Observe the electrical connection schematic (Figure 5, 2.12) for the stepper motor driver,
12V power supply, and stepper motor.
2.13) Connect the stepper motor driver, 12V power supply, and stepper motor as specified in
the circuit diagram (Figure 3, 2.12) to complete construction of the motorized optical switch.
2.14) Screw in the optical switch components and tungsten-halogen light source to an optical
breadboard or optical table near the previously constructed (Figure 4, 1.24) high-resolution
fluorescence microendoscopy assembly.
2.15) Attach one end of a 550 µm, 0.22 NA patch cable to the 1.0 in. fiber adaptor plate of the
motor arm assembly.
2.16) Attach the other end of the 550 µm, 0.22 NA patch cable to the fiber connector of the
USB spectrometer.
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2.17) Screw in the five distal probe cables to the respective 1.0 in. fiber adaptor plates on the
instrumentation to finish completion of the multimodal high-resolution imaging and sub-diffuse
reflectance spectroscopy fiber-bundle microendoscope.
2.17.1) Screw in the central 1 mm-diameter image fiber cable to the 1.0 in. fiber adaptor
plate mentioned in step 1.9.2.
2.17.2) Screw in the leftmost 200 µm multimode fiber cable to the 1.0 in. fiber adaptor
plate mentioned in step 2.6.
2.17.3) Screw in the 2nd 200 µm multimode fiber cable to the leftmost 1.0 in. fiber
adaptor attached to the tungsten-halogen lamp mentioned in step 2.9.2.
2.17.4) Screw in the 3rd 200 µm multimode fiber cable to the middle 1.0 in. fiber adaptor
plate mentioned in step 2.9.2.
2.17.5) Screw in the 4th 200 µm multimode fiber cable to the rightmost 1.0 in. fiber
adaptor plate mentioned in step 2.9.2.
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Figure 5. Assembly of the sub-diffuse reflectance spectroscopy modality. The
sub-diffuse reflectance spectroscopy modality can be constructed using a basic
tungsten-halogen lamp coupled to an objective lens to focus light through the 200
μm multimode delivery fiber, and a spectrometer. Additionally, a custom-built
motorized optical switch can be constructed within the lamp-fiber-spectrometer
path to switch between each SDS. Investigators using multiple spectrometers to
acquire from multiple SDSs can bypass the optical switch component.
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2.3.5 Characterization of the High-Resolution Microendoscopy Modality
The instrumentation was characterized to determine the following specifications: 1)
spatial resolution, 2) magnification, 3) percent of maximum field-of-view, and 4) sampling
frequency. These values were determined with three objective/tube lenses with focal lengths of
50, 100, and 150 mm. For each lens, a 10X/0.30 NA infinity-corrected objective lens was used.
Next, the ability of the DRS modality to extract optical properties (absorption and reduced
scattering coefficients) was quantified using a lookup table (LUT) approach (Rajaram et al.,
2008; Rajaram, Aramil, et al., 2010) Finally, sampling depth was determined for the broadband
DRS modality (Hennessy et al., 2014).
First, spatial resolution and maximum field-of-view (FOV) was determined by the
geometry of the fiber-optic probe. The image fiber consists of approximately 50,000 individual
4.5 µm-diameter fiber elements with center-to-center spacing of 4.5 µm. The probe is placed in
direct contact with a sample; therefore, the optimal spatial resolution that can be achieved is 4.5
µm. In addition, the maximum FOV was approximately 0.8 mm2, which was determined by the
diameter (≈ 1 mm) of the image fiber. Depending on the objective/tube lens configuration, values
for magnification, percent-of-maximum FOV, and sampling frequency vary.
A positive 1951 USAF resolution test target was back-illuminated with a white LED and
imaged at group 3/element 3 (linewidth = 49.50 µm) with three tube lenses (focal lengths = 50,
100, and 150 mm). The number of image sensor pixels per micron within the images was then
computed. This number was multiplied by the width of the individual pixels (2.5 µm/pixel) to
obtain magnification. Percent of maximum FOV was determined by dividing the sampled area
projected onto the image sensor by the maximum FOV (0.8 mm2). Finally, sampling frequency
was determined by multiplying the individual fiber element diameter (4.5 µm) by the number of
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pixels per micron within the images. Equations for obtaining spatial resolution, magnification,
percent of maximum FOV, and sampling frequency are shown below as Eq. (1), Eq. (2), Eq. (3),
and Eq. (4), respectively. In the following equations, R is spatial resolution, D is diameter of
individual fiber elements (4.5 μm), M is magnification, N is the number of pixels per micron, W
is pixel width (2.5 μm), FOV is percent of maximum field-of-view, A is area, and F is sampling
frequency.
𝜇𝑚
𝑅(𝜇𝑚) = 𝐷𝑓𝑖𝑏𝑒𝑟𝑠 (
) ∙ 𝑓𝑖𝑏𝑒𝑟
𝑓𝑖𝑏𝑒𝑟

(1)

𝑝𝑖𝑥𝑒𝑙
𝜇𝑚
𝑀 = 𝑁𝑝𝑖𝑥𝑒𝑙 (
) ∙ 𝑊𝑝𝑖𝑥𝑒𝑙 (
)
𝜇𝑚
𝑝𝑖𝑥𝑒𝑙

(2)

𝐹𝑂𝑉(%) =

𝐴𝑠𝑎𝑚𝑝𝑙𝑒 (𝜇𝑚2 )
𝐴𝑚𝑎𝑥𝑖𝑚𝑢𝑚 (𝜇𝑚2 )

(3)

𝜇𝑚
𝑝𝑖𝑥𝑒𝑙
𝐹𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 = 𝐷𝑓𝑖𝑏𝑒𝑟 (
) ∙ 𝑁𝑝𝑖𝑥𝑒𝑙 (
)
𝑓𝑖𝑏𝑒𝑟
𝜇𝑚

(4)

2.3.6 Generation of and validation of lookup tables for volume-averaged optical property
extraction
The second objective of this study was to use the DRS modality to extract volumeaveraged optical parameters. To accomplish this, reflectance lookup tables (LUTs) were
generated describing the relationship between absolute reflectance and optical properties (µs’ and
µa) for the two SDSs (374 and 730 µm). The target ranges of the LUTs were µs’ and µa between
5-26 cm-1 and 0-10 cm-1, respectively. These LUTs required calibration phantoms of similar
order of magnitude as biological tissue (Rajaram et al., 2008; Sandell and Zhu, 2011).
Calibration phantoms were constructed to exceed the target range using deionized water
as the solvent (Rajaram et al., 2008). The scattering agent was 1.0 µm-diameter polystyrene
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microspheres (07310-15, Polysciences, USA) and the associated µs’ range (3-31 cm-1) was
calculated using Mie theory (Nichols et al., 2012; Sharma et al., 2014; Fu et al., 2010). The
absorbing agent was a combination of yellow, red, and blue food dye (McCormick & Company,
USA), in ratio of 20:6:2, which contained propylene glycol, Yellow 5, Red 40, Red 3, Blue 1,
and 0.1% propylparaben. The µa range (0-47 cm-1) was calculated by measuring the dye solution
in deionized water using a spectrophotometer (5102-00, PerkinElmer, USA) and Beer’s Law. All
calibration phantoms were homogenous so µs’ and µa were identical throughout the phantom
volume.
A total of 12 liquid calibration phantoms was created which was sufficient to build the
LUTs. Six of the 12 phantoms were considered “scattering-only” and contained only deionized
water and polystyrene microspheres without dye. Deionized water and polystyrene microspheres
were gently mixed inside 7 mL scintillation vials (66022-300, VWR, USA) to yield six µs’
ranges of 3.0-4.9, 4.4-7.1, 6.4-10.2, 9.2-14.7, 13.2-21.2, and 19.5-31.0 cm-1. These values were
chosen so there was sufficient overlap between the maximum µs’ value of one phantom at 450
nm and the minimum µs’ value of another phantom at 750 nm. Sufficient overlap was determined
such that the minimum µs’ value of one phantom was no greater than 90% of the maximum µs’
value of the proceeding phantom. This ensured the six scattering-only phantoms spanned a
continuous µs’ range. Eq. 5 expresses this relationship in which n is the phantom number.
′
′
𝜇𝑠,𝑚𝑖𝑛,𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝑛)
≤ 0.9 ∙ 𝜇𝑠,𝑚𝑎𝑥,𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝑛−1)
,

(5)

The remaining six phantoms contained both polystyrene microspheres and the dye
combination. Deionized water, polystyrene microspheres, and dye were gently mixed inside 7
mL scintillation vials to yield a continuous µs’ range of 3-31 cm-1 and continuous µa range of 0-
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47 cm-1. The wavelength-dependent variations in μs’ and μa provide the wide range of scattering
and absorbing values.
To generate the reflectance LUTs, the probe was placed in each phantom so it was
completely submerged at a distance of 2 cm from the bottom of the 7 mL scintillation vial.
Broadband DRS data (450-750 nm) were recorded at each SDS (374 and 730 µm) with an
integration time of 400 ms. Five spectra were averaged for all measurements. Spectra were
converted to absolute reflectance values by calibrating with a Spectralon® 20% diffuse
reflectance standard (SRS-20-010, Labsphere, USA) which was spectrally flat between 200-2600
nm. A custom, 3D printed probe holder was used to fix the distance between the probe tip and
the Spectralon® 20% diffuse reflectance standard to acquire maximum reflectance at each SDS
(Figure 6 and 7).

79

Figure 6. Calibration of the sub-diffuse reflectance spectroscopy modality. For
experimental calibration, the fiber-optic probe tip must be placed at different
perpendicular distances from the 20% diffuse reflectance standard depending on
the SDS. To consistently achieve these perpendicular distances across all
experiments, a calibration standard device was designed (device cross section
shown in (a)) to hold the probe at exact distances from the 20% diffuse
reflectance standard. In this specific fiber-optic probe setup, light from the
tungsten-halogen lamp is shown through the optical switch at source-detector
separations of (b) 374 μm and (c) 730 μm (with motor and motor arm removed
from the optical path for clarity). Distances of (d) 2.1 mm for the 374 μm SDS,
and (e) 3.9 mm for the 730 μm SDS are required for calibration.

Figure 7. The final design, including during 3D printing
All spectra were corrected for background noise (Glennie et al., 2014; Rajaram, Aramil,
et al., 2010; Rajaram et al., 2008; Nichols et al., 2015; Nichols et al., 2012). After acquiring
absolute reflectance spectra at a resolution of 0.35 nm, the LUTs relating reflectance (R) to µs’
and µa were generated using MATLAB. Raw data from the 12 calibration phantoms (C.P. #1-12)
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was interpolated to generate a color-mapped mesh with an optical property resolution of 0.02 cm1

. The reflectance LUTs were interpolated in the target μs’ and μa ranges of 5-26 cm-1 and 0-10

cm-1, respectively.
To validate the reflectance LUTs, a set of liquid validation phantoms with known optical
properties was built of similar order of magnitude as biological tissue (Sandell and Zhu, 2011;
Rajaram et al., 2008). Validation phantoms were constructed in a similar manner to calibration
phantoms, but contained bovine hemoglobin (H2625, Sigma-Aldrich, USA), rather than food
dye, as the absorbing agent. The µs’ was calculated using Mie theory and µa was calculated by
measuring a solution of bovine hemoglobin in deionized water using a spectrophotometer (510200, PerkinElmer, USA) and Beer’s Law. It was necessary to validate the LUTs using a different
absorber and different scattering ranges than those used to generate the LUTs so that the
interpolated range of the LUTs were tested. All validation phantoms were homogenous so µs’
and µa were identical throughout the phantom volume.
A 3 x 3 (9 total) set of validation phantoms was created, corresponding to three µs’ ranges
and three µa ranges. Deionized water, polystyrene microspheres and diluted bovine hemoglobin
were gently mixed inside 7 mL scintillation vials. This yielded µs’ values from 5-26 cm-1 and µa
values from 0-10 cm-1 to validate 100% of the reflectance LUTs. Figure 8 shows the µs’ and µa
for the calibration phantoms (C.P. 1-12) and validation phantoms (V.P. 1-9).
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Figure 8. Comparison of the optical properties of the (a, b) 6x2 (12 total)
calibration phantoms (C.P.) and the (c, d) 3x3 (9 total) validation phantoms
(V.P.). Calibration phantoms were made with polystyrene microspheres and a
combination of yellow, red, and blue dye and the validation phantoms were made
with polystyrene microspheres and bovine hemoglobin as the scattering and
absorbing agents, respectively. Calibration phantoms had μs’ spanning 3-31 cm-1
and μa spanning 0-47 cm-1 and the validation phantoms had a μs’ spanning 5-26
cm-1 and μa spanning 0-10 cm-1 to validate the target LUT range.
Broadband DRS data on validation phantoms were collected in the same method as the
calibration phantoms. The LUT-based inverse model was used to extract µs’ and µa from the
validation phantoms. Theoretical optical properties of the validation phantoms were compared to
extracted optical properties and reported as percent errors. To quantify percent errors, the LUTbased inverse model extracted μs’ and μa for the 3x3 validation phantoms at a spectral resolution
of 0.35 nm and percent errors were calculated using Eq. 6 and Eq. 7,
′
′
𝜇𝑠,𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑
− 𝜇𝑠,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
| ∙ 100%
′
𝜇𝑠,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙

(6)

𝜇𝑎,𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 − 𝜇𝑎,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
| ∙ 100%,
𝜇𝑎,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙

(7)

𝐸𝑟𝑟𝑜𝑟%,𝜇𝑠′ = |
𝐸𝑟𝑟𝑜𝑟%,𝜇𝑎 = |

2.3.7 Generation of and validation of lookup tables for sampling depth quantification
The third objective of this study was to determine the sampling depth of the DRS
modality. To accomplish this, sampling depth lookup tables (LUTs) were generated describing
the relationship between sampling depth and volume-averaged optical properties (µs’ and µa) for
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the two SDSs (374 and 730 µm). The target ranges of the sampling depth LUTs were µs’ and µa
between 5-26 cm-1 and 0-10 cm-1, respectively. The same calibration phantoms as described
previously were used to generate the sampling depth LUTs.
A highly absorbing phantom layer (μa ≥ 100 cm-1 for all wavelengths between 450-750
nm) was created in a 5 mL beaker using 6.5% w/w India Ink in PDMS (Hennessy et al., 2014; Di
Ninni et al., 2010). Contributions from specular reflection were proven negligible by placing the
probe in contact with the absorbing layer and acquiring DRS data between distances of 0-2 mm
in 50 µm increments (Hennessy et al., 2014).
Next, the six dye-containing calibration phantoms (Figure 8, C.P. 7-12) were placed on
top of the highly absorbing layer within the beaker. Spectra (450-750 nm) at each SDS were
taken by varying the distance of the probe-tip and absorbing layer between 0-2 mm in 50 µm
increments (Hennessy et al., 2014). Sampling depth is been defined as the depth reached by 50%
of photons (Hennessy et al., 2014). At a certain probe-absorbing layer distance (around 2 mm),
there were no significant changes in signal intensity, meaning that nearly 100% of incident
photons were not reaching the highly absorbing layer. Figure 9 shows how sampling depth was
quantified for the DRS modality in representative data (Hennessy et al., 2014). As the probe is
translated away from the absorbing layer, as shown in Figure 9(a), reflectance increases until
plateauing as shown in Figure 9(b). A depth (x-axis) can then be identified that correlates with
the 50% cutoff point (y-axis) which is defined as the sampling depth as shown in Figure 9(c)
(Hennessy et al., 2014).
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Figure 9. The probe is placed (a) in contact with the highly absorbing (µa ≥ 100
cm-1 for 450-750 nm) inside a 5 mL beaker and translated upwards in 50 µm
increments to (b) acquire DRS data from a calibration phantom (C.P. 11) at a 374
µm SDS. (c) Representative data from the 374 µm SDS shows the percentage of
photons not reaching the highly absorbing layer as a function of depth for C.P. 11
at 585 nm. Sampling depth is defined as the depth reached by 50% of photons.
The process from Figure 3 was repeated for all wavelengths at a spectral resolution of
0.35 nm for the 6 calibration phantoms (C.P. 7-12). Raw data was interpolated in MATLAB to
generate a color-mapped mesh with a maximum optical property resolution of 0.02 cm-1. The
sampling depth LUTs were interpolated in a target μs’ range of 5-26 cm-1 and μa range of 0-10
cm-1.
To validate sampling depth, spectra (450-750 nm) at each SDS of the previously
described validation phantoms were acquired by varying the distance of the probe-tip and
absorbing layer between 0-2 mm in 50 µm increments. To quantify percent errors, sampling
depths of the validation phantoms were compared to the sampling depths (D) from the
calibration phantoms. Percent errors were calculated using Eq. 8,
𝐷𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 − 𝐷𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑖𝑜𝑛
𝐸𝑟𝑟𝑜𝑟%,𝐷 = |
| ∙ 100%
𝐷𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑖𝑜𝑛

(8)
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2.3.8 Hybrid Cell Phantoms
To demonstrate the three modalities, two hybrid cell phantoms were constructed using
PDMS as a substrate material and titanium dioxide (Sigma Aldrich, USA) and nigrosin (Sigma
Aldrich, USA) as the scattering and absorbing agents, respectively (Greening et al., 2014). Both
phantoms consisted of a 2.5 cm thick layer containing a scattering concentration of 8.0 mg/g
TiO2/PDMS and absorbing concentration of 5.0 µL/g 1% w/v distilled nigrosin/PDMS. The
second phantom consisted of an additional 500 µm thin absorbing layer which had had a
scattering concentration of 8.0 mg/g TiO2/PDMS and absorbing concentration of 10.0 µL/g 1%
w/v distilled nigrosin/PDMS (Greening et al., 2014).
After curing, hybrid cell phantoms were autoclaved, and MDA-MB-468 breast
adenocarcinoma cells were cultured on top. MDA-MB-468 breast adenocarcinoma cells (ATCC,
USA) were cultured up to the fourth passage in Dulbecco’s Modified Eagle Medium (DMEM)
(ATCC, USA) containing 10% fetal bovine serum (ATCC, USA) and 5% antibiotics (Sigma
Aldrich, USA) at 37°C in 5% CO2. 24 hours after passaging, 200,000 cells in 4 mL DMEM were
seeded onto the phantoms. Each phantom was then transferred to the fiber-optic probe tip. A
0.01% w/v solution (1 mL) of proflavine in saline was added to the cell culture media to provide
fluorescent contrast of the nuclei (Prieto, Powless, Boice, et al., 2015). The 455 nm LED and 635
nm laser provided optical powers at the sample plane of 1.00 mW and 0.25 mW, respectively.
Both high-resolution fluorescence and DRIM data were collected simultaneously. DRIM data
were quantified by using a MATLAB script to compute a line plot through the center of the
image circle and plotting intensity over continuous SDS between 400 and 1,300 µm. Ten raw
DRIM images were averaged. Immediately following this, the tungsten-halogen lamp delivered
0.35 mW of power at the sample plane. Broadband DRS measurements were then acquired at
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both tested SDSs of 374 and 730 µm. For this experiment, both cameras were set to an exposure
time of 150 ms and gain of 10 dB. The spectrometer had an integration time of 0.5 s and boxcar
width (Kiisk, 2014) of 3. Three spectra were averaged at each SDS for both hybrid phantoms.
The hypothesis for this experiment was that there would be no discernable difference
between high-resolution image data of cultured MDA-MB-468 breast adenocarcinoma cells
between the two phantoms, but differences would be seen in the reflectance intensities for DRIM
and DRS data due to the underlying absorbing layer. Table 1 shows specifications for all
phantom layers.
Table 1. Specifications for non-biological components of hybrid tissue-simulating phantoms
Phantom Number
1 (single-layer)
2 (double-layer)
Layer
Bottom
Top
Bottom
Top
Thickness (mm)
25
0
25
0.5
[Scattering] (mg/g TiO2/PDMS)
8.0
0
8.0
8.0
Estimated µs’ (cm-1)
10.0
0
10.0
10.0
[Absorption] (µL/g dist. Nigrosin/PDMS)
5.0
0
5.0
10.0
Estimated µa (cm-1)
1.0
0
1.0
2.0
2.3.9 In vivo human melanocytic nevus
The trimodal technique was tested on a selected benign melanocytic nevus and adjacent
normal skin from a healthy Caucasian volunteer. All procedures were approved by the University
of Arkansas Institutional Review Board (IRB #15-09-149). A benign melanocytic nevi was
chosen as a demonstration because of its similar cellular arrangement to surrounding normal
tissue. Contributions from melanin cannot be discerned using high-resolution fluorescence
imaging, but these highly absorbing contributions become apparent when using the integrated
sub-diffuse reflectance modalities, DRIM and DRS (Zonios et al., 2008; Tseng et al., 2009).
Highlighter ink, which contains the fluorescence compound, pyranine, was applied to the
skin instead of proflavine. Excitation of pyranine was accomplished using the 455 nm LED as
the excitation source, similar to proflavine. However, unlike proflavine, pyranine does not
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intercalate DNA and thus preferentially stains cell membranes rather than nuclei. The probe tip
was placed in direct contact with the skin surface while the 455 nm LED, 635 nm laser, and
tungsten-halogen lamp provided optical powers of 1.00 mW, 0.25 mW, and 0.35 mW,
respectively. Both high-resolution fluorescence imaging and DRIM data were collected with an
exposure time of 150 ms and gain of 10 dB whereas broadband DRS data used an integration
time of 500 ms and boxcar width of 3 (Kiisk, 2014). Ten high-resolution fluorescence images,
ten DRIM data, and three DRS data were acquired from each site. The best qualitative highresolution fluorescence image was selected while ten DRIM and three DRS data were averaged
together. After acquisition, the LUT-based inverse model was used to extract µs’ and μa (@ 630
nm) from the in vivo DRS data of the melanocytic nevus and adjacent normal skin tissue
(Rajaram, Gopal, et al., 2010; Rajaram et al., 2008; Rajaram, Reichenberg, et al., 2010; Rajaram,
Aramil, et al., 2010).
The hypothesis for this experiment was that there would be no discernable difference
between high-resolution image data between the keratinocytes of the benign melanocytic nevus
and surrounding tissue, but differences would be seen in the reflectance intensities for DRIM and
DRS data due to increases in melanin concentration.
2.3.10 Ex vivo murine colon tissue
As a demonstration of the technique in a murine model, a 16-week old wild-type
(C57BL/6J) mouse (Jackson Laboratories, USA) was housed in a room with a 16:8-hour lightdark cycle and had access to standard rodent food (8640 Teklad 22/5 Rodent Diet, Harlan
Sprague Dawley Inc., USA) and water ad libitum. Seven days prior to data collection, the mouse
was switched to a 50/50 mix of standard rodent food and purified food (AIN-93G Purified Diet,
Harlan Sprague Dawley Inc., USA). The mouse was switched to 100% purified food four days
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prior to data collection and no food 24 hours prior. All procedures were approved by the
University of Arkansas Institutional Animal Care and Use Committee (IACUC, #15009) (Moser
et al., 1990; Su et al., 1992; Karim and Huso, 2013).
A 1 cm2 square section of colonic tissue (4-5 cm from anus) was isolated. A segment of
this tissue site was immediately placed in 10% formalin for 24 hours for fixation prior to H&E
staining. The 4-5 cm section was placed lumen-side up on a solid PDMS-based phantom. An
underlying PDMS-based phantom was used to eliminate transmitted light because of the thinness
of tissue (≈ 200 μm thick) (Lim et al., 2011; Shangguan et al., 1998; Simpson et al., 1998). The
phantom had a refractive index of 1.4 to match that of tissue to avoid artifacts due to Fresnel
reflection and contained 1% w/v nigrosin/EtOH (5.0 µL/g PDMS, µa ≈ 1.0 cm-1 at 635nm) and
TiO2 (8.0 mg/g PDMS, µs’ ≈ 10 cm-1 at 635nm) to approximate the optical coefficients of
colonic tissue at 635 nm (Pogue and Patterson, 2006; Siegman, 2010; Sandell and Zhu, 2011;
Bashkatov et al., 2014; Wei et al., 2005; Wall and Barton, 2014).
Cold PBS at 4°C was used to keep tissue moist throughout data collection which took
place within an hour after time of death. A 4°C, 0.01% w/v solution (1 mL) of proflavine in
saline was topically applied to the tissue sample immediately prior to data collection. The 455
nm LED, 635 nm laser, and tungsten-halogen lamp provided optical powers at the sample plane
of 1.00 mW, 0.25 mW, and 0.35 mW, respectively. High-resolution fluorescence imaging and
DRIM data were collected with an exposure time of 150 ms and gain of 10 dB whereas
broadband DRS data used an integration time of 500 ms and boxcar width of 3 (Kiisk, 2014).
Ten high-resolution fluorescence images, ten DRIM data, and three DRS data were acquired
from the colon section. The best qualitative high-resolution fluorescence image was selected for
comparison to H&E while the ten DRIM and three DRS data were averaged.
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2.3.11 In vivo assessment of oral structural and optical properties
The final objective of this study was to extract optical parameters from in vivo oral
mucosa and elucidate the differences of the optical parameters for each SDS (374 and 730 μm).
The multimodal technique was demonstrated in the inner lip of thirteen healthy volunteers, with
no history of tobacco use, between the ages of 18-35. Institutional Review Board approval (IRB
#15-09-149) was obtained from the Human Subjects Research program at the University of
Arkansas for all aspects of this study. The methods described were carried out in accordance
with the approved guidelines, and informed consent was obtained from all participants.
Extracting optical parameters required two steps. First, in vivo data acquisition was
carried out with custom LabVIEW software (Greening, James, Powless, et al., 2015). The probe
was directly placed in contact with the inner lip and broadband DRS were acquired at both SDSs
(374 and 730 µm). The tungsten-halogen lamp delivered 0.35 mW of power at the probe tip for
500 ms. Additionally, in one volunteer, a single high-resolution fluorescence image was taken
using topical proflavine (0.01% w/v in saline) as a contrast agent with an exposure of 100 ms and
gain of 5 dB, thus demonstrating the capability of the probe to sequentially and non-invasively
extract image and optical property data. Second, for post-processing, raw broadband DRS data
was imported into custom MATLAB software which was integrated with the LUT-based inverse
model and sampling depth LUT to extract optical parameters. The use of this post-processing
algorithm to extract optical parameters has been previously described (Rajaram, Reichenberg, et
al., 2010; Rajaram, Gopal, et al., 2010; Rajaram, Aramil, et al., 2010).
The optical parameters extracted in this study were volume-averaged scattering exponent
(B), hemoglobin concentration (THC), and oxygen saturation (StO2). Sampling depth was also
quantified which is a function of the underlying optical parameters (Rajaram, Gopal, et al., 2010;
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Rajaram et al., 2008; Sharma et al., 2013; Hennessy et al., 2014). The scattering exponent relates
to the size of a tissue’s scattering particles, and thus can provide reasoning for changes in
scattering when comparing groups within the same SDS (Mourant et al., 1998). Hemoglobin
concentration and oxygen saturation are commonly derived measurements in optical
spectroscopy to assess angiogenesis, and since blood vessel density has been shown to increase
as oral tissue progresses from normal to dysplastic, extracting these parameters was important
(Mourant et al., 2014). These optical parameters and their relation to µs’ and µa are given in Eq.
9 and Eq. 10. The μs’ was calculated based on Eq. 9,

𝜇𝑠′ (𝜆)

=

𝜇𝑠′ (𝜆0 )

𝜆 −𝐵
∙( )
𝜆0

(9)

where μs’(λ) is the reduced scattering coefficient (cm-1) at any wavelength, λ is a
wavelength (nm), λ0 is 630 nm, and B is the scattering exponent (Sharma et al., 2013). The μa
was calculated based on Eq. 10,
1
𝜇𝑎 (𝜆) = 2.303 ∙ [𝐻𝑏] ∙ (
) ∙ [𝛼 (𝜀𝐻𝑏𝑜𝑥𝑦 ) + (1 − 𝛼) (𝜀𝐻𝑏𝑑𝑒𝑜𝑥𝑦 )]
𝑀𝑊
where μa is the absorption coefficient (cm-1) , THC is the bulk tissue hemoglobin

(10)

concentration mg/mL), MW is the gram molecular weight of hemoglobin which is assumed to be
64,500 g/mole (Prahl, 1999), α is the bulk tissue oxygen saturation, and ε is the molar extinction
coefficient (cm-1M-1) of oxygenated hemoglobin (Hboxy) and deoxygenated hemoglobin (Hbdeoxy).

Some groups have also included a packaging correction factor when calculating µa for

sampling wavelengths below 450 nm, but this was shown to have no impact on the LUT-based
inverse model fits presented here since spectra were taken between 500-750 nm (Rajaram,
Gopal, et al., 2010).
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Figure 10 shows the experimental setup with the instrumentation, hybrid fiber-bundle
probe, and post-processing software. For this experiment, it was hypothesized that the 730 μm
SDS would yield reduced B values due longer SDSs having greater reflectance from longer
wavelengths. Alternatively, the 730 μm SDS should yield greater THC values because of
increased sampling into the sub-epithelia, where the blood vessels exist (Sharma et al., 2013;
Chang et al., 2009). StO2 was expected to be comparable when sampling at different depths since
changes in StO2 have been shown to not be depth dependent (Bezemer et al., 2009). Finally, we
expected increased sampling depth for the longer SDS (Hennessy et al., 2014; Sharma et al.,
2013). Results from this study were expected to show the value of including two different subdiffuse reflectance spectroscopy SDSs along with a high-resolution fluorescence imaging
capability.

Figure 10. An image of the experimental setup showing the optical
instrumentation, post-processing software based in MATLAB showing a highresolution fluorescence image of the inner lip, LUT-based inverse model fit of
raw reflectance data, sampling depth, µs’, and µa from one volunteer (image
center), and the proximal and distal hybrid fiber-bundle probe.
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2.4 Results
2.4.1 Characterization of the High-Resolution Microendoscopy Modality
Figure 11 shows images taken of a positive 1951 USAF resolution test target at group
3/element 3 (linewidth = 49.50 µm). These images were used to quantify spatial resolution,
magnification, percent maximum FOV, and sampling frequency, listed in Table 2. The 50 mm
tube lens (Figure 11(a)) was chosen for use with the 10X/0.30 NA infinity-corrected objective
lens for data collection because of the desirable percent maximum FOV (%) and sampling
frequency (pixels/fiber element) which were 100% and 5.4, respectively. This configuration
maximizes the field-of-view while satisfying the Nyquist sampling requirement.

Figure 11. Images of group 3/element 3 (linewidth = 49.50 µm) of a positive
1951 USAF resolution test target taken with a 10X/0.30 NA infinity-corrected
objective lens and tube lenses with focal lengths of (a) 50 mm, (b) 100 mm, and
(c) 150 mm. The yellow arrow points to the same target on each image.
Table 2. System specifications for the high-resolution modality with different tube lenses
Focal Length of Tube Lens
50 mm
100 mm
150 mm
Spatial Resolution [µm]
4.5
4.5
4.5
Image sensor pixels/µm [pixels/µm]
1.21
2.65
3.61
Magnification on CCD sensor
3.0
6.6
9.0
Percent of Maximum FOV
100%
56%
30%
Sampling Frequency [pixels/fiber]
5.4
11.9
16.2
2.4.2 Generation of and validation of lookup tables for volume-averaged optical property
extraction
Figure 12 (a, b) shows the reflectance LUTs (μs’ = 5-26 cm-1 and μa = 0-10 cm-1) overlaid
with the respective reflectance data from the dye-based calibration phantoms. Similarly, Figure
12 (d, e) shows the reflectance LUTs overlaid with the respective data from the bovine
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hemoglobin-based validation phantoms. Validation phantom data that perfectly overlays the
LUT would indicate a 0% error; however, minor errors do exist. Additionally, Figure 12 (c, f)
shows a ratio of the 730 to 374 μm SDS LUTs. The mean ratio is 1.14, with a standard deviation
of 0.27, indicating a variable reflectance ratio as μs’ and μa vary. Notice that at high reduced
mean free paths (low μs’ and μa) in Figure 12 (c, f), the reflectance ratio is at a maximum of 1.69,
and at low reduced mean free paths (high μs’ and μa), the reflectance ratio is at a minimum of
0.58. This trend supports the observation that longer SDSs are more sensitive to lower scattering
values, especially at longer wavelengths. Similarly, shorter SDSs are more sensitive to higher
scattering values. Thus, this reflectance ratio trend supports the validity of our LUTs.

Figure 12. 100% (μs’ = 5-26 cm-1, μa = 0-10 cm-1) of both reflectance LUTs were
validated with acceptable percent errors less than 10%. Following validation,
optical properties can be reliably extracted from samples with unknown optical
properties using the LUT-based inverse model. (a, b) Reflectance LUTs were
interpolated with raw data from calibration phantoms and (c) shows a ratio of the
730 µm SDS to 374 µm SDS LUTs. (d, e) Reflectance LUTs were validated with
raw data from the bovine hemoglobin-based validation phantoms and (f) shows
the validated ratio of the 730 µm SDS to 374 µm SDS LUTs.
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The LUT-based inverse model correctly estimated µs’ of the validation phantoms with
average percent errors of 1.6% and 2.5% for the 374 and 730 µm SDS, respectively. Minimum
and maximum percent errors for µs’ extraction were 0.1% and 5.3% for the 374 µm SDS and
1.2% and 11.4% for the 730 µm SDS, respectively. Additionally, the LUT-based inverse model
correctly estimated µa of the validation phantoms with average percent errors of 4.2% and 7.2%
for the 374 and 730 µm SDS, respectively. Minimum and maximum percent errors for µa
extraction were 2.1% and 18.4% for the 374 µm SDS and 0.1% and 22.1% for the 730 µm SDS,
respectively.
Average percent errors were comparable to similar studies (< 10%) and considered
acceptable (Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Rajaram et al., 2008;
Rajaram, Reichenberg, et al., 2010; Vishwanath et al., 2011; Yu et al., 2010; Yu et al., 2008;
Nichols et al., 2012; Sharma et al., 2013; Sharma et al., 2014). Thus, 100% of the optical
property range of the LUTs were validated, and could be used to reliably extract volumeaveraged optical properties from unknown samples. Figure 13 shows the ability of the
reflectance LUTs to extract accurate µs’ and µa.
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Figure 13. The LUT-based inverse model correctly estimated µs’ with average
percent errors of 1.6% and 2.5% for the 374 and 730 µm SDS, respectively, and
correctly estimated µa with average percent errors of 4.2% and 7.2% for the 374
and 730 µm SDS, respectively. The ability to extract optical properties is shown
with a perfect fit line.
2.4.3 Generation of and validation of lookup tables for sampling depth quantification
Sampling depth ranged between 240 to 530 µm and 300 to 680 µm for the 374 and 730
µm SDSs, respectively (Figure 14). In both cases, maximum sampling depth occurred when µs’
and µa were 0 cm-1 and minimum sampling depth occurred at the maximum µs’ (26 cm-1) and
maximum µa (10 cm-1) in the target range of the LUTs. After validation with hemoglobin-based
validation phantoms, sampling depth was estimated with average percent errors of 1.9% and
1.6% for the 374 and 730 µm SDS, respectively. Minimum and maximum percent errors for µs’
extraction were 1.8% and 5.3% for the 374 µm SDS and 1.1% and 2.1% for the 730 µm SDS,
respectively. Average percent errors, all under 2%, were considered acceptable in this study.
Additionally, the ratio of sampling depths for the 730 to 374 µm SDS were calculated for the
entire LUT range (Figure 14 (c, f)). On average, the sampling depth ratio was 1.20 with a
standard deviation of 0.08, and relatively flat as expected. This indicates the sampling depth of
the longer SDS is approximately 1.2x that of the shorter SDS across all wavelengths.
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Figure 14. 100% (μs’ = 5-26 cm-1, μa = 0-10 cm-1) of both sampling depth LUTs
were validated with acceptable percent errors much less than 10%. (a, b)
Sampling depth LUTs were interpolated with raw data from calibration phantoms
and (c) shows a ratio (1.2x) of the 730 µm SDS to 374 µm SDS sampling depths.
(d, e) Sampling depths LUTs were validated with raw data from the bovine
hemoglobin-based validation phantoms and (f) shows the validated ratio of the
730 µm SDS to 374 µm SDS sampling depths.
2.4.4 Hybrid Cell Phantoms
A representation of the hybrid cell phantoms are shown in Figure 15(a, d). Sample data
from the high-resolution, fiber-based fluorescence imaging modality are shown for both hybrid
cell phantoms in Figure 15(b, e). DRIM data are shown in Figure 15(c, f) and the quantification
of these maps is shown in Figure 15(g). DRIM data were quantified by using a MATLAB script
to take a line plot through the center of the image circle and plotting intensity (in pixel values)
over continuous SDS between 400 and 1,300 µm. Finally, broadband DRS data for both SDSs
(374 and 730 µm) from both hybrid cell phantoms are shown in Figure 15(h, i).
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Our hypothesis was supported. There was no discernable difference between highresolution image data of cultured breast adenocarcinoma cells between the two phantoms, but
clear differences were seen in reflectance for the DRIM and DRS data. DRIM data shows greater
signal closer to the 635 nm source delivery fiber, and intensity is markedly reduced for the
double-layer phantom containing the more highly absorbing underlying layer. The overall shape
of the DRIM profiles remains similar between samples, as expected. The shape of DRIM profiles
are similar to those predicted by established Monte Carlo models of reflectance (Martinelli et al.,
2011). For the DRS data, intensity changes are due to increases in nigrosin concentration, which
have a flat absorption spectra across the tested wavelengths (Greening et al., 2014). Also note
that for the 730 µm SDS, there are increased reflectance contributions from longer wavelengths
when compared to the 374 μm SDS, consistent with the 730 µm SDS sampling a greater depth
range (Hennessy et al., 2014).
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Figure 15. Demonstration of the three modalities showing data from the hybrid
cell phantoms containing (a-c) one or (d-f) two layers. The figure shows (a, d) a
SolidWorks representation of the single and double layer hybrid cell phantoms
(with white arrows pointing at layers), (b, e) enhanced high-resolution
fluorescence images after topical staining of MDA-MB-468 breast
adenocarcinoma cells with proflavine (scale bar = 225 µm), (c, f) DRIM data
(scale bar = 225 µm, color bar = 0-130), (g) quantification of the DRIM data
taken across the face of the image fiber (400-1,300 µm SDS from laser source),
(h) broadband DRS data (374 µm SDS), and (i) broadband DRS data (730 µm
SDS).
2.4.5 In vivo human melanocytic nevus
For the healthy skin tissue and adjacent melanocytic nevus, data were collected for all
three modalities, shown in Figure 16. A DSLR image of both tissue sites is shown in Figure 16(a,
d) alongside the high-resolution fluorescence image (Figure 16(b, e)), DRIM data (Figure 16(c, f,
g)), and broadband DRS at both SDSs of 374 and 730 µm (Figure 16(h, i)).
Our hypothesis was supported. There were no discernable differences between highresolution image data between the keratinocytes of the benign melanocytic nevus and
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surrounding tissue. In addition, differences were seen in DRIM and DRS modalities due to
increased melanin concentration, contributing to increased μa (Jacques, 2015).
Keratinocyte morphology can be distinguished in both sites in the high-resolution
fluorescence images. Nuclei are not visualized in Fig 16(b, e) because pyranine-derived ink does
not intercalate DNA, and thus only the cell membranes boundaries are visualized.
Next, a comparison of DRIM data shows markedly different reflectance intensities across
the face of the image fiber. The overall shape of the DRIM profiles remains similar between
samples, as expected. The shape of DRIM profiles are similar to those predicted by established
Monte Carlo models of reflectance (Martinelli et al., 2011). Finally, in vivo broadband DRS data
was fit using the validated LUT-based model approach as previously described. Raw data (dots)
and model fits (lines) are plotted together in Figure 16(h, i). DRS data shows Q-bands of
hemoglobin at 542 and 577 nm for surrounding healthy tissue, although these Q-bands are
masked by melanin contributions in the benign melanocytic nevus. The appearance of the Qbands in the reflectance spectra indicated that our instrument was sampling into the vascularized
dermis (Prahl, 1999).
Next, the LUT-based model extracted μs’ and μa from the normal skin and melanocytic
nevus for both SDSs (374 and 730 μm). All listed optical properties were referenced at 630 nm.
For normal skin, μs’ was estimated at 16.0 and 11.6 cm-1 while μa was estimated at 0.9 cm-1 for
both the 374 and 730 μm SDS, respectively. For the melanocytic nevus, μs’ was estimated at 23.9
and 28.0 cm-1 while μa was estimated at 13.8 and 12.3 cm-1 for the 374 and 730 μm SDS,
respectively. These values for normal skin, as well as the relative increase in both μs’ and μa for
the melanocytic nevus, are consistent with previously published results (Tseng et al., 2009; van
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Leeuwen-van Zaane et al., 2013; Rajaram, Reichenberg, et al., 2010; Meglinski and Matcher,
2002; Garcia-Uribe et al., 2011).

Figure 16. Demonstration of technique showing data from (a-c) human healthy
skin tissue and (d-f) adjacent melanocytic nevus. The figure shows (a, d) a digital
image of the healthy skin and adjacent melanocytic nevus (scale bar = 1 mm), (b,
e) cropped and enhanced high-resolution fluorescence images after topical
staining with pyranine-derived highlighter ink (scale bar = 50 µm), (c, f) DRIM
data (scale bar = 225 µm, color bar = 0-225), (g) quantification of the DRIM data
taken across the face of the image fiber (400-1,300 µm SDS from 635 nm laser
source), (h) broadband DRS data (374 µm SDS), and (i) broadband DRS data
(730 µm SDS). Raw data are shown as dots and the LUT-based inverse model fits
are shown as a curve.
2.4.6 Ex vivo murine colon tissue
For the healthy (C57BL/6J) mouse, data was collected for all three modalities, shown in
Figure 17. A DSLR image of the resected piece of colon is shown in Figure 17(a) alongside the
associated histology (Figure 17(b)) and high-resolution fluorescence image (Figure 17(c)),
DRIM (Figure 17(d)), and broadband DRS at both SDSs of 374 and 730 µm (Figure 17(f, g)).
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For the DRIM data, a line plot was taken through the center of each intensity map (Figure 17(d))
to create a plot of intensity as a function of SDS between 400 and 1,300 µm, shown in Figure
17(e).
Note the ability to clearly resolve glandular structure in the murine colon alongside
spatially resolved sub-diffuse reflectance intensity. For the DRIM data, the overall shape is
similar to previous results presented here with a shape similar to that predicted by Monte Carlo
models of reflectance (Martinelli et al., 2011). The Soret bands due to hemoglobin can be clearly
distinguished from the DRS data. The Q-bands (542 and 577 nm) are less apparent, most likely
due to contributions from the underlying phantom layer. Also note that for the 730 µm SDS,
there was increased reflectance contributions from longer wavelengths when compared to the
374 μm SDS. This data demonstrates that data can be acquired from murine colon tissue. Future
studies will forego the use of an underlying phantom in in vivo studies to elucidate the
effectiveness of the DRIM and DRS modalities within a larger sample size.
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Figure 17. Demonstration of the three modalities showing data from a 16-week
old wild-type (C57BL/6J) male mouse. The figure shows (a) digital image of the
4-5 cm colon tissue (lumen side facing up, scale bar = 5 mm), (b) histology of an
adjacent section (scale bar = 50 µm), (c) cropped and enhanced high-resolution
fluorescence image after topical staining with 0.01% w/v proflavine (scale bar =
50 µm), (d) DRIM data (scale bar = 225 µm, color bar = 0-200), (e) quantification
of the DRIM data taken across the face of the image fiber (400-1,300 µm SDS
from 635 nm laser source), (f) broadband DRS data (374 µm SDS), and (g)
broadband DRS data (730 µm SDS).
2.4.7 In vivo assessment of oral structural and optical properties
Thirteen volunteers underwent data collection in the oral mucosa via the hybrid imaging
and spectroscopy microendoscope (Figure 18). One high-resolution fluorescence image is
presented in Figure 18 (a) which shows the 1 mm-diameter image circle of the image fiber in
direct contact with proflavine-stained oral mucosa. Individual cell nuclei appear as distinct white
spots in the image. Figure 18 (b) shows representative absolute reflectance data from both the
374 and 730 μm SDS from a single volunteer. Reflectance is presented as black dots and the
LUT-based inverse model (Figure 12) and an established hemoglobin absorption spectrum
(Prahl, 1999) was used to fit the data via custom post-processing software based in MATLAB.
The fitted reflectance is a function of the volume-averaged optical parameters, B, THC, and StO2
(Eq. 9 and Eq. 10). These values are presented as averages with standard deviations from the 13
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volunteers in Figure 18 (d-f) and Table 1. Sampling depth was quantified and presented in Figure
10 (c) after μs’ and μa were determined using the LUT-based inverse model (Figure 13).
The 730 μm SDS typically demonstrates increased reflectance values, especially at
wavelengths greater than 600 nm, indicating a greater contribution from the red and near-infrared
region at larger source-detector separations. This phenomenon was responsible for the decreased
B values at the longer SDS of 0.48 compared to 0.80 of the shorter SDS as shown in Figure 18
(d). Average THC was significantly different at 2.39 and 2.91 mg/mL for the 374 and 730 μm
SDS, respectively (Fig 18 (e)). These values support our hypothesis and demonstrate increased
THC for the longer SDS compared to the shorter SDS. Average StO2 was not significantly
different at 94.1% and 91.7% for the 374 and 730 μm SDS, respectively (Figure 18 (f)),
supporting our hypothesis that oxygen saturation does not significantly vary with sampling
depth. Finally, sampling depth ranged between 355 and 447 μm for the 374 μm SDS and
between 435 and 563 μm for the 730 μm SDS, with the sampling depth minima occurring at the
first Q-band of hemoglobin at 542 nm and the sampling depth maxima occurring at the furthest
tested wavelength at 750 nm. Complete paired t-test statistics for optical parameters are shown in
Table 3.
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Figure 18. Comparison of qualitative and quantitative data acquired by the hybrid
imaging and spectroscopy technique from 13 healthy volunteers showing (a) a
high-resolution fluorescence image of apical oral mucosa from the inner lip of one
volunteer (scale bar = 200 μm), (b) representative absolute reflectance profiles
showing reflectance data and the overlaid LUT-based inverse model fits from the
same volunteer from (a), (c) average sampling depths for each SDS, (d) scattering
exponent (B), (e) hemoglobin concentration (THC), and (f) oxygen saturation
(StO2). Error bars from (c-f) represent standard deviation.
Table 3. Paired t-test statistics for extracted in vivo oral optical properties from LUT-based
inverse model
374 μm SDS (n=13)
730 μm SDS (n=13)
Optical
Significance
P-Value
Property
(Y/N), α=0.01
Mean
Std. Dev. Mean
Std. Dev.
B
0.80
0.19
0.48
0.25
8.8x10-4 Y
THC (mg/mL)
2.39
0.44
2.91
0.65
8.8x10-3 Y
StO2 (%)
94.1
10.0
91.7
9.10
4.6x10-1 N
2.5 Discussion
We have demonstrated a hybrid spectroscopy and imaging probe capable of acquiring
qualitative and quantitative data by combining high-resolution microendoscopy and broadband
DRS. High-resolution fiber-bundle microendoscopy provides a highly resolved and magnified
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image of apical epithelial architecture in a small 1 mm-diameter field-of-view while DRS
provides quantitative optical parameters of tissue in approximately the same image region
(Figure 1 and 2). By combining these two modalities, we can co-register qualitative image data
and quantitative spectral data within a single probe. Co-registration is important because this
technique can be potentially used to not only detect dysplasia using two different modalities, but
also to monitor personalized response of sub-surface dysplastic lesions to anti-tumor therapy at
two different source-detector separations.
We characterized our technique in terms of spatial resolution, magnification, field-ofview, sampling frequency, optical property extraction, and sampling depth (Figure 11-13, Table
2). The technique was demonstrated in optical phantoms containing cultured MDA-MB-468
breast adenocarcinoma cells (Figure 15, Table 1), an in vivo human melanocytic nevus of the
skin (Figure 16), and ex vivo murine colon epithelial tissue (Figure 17). The validated LUTbased inverse model was used to extract tissue optical properties of the in vivo human
melanocytic nevus and surrounding healthy skin tissue.
High-resolution fluorescence imaging, using a coherent fiber bundle image fiber, was
chosen as the first modality because of its established success in diagnosis of dysplasia in various
endoscopically accessible organs. This modality can provide highly-resolved qualitative data
regarding structure and morphology of the apical layers of epithelial tissue. However, alone, it
lacks the capability of providing functional information and imaging deeply into tissue. To
overcome this limitation, broadband DRS was chosen as a second modality to provide
quantitative functional, rather than structural, information at various sampling depth ranges in
tissue. Thus, these modalities have great complimentary potential. A third modality, DRIM, was
developed to provide 2D, spatially-resolved image maps of sub-diffuse reflectance intensity of

105

the same image area and field-of-view as the high-resolution fluorescence imaging modality.
These additionally modalities, DRS and DRIM, can collect information below the surface, which
wasn’t possible with conventional end-on fiber bundle microendoscopy (Gu et al., 2014;
Muldoon et al., 2007; Pierce, Guan, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; Chang et
al., 2013; Keahey et al., 2015; Parikh et al., 2014; Kanick et al., 2014; Kanick et al., 2009;
Hennessy et al., 2014; Jayanthi et al., 2011; Zonios et al., 1999; Marin et al., 2005; Greening,
Powless, et al., 2015; Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Rajaram et al.,
2008; Rajaram, Reichenberg, et al., 2010).
Other techniques have attempted to address similar technical limitations. For example,
high-resolution imaging techniques have been coupled with wide-field autofluorescence
imaging, such as with the commercially available VELscope, to increase field-of-view while
increasing diagnostic specificity in dysplastic lesions (Pierce, Schwarz, et al., 2012). However,
no functional depth-sensitive information is acquired. Several clinically available systems
capable of providing highly resolved morphological information at varying depths are the Pentax
ISC-1000 confocal endomicroscopy system (Pentax/Hoya, Japan and Optiscan Pty Ltd,
Australia), and the Cellvizio system (Mauna Kea Technology, France), which have the capability
of being coupled to conventional video endoscopes for combined widefield and confocal
imaging (Jabbour et al., 2012). These commercial systems have significantly increased
sensitivity and specific in cancer diagnostics, but still lack the quantitative features that make
spectroscopy attractive. Additionally, the scanning optics necessary for such confocal systems
can be costly to miniaturize (Jabbour et al., 2012). Our instrumentation design eliminates the
need for scanning optics in favor of simple optics that combine high-resolution probe-based
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fluorescence imaging with additional spectroscopy and reflectance modalities that can be
potentially miniaturized for clinical use.
In this study, we designed two sets of liquid phantoms (Figure 8) to generate and validate
a LUT-based inverse model that was used to extract material optical parameters from raw DRS
data for each SDS (Figure 12). As of the current report, the LUTs are valid for µs’ between 5-26
cm-1 and µa between 0-10 cm-1. These ranges of optical properties are sufficient to acquire
accurate DRS data for many tissue types between 500-750 nm. Furthermore, our calibration and
validation methods were optimized until all average percent errors were below 10% (Figure 12
and 7), a benchmark error value comparable to many similar studies (Rajaram, Aramil, et al.,
2010; Rajaram, Gopal, et al., 2010; Rajaram et al., 2008; Rajaram, Reichenberg, et al., 2010;
Bish et al., 2011; Bish et al., 2014; Sharma et al., 2013; Sharma et al., 2014; Nichols et al.,
2012; Nichols et al., 2015; Yu et al., 2008; Yu et al., 2010; Vishwanath et al., 2011; Hennessy et
al., 2013).
In the same set of calibration phantoms (Figure 8), sampling depth was determined for
each SDS (Hennessy et al., 2014). A demonstration of calculating sampling depth was presented
(Figure 9) and an empirical relationship was determined for sampling depth as a function of µa
and µs’ (Figure 14). Sampling depths were comparable to a similar study by Hennessy et al
(Hennessy et al., 2014).
Next, the bench-top technique was applied to in vivo oral mucosa by collecting DRS data
from the inner lip of 13 healthy volunteers (Figure 10). The LUT-based inverse model was used
to extract the wavelength-dependent B, THC, and StO2 values from all 13 volunteers (Figure 18).
The representative reflectance data demonstrates increased reflectance for the 730 μm SDS
compared to the 374 μm SDS at wavelengths greater than approximately 600 nm, consistent with
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previous findings (Greening, James, Powless, et al., 2015; Mirabal et al., 2002). It is well known
that longer SDSs penetrate deeper into tissue, and thus longer wavelengths will dominate
reflectance for longer SDSs (Sharma et al., 2013; Hennessy et al., 2014; Mirabal et al., 2002).
This phenomenon is apparent when analyzing the scattering exponent (B). At longer separations,
B values decrease because of greater reflectance from longer wavelengths.
The extracted absorption-based optical properties, THC and StO2, were comparable to
other studies (Amelink et al., 2011; Rajaram, Gopal, et al., 2010). The longer 730 μm SDS
extracted greater THC compared to the shorter 374 μm SDS. This supports our hypothesis that
the longer SDS sampled deeper into the tissue vasculature, although it is clear the vasculature is
still being sampled with the 374 μm SDS (Prahl, 1999; Sharma et al., 2013; Chang et al., 2009).
This penetration into the vasculature was expected since sampling depth in the short SDS was
greater than 300 µm, which exceeds the non-vascularized epithelial thickness of the oral cavity
(Greening, James and Muldoon, 2015). We anticipate the standard deviations for THC and StO2
values (Figure 18 and Table 3) to be most likely due to variations in the pressure applied
between the probe tip and volunteer’s inner lip. It has been shown that probe-pressure variations
among measurements can induce large errors in THC and StO2, so future studies will seek to
develop a real-time probe-pressure monitoring system similar in concept to those reported in
other studies (Yu et al., 2014).
The study presented here was an extensive validation of the quantitative spectroscopy
modality of this technique. Since this technique has been validated, its ability to monitor tissue
health in response to anti-tumor therapy can be further evaluated in pre-clinical and clinical
studies. Additionally, future studies will explore quantitative measures regarding the highresolution fluorescence imaging modality, such as automated nuclear-to-cytoplasmic ratio and
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cells-per-area calculations and co-register these values with DRS extracted optical parameters.
Since this hybrid imaging and spectroscopy technique lacks a widefield imaging modality, future
trials will explore designing probes with identical probe-tip geometries that are compatible with
conventional endoscopes.
The multimodal high-resolution imaging and sub-diffuse reflectance spectroscopy fiberbundle microendoscope reported here can be optimized and used by investigators for a variety of
applications including endoscopic or handheld use for human or animal studies. It thus provides
a flexible method for visualizing in vivo apical tissue micro-architecture alongside measurements
of hemoglobin concentration, melanin concentration, and tissue oxygen saturation from two
different tissue depths. This article describes the specifications for the fiber-optic probe, outlined
a protocol for assembling the high-resolution imaging system and sub-diffuse reflectance
imaging system, and shown its application in human tissues in vivo, using pyranine ink as the
fluorescent contrast agent for tissue visualization. Other inks, such as proflavine or fluorescein,
can be used instead of pyranine ink with appropriate approval (Chang et al., 2013; Muldoon et
al., 2011; Greening, James, Powless, et al., 2015; Prieto, Powless, Boice, et al., 2015; Muldoon
et al., 2010).
Any probe feature may be modified from this design. For the high-resolution
fluorescence microendoscopy modality, the 1 mm-diameter image fiber consisted of 50,000
individual core fibers with 4.5 µm spacing, resulting in a constant sub-cellular spatial resolution
of 4.5 µm. Investigators wanting a different sized image fiber to obtain a smaller or larger fieldof-view can find these image fibers readily available with diameters between 0.14 and 1.40 mm.
A tube lens with focal length of 50 mm was chosen such that the CMOS sensor captured the full
1-mm field-of-view from the image fiber. When keeping the objective lens constant, increasing
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the focal length of the tube lens will increase magnification and sampling frequency but decrease
field-of-view (Greening, James, Powless, et al., 2015). Thus, the magnification of the objective
lens, focal length of the tube lens, size of the image sensor, and size of the image fiber can and
should be optimized depending on need. Finally, filters and excitation light source may be
modified depending on the excitation/emission spectra of fluorescent dyes (Muldoon et al., 2010;
Chang et al., 2013; Prieto, Powless, Boice, et al., 2015; Muldoon et al., 2011). In addition to
modifying the probe and high-resolution fluorescence microendoscopy instrumentation, the subdiffuse reflectance spectroscopy instrumentation can be modified.
For the sub-diffuse reflectance spectroscopy modality, different sized multimode fibers
can be used at each SDS. Smaller diameter multimode fibers will be able to deliver and collect
light over a smaller area, but it is recommended to use an array of identically spaced fibers to
increase signal-to-noise if fiber diameters less than 200 µm are used. Investigators analyzing skin
or oral tissue may benefit from an overall larger probe to increase field-of-view and signal-tonoise, but in narrower luminous organs, such as the esophagus or gastrointestinal tract,
investigators will face added constraints regarding probe size, especially for compatibility with
the biopsy port of conventional endoscopes (Parikh et al., 2014). Other spectroscopy components
that may be modified include the broadband light source and motorized optical switch. A
tungsten-halogen lamp was chosen in this case, although other light sources can and have been
used in other studies, including xenon arc lamps and LEDs, which may increase signal-to-noise
and lower integration times (Rajaram, Reichenberg, et al., 2010; Yu et al., 2014; Bish et al.,
2014). The motorized optical switch presented here was custom built to handle up to three SDSs,
but can be modified to include more or less inputs. It should be noted that the motorized optical
switch does add an additional optical component between the broadband light source and
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spectrometer, decreasing signal-to-noise. The switch may not be necessary for investigators with
multiple spectrometers that acquire data simultaneously, but including an optical switch
component ultimately reduces instrumentation cost by approximately $3,000USD per SDS.
Construction of the instrumentation (Figure 4 and 5) is fairly straightforward. The most
critical step in this protocol is the calibration of the sub-diffuse reflectance spectroscopy
modality (Figure 6 and 7). Calibration must be completed immediately prior to spectral data
collection. Once calibration has been completed, ensure no pieces of the instruments are shut
off or re-calibration may be necessary. Proper calibration is necessary to obtain accurate
reflectance spectra, and thus obtain accurate values for underlying melanin concentration,
hemoglobin concentration, and tissue oxygen saturation from an unknown sample. Conveniently,
most investigators use similar calibration techniques which have been well described (Greening,
James, Powless, et al., 2015; Rajaram, Gopal, et al., 2010; Rajaram, Reichenberg, et al., 2010;
Nichols et al., 2012). Information regarding software requirements for converting reflectance
spectra into optical parameters can be found elsewhere (Rajaram et al., 2008; Greening, James
and Muldoon, 2015; Greening, James, Powless, et al., 2015).
In regard to troubleshooting, spectra resulting in poor fits (average percent errors greater
than 10% between raw data and fitted data) will yield unreliable values for the three tissue
physiological parameters (THC, [Mel], and StO2) presented here. Poor fits are most likely the
result of either movement between the probe and skin site during data acquisition, narrow
boundary conditions in the post-processing code, or unreliable a priori values of THC and [Mel]
(Prahl, 1999; Greening, James, Powless, et al., 2015; Rajaram et al., 2008; Greening, James and
Muldoon, 2015). Improvements in these three common error occurrences should fix the accurate
fitting of sub-diffuse reflectance spectra. Thus, data collection can be improved by reducing
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spectrometer integration time to reduce motion artifacts within the spectra. Additionally,
boundary conditions represent the range of possible computational output values for THC, [Mel],
and StO2 following post-processing. In these studies, boundary conditions were 0-10 mg/mL for
THC (Prahl, 1999; Rajaram, Aramil, et al., 2010), 0-40 mg/mL for [Mel] (Karsten and Smit,
2012; Glennie et al., 2015), and 0-100% for StO2 (Lim et al., 2011), which are based on values
from previous studies (Prahl, 1999; Karsten and Smit, 2012; Lim et al., 2011; Rajaram, Aramil,
et al., 2010; Glennie et al., 2015). If measuring tissue without melanin, the lower and upper
bounds for [Mel] can both simply be set to 0 mg/mL. Finally, it is recommended to use
established a priori absorbance values for hemoglobin and melanin published by Prahl et al
(Prahl, 1999). These simple improvements should fix the accurate fitting of sub-diffuse
reflectance spectra, and if questions remain, spectra can be validated with phantoms with known
optical properties (reduced scattering and absorption coefficients).
The primary limitation to this multimodal imaging and spectroscopy fiber-bundle
microendoscopy platform is the lack of a widefield imaging modality. The high-resolution
fluorescence microendoscopy modality has a circular field-of-view that is 1 mm in diameter,
making it difficult to rapidly scan a large area of tissue. One computational method to overcome
this limitation is image mosaicking, a technique used to provide a broader field-of-view by
stacking adjacent micro-scale images into a single, larger image map (Prieto, Powless, Lai, et al.,
2015). Such image mosaicking has been previously demonstrated by Prieto et al. to investigate
colonic image features (Prieto, Powless, Lai, et al., 2015). An instrumentation modification to
overcome this limitation would be making the probe compatible with the biopsy port of a
conventional endoscope, such as the probe presented by Parikh et al. to investigate colorectal

112

neoplasia (Parikh et al., 2014). This feature combines the advantages of a wide field-of-view
with micro-scale imaging of high-resolution fluorescence microendoscopy (Parikh et al., 2014).
Overall, this technique was demonstrated on in vivo human skin and shows the value of
co-registering high-resolution tissue micro-architectural images with the underlying melanin
concentration, hemoglobin concentration, and tissue oxygen saturation. This technique can be
used by researchers wishing to investigate the link between structural and functional tissue
abnormalities in vivo or analyzing tissue functional changes in the absence of observable
structural changes. Future studies will investigate the viability of this technique in various
epithelial disease states.
2.6 Conclusion
We have developed a hybrid spectroscopy and imaging technique comprising of a
conventional fluorescence fiber-bundle microendoscopy platform coupled with a series of offaxis broadband spectroscopy (DRS) channels. Since dysplasia can initially arise near the
epithelial basement membrane, collecting structural and functional information from deeper
within the tissue microenvironment is critical for many applications, including detection of early
dysplasia, analysis of tumorigenesis, and monitoring of therapeutic response. As a result, this
hybrid imaging and spectroscopy platform may be capable of collecting a wealth of information
about the structural and functional properties of tissue at various imaging sites in ex vivo and in
vivo models. Finally, the potential of this technique to be coupled to the biopsy port of a
conventional endoscope makes further clinical translation and complimentary optical biopsy in
the oral cavity and other epithelial tissues feasible.
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Chapter 3 (Specific Aim 2): Characterization of poly(dimethylsiloxane)-based tissuesimulating phantoms with tunable reduced scattering and absorption coefficients with
applications for diffuse reflectance spectroscopy

3.1 Introduction
The translation of novel optical imaging techniques from a basic laboratory setting to a
clinical setting requires substantial calibration and validation, which is often performed on
tissue-simulating materials known as phantoms. Tissue-simulating phantoms have several broad
applications in regard to imaging systems including optimizing software and hardware, gathering
preclinical data in advance of clinical trials, and are necessary for providing proof of
reproducibility between trials of certain optical imaging techniques (de Bruin et al., 2010; Saager
et al., 2010; Cerussi et al., 2012). For example, optical coherence tomography (OCT) may use
phantoms to determine vital instrumentation characteristics including axial and lateral resolution
and point spread function (Gu et al., 2012; Agrawal et al., 2013). Diffuse Optical Spectroscopic
Imaging (DOSI) techniques may use phantoms for initial calibration and stability measurements
between trials (Cerussi et al., 2012). Features of phantoms that are viewed as especially
important include precise control of phantom geometry, the ability to easily modify and quantify
scattering and absorption properties across commonly used wavelengths, stability over time, a
comparable refractive index to human tissue, and the ability to introduce thin layers of different
optical properties to simulate heterogeneities commonly seen in tissue (de Bruin et al., 2010;
Saager et al., 2010; Cerussi et al., 2012; Moffitt et al., 2006; Pogue et al., 2006). These
heterogeneities may represent layers of different cell types as seen in the interface between the
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dermis and epidermis of the skin, or as malignant morphological changes in a single tissue type
as a result of disease (de Bruin et al., 2010).
Optical phantoms are a widely used tool to validate optical instrumentation. In essence,
phantoms are “false-tissues” made of various materials and can be liquid, solid, or gelatinous.
Generally, phantoms are made to either simulate a tissue’s optical, mechanical, chemical, or
physical properties, or a combination of these. These structures are typically comprised of a base
substrate material which can be doped with certain additives that give the material specific
optical, mechanical, or chemical properties. Additionally, depending on the substrate material
used and desired geometry, optical phantoms can be molded into a variety of shapes and sizes for
different applications (Pogue et al., 2006; Greening et al., 2014; Lamouche et al., 2012).
This chapter opens with a review of optical phantoms as validation tools for imaging and
spectroscopy platforms, with a majority of the discussed optical instrumentation being probebased. This will provide insight into the use of optical phantoms within the context of current
biomedical optics research. Following this, the “diffuse” and “sub-diffuse” scattering regimes
governing light transport through tissue will be addressed. Distinguishing between the “diffuse”
and “sub-diffuse” scattering regimes is important for several reasons including 1) generating
design requirements for probe-based instrumentation, especially for determining appropriate
source-detector separations in spectroscopy probes, 2) evaluating the accuracy of computational
or numerical models of light transport, and 3) understanding the optical properties of target
human tissues and designing optical phantoms to mimic such tissues. Finally, this chapter
concludes with a tutorial on how to construct thin, solid, multilayer tissue-simulating phantoms
using a spin-coating technique for a variety of applications, and a tutorial on how to construct
liquid phantoms to build a lookup table (LUT) inverse model to extract optical properties using
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diffuse or sub-diffuse reflectance spectroscopy.
3.2 Phantoms in Probe-Based Optical Systems
Each subtype of optical phantom discussed in this section will be described based on their
intended application, substrate material, scattering and absorbing agents, corresponding reduced
scattering coefficients (μs’) and absorption coefficients (μa), and experimental design.
Additionally, the probe and/or detector used to acquire data will be briefly described. Optical
phantoms for validating instrumentation in high-resolution microendoscopy, hyperspectral
imaging, diffuse optical tomography, reflectance spectroscopy, fluorescence spectroscopy, and
Raman spectroscopy will be discussed.
3.2.1 High-resolution microendoscopy
High-resolution microendoscopy is a non-invasive, imaging technique that couples a light
source to a small image fiber probe. The probe is placed in contact with an exogenously stained
sample, is excited via an illumination source, and then fluorescence emission travels back
through the probe, distal optics, and into an image sensor to provide high-resolution, spatially
resolved images of tissue morphology. Contrast may be provided by a variety of exogenous
tissue stains. Various high-resolution microendoscopy techniques have been explored to reduce
signal contributions from outside the focal plane, including two-photon and confocal
microendoscopic systems, as well as structured illumination (SI). Optical phantoms are a useful
tool in high-resolution microendoscopy to investigate imaging parameters or for a demonstration
of technique prior to imaging ex vivo or in vivo tissue samples (Bedard et al., 2012; S. S. Chang
et al., 2013; Campbell et al., 2010; Muldoon et al., 2008; Muldoon et al., 2007; Muldoon et al.,
2011; Kyrish et al., 2013; Louie et al., 2014; Parikh et al., 2014; Prieto et al., 2015; Pierce,
Guan, et al., 2012; Pierce, Schwarz, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; Shin et
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al., 2015; Shukla et al., 2011; Koucky et al., 2013; Gu et al., 2010; Shahmoon et al., 2013;
Keahey et al., 2015; Maitland et al., 2006; Makhlouf et al., 2011; Rogers et al., 2008). Figure 1
shows a simple schematic of high-resolution microendoscopy instrumentation. Note that some of
the specific research discussed in the following paragraphs employs modified instrumentation.

Figure 1. Simple schematic of high-resolution microendoscopy instrumentation
showing an LED delivering light through an excitation filter (Ex.F.), lens (Lens),
dichroic mirror (D.M.), and objective lens (Obj.) through a probe to a phantom.
Fluorescence emission light travels through the probe, objective (Obj.), dichroic
mirror (D.M.), tube lens (T.L.), emission filter (Em.F.), and camera (Cam.).
One common technique for optical phantom creation is constructing cell-based phantoms
using buffered collagen type I from rat tail tendons as a substrate material. For this technique,
collagen type I is added to a pellet of target epithelial cells cultured via conventional in vitro
methods, such as human cervical adenocarcinoma cells, cervical squamous cell carcinoma, or
oral squamous cell carcinoma. This mixture is transferred to a well plate and allowed to culture
until the collagen-cell matrix forms a gel with a desired thickness. The resultant gel is densely
packed with collagen and epithelial cells throughout (Gu et al., 2010; Maitland et al., 2006;
Rogers et al., 2008; Sokolov et al., 2003). Studies have modified this technique with various cell
types and exogenous contrast agents for high-resolution microendoscopic imaging. One study
used a non-linear, probe-based microendoscope to investigate a collagen-based optical phantom
containing human cervical adenocarcinoma (HeLa) cells for targeted photothermal therapy
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microsurgery. The HeLa cells were labeled with transferrin-conjugated gold nanorods and mixed
with propidium iodide. The probe was placed in gentle contact with the phantom surface and a
near infrared (NIR) laser irradiated the phantom at the nanorod peak absorption (790 nm) from
0-252 μm in depth at 4 μm increments to induce HeLa cell necrosis. Then, a 740 nm laser was
used to image the propidium iodide, which was used to stain necrotic cell death. In this way, the
HeLa cell-based phantom’s response to photothermal therapy could be quantified (Gu et al.,
2010). In another case, collage type I was infused with human cervical squamous cell carcinoma
(SiHa) cells to demonstrate the imaging and video capture capabilities of a single fiber
reflectance confocal microendoscope (SFCM) with a 140 μm x 100 μm field-of-view (FOV). For
this system, the probe was placed in contact with the SiHa cell-based phantom surface and a 635
nm laser diode and micro-electro-mechanical system (MEMS) scanning device were used to
raster scan the full FOV (Maitland et al., 2006). As another demonstration of a separate highresolution imaging device, optical phantoms were created using collagen type I as the substrate
material with suspended human oral squamous cell carcinoma cells (1483 line). The cell-based
collagen phantom was labeled with 10 nM streptavidin-coated quantum dots,(Stanisavljevic et
al., 2015) small semiconductor materials whose fluorescent properties are governed by their size,
and gold nanoparticles, and then fixed in 10% formalin to preserve the phantom’s structure. For
imaging of fluorescent contrast agents within the collagen-based phantom, the probe contained a
multimode fiber coupled to a 450 nm LED with a circular 250 μm-diameter FOV (Rogers et al.,
2008; Sokolov et al., 2003). In addition to cells, other groups use fluorescent beads to
characterize or demonstrate their high-resolution microendoscopy systems.
Three-dimensional phantoms can be created using water and agar, instead of collagen, as
the substrate material and Intralipid, a soybean oil emulsion, as the scattering agent.
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Microendoscopy studies typically use this design to study the effects of out-of-plane scattering,
which can decrease image contrast (Koucky et al., 2013; Keahey et al., 2015). One confocalbased microendoscopy study built agar-based phantoms with 14.8 μm-diameter green fluorescent
beads as the fluorescent agent. Intralipid was added at increasing concentrations from 0%, 0.5%,
and 2.0% to create non-scattering, low-scattering, and high-scattering phantoms molded into a
petri dish. At 520 nm, the low and high scattering phantoms had a μs’ of 10.8 and 25.4 cm-1. The
3D phantoms were imaged by placing a 455 nm LED-coupled probe in contact with the phantom
and exciting fluorescence from the beads. Additionally, the phantom was imaged with the
objective lens only to acquire in-focus images of beads at various depths within the phantom
(Koucky et al., 2013). Another similar microendoscopy study, using structured illumination,
constructed optical phantoms using agar and deionized water as the substrate material and
Intralipid as the scattering agent. Fluorescent polystyrene microspheres were used as the
fluorescent agent. The phantom was constructed to simulate the optical properties of cervical
columnar epithelium and was imaged by placing the 455 nm LED-coupled probe in gentle
contact with the phantom surface to acquire images with and without structured illumination for
comparison (Keahey et al., 2015).
Thus far, the explored experimental setups have revolved around using a probe in contact
with the phantom surface, although one technique uses microendoscopy submerged within a
blood-mimicking liquid phantom (Shahmoon et al., 2013). The purpose of this technique is to
quantify hemoglobin concentration using a microendoscopy imaging probe. A liquid phantom
was created with a mixture of water as the substrate material, and Intralipid and human
hemoglobin and Intralipid as the scattering and absorbing agents, respectively, to mimic human
blood. The mixture was flowed through a 400 μm-diameter channel within a solid phantom block
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made of polyurethane and titanium dioxide (TiO2). Different oxygenation levels of hemoglobin
were used to test the instrument’s capability of monitoring hemoglobin concentration. A 532 nm
laser-coupled probe was submerged within the flow channel to illuminate the liquid hemoglobin
phantom to quantify the difference between absorbance intensities to indicate hemoglobin
concentration (Shahmoon et al., 2013).
As demonstrated, optical phantom use in microendoscopy has myriad applications,
including but not limited to demonstration of imaging technique, photothermal therapy, and
investigating methods to reduce out-of-focus light (Koucky et al., 2013; Gu et al., 2010;
Shahmoon et al., 2013; Keahey et al., 2015; Maitland et al., 2006; Rogers et al., 2008; Makhlouf
et al., 2011).
3.2.2 Hyperspectral imaging
Hyperspectral imaging is a non-invasive hybrid technique that combines spectroscopy
and imaging. A two-dimensional (2D) detector array is used to collect images of a region of
interest. The novelty of hyperspectral imaging is that each pixel on the 2D detector array also
collects a spectrum that can potentially span the entire UV-NIR region. This generates what is
known as a hypercube, a 3D dataset containing spectral and spatial information. Since
hyperspectral imaging produces spectra at each pixel, optical properties at each pixel can often
be quantified using LUT inverse models, Monte Carlo (MC) inverse models, or diffusion models
(Lu et al., 2014; Bish et al., 2014; Lue et al., 2012; Xu et al., 2012; Tseng et al., 2011; Zonios et
al., 1999). Figure 2 shows a simple schematic of hyperspectral imaging instrumentation. Note
that some of the specific research discussed in the following paragraphs employs modified
instrumentation.
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Figure 2. Simple schematic of hyperspectral imaging instrumentation showing a
source (Wht. Light) delivering broadband light through a polarizer (Pol.) and lens
(Lens) to a phantom. Emitted light from the phantom passes through a lens
(Lens), polarizer (Pol.), and another lens (Lens) into a spectrograph.
Water-based liquid phantoms are the most common medium for phantom construction in
hyperspectral imaging. One study developed two sets of optical phantoms to test the accuracy of
a LUT-based inverse model in estimating μs’ and total hemoglobin concentration (THC) using a
handheld hyperspectral imaging system. The first set of water-based liquid phantoms were
constructed inside a container and polystyrene microspheres and red food dye were added to
simulate scattering and absorbing properties, respectively. Hyperspectral images were taken of
the phantoms and spectra from each pixel were used to create a LUT of reflectance as a function
of μs’ and absorber concentration. Accuracy of the LUT was validated on a second set of waterbased phantoms containing polystyrene microspheres and human lyophilized powder and was
shown to be accurate with μs’ values between 10 to 30 cm-1 and THC between 0 to 3 mg/mL.
Following validation, the hyperspectral imaging system was tested on in vivo skin (Bish et al.,
2014).
A similar study acquired hyperspectral images of optical phantoms to validate the ability
of an MC inverse model, rather than a LUT inverse model, to extract tissue optical properties.
Three liquid phantoms were prepared inside a clear cylinder 10 mm in diameter and 200 mm in
height using polystyrene microspheres and red ink as the scattering and absorbing agents,
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respectively. Ranges of μs’ were from ~10 to 20 cm-1 and ranges of μa were from ~0 to 4 cm-1. A
fiber bundle containing an image-fiber coupled to a hyperspectral imaging camera and off-axis
broadband source fiber was dipped into the liquid phantoms to acquire spatially-resolved diffuse
reflectance spectra. These spectra were compared to simulated reflectance spectra from MC
models (Tseng et al., 2011). In addition to using inverse models such as LUT and MC models,
diffusion models have also been developed to extract a sample’s optical properties with low
errors.
The diffusion model can be applied in a similar mechanism to LUT and MC inverse
models, in which phantoms with known optical properties are created and actual spectral data is
compared to spectral data predicted by the diffusion model. For example, one group developed
hyperspectral instrumentation to delineate tumor margins during surgery by quantifying optical
properties, specifically THC. To quantify THC in vivo, 15 liquid-based phantoms were first
prepared with 2% Intralipid as the scattering agent, and either hemoglobin or blood as the
absorbing agent. Liquid phantoms with known THC were pipetted into a container until the
liquid was 2.5 mm deep and diffuse reflectance spectra were acquired from each pixel of the
hyperspectral scanner. The diffusion model was shown to be accurate for extracting THC from
~0 to 6 mg/mL. Following phantom validation testing, the scanner was used to delineate tumor
margins in resected, diseased breast tissue (Lue et al., 2012; Zonios et al., 1999). Building
phantoms is an important step for instrumentation and model validation. However, there is a
need for readily available phantoms for investigators to use to cut down on the time and research
costs required to build such validation tools (Xu et al., 2012).
To address this need for standardization, digital tissue phantoms (DTPs) have recently
been developed that could potentially be accessed by investigators and medical device

131

manufacturers around the world for their validation needs. The DNP was specifically created for
hyperspectral imaging applications to measure oxygenation in chronic ischemic wounds. The
DTP was built by acquiring hyperspectral data cubes from a biological system and digitally
reproducing the cube. The liquid phantoms for DNP construction were made using phosphate
buffered saline (PBS) as a substrate material, powdered milk solution as the scattering agent, and
4% porcine whole blood and India ink as the absorbing agents, yielding a μs’ of 6.0 cm-1 at 690
nm. The hyperspectral data cube was acquired with a hyperspectral linear camera at 240
wavelengths between 380 and 885 nm at phantom oxygenation levels between 4-96% (Xu et al.,
2012).
The primary objective for constructing phantoms for hyperspectral imaging is to validate
a model’s ability to extract optical properties of phantoms with known values. Additionally,
work has been done to standardize and digitize this technique for hyperspectral imaging
applications (Lu et al., 2014; Bish et al., 2014; Lue et al., 2012; Xu et al., 2012; Tseng et al.,
2011; Zonios et al., 1999).
3.2.3 Diffuse optical tomography
Diffuse optical tomography (DOT) is a non-invasive imaging technique that aims to
quantify optical properties of tissues using various image reconstruction algorithms. Far red and
near-infrared light, encompassing the spectral region between 650-1000 nm, is delivered to tissue
and collected. Light in this range can penetrate several centimeters into a sample because of the
low μa of water, lipids, and hemoglobin. Collected light is used to construct tomographic maps of
tissue optical properties using various image reconstruction algorithms (Dehghani et al., 2009;
Mora et al., 2015; Gonzalez-Rodriguez et al., 2015; Bi et al., 2015; Wu et al., 2014; Saikia et al.,
2014; Valim et al., 2013; Ansari et al., 2014; Guggenheim et al., 2013; Puszka et al., 2013;
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Sharikova et al., 2014; Tavakoli et al., 2011). Figure 3 shows a simple schematic of DOT
instrumentation. Note that some of the specific research discussed in the following paragraphs
employs modified instrumentation.

Figure 3. Simple schematic of diffuse optical tomography instrumentation
showing a laser delivering light to a mirror (Mir.) and lens (Lens) and is raster
scanned across a phantom using a mirror galvanometer (Gal.). Emitted light is
delivered to a lens (Lens) and image sensor (Cam.) which is controlled with a
delay mechanism (Delay).
Most optical phantom studies for DOT involve validating an image reconstruction
algorithm within optical phantoms containing heterogeneities to investigate the instrument’s
ability to detect or delineate these inclusions. For the DOT phantom studies presented here,
heterogeneities are solids that are contained within a surrounding bulk solid or liquid substrate
material. For example, one study constructed breast-tissue mimicking phantoms with known
optical properties (μs’ = 1.14 cm-1, μa = 0.07 cm-1 at 780 nm). Optical phantoms were constructed
using agarose as the substrate material to create a gel-based phantom with 10% Intralipid as the
scatterer and India ink as the absorber. Cylindrical heterogeneities (0.7 cm in diameter)
simulating the optical properties of malignant breast tissue (μs’ = 1.92 cm-1, μa = 0.15 cm-1 at 780
nm) were placed inside the normal phantoms at varying locations and the image reconstruction
algorithm was used to identify and delineate the inclusion (Ansari et al., 2014). Similarly, DOT
image reconstruction algorithms have been demonstrated in cylindrical gel-based optical
phantoms with TiO2 as the scatter and whole porcine blood as the absorber. Within this
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cylindrical phantom, a 25 mm-diameter hole was drilled 10 mm from the phantom’s edge which
was filled with a 0.75% Intralipid and 4% porcine blood. This created a heterogeneity that
contained an approximately 2:1 ratio of total hemoglobin compared to the background phantom.
Six wavelengths between 649-850 nm were used to acquire images, and the DOT image
reconstruction algorithm was subsequently applied (Dehghani et al., 2009).
Solid optical phantoms with heterogeneities are also beneficial for small animal imaging
using DOT. For example, phantoms can be designed to simulate the size and optical properties of
a whole mouse. This mouse-simulating phantom was designed to be of similar size to a mouse
and was made in a 25 mm-diameter, 50 mm-long cylinder. The phantom was built with a
spatially homogenous solid plastic as the substrate material with varying μs’ between 16.3 and
17.9 cm-1 and μa between 0.07 and 0.12 cm-1 within a spectral range of 500 to 850 nm. Two 6
mm-diameter holes were drilled in the phantom in which either inclusions or backgroundmatching rods could be added. Images were collected of the phantom under different
illumination patterns and the reconstruction algorithm was applied to produce an reconstructed
image of the inclusion rods (Guggenheim et al., 2013).
Other groups have explored their DOT instrument’s capability to resolve solid inclusions
within a surrounding liquid phantom. For example, time-resolved DOT at short source-detector
separations was investigated using a liquid phantom built inside a 17 cm (length), 10 cm (width),
and 7 cm (height) container. The liquid phantom was made using water, Intralipid and black ink,
corresponding to a μs’ and μa were 10 cm-1 and 0.1 cm-1 of 820 nm. Inside the container was a
solid, resin-based cylinder doped with TiO2 and black ink that served as an inclusion to measure
depth sensitivity. At 820 nm, the cylinder’s μs’ and μa were 10 cm-1 and 0.6 cm-1. NIR spectral
measurements were taken with an 820 nm light source at 6 source-detector separations between 5
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and 15 mm and a reconstruction algorithm was applied (Puszka et al., 2013). Similarly, a
prostate-simulating optical phantom with μs’ of 7 cm-1 and μa of 0.3 cm-1 was created inside
container. Two solid PVC-based inclusions were added to the liquid phantom. The first inclusion
had a μs’ of 15 cm-1 and μa of 0.5 cm-1 and the second had a μs’ of 15 cm-1 and μa of 0.9 cm-1. A
robotically-controlled DOT platform and custom reconstruction algorithm, based on the steadystate light diffuse equation, was used to reconstruct images of the inclusions within the prostatesimulating phantoms (Sharikova et al., 2014). In another study, a bulk liquid phantom was made
to simulate healthy breast tissue. The breast tissue-simulating phantom was constructed with
0.8% Intralipid to yield a μs’ range from 6.9 to 7.8 cm-1 and a near-negligible μa range from 0.02
to 0.03 cm-1 at 780 nm. A low-contrast breast lesion phantom was made using a solid plastisol, a
suspension of polyvinyl chloride (PVC), as the substrate material to have μs’ and μa of 5.6 cm-1
and 0.075 cm-1. Additionally, a high-contrast breast lesion phantom was made, also using solid
plastisol, to have μs’ and μa of 6.53 cm-1 and 0.158 cm-1. These low and high-contrast
heterogeneities were submerged at different depths with the background Intralipid-based
phantom and measurements were taken with a handheld DOT system and post-processed using
the depth-correction algorithm (Tavakoli et al., 2011).
As discussed here, optical phantoms for DOT applications usually have some type of
optical or mechanical inclusion that can be detected after an image reconstruction algorithm has
been applied to DOT-acquired data (Dehghani et al., 2009; Ansari et al., 2014; Tavakoli et al.,
2011; Sharikova et al., 2014; Puszka et al., 2013; Guggenheim et al., 2013).
3.2.4 Diffuse reflectance spectroscopy
Diffuse reflectance spectroscopy is a non-invasive spectroscopic technique in which a
light source, typically a broadband source, is coupled to a fiber-optic cable embedded within a
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small probe. Light is delivered to tissue by placing the probe in contact or near-contact with the
tissue surface. Light reflects back into an adjacent, embedded fiber-optic cable that delivers
reflected light to a spectrometer to recover tissue spectra. Models, such as LUT, MC, and
diffusion models can be used in conjunction with the tissue reflectance spectra to extract the
tissue’s optical properties, similar to techniques discussed with hyperspectral imaging (Alerstam
et al., 2008; Baran, Fenn, et al., 2013; Bender et al., 2009; Bosschaart et al., 2011; Bremmer et
al., 2011; Bremmer et al., 2013; Bydlon et al., 2010; Chang et al., 2011; Dhar et al., 2012; Fu et
al., 2010; Sharma et al., 2014; Nichols et al., 2012; Glennie et al., 2014; Rajaram et al., 2008;
Rajaram, Aramil, et al., 2010; Rajaram, Reichenberg, et al., 2010; Rajaram, Gopal, et al., 2010).
Figure 4 shows a simple schematic of reflectance spectroscopy instrumentation. Note that some
of the specific research discussed in the following paragraphs employs modified instrumentation.

Figure 4. Simple schematic of reflectance spectroscopy instrumentation showing
a broadband source (Wht. Light) delivering light through a probe to a phantom.
Emitted light from the phantom passes through the probe into a spectrometer.
The most common types of phantoms used in reflectance spectroscopy are water-based
liquid phantoms. Water-based phantom make it easy and convenient to build and validate LUTs
for the purpose of optical property extraction. In one study, a discrete matrix of optical phantoms
made with polystyrene beads and India ink was created to span a wide range of known μs’ (4-47
cm-1) and μa (0-25 cm-1). A diffuse reflectance spectra was acquired from each phantom in the
matrix and these reflectance values were interpolated to generate a topographic LUT describing
the relationship between reflectance, µa, and µs’ in three-dimensional (3D) space. The
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topographic LUT was validated on a second set of optical phantoms made with polystyrene
beads and red food dye with μs’ between ~5-35 cm-1 and μa between ~0-25 cm-1. The validated
LUT was used to extract optical properties from cancerous skin tissue.(Sharma et al., 2014)
Another similar LUT study investigated broadband diffuse reflectance spectra between 350-750
nm for phantoms made with water, polystyrene microspheres and India ink to span a wide range
of known μs’ (2-71 cm-1) and μa (0-53 cm-1). The LUT was validated on a second set of tissue
simulating phantoms made with water, polystyrene microspheres as the scatterer and powdered
hemoglobin as the absorber (Rajaram, Reichenberg, et al., 2010). The LUT was used to extract
in vivo optical properties from a malignant basal cell carcinoma. Another method for optical
property extraction are computational models, such as MC-based inverse models.
One study validated an MC-based inverse model by constructing optical phantoms in a 3
liter container using deionized water as the substrate material, 20% Intralipid as the scattering
agent, and either manganese meso-tetra porphine (MnTPPS) or isolated human erythrocytes as
the absorber. The probe, consisting of one delivery fiber and six surrounding collection fibers,
was dipped into the phantoms 3 cm below the surface to simulate an infinite homogenous
medium. Optical property extraction was shown to be valid between a μs’ range from ~15 to 30
cm-1 and a μa range from ~0.1 to 1.3 cm-1. Additionally, oxygen partial pressure of the
erythrocyte-based phantoms were monitored using an oxygen-sensitive microelectrode (Baran,
Fenn, et al., 2013). Another group limited their study to using breast tissue-simulating phantoms
to evaluate the robustness of their inverse MC model for optical property extraction. The optical
phantom was made using deionized water as the substrate material and polystyrene microspheres
and powered hemoglobin and/or crocin as the scatterer and absorber, respectively. Powdered
hemoglobin was used to simulate blood and crocin was used to simulate beta-carotene, the most
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common absorbers in breast tissue. The μs’ and μa ranged from ~5-25 cm-1 and ~0-3 cm-1,
respectively, while THC ranged from 0-30 μM and [crocin] ranged from 0-500 μM. Multiple
probe geometries were explored for wavelength ranges between 350-600 nm (Bender et al.,
2009). A similar study used an MC inverse model to extract μs’ between 3-10 cm-1, THC
between 40-80 μM, and [crocin] between 0-400 μM from a breast-tissue mimicking phantom
(Bydlon et al., 2010). This technique for evaluating MC inverse models in breast tissuemimicking phantoms has also been translated to other tissue types, including cervical epithelium.
Cervical epithelia-mimicking phantoms, made with distilled water as the substrate material and
polystyrene microspheres and lyophilized human hemoglobin, were used to test the accuracy of
an MC model so that it could be used in low-resource settings. The μs’ and μa ranged from 8.4 to
10.4 cm-1 and 0.04 to 0.39 cm-1 over a range of 450-600 nm, respectively. The probe consisted of
6 illumination fibers surrounding a single collection fiber and was submerged within the liquid
cervical-simulating phantoms for measurements and the MC inverse model extracted the optical
properties (Chang et al., 2011).
In addition to LUT and MC models, diffusion models have been shown to be accurate in
neonatal skin-simulating phantoms. These phantoms were made with water as the substrate
material and 1.5% Intralipid and non-scattering, magenta dye as the scattering and absorbing
agents, respectively. This corresponded to a μs’ range of 3 to 37 cm-1 and a μa range of 0 to 27
cm-1. These neonatal skin phantoms allowed the investigators to assess their ability to extract
optical properties using the steady state diffusion approximation to the photon transport equation
and determine instrumentation probing depth. The probe consisted of one illumination fiber and
four collection fibers coupled to an imaging spectrograph and was submersed at varying
distances (0-5 mm in 100 μm steps) from the bottom a blackened container holding a neonatal
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skin-simulating phantom. Following phantom measurements, the investigators assessed the
optical properties of neonatal skin in vivo (Bosschaart et al., 2011).
Reflectance spectroscopy is primarily concerned with using their probe-based
instrumentation and model to non-invasively extract optical properties from in vivo tissue. In
order to do this, the technique must be validated on phantoms with known optical properties
(Chang et al., 2011; Rajaram et al., 2008; Sharma et al., 2014; Baran, Fenn, et al., 2013; Bender
et al., 2009; Bosschaart et al., 2011; Bydlon et al., 2010).
3.2.5 Fluorescence spectroscopy
Fluorescence spectroscopy is a non-invasive probe-based spectroscopy technique that
uses one or several excitation wavelengths to excite endogenous tissue fluorescence. A
monochromatic excitation source is coupled to a flexible, fiber-optic cable(s) embedded in a
probe. When the probe is in contact with tissue, the fluorescent molecule of interest is excited
with a wavelength within the molecule’s absorption spectrum. The molecule will absorb this
energy, rise to an excited state, and then relaxes back down to ground state by emitting a photon
of a longer wavelength. Fluorescent signal is recovered by one or more adjacent fiber-optic
probes coupled to a detector such as a spectrometer. Phantoms in fluorescence spectroscopy are
generally used to test instrumentation response for detecting fluorescence in the presence of
background scattering and absorbing agents (Ramanujam, 2000; Choi et al., 2011; Kanick,
Davis, et al., 2014; Du Le et al., 2014; Gamm et al., 2014; Baran and Foster, 2013; Croce et al.,
2014; C. Y. Chang et al., 2013; Liu et al., 2011). Figure 5 shows a simple schematic of
fluorescence spectroscopy instrumentation. Note that some of the specific research discussed in
the following paragraphs employs modified instrumentation.
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Figure 5. Simple schematic of fluorescence spectroscopy instrumentation
showing a source delivering light through an excitation filter (Ex.F.) through a
probe to a phantom. Emitted light from the phantom passes through the probe and
emission filter (Em.F.) into a spectrometer.
Optical phantoms have been developed to measure the minimum concentration of added
fluorophore that could be detected in the presence of background scattering, absorbing, and
autofluorescence. One set of phantoms was built using water as the substrate material with 1%
Intralipid, 1% bovine whole blood, and protoporphyrin IX (PpIX) as the scattering, absorption,
and fluorescent agents, respectively. 5% Tween 20 was also mixed to prevent aggregation of the
additives. Resultant μs’ was between 10 – 50 cm-1 and blood volume fraction was between 0.5 –
2.5%. PpIX was added in 16 increasing concentrations between 0.1 and 4000 nM. The lower
limit of PpIX detection was shown to be 1.95 or 250 nM for 405 nm or 639 nm, respectively
(Kanick, Davis, et al., 2014). Another group designed similar optical phantoms using deionized
water as the substrate material, diluted 20% Intralipid as the scatterer, and manganese meso-tetra
porphine (MnTPPS) (2-12 μM) as the absorber to simulate hemoglobin absorption. Instead of
PpIX, doxorubicin hydrochloride (1.5-50 μM) was used as the fluorescence agent. Fluorescence
spectra of these liquid phantoms were collected via a 0.8 mm epi-illumination probe coupled to a
488 nm laser to recover intrinsic fluorescence and other optical properties (Baran and Foster,
2013). These intrinsic fluorescence spectra were fit using a modified inverse MC model.
Modified inverse MC models have been used in other cases to accurately estimate fluorophore
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contribution in the presence of increasing non-fluorescent absorber. To validate this absorptioncorrected MC model, optical phantoms were created using PBS as the substrate material and
20% Intralipid as the scatterer, yielding μs’ between 0.05 and 65.8 cm-1 at 405 nm. Fluorescein,
with a negligible μa, was added as the fluorescence agent at a constant 1 μM concentration.
Finally, increasing concentration of isolated human red blood cells were added as the absorber
(μa = 0-26 cm-1 at 405 nm) to demonstrate that fluorescence spectra can be corrected for
absorption using the custom, empirical MC model (Gamm et al., 2014).
Thus far, methods of fluorescence spectroscopy have been explored that include an
exogenous fluorophore within their optical phantom design, such as PpIX, doxorubicin
hydrochloride, and fluorescein, to test probe sensitivity or validate MC models. Fluorescence
spectroscopy research has also explored the endogenous fluorescence of optical phantoms
containing no exogenous fluorophores. This research hoped to determine whether common
scattering agents, such as Intralipid and polystyrene microspheres, contributed to background
fluorescence in the 350-650 nm wavelength range. For this study, Intralipid-based phantoms
were made at concentrations of 0.25%, 0.5%, 1%, 1.5%, 2%, 3%, and 5% in deionized water
within 12 mL test tubes. Additionally, polystyrene microsphere-based phantoms were made at
w/v concentrations of 0.72%, 0.4%, and 0.2%. Fluorescence measurements were made using a
355 nm laser coupled to a 600 μm fiber for illumination and detection. With this knowledge of
endogenous fluorescence from Intralipid and polystyrene microspheres, correction factors could
be added to models to correctly extract optical properties and fluorescence from optical
phantoms (Du Le et al., 2014).
Additionally, optical phantoms can be designed, not only to validate modified MC
models, but to test the depth sensitivity of a fluorescence spectroscopy probe. Depth sensitivity
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can be quantified by creating a two-layer phantom model. In one study, two 300 μm thick
phantom layers were constructed using water and agarose powder as the substrate material mixed
with different types of quantum dots (Qdot) (Stanisavljevic et al., 2015). The bottom layer was
mixed with Qdot 655 and molded into a 13 mm-diameter cylinder, 300 μm thick. The top layer
was mixed with varying concentrations of Qdot 565 and was molded on top of the bottom layer.
Both layers had negligible scattering and absorption. A 405 nm laser diode was coupled to a noncontact probe and fluorescent signal from the phantoms was detected by a broadband
spectrometer via an integrated collection fiber to quantify detection of the bottom layer (Choi et
al., 2011).
Optical phantoms in fluorescence spectroscopy are often used to validate MC inverse
models, similar to those presented for reflectance spectroscopy, with modifications that account
for fluorescence of added fluorophores. Additionally, fluorescence-based optical phantoms are
used to test instrument sensitivity to fluorophore concentration or depth-sensitivity (Choi et al.,
2011; Kanick, Davis, et al., 2014; Du Le et al., 2014; Gamm et al., 2014; Baran and Foster,
2013).
3.2.6 Raman spectroscopy
Raman spectroscopy is a non-invasive spectroscopy technique based on the principal of
inelastic scattering. A monochromatic source injects light into the sample and target molecules
within the sample absorb energy, generating molecule-specific vibrations. Therefore, emitted
light from tissue undergoes a frequency shift compared to the excitation light due to the induced
vibrational state. This shift is called a Raman shift (Kourkoumelis et al., 2015; Agenant et al.,
2014; Esmonde-White et al., 2011; Okagbare et al., "Fluorocarbon Fiber-Optic Raman Probe for
Non-Invasive Raman Spectroscopy," 2012; Demers et al., 2012; Chen et al., 2014; Barman et
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al., 2009; Srinivasan et al., 2008; Stone et al., 2008; Okagbare et al., 2010; Okagbare et al.,
"Polymer-Capped Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012).
Figure 6 shows a simple schematic of Raman spectroscopy instrumentation. Note that some of
the specific research discussed in the following paragraphs employs modified instrumentation.

Figure 6. Simple schematic of Raman spectroscopy instrumentation showing a
laser source delivering light through an excitation filter (Ex.F.), mirror (Mir.),
dichroic mirror (D.M.), and objective lens (Obj.) through a probe to a phantom.
Emitted light passes through the probe, objective lens (Obj.), dichroic mirror
(D.M.), lens (Lens), and notch filter (N.F.) to a detector.
Optical phantoms for Raman spectroscopy are typically solid phantoms that are used to
simulate the optical and geometric properties of a tissue type, such as cartilage and bone.
Additionally, phantoms have been created for other purposes such as quantifying Raman
spectroscopy probe sampling depth and detecting blood analytes in liquid phantoms.
One such phantom is an optical phantom that simulates a rat tibia. The rat tibia phantoms
were made using a solid gelatin material as the substrate using a silicone rubber mold. The
gelatin was doped with Intralipid as the scattering agent and hemoglobin as the absorber.
Additionally, hydroxyapatite was added to simulate the chemical makeup of rat tibia. An 830 nm
laser coupled to an illumination fiber bundle provided light to the sample and similar collection
fibers delivered Raman signal to a spectrograph (Okagbare et al., "Fluorocarbon Fiber-Optic
Raman Probe for Non-Invasive Raman Spectroscopy," 2012; Okagbare et al., "Polymer-Capped
Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012; Okagbare et al., 2010).
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A similar study constructed a cylindrical rat leg-simulating phantom (27 mm diameter) using
agar and water as the substrate material to create a gel. Scattering and absorption were controlled
using 1% Intralipid and 0.01% India ink to yield μs’ of 10 cm-1 and μa of 0.1 cm-1 at 830 nm.
Teflon rods, simulating bone, at different sizes (5 and 12.5 mm diameter) were inserted into the
agar-based phantom. Raman collection fibers were placed around the surface to collect Raman
signal to assess the ability of creating tomographic maps of different regions within the phantom
(Demers et al., 2012). Bone-simulating phantoms, such as these presented, have been modified
to test another hypothesis that Raman spectroscopy of subchondral bone is attenuated due to
optical scattering of surrounding cartilage. To test this hypothesis, a bone-simulating optical
phantom was made by dissolving gelatin in PBS. A 5 mm thick bone layer was created with 0.2
g/mL hydroxyapatite and 10% v/v Liposyn II. On top of the bone layer, a 6 mm thick cartilage
layer was created with 3 mg/mL chondroitin sulfate at 0%, 10%, or 20%. The bone layer was
cast in a Petri dish and the cartilage layer was cast on the same Petri dish once the bone layer had
cured. The investigators took Raman spectra using 830 nm excitation laser coupled to a single,
hand-held probe (Esmonde-White et al., 2011). Two-layer phantoms can also be used to quantify
depth sensitivity in Raman spectroscopy probes.
To quantify depth sensitivity, one study built a two-layer phantom in which the top layer
consisted of 20% Intralipid in water with variable thicknesses. Thickness was controlled based
on the volume of solution residing above the bottom layer, which was a 170 μm thick
polyethylene terephthalate (PET) slide to mimic stromal tissue. The top layer thickness was
increased from 0 to 1,500 μm in 50 μm increments until signal from the bottom layer was
negligible. Both a superficial and non-superficial Raman probe were compared, and depth
sensitivity was 200 and 300 μm, respectively (Agenant et al., 2014).
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Presented here are liquid phantoms used in Raman spectroscopy to demonstrate a method
to detect blood analytes within the phantom. The optical phantoms were made using distilled
water as the substrate material with Intralipid (μs’ = 24-130 cm-1 at 830 nm) and India ink (μa =
0.08-1.3 cm-1 at 830 nm) serving as the primer scattering and absorbing agents. Additionally, the
blood analytes, glucose and creatinine, were pipetted into the solution at concentrations ranging
from 4-30 mM, spanning the range from hypoglycemic to hyperglycemic levels in humans.
Aliquots of this solution were placed in a fused silica cuvette for Raman spectroscopic analysis
to predict a phantoms’ analyte concentration based on a custom calibration model (Barman et al.,
2009).
Raman spectroscopy is a broadly applicable to many subfields in biomedicine and many
investigators demonstrate their technique or characterize their instrumentation using tissuemimicking optical phantoms (Demers et al., 2012; Okagbare et al., 2010; Okagbare et al.,
"Polymer-Capped Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012;
Esmonde-White et al., 2011; Agenant et al., 2014; Barman et al., 2009; Okagbare et al.,
"Fluorocarbon Fiber-Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012).
3.3 Requirements for small endoscopic instrumentation
The major objective of the probe-based methods outlined in the previous sections are to
non-invasively characterize tissue based on its qualitative appearance or optical properties, most
prevalent being μs’ and μa, among others. Optical phantoms provide a necessary step in
evaluating parameters of these non-invasive or minimally invasive imaging and spectroscopy
techniques. However, before such research goals can be realized, an understanding of several key
aspects is necessary. First, it is vital to understand the type of tissue one hopes to work with,
including its size and mechanical, chemical, and optical properties. Second, it is useful to
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understand the models describing how light propagation through these tissues is typically
understood. Therefore, in this next section, the biology of common epithelial structures is
described in terms of size and optical properties, which are important for designing optical
phantoms that mimic these tissues. Next, the sub-diffuse scattering regime will be described, a
common physical regime within optical imaging when using small spectroscopy probes with
small source-detector separations.
3.3.1 Sub-diffuse scattering regime
Light propagation in tissue can be fully described by the radiative transport equation
(RTE). The RTE states that the total radiance for photons traveling in a specific direction through
time and space is equal to the sum of all sources that affect (increase or decrease) radiance.
Radiance is defined as the quantity of photons per unit volume. A more detailed description of
the RTE can be found in numerous sources (Liemert et al., 2012; Liemert et al., 2014; Wilson et
al., 2011). The RTE has been successfully used to model photon transport in turbid media, such
as tissue or tissue-simulating phantoms. However, the RTE is mathematically and
computationally intensive, and because of this, research has sought to create simpler models that
approximate the RTE (Liemert et al., 2014; Liemert et al., 2012; Wilson et al., 2011; Kim et al.,
2006; Kim, 2004; Kim et al., 2003).
One such simplification used in biological tissues is the diffuse approximation. The
diffusion approximation is a method that has been used to determine μs’ and μa in tissue (Wilson
et al., 2011; Reif et al., 2007; Gibson et al., 2005; Kim, 2004; Kim et al., 2003). However, the
diffusion approximation is only valid in turbid media if the following requirements are met: 1)
the μs’ must be much greater than the μa, and 2) large source-detector separations must exist
(Reif et al., 2007). Some sources have also claimed that the diffusion approximation is not valid
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in media that exhibit anisotropic scattering (Gibson et al., 2005). These requirements ensure that
any collected photons have traveled through large volumes of tissue. In turn, this ensures that
extracted optical properties represent an accurate average of the real optical properties. However,
in many cases, investigators are interested in using small endoscopy devices, as mentioned in the
previous section, to sample thin tissues with a small sampling depth. This is the case for
dysplasia or cancers that are confined to the epithelium, which is only between 100-500 µm thick
(Rajaram et al., 2008).
Therefore, a distinction must be made between what is meant by the diffuse regime, in
which the diffusion approximation is valid, and the sub-diffuse regime, in which the diffusion
approximation is not valid (Reif et al., 2007; Subramanian et al., 2007; Turzhitsky, Rogers, et
al., 2010; Turzhitsky, Radosevich, et al., 2010; Bosschaart et al., 2011; Kanick, McClatchy, et
al., 2014). For many of the cases listed here, the validity of the diffusion approximation begins to
fail for one of two reasons. The first reason is that μs’ is not much greater than μa (Reif et al.,
2007; Turzhitsky, Radosevich, et al., 2010; Turzhitsky, Rogers, et al., 2010; Subramanian et al.,
2007; Bosschaart et al., 2011). The μs’ is considered “not much greater” than the μa when albedo
is less than 0.9 (Rajaram et al., 2008). Albedo is defined by Eq. 1,

𝐴=

(𝜇𝑠′ )
(𝜇𝑠′ − 𝜇𝑎 )

(1)

where A is the albedo [unitless], µs’ is the reduced scattering coefficient [cm-1] and µa is the
absorption coefficient [cm-1] (Rajaram et al., 2008; Bish et al., 2014; Bremmer et al., 2011). The
second reason the diffusion approximation begins to fail is the use of small source-detector
separations common to small endoscopic probes. A source-detector separation is considered
“small” if it is less than approximately one reduced mean free path (Rajaram et al., 2008;
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Subramanian et al., 2007; Bosschaart et al., 2011; Kanick, McClatchy, et al., 2014). The reduced
mean free path is defined by Eq. 2,
𝑀𝐹𝑃𝑟𝑒𝑑𝑢𝑐𝑒𝑑 =

1
(𝜇𝑠′ + 𝜇𝑎 )

(2)

where MFPreduced is the reduced mean free path (cm), µs’ is the reduced scattering coefficient
[cm-1], and µa is the absorption coefficient [cm-1] (Rajaram et al., 2008; Bosschaart et al., 2011).
Consider the case in which an investigator is using a spectroscopy probe to non-invasively
quantify the optical properties of skin at 630 nm. Skin tends to have a µs’ of approximately 20
cm-1 and µa of approximately 0.4 cm-1 at 630 nm, although there is a wide range associated with
skin optical properties (Sandell et al., 2011). If this were the case, the albedo and reduced mean
free path would be 0.98 and 490 µm, respectively. This theoretical value for albedo satisfies the
requirements for the diffusion approximation. However, if an investigator is using sourcedetector separations less than 490 µm which is often the case, the diffusion approximation may
begin to fail. In such a situation, we define the volume of tissue being probed to be in the “subdiffuse scattering regime” rather than the “diffuse scattering regime” (Rajaram et al., 2008;
Turzhitsky, Radosevich, et al., 2010; Turzhitsky, Rogers, et al., 2010; Subramanian et al., 2007).
The reason this distinction is important is that light in the sub-diffuse transport regime
requires modified model-based interpretations. Mathematical models that describe light transport
in the sub-diffuse regime require additional knowledge of the first and second Legendre
moments, which is based on backscattering probability (Kanick, McClatchy, et al., 2014). Figure
7 shows a three-dimensional, color-mapped representation of albedo and reduced mean free path
as a function of μs’ and μa for visualization. Albedo increases with higher μs’ and lower μa. The
reduced mean free path increases with lower μs’ and μa values. Both three-dimensional graphs
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are shown for μs’ between 5-40 cm-1 and μa between 0-40 cm-1.

Figure 7. This figure shows the relationship between µs’ and µa and the (a) albedo
and (b) reduced mean free path of tissue. Notice that increasing µs’ and decreasing
µa increases albedo. For the diffusion approximation to be valid, albedo must be
greater than 0.9. For tissues with albedo less than 0.9, optical imaging and
spectroscopy occurs in the sub-diffuse regime. Alternatively, notice that
decreasing µs’ and µa increases the reduced mean free path of tissue. For the
diffuse approximation (and thus the diffuse regime) to be valid, source-detector
separations for spectroscopy probes must be greater than one reduced mean free
path.
3.3.2 Geometry and optical properties of epithelial tissue
We next present a review of the geometry and optical properties of several types of
epithelial tissues that are often the target of analysis in imaging and spectroscopy systems. Tissue
thickness, albedo and reduced mean free path will be provided to correlate with the previous
section. This section aims to 1) provide an organized set of relevant information regarding
epithelial tissues, 2) guide the design of imaging and spectroscopy probes, and 3) facilitate an
understanding of the basic optic and geometric parameters defining the “diffuse regime” and
“sub-diffuse regime”. Understanding how the diffuse and sub-diffuse regimes are affected by
tissue properties such as albedo and reduced mean free path and a probe’s source-detector
separation can facilitate design of tissue-mimicking optical phantoms.
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3.4 Considerations for thin tissue-simulating PDMS phantoms
When considering optical imaging techniques, a primary feature of phantom development
is the control of optical properties (reduced scattering and absorption coefficients) to mimic
human tissue (Pogue et al., 2006; Ayers et al., 2008). Optical properties of myriad human tissues
have previously been characterized and can provide a guideline for phantom design (Sandell et
al., 2011). In addition, some applications are required to probe deep layers of tissues, such as the
basement membrane or submucosa, which can exist up to 800 or more microns below the apical
surface (Liu et al., 2006; Harris et al., 1992). In such cases, modulation of the phantom geometry
on the scale of tens to hundreds of microns is crucial in phantom development (de Bruin et al.,
2010; Chang et al., 2012; Koschwanez et al., 2009; Guimarães et al., 2007). Therefore, the
ability to reproducibly create thin tissue-like phantoms with tunable optical properties may be
beneficial for a wide range of optical image techniques (de Bruin et al., 2010; Cerussi et al.,
2012; Pogue et al., 2006; Ayers et al., 2008).
Many other groups have attempted to address this need for their applications. Bruin et al.
demonstrated a method to produce 50 μm thick phantoms by curing PDMS between two glass
plates. These phantoms contained either silicon or titanium dioxide as the scattering agent and
ABS 551, a green dye, as the absorber (de Bruin et al., 2010). Saager et al. demonstrated a
method to produce 90 μm thick phantoms by curing PDMS in a custom well plate using titanium
dioxide as the scattering agent and either coffee, nigrosin, or India ink as the absorber (Saager et
al., 2010). Finally, Bae et al. demonstrated a method to use a spin coater to spin epoxy down to
ultra-thin (5 μm) layers. India ink was used as the absorber (Bae et al., 2013). Although these
methods provided rigorous validation of tissue-simulating phantoms, all have specific limitations
which we seek to address. Bruin et al. reported their optical properties only in terms of the
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attenuation coefficient (μt) instead of the more conventional reduced scattering (µʹs) and
absorption (μa) coefficients commonly used to quantify tissue optical properties (de Bruin et al.,
2010). Saager et al. thoroughly reported on the wavelength dependence of their phantoms but do
not provide information on the dependence of these optical properties on the concentrations of
absorbing and scattering agents (Saager et al., 2010). Finally, Bae et al. introduced a spin coating
technique to produce ultra-thin layers. The resulting multi-layered phantoms with included
heterogeneities were permanent, meaning thin layers cannot be easily interchanged (Bae et al.,
2013).15 We seek to combine various aspects of the phantom design procedures briefly reviewed
here to create unique tissue-simulating optical phantoms (de Bruin et al., 2010; Saager et al.,
2010; Bae et al., 2013).
We introduce a method to produce thin, interchangeable phantom layers with tunable
optical properties using poly(dimethylsiloxane) (PDMS), an optically clear, silicone-based
elastomer, to simulate epithelium (Pogue et al., 2006; Ayers et al., 2008; Sandell et al., 2011;
Liu et al., 2006).9-12 PDMS was chosen because of its durability, optical stability over time,
comparable refractive index to human tissue (1.4), and the easy manipulation of both layer
thickness and optical properties through the addition of scattering and absorbing agents (de Bruin
et al., 2010; Cerussi et al., 2012; Pogue et al., 2006).
Phantom thickness was controlled by spinning uncured PDMS on a clean, non-patterned
silicon wafer in a spin coater, in which the spin speed (100 to 1000 rpm) was manipulated to
reproducibly create thin PDMS optical phantoms between 115 and 880 microns (Bae et al.,
2013; Koschwanez et al., 2009). Thicker phantoms were constructed by pouring uncured PDMS
into a mold. Preparing phantom layers in the range of 100 to 300 microns is especially important
to model many tissue types, such as the skin, gingivae, esophagus, and cervix, among others (de
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Bruin et al., 2010; Harris et al., 1992; Guimarães et al., 2007; Rocha et al., 2010; Baxi et al.,
2014).
Phantom optical properties were controlled by introducing varying concentrations of
titanium dioxide and alcohol-soluble nigrosin as the scattering and absorbing agents, respectively
(de Bruin et al., 2010; Pogue et al., 2006; Ayers et al., 2008; Sandell et al., 2011; Liu et al.,
2006). The reduced scattering and absorption coefficients of PDMS-based phantoms with
increasing concentrations of titanium dioxide and alcohol-soluble nigrosin were quantified by
spatial frequency domain imaging (SFDI) at six discrete wavelengths (591, 631, 659, 691, 731,
and 851 nm) across the visible to near-infrared spectrum (Cuccia et al., 2009; Cuccia et al.,
2005). Optical characterization with SFDI outside this wavelength range was unreliable (data not
shown). Based on the data presented here, lookup tables have been provided that list appropriate
concentrations of titanium dioxide and alcohol-soluble nigrosin to use based on desired reduced
scattering and absorption coefficients. These lookup tables may be useful for researchers
interested in developing similar phantoms for their specific imaging applications.
Once phantoms were characterized, individual thin phantom layers were stacked to create
thicker, multi-layer phantoms, which can model an optically heterogeneous tissue of interest
(Saager et al., 2010; Agrawal et al., 2013; Chang et al., 2012). Using SFDI, optical properties of
multi-layer phantoms were compared to single-layer phantoms with identical concentrations of
titanium dioxide and alcohol-soluble nigrosin for validation. Furthermore, multi-layered
phantoms were imaged using OCT B-scanning for validation and qualitative purposes.
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3.5 Materials and methods
3.5.1 Design of thin PDMS-based optical phantom layers for thickness characterization
For each thin phantom, 6.5 ± 0.1 grams of PDMS (Sylgard 184 Silicone Elastomer Kit,
Dow Corning, USA) elastomer base was dispensed into an ARE-100 conditioning mixer cup
(Intertronics, UK). Next, the curing agent was dispensed into a 7 mL scintillation vial (VWR,
USA) based on a 10:1 ratio of base to curing agent. Titanium dioxide (Sigma-Aldrich, USA) and
alcohol-soluble nigrosin (Sigma-Aldrich, USA, SKU: 211680-25G) were used to control the
reduced scattering coefficient (µʹs) and absorption coefficient (µa), respectively. Titanium
dioxide (TiO2) was weighed and dispensed into the 7 mL scintillation vial containing the curing
agent. Next, a 1% w/v solution of nigrosin in ethanol was prepared and added to the scintillation
vial. The mixture in the scintillation vial was mixed for one minute on a vortex mixer (VWR,
USA) to disperse large particles of TiO2. Following this, the scintillation vial was placed in a
Model 3510 sonicator (Branson Ultrasonics Corporation, USA) for 30 minutes to disperse small
particles of TiO2 and nigrosin emulsions in the curing agent solvent. The process of vortexing for
one minute and sonicating for 30 minutes was repeated a total of five times to ensure uniform
scattering and absorption throughout.
The mixture of curing agent, TiO2, and 1% w/v nigrosin/EtOH was then dispensed into
the mixing cup containing the PDMS elastomer base. This final mixture was thoroughly mixed
and degassed for three cycles in an ARE-100 conditioning mixer (Intertronics, UK) for a total of
12 minutes. Immediately following mixing and conditioning in the ARE-100 conditioning mixer,
the uncured mixture was placed in an oven at 70°C for three minutes to initiate curing. The
PDMS mixture was removed from the oven and slowly poured onto the center of a 10 cm silicon
wafer (University Wafer, USA) within a G3P-8 Spin Coater (SCS Spin Coating Systems, USA).
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The spin coater was optimized to accelerate to its peak speed in four seconds, spin at
maximum speed for 20 seconds, and then decelerate to zero RPM in four seconds. Once the spin
coater reaches zero RPM, the silicon wafer, containing a thin film of partially cured PDMS
mixture, was removed and placed in an oven at 70°C for two hours to complete curing.
Thin phantoms were created at spin speeds of 100, 200, 300, 400, 500, 700 and 1000
RPM, with three trials of each. Each phantom at a particular spin coater speed was sampled six
times for a total of 18 thickness measurements at each speed, shown in Figure 2. Thickness was
quantified by analyzing transmittance images of PDMS phantom layers. A transverse cut was
made in each phantom and imaged using a wide-field microscope with a Nikon Plan Fluor 10X,
0.30 NA objective and Nikon DS-Fi2 camera. Calibration of image scale was performed with a
positive USAF 1951 resolution target. Images were analyzed using the MATLAB Image
Analysis Toolbox (Mathworks, USA).
3.5.2 Design of PDMS-based optical phantoms for characterization of reduced scattering and
absorption coefficients
The µʹs and µa of phantoms containing varying amounts of TiO2 and 1% w/v
nigrosin/EtOH were quantified with spatial frequency domain imaging (SFDI) (Cuccia et al.,
2005; Cuccia et al., 2009). For analysis with SFDI, thicker phantoms (2.5 cm thick) were built
using an ARE-100 conditioning mixer cup (Intertronics, UK) as a mold. Construction of thick
phantoms followed the same procedure as the construction of thin phantoms up until the point
the spin coater was introduced. Instead of using a spin coater to spin partially cured PDMS into a
thin layer, completely mixed PDMS was placed in an oven at 70°C for two hours to complete
curing. 16 phantoms were created using this technique. Eight phantoms (#1-8 in Table 1)
contained a constant amount of 1% w/v nigrosin/EtOH solution with increasing concentration of
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TiO2 in PDMS elastomer base to manipulate µʹs. Nine phantoms (#1 and 9-16 in Table 1)
contained a constant amount of TiO2 with increasing concentration of 1% w/v nigrosin/EtOH
solution in PDMS elastomer base to manipulate µa. As an example, since 50 grams of PDMS
elastomer base were used to create Phantom #5, 0.25 grams of TiO2 and 25 μL of 1% w/v
nigrosin/EtOH were added. Table 1 shows the breakdown of each phantom created for the
quantification of optical properties by SFDI. In addition, Figure 8 shows an aerial view of all 16
phantoms represented in Table 1. Figures 12-15 provide analysis on the resulting µʹs and µa.
Table 1. Amounts of titanium dioxide (scattering agent) and nigrosin/ethanol solution (absorbing
agent) per thick (2.5 cm) “semi-infinite” phantom quantified by SFDI
Phantom
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

1% w/v
Nigrosin/EtOH
[µL/g]
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
1.0
2.0
3.0
4.0
5.0
7.0
10.0
40.0

TiO2
[g/g]
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0.008
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
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Figure 8. Aerial view of the 16 phantoms used in the SFDI characterization of µʹs
and µa, corresponding to Table 1. Phantoms used in this study are #1-4 (1st row),
#5-8 (2nd row), #9-12 (3rd row), and #13-16 (4th row).
3.5.3 Construction of multi-layer phantoms for inclusion of heterogeneities
One multi-layer phantom was constructed, quantified by SFDI, and compared to a singlelayer, “semi-infinite” control phantom with identical concentrations of optical agents (Cuccia et
al., 2005; Cuccia et al., 2009). The primary concern during construction of multi-layer phantoms
was the formation of air pockets between two adjacent layers. One possible technique to avoid
air pocket formation was directly spinning uncured PDMS over an existing base layer to build
multi-layer tissue-simulating phantoms. While this method can successfully eliminate air pocket
formation, it was not be suitable for creating thin layers that were easily interchangeable (Bae et
al., 2013). Instead, our method allowed for thin PDMS layers to readily be stacked and removed,
creating diverse sets of multi-layer phantoms for various optical imaging purposes. First, two 2.5
cm thick “semi-infinite” phantom layers were molded and cured in an ARE-100 conditioning
mixer cup (Intertronics, UK), containing 0.002g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per
gram PDMS elastomer base. Then, using the described spin coating method, two 200-micron
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layers were constructed, containing exactly the same concentrations of optical agents. After the
two 200-micron layers finished curing, they were carefully peeled off the silicon wafer. The
layers were cut using a scalpel into approximately 3 cm2 squares. Each thin-layer square was
placed into a 70% ethanol/DI water solution and sonicated for 10 minutes to remove dust and
other surface contaminants. Following this, two drops of ethanol were placed on one of the 2.5
cm “semi-infinite” base layers. One 200-micron layer was placed directly on top of the ethanol
drops so that no visible air bubbles remained. This two-layer phantom was placed in an oven at
70°C for three minutes to allow evaporation of the ethanol, creating two adjacent layers without
air pockets. These steps were repeated for the second 200-micron layer on the same multilayered phantom (Phantom #18 in Table 2). To the second 2.5 cm “semi-infinite” base layer, no
thin layers were added (Phantom #17 in Table 2). Table 2 shows the geometric specifications of
the two phantoms.
Table 2. Thickness specifications for single-layer and multi-layer control phantoms (for all
layers: 0.002g TiO2 and 2.0 µL 1% w/v Nigrosin/EtOH in PDMS elastomer base)
Thickness [µm]
Phantom #17 (single-layer) Phantom #18 (multi-layer)
Top Layer
N/A
200
Middle Layer
N/A
200
Bottom Layer
25,000
25,000
Both phantoms were subjected to SFDI analysis to quantify µʹs and µa at the six discrete
wavelengths shown in Figure 16 and 17. This analysis served to validate the process of creating
multi-layer phantoms without air pocket formation. In addition, SFDI analysis on multi-layered
phantoms served to validate that thin (<880 µm) and thick (2.5 cm) phantoms layers with
identical concentrations of optical agents have comparable optical properties. Because all layers
contain identical concentrations of TiO2 and 1% w/v nigrosin/EtOH, µʹs and µa should be
identical for both single-layer and multi-layer phantoms (Figure 16 and 17).
Additionally, one more three-layer multi-layer phantom was constructed and imaged
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using an OCT B-scan for qualitative purposes. First, one 2.5 cm thick phantom layer was molded
and cured in an ARE-100 conditioning mixer cup (Intertronics, UK), containing 0.002 g titanium
dioxide and 2.0 µL 1% w/v nigrosin/EtOH per g PDMS elastomer base. Then, using the
described spin coating method, two 200-micron layers were constructed. The first 200-µm layer
contained 0.006 g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per g PDMS elastomer base, tripling
the scattering agent concentration while keeping the absorbing agent concentration constant. The
second 200-micron layer contained 0.002g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per g PDMS
elastomer base (identical to the base layer). The first (optically different) thin layer was placed
between the base layer and second (optically identical) thin layer to produce a heterogeneous
multi-layer phantom that was imaged by an OCT B-scanning technique. These phantom images
are compared to various types of human epithelium (skin and oral mucosa) in Figure 18. Table 3
shows the geometric and optical specifications of the heterogeneous multi-layer phantom for this
comparative study using OCT. Optical coherence tomography (OCT) imaging was performed on
a custom-built spectral-domain OCT platform with a center wavelength of 1325 nm, axial
resolution of 8.0 m (in air), lateral resolution of 22.5 m, and maximum imaging depth of 3.0
mm (in air) (Higgins et al., 2014). For phantom imaging (Figure 18), OCT cross-sections (Bscans) contained 500 A-lines acquired over a 5 mm scan width. B-scan images were generated
by standard SD-OCT processing (spectrometer wavelength calibration, interpolation to evenly
spaced samples in k-space, and Fourier transformation) (Higgins et al., 2014). The OCT system
used here operates at 1325 nm, further out into the near-infrared range than our SFDI system was
capable of testing (591-851 nm). The majority of OCT imaging of tissues (including the
epithelial tissues in which our phantoms seek to mimic) is done in the 1325 nm region (Higgins
et al., 2014). Therefore, OCT B-scans were used for comparative purposes and not to
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characterize optical properties of phantoms.
Table 3. Thickness and optical concentration specifications for multi-layer phantom imaged by
an OCT B-scanning technique
Phantom #19
Layer 1 Layer 2 Layer 3
Thickness [µm]
25,000 200
200
TiO2 [g/g]
0.002
0.006
0.002
1 w/v% Nigrosin/EtOH [uL/g]
2
2
2
3.5.4 Semi-infinite phantom model of dysplastic progression
Once optical property extraction and sampling depth were validated, we tested the
capabilities of the DRS modality of the hybrid fiber-bundle in a dysplasia-mimicking phantom
model (Zhu et al., 2011). Figure 9 (a-c) shows a simplified representation of dysplastic
progression starting at the basement membrane and proliferating upwards into surrounding
healthy tissue (Speight, 2007; Warnakulasuriya et al., 2008). Early dysplasia is known to
significantly increase epithelial scattering by nearly two-fold (Arifler et al., 2003; Collier et al.,
2003; Clark et al., 2004). To simulate this phenomenon, three solid scattering-only phantoms,
shown in Figure 9 (d-f), were created (Zhu et al., 2011). Since scattering contributes much more
to reflectance intensity compared to absorption, the µa was held constant at 0 cm-1 (Clark et al.,
2004). Additionally, the phantom “epithelia” was made to be 300 µm thick to approximately
simulate the thickness of oral mucosa (Greening et al., 2015). With the understanding that the
374 and 730 μm SDSs sample different depths, it was expected that the 374 μm SDS may be
more sensitive to shallower, epithelial-confined scattering changes associated with early
dysplasia.
The three phantom models have a semi-infinite geometry, a common geometry used in
various models of photon transport in tissues with sub-surface optical heterogeneities (Zhu et al.,
2011). The semi-infinite geometry requires an optically thick base layer (bottom gray layer in
Figure 9 (d-f)) that can be considered infinitely thick in the z direction since no photons penetrate
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through this layer. In this experiment, the semi-infinite base layer was 1 cm thick. Additionally,
all layers can be considered infinite in the x and y directions since no photons penetrate laterally
outside this plane (Zhu et al., 2011).

Figure 9. A simplified representation of dysplastic proliferation arising at the
basement membrane in the oral cavity (a-c) showing normal cells (gray with
nuclei), dysplastic cells (light gray with nuclei), basement membrane (dark gray),
and the stroma (gray). The associated dysplasia-mimicking phantom models (d-f)
simulate this progression. Two SDSs (374 and 730 μm) deliver and collect
broadband light at different depths (detected photons shown here as blue and red
crescents, respectively). Each of thin phantom layers was 150 μm thick for a total
phantom thickness of 300 μm to simulate the thickness of oral epithelium.
Phantoms were created using poly(dimethylsiloxane) (PDMS) as the substrate material,
and titanium dioxide (TiO2) as the scattering agent. PDMS was used because of its optical clarity
(μs’ and μa = 0 cm-1 between 500-750 nm), comparable refractive index to human tissue (~1.4),
optical stability over time, physical durability, and ability to form multilayer geometries
(Greening et al., 2014). Since µs’ contributes to reflectance intensity much more than µa, no
absorbing agent was used (Clark et al., 2004).
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The semi-infinite layer and 150 µm thick healthy tissue-mimicking layers were designed
with 0.25% w/w TiO2 in PDMS (2.5 mg TiO2 per 1.0 g PDMS) to yield a µs’ of ~7 cm-1 at 630
nm which is comparable to healthy tissue (Chang et al., 2009; Greening et al., 2014). The 150
µm thick dysplasia-mimicking layers were designed with 0.50% w/w TiO2 in PDMS (5.0 mg per
1.0 g PDMS) to yield a µs’ of ~14 cm-1 at 630 nm (Greening et al., 2014; Chang et al., 2009).
This represented a two-fold increase in scattering which is representative of the increased
scattering ratio of dysplastic to healthy epithelial tissue (Collier et al., 2003; Clark et al., 2004;
Arifler et al., 2003). For each geometry in Figure 9, two 150 µm layers were stacked to generate
the desired phantom (Greening et al., 2014; Greening et al., 2015). The total phantom
“epithelial” thickness was thus 300 μm, not including the “stromal” semi-infinite base layer,
which was 1 cm thick. All thin phantom layers were created using a previously described spin
coating technique (Greening et al., 2015; Greening et al., 2014).
The volume-averaged µs’ was extracted between 500-750 nm for each phantom. Ten
DRS measurements were averaged for each geometry (Phantoms 1-3) and SDS with an
integration time of 500 ms. We hypothesized that the 374 µm SDS would show larger deviations
in volume-averaged µs’ compared to the 730 µm SDS because the changes in scattering were
confined to the upper 300 µm of the phantom. The 730 µm would be sampling significantly
more into the underlying “stromal” semi-infinite layer, in which µs’ was held constant for this
experiment. Results from this study were expected to indicate that the shorter SDS would be
more sensitive to scattering changes associated with dysplastic epithelium.
3.5.5 Collaboration with the Boston University Department of Biomedical Engineering: TwoLayer Tissue-Simulating Optical Phantoms
The following section was directly adapted from Syeda Tabassum, Vivian Pera and
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Darren Roblyer from Boston University, with whom we provided tissue-simulating PDMS
phantoms for their experiments (Tabassum et al., 2018).
A set of two-layer solid silicone phantoms was fabricated to optically simulate
subcutaneous tumors in a mouse with a range of optical properties. These phantoms were used to
test the accuracy of Gardner LUT inversion algorithms. The phantoms consisted of a thin skin
layer above a tumor layer. Four different two-layer phantoms were fabricated, all of which used
the same skin layer. In all phantoms, silicone was used as the base solvent, nigrosin as the
absorber, and titanium dioxide as the scatterer. The optical properties of the phantoms were
adjusted by varying the amount of absorber and scatterer during fabrication as previously
described (Ayers et al., 2008; Tabassum et al., 2018).
The thin upper layer phantom was made by adapting a previously described technique
(Saager et al., 2010). First, an aluminum phantom mold was fabricated by machining a well that
was 330 μm in depth and 1.5 in. × 1.5 in. in the lateral dimensions using a computer-controlled
milling machine (SV-2414S-M, Sharp Industries). After the phantom ingredients were mixed
together, the liquid mixture was poured into the aluminum mold. A microtome blade was used to
draw and spread the mixture evenly across the well, and the edges of the blade remained in
contact with the top surface of the mold at all times. The phantom was then left to cure,
uncovered, overnight. During curing, the silicone layer was observed to shrink in the center of
the well. Once cured, the thin silicone layer was removed from the mold and cut to the size of
100 × 100 to remove the uneven and thicker edge. The thickness of the phantom was confirmed
using caliper measurements by confining the thin layer between two microscope slide coverslips
for stability and consistency. Because the top layer phantom was too thin for accurate optical
property measurements with diffuse imaging techniques, a much larger, 2.5-cm thick
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homogeneous phantom was made from the same batch of material and SFDI was used to extract
the optical properties (Tabassum et al., 2018).
Similarly, for the bottom (tumor) layer, four homogeneous phantoms were fabricated in
collaboration with Dr. Muldoon’s group (Greening et al., 2014) and measured with SFDI. The
thickness of each phantom was 2.5 cm, and the μa and μ0s values of each phantom were targeted
to span known mouse tumor optical properties. The skin layer and tumor layer phantoms were
stacked to create the two-layer phantoms. First, the thin skin layer phantom was cleaned using an
alcohol wipe. Then a small amount of ethanol was poured on a thick tumor layer phantom, and
the thin layer was directly placed on top of the tumor layer, making sure that no visible air
bubbles remained. The two-layer phantom was left under the chemical hood overnight to allow
the ethanol to evaporate without leaving any air pockets between the layers. An example of one
of the two-layer phantoms is shown in Figure 10(c). The procedure was repeated 4 times to
generate the four two-layer phantoms (Tabassum et al., 2018).

Figure 10. (a) Schematic of tissue model for the homogenous case, (b) schematic
of the tissue model for the two-layer case, and (c) an example of a custom-made
two-layer silicone phantom used to validate the accuracy of the resulting twolayer inverse algorithm (Tabassum et al., 2018).
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3.6 Results
3.6.1 Characterization of thickness of thin PDMS-based optical phantoms
Figure 11 shows the relationship between the primary, maximum 20-second spin speed
and resulting thickness of PDMS layers. Seven different spin speeds were used (100, 200, 300,
400, 500, 700, and 1000 rpm) to characterize the resulting thickness (between 115 and 880 µm)
of thin PDMS-based phantoms.

Figure 11. Relationship between thickness of thin-layer phantoms and maximum
20-second spin speed of a spin coater. Here, phantoms were constructed between
approximately 115 and 880 µm. The R2 value for the curve of best fit is 0.988.
Best fit lines were generated by the MATLAB curve-fitting toolbox (power fit).
3.6.2 Characterization of reduced scattering coefficient of PDMS-based optical phantoms
Figure 12 shows the relationship between TiO2 (scattering agent) in PDMS elastomer
base [g/g] and the resulting µʹs [cm-1] for six discrete wavelengths [nm] measured by SFDI (591,
621, 659, 691, 731, and 851 nm). Eight phantoms (#1-8 in Table 1) were used in this study
which contained a constant amount of 1% w/v nigrosin/Et/OH (absorbing agent) and increasing
concentration of TiO2 in PDMS elastomer base [g/g].
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Figure 12. Relationship between µʹs [cm-1] and TiO2 concentration in PDMS
elastomer base [g/g] measured at six discrete wavelengths (591, 621, 659, 691,
731, and 851 nm) using spatial frequency domain imaging (SFDI) analysis. Here,
µʹs values range between approximately 1 and 21 cm-1. R2 values for best fit lines
from 591 to 851 nm are 0.994, 0.994, 0.994, 0.995, 0.995, and 0.998, respectively.
Best fit lines were generated by the MATLAB curve-fitting toolbox (linear fit).
In addition, µʹs was measured at increasing 1% w/v nigrosin/EtOH concentrations in
PDMS elastomer base to determine if increasing the chosen absorbing agent would affect the
bulk scattering properties. Figure 13 shows the relationship between 1 w/v% of nigrosin/EtOH
concentration and the resulting µʹs [cm-1]. Results from Phantom #16 are not shown in Figure 4.
The phantoms used in this experiment (#1, 9-15 in Table 1) all contained identical concentrations
of the chosen scattering agent, TiO2 (0.001 g/g).
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Figure 13. Relationship between µʹs [cm-1] and 1% w/v nigrosin/EtOH
concentrations in PDMS elastomer base [μL/g] measured at six discrete
wavelengths (591, 621, 659, 691, 731, and 851 nm) using spatial frequency
domain imaging (SFDI) analysis. Best fit lines were generated by the MATLAB
curve-fitting toolbox (linear fit).
3.6.3 Characterization of absorption coefficient of PDMS-based optical phantoms
Figure 14 shows the relationship between 1 w/v% of nigrosin/EtOH (absorbing agent) in
PDMS elastomer base [μL/g] and the resulting µa [cm-1] for six discrete wavelengths measured
by SFDI (591, 621 ,659, 691, 731, and 851 nm). Nine phantoms (#1 and 9-16 in Table 1) were
used in this study which contained a constant amount of TiO2 (scattering agent) and increasing
1% w/v nigrosin/EtOH concentration in PDMS elastomer base.

166

Figure 14. Relationship between µa [cm-1] and 1% w/v nigrosin/EtOH
concentration in PDMS elastomer base [μL/g] measured at six discrete
wavelengths (591, 621, 659, 691, 731, and 851 nm) using spatial frequency
domain imaging (SFDI) analysis. Here, µa values range between approximately 0
and 1.5 cm-1. Best fit curves, generated by the MATLAB curve-fitting toolbox
(power fit), are shown for the 591 nm (dashed) and 851 nm (dotted) wavelengths,
respectively.
In addition, µa was measured at increasing TiO2 concentrations in PDMS elastomer base
to determine if increasing the chosen scattering agent would affect the bulk absorbing properties.
Figure 15 shows the relationship between TiO2 concentration and the resulting µa [cm-1]. Eight
phantoms (#1-8 in Table 1) were used in this study which contained identical concentrations of
the chosen absorbing agent, 1% w/v nigrosin/EtOH (0.5 µL/g).
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Figure 15. Relationship between µa [cm-1] and TiO2 concentration in PDMS
elastomer base [g/g] measured at six discrete wavelengths (591, 621, 659, 691,
731, and 851 nm) using spatial frequency domain imaging (SFDI) analysis.
3.6.4 Validation of multi-layer PDMS-based optical phantoms
For the two phantoms specified in Table 2 (Phantom # 17 and 18), µʹs [cm-1] and µa [cm1

] were quantified with SFDI (Cuccia et al., 2005; Cuccia et al., 2009). Phantom #17 (square

data points in Figure 16 and 17) consisted of only one thick 2.5 cm base layer, containing 0.002
g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per gram PDMS elastomer base. Phantom #18
(diamond data points in Figure 16 and 17) consisted of one thick 2.5 cm base layer with two
overlying 200-µm layers, all containing 0.002 g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per
gram PDMS elastomer base. This experiment attempted to validate the creation of multi-layer
phantoms by comparing the overall optical properties (µʹs and µa) of a single-layer and multilayer phantoms with all layers containing identical concentrations of scattering and absorbing
agents. Figure 16 shows the relationship between the wavelength and resulting µʹs while Figure
17 shows the relationship between the wavelength and resulting µa for the single-layer (Phantom
#17) and multi-layer (Phantom #18) phantoms specified in Table 2.
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Figure 16. Comparison of µʹs [cm-1] between a single-layer and multi-layer
phantom with identical concentrations of scattering and absorbing agents
measured at six discrete wavelengths (591, 621, 659, 691, 731, and 851 nm) using
spatial frequency domain imaging (SFDI) analysis. Average aggregate error was
7.7%.

Figure 17. Comparison of µa [cm-1] between a single-layer and multi-layer phantom
with identical concentrations of scattering and absorbing agents measured at six discrete
wavelengths (591, 621, 659, 691, 731, and 851 nm) using spatial frequency domain
imaging (SFDI) analysis. Average aggregate error was 10.9%.
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Figure 18 represents an OCT B-scan comparison between multi-layered phantoms and
several types of human epithelium from a normal volunteer (fingertip epithelium, wrist
epithelium, and oral mucosa).

Figure 18. Images of multi-layered PDMS-based phantoms compared to OCT Bscans of various human epithelium. (a) OCT B-scan of a three-layer phantom.
Thickness in layers 1 and 2 (L1 and L2) were approximately 200 µm,
respectively. TiO2 concentration in layers 1, 2, and 3 (L3) were 0.002, 0.006, and
0.002 [g/g], respectively. 1 w/v% nigrosin/EtOH concentration was 2.0 μL/g in all
layers. The comparative images show OCT B-scans from a normal volunteer of
the (b) fingertip showing the epidermis (Epid) and dermis (Der), (c) wrist
showing the epidermis (Epid) and dermis (Der), and (d) oral mucosa showing the
epithelium (Epit) and lamina propria (LP) Scale bars represents 500 μm.
3.6.5 Lookup Tables for Optical Properties of Solid PDMS-Based Phantoms
The following lookup tables can be used as a guideline to determine approximate
concentrations of the studied absorbing agent (1% w/v Nigrosin/Ethanol) and scattering agent
(Titanium dioxide) given a desired absorption coefficient (µa) and reduced scattering coefficient
(µʹs) at a specific wavelength when designing PDMS-based tissue-simulating phantoms. Six
lookup tables are included, corresponding to the six wavelengths (591, 631, 659, 691, 731, and
851 nm) used in this study. It should be noted that individual concentrations listed in this table
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were not explicitly measured. Instead, the individual concentrations listed here were acquired
based on empirical mathematical models fitting the presented data. While the tables do fit the
presented data, extensive validation of these tables was not performed. Therefore, optical
properties should always be independently validated.
To use these lookup tables, first choose a desired µa to obtain the correct concentration of
1% w/v nigrosin/EtOH in PDMS elastomer base [µL/g]. Then, choose a desired µʹs and line up
this row with the column corresponding to the chosen µa to obtain the correct concentration of
TiO2 in PDMS elastomer base [g/g].
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Table 4. Lookup table to determine the required concentrations of absorbing and scattering
agents from desired absorption and reduced scattering coefficients at 591 nm (Greening et al.,
2014).
Absorption Coefficient µa [cm-1]
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g]
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.0
1.3
1.7
2.1
2.4
2.8
3.1
3.5
4.1
4.9
Reduced Scattering Coefficient µʹs [cm-1]
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3
1
0.1
0.1
0.1
0.2
0.2
0.2
0.2
0.3
0.3
0.5
2
0.5
0.5
0.6
0.6
0.7
0.7
0.8
0.9
1.0
1.2
3
0.9
1.0
1.0
1.1
1.2
1.3
1.3
1.4
1.7
2.0
4
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2.0
2.3
2.8
5
1.7
1.8
1.9
2.0
2.2
2.3
2.4
2.6
3.0
3.6
6
2.2
2.3
2.4
2.5
2.7
2.8
3.0
3.2
3.6
4.4
7
2.6
2.7
2.8
3.0
3.2
3.3
3.5
3.8
4.3
5.1
8
3.0
3.1
3.3
3.5
3.6
3.9
4.1
4.4
4.9
5.9
9
3.4
3.5
3.7
3.9
4.1
4.4
4.7
5.0
5.6
6.7
10
3.8
4.0
4.2
4.4
4.6
4.9
5.2
5.5
6.2
7.5
11
4.2
4.4
4.6
4.9
5.1
5.4
5.8
6.1
6.9
8.2
12
4.6
4.8
5.1
5.3
5.6
5.9
6.3
6.7
7.5
9.0
13
5.0
5.3
5.5
5.8
6.1
6.5
6.9
7.3
8.2
9.8
14
5.4
5.7
6.0
6.3
6.6
7.0
7.4
7.9
8.8
10.6
15
5.8
6.1
6.4
6.7
7.1
7.5
8.0
8.5
9.5
11.3
16
6.3
6.5
6.9
7.2
7.6
8.0
8.5
9.0
10.2 12.1
17
6.7
7.0
7.3
7.7
8.1
8.6
9.1
9.6
10.8 12.9
18
7.1
7.4
7.8
8.2
8.6
9.1
9.6
10.2 11.5 13.7
19
7.5
7.8
8.2
8.6
9.1
9.6
10.2 10.8 12.1 14.5
20
7.9
8.3
8.7
9.1
9.6
10.1 10.7 11.4 12.8 15.2
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1.1
5.8

1.2
6.6

1.3
7.1

1.4
13.9

0.6
1.6
2.6
3.5
4.5
5.4
6.4
7.4
8.3
9.3
10.2
11.2
12.1
13.1
14.1
15.0
16.0
16.9
17.9
18.8

0.9
2.2
3.4
4.7
5.9
7.2
8.4
9.7
10.9
12.2
13.4
14.7
15.9
17.2
18.4
19.7
20.9
22.2
23.4
24.7

1.1
2.6
4.0
5.5
7.0
8.4
9.9
11.3
12.8
14.2
15.7
17.1
18.6
20.0
21.5
22.9
24.4
25.8
27.3
28.7

1.1
2.6
4.0
5.5
7.0
8.4
9.9
11.3
12.8
14.2
15.7
17.1
18.6
20.0
21.5
22.9
24.4
25.8
27.3
28.7

Table 5. Lookup table to determine the required concentrations of absorbing and scattering
agents from desired absorption and reduced scattering coefficients at 631 nm (Greening et al.,
2014).
Absorption Coefficient µa [cm-1]
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g]
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.0
1.4
1.7
2.1
2.5
2.9
3.2
3.6
4.2
5.1
Reduced Scattering Coefficient µʹs [cm-1]
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3
1
0.2
0.2
0.2
0.2
0.3
0.3
0.3
0.4
0.4
0.6
2
0.7
0.7
0.7
0.8
0.8
0.9
1.0
1.0
1.2
1.4
3
1.1
1.2
1.3
1.3
1.4
1.5
1.6
1.7
1.9
2.3
4
1.6
1.7
1.8
1.9
2.0
2.1
2.2
2.4
2.6
3.1
5
2.1
2.2
2.3
2.4
2.5
2.7
2.8
3.0
3.4
4.0
6
2.5
2.7
2.8
2.9
3.1
3.3
3.5
3.7
4.1
4.8
7
3.0
3.1
3.3
3.5
3.7
3.9
4.1
4.3
4.8
5.7
8
3.5
3.6
3.8
4.0
4.2
4.4
4.7
5.0
5.6
6.6
9
3.9
4.1
4.3
4.5
4.8
5.0
5.3
5.7
6.3
7.4
10
4.4
4.6
4.8
5.1
5.3
5.6
6.0
6.3
7.0
8.3
11
4.9
5.1
5.3
5.6
5.9
6.2
6.6
7.0
7.8
9.1
12
5.4
5.6
5.9
6.1
6.5
6.8
7.2
7.6
8.5
10.0
13
5.8
6.1
6.4
6.7
7.0
7.4
7.8
8.3
9.2
10.8
14
6.3
6.6
6.9
7.2
7.6
8.0
8.4
9.0
10.0 11.7
15
6.8
7.1
7.4
7.8
8.2
8.6
9.1
9.6
10.7 12.6
16
7.2
7.6
7.9
8.3
8.7
9.2
9.7
10.3 11.4 13.4
17
7.7
8.0
8.4
8.8
9.3
9.8
10.3 10.9 12.2 14.3
18
8.2
8.5
8.9
9.4
9.8
10.4 10.9 11.6 12.9 15.1
19
8.6
9.0
9.4
9.9
10.4 11.0 11.6 12.3 13.6 16.0
20
9.1
9.5
10.0 10.4 11.0 11.5 12.2 12.9 14.4 16.8
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1.1
5.9

1.2
6.8

1.3
7.3

1.4
14.5

0.7
1.8
2.8
3.8
4.9
5.9
6.9
8.0
9.0
10.0
11.1
12.1
13.1
14.1
15.2
16.2
17.2
18.3
19.3
20.3

1.0
2.3
3.6
4.9
6.2
7.5
8.8
10.1
11.4
12.7
14.0
15.3
16.6
17.9
19.1
20.4
21.7
23.0
24.3
25.6

1.1
2.5
3.9
5.3
6.7
8.1
9.5
10.9
12.3
13.7
15.1
16.4
17.8
19.2
20.6
22.0
23.4
24.8
26.2
27.6

1.1
2.5
3.9
5.3
6.7
8.1
9.5
10.9
12.3
13.7
15.1
16.4
17.8
19.2
20.6
22.0
23.4
24.8
26.2
27.6

Table 6. Lookup table to determine the required concentrations of absorbing and scattering
agents from desired absorption and reduced scattering coefficients at 659 nm (Greening et al.,
2014).
Absorption Coefficient µa [cm-1]
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g]
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.0
1.4
1.8
2.2
2.6
3.0
3.3
3.7
4.4
5.2
Reduced Scattering Coefficient µʹs [cm-1]
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3
1
0.3
0.3
0.3
0.3
0.4
0.4
0.4
0.5
0.5
0.7
2
0.8
0.8
0.9
0.9
1.0
1.1
1.1
1.2
1.4
1.6
3
1.3
1.4
1.5
1.5
1.6
1.7
1.8
1.9
2.2
2.5
4
1.8
1.9
2.0
2.1
2.2
2.4
2.5
2.6
3.0
3.4
5
2.4
2.5
2.6
2.7
2.9
3.0
3.2
3.4
3.8
4.3
6
2.9
3.0
3.2
3.3
3.5
3.7
3.9
4.1
4.6
5.3
7
3.4
3.6
3.7
3.9
4.1
4.3
4.6
4.8
5.4
6.2
8
3.9
4.1
4.3
4.5
4.7
5.0
5.3
5.6
6.2
7.1
9
4.5
4.7
4.9
5.1
5.4
5.6
5.9
6.3
7.0
8.0
10
5.0
5.2
5.4
5.7
6.0
6.3
6.6
7.0
7.8
8.9
11
5.5
5.8
6.0
6.3
6.6
6.9
7.3
7.7
8.6
9.8
12
6.0
6.3
6.6
6.9
7.2
7.6
8.0
8.5
9.4
10.8
13
6.6
6.8
7.2
7.5
7.9
8.3
8.7
9.2
10.2 11.7
14
7.1
7.4
7.7
8.1
8.5
8.9
9.4
9.9
11.0 12.6
15
7.6
7.9
8.3
8.7
9.1
9.6
10.1 10.6 11.8 13.5
16
8.1
8.5
8.9
9.3
9.7
10.2 10.8 11.4 12.6 14.4
17
8.7
9.0
9.4
9.9
10.3 10.9 11.5 12.1 13.4 15.4
18
9.2
9.6
10.0 10.5 11.0 11.5 12.1 12.8 14.2 16.3
19
9.7
10.1 10.6 11.1 11.6 12.2 12.8 13.6 15.0 17.2
20
10.2 10.7 11.1 11.7 12.2 12.8 13.5 14.3 15.9 18.1
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1.1
6.0

1.2
6.8

1.3
7.5

1.4
12.6

0.8
1.9
2.9
4.0
5.1
6.1
7.2
8.3
9.4
10.4
11.5
12.6
13.6
14.7
15.8
16.8
17.9
19.0
20.0
21.1

1.0
2.3
3.6
4.8
6.1
7.4
8.7
9.9
11.2
12.5
13.8
15.0
16.3
17.6
18.9
20.1
21.4
22.7
24.0
25.2

1.1
2.4
3.8
5.1
6.5
7.8
9.2
10.5
11.9
13.2
14.6
15.9
17.3
18.6
20.0
21.3
22.7
24.0
25.4
26.7

1.1
2.4
3.8
5.1
6.5
7.8
9.2
10.5
11.9
13.2
14.6
15.9
17.3
18.6
20.0
21.3
22.7
24.0
25.4
26.7

Table 7. Lookup table to determine the required concentrations of absorbing and scattering
agents from desired absorption and reduced scattering coefficients at 691 nm (Greening et al.,
2014).
Absorption Coefficient µa [cm-1]
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g]
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.0
1.4
1.8
2.3
2.7
3.1
3.5
3.9
4.7
5.4
Reduced Scattering Coefficient µʹs [cm-1]
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3
1
0.4
0.4
0.5
0.5
0.5
0.5
0.6
0.6
0.7
0.8
2
1.0
1.0
1.1
1.1
1.2
1.2
1.3
1.4
1.5
1.7
3
1.6
1.6
1.7
1.8
1.9
1.9
2.0
2.2
2.4
2.6
4
2.1
2.2
2.3
2.4
2.5
2.6
2.8
2.9
3.2
3.6
5
2.7
2.8
2.9
3.0
3.2
3.3
3.5
3.7
4.1
4.5
6
3.3
3.4
3.5
3.7
3.9
4.0
4.2
4.5
4.9
5.4
7
3.8
4.0
4.1
4.3
4.5
4.7
5.0
5.2
5.7
6.4
8
4.4
4.6
4.8
5.0
5.2
5.4
5.7
6.0
6.6
7.3
9
5.0
5.2
5.4
5.6
5.9
6.1
6.4
6.8
7.4
8.2
10
5.5
5.7
6.0
6.2
6.5
6.8
7.2
7.5
8.3
9.2
11
6.1
6.3
6.6
6.9
7.2
7.5
7.9
8.3
9.1
10.1
12
6.7
6.9
7.2
7.5
7.9
8.2
8.6
9.1
10.0 11.0
13
7.2
7.5
7.8
8.2
8.5
8.9
9.4
9.8
10.8 12.0
14
7.8
8.1
8.4
8.8
9.2
9.6
10.1 10.6 11.6 12.9
15
8.4
8.7
9.0
9.4
9.9
10.3 10.8 11.4 12.5 13.8
16
8.9
9.3
9.7
10.1 10.5 11.0 11.6 12.1 13.3 14.7
17
9.5
9.9
10.3 10.7 11.2 11.7 12.3 12.9 14.2 15.7
18
10.1 10.5 10.9 11.4 11.9 12.4 13.0 13.7 15.0 16.6
19
10.6 11.0 11.5 12.0 12.5 13.1 13.7 14.5 15.9 17.5
20
11.2 11.6 12.1 12.6 13.2 13.8 14.5 15.2 16.7 18.5
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1.1
6.1

1.2
6.8

1.3
7.3

1.4
9.1

0.9
1.9
3.0
4.0
5.0
6.1
7.1
8.2
9.2
10.2
11.3
12.3
13.4
14.4
15.4
16.5
17.5
18.6
19.6
20.6

1.0
2.2
3.4
4.6
5.7
6.9
8.1
9.3
10.4
11.6
12.8
14.0
15.2
16.3
17.5
18.7
19.9
21.0
22.2
23.4

1.1
2.3
3.5
4.7
5.9
7.2
8.4
9.6
10.8
12.0
13.2
14.5
15.7
16.9
18.1
19.3
20.6
21.8
23.0
24.2

1.1
2.3
3.5
4.7
5.9
7.2
8.4
9.6
10.8
12.0
13.2
14.5
15.7
16.9
18.1
19.3
20.6
21.8
23.0
24.2

Table 8. Lookup table to determine the required concentrations of absorbing and scattering
agents from desired absorption and reduced scattering coefficients at 731 nm (Greening et al.,
2014).
Absorption Coefficient µa [cm-1]
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g]
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.0
1.5
1.9
2.4
2.8
3.3
3.8
4.3
5.1
5.8
Reduced Scattering Coefficient µʹs [cm-1]
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3
1
0.5
0.5
0.5
0.6
0.6
0.6
0.7
0.7
0.8
0.9
2
1.1
1.2
1.2
1.3
1.3
1.4
1.4
1.5
1.7
1.8
3
1.7
1.8
1.9
1.9
2.0
2.1
2.2
2.4
2.6
2.8
4
2.3
2.4
2.5
2.6
2.7
2.9
3.0
3.2
3.5
3.8
5
2.9
3.1
3.2
3.3
3.5
3.6
3.8
4.0
4.4
4.8
6
3.6
3.7
3.8
4.0
4.2
4.4
4.6
4.9
5.3
5.8
7
4.2
4.3
4.5
4.7
4.9
5.1
5.4
5.7
6.2
6.8
8
4.8
5.0
5.2
5.4
5.6
5.9
6.1
6.5
7.1
7.7
9
5.4
5.6
5.8
6.1
6.3
6.6
6.9
7.4
8.0
8.7
10
6.0
6.2
6.5
6.8
7.0
7.4
7.7
8.2
8.9
9.7
11
6.6
6.9
7.1
7.4
7.8
8.1
8.5
9.0
9.8
10.7
12
7.2
7.5
7.8
8.1
8.5
8.9
9.3
9.9
10.7 11.7
13
7.9
8.1
8.5
8.8
9.2
9.6
10.1 10.7 11.6 12.7
14
8.5
8.8
9.1
9.5
9.9
10.4 10.8 11.5 12.5 13.6
15
9.1
9.4
9.8
10.2 10.6 11.1 11.6 12.3 13.4 14.6
16
9.7
10.1 10.5 10.9 11.3 11.9 12.4 13.2 14.3 15.6
17
10.3 10.7 11.1 11.6 12.1 12.6 13.2 14.0 15.2 16.6
18
10.9 11.3 11.8 12.3 12.8 13.3 14.0 14.8 16.1 17.6
19
11.5 12.0 12.4 12.9 13.5 14.1 14.8 15.7 17.0 18.6
20
12.1 12.6 13.1 13.6 14.2 14.8 15.5 16.5 17.9 19.5
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1.1
6.5

1.2
7.3

1.3
9.3

1.4
17.3

1.0
2.0
3.1
4.2
5.3
6.4
7.5
8.5
9.6
10.7
11.8
12.9
13.9
15.0
16.1
17.2
18.3
19.4
20.4
21.5

1.0
2.2
3.4
4.5
5.7
6.8
8.0
9.2
10.3
11.5
12.6
13.8
15.0
16.1
17.3
18.4
19.6
20.8
21.9
23.1

1.0
2.2
3.4
4.5
5.7
6.8
8.0
9.2
10.3
11.5
12.6
13.8
15.0
16.1
17.3
18.4
19.6
20.8
21.9
23.1

1.0
2.2
3.4
4.5
5.7
6.8
8.0
9.2
10.3
11.5
12.6
13.8
15.0
16.1
17.3
18.4
19.6
20.8
21.9
23.1

Table 9. Lookup table to determine the required concentrations of absorbing and scattering
agents from desired absorption and reduced scattering coefficients at 851 nm (Greening et al.,
2014).
Absorption Coefficient µa [cm-1]
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g]
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.0
1.7
2.4
3.1
3.8
4.4
5.2
5.9
6.7
7.7
Reduced Scattering Coefficient µʹs [cm-1]
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3
1
0.6
0.6
0.7
0.7
0.7
0.7
0.8
0.8
0.8
0.8
2
1.4
1.4
1.4
1.5
1.5
1.6
1.6
1.7
1.8
1.8
3
2.1
2.1
2.2
2.3
2.4
2.4
2.5
2.6
2.7
2.8
4
2.8
2.9
3.0
3.1
3.2
3.3
3.4
3.5
3.7
3.7
5
3.6
3.7
3.8
3.9
4.0
4.1
4.3
4.4
4.6
4.7
6
4.3
4.4
4.5
4.7
4.8
5.0
5.2
5.4
5.6
5.7
7
5.0
5.2
5.3
5.5
5.7
5.8
6.0
6.3
6.5
6.6
8
5.8
5.9
6.1
6.3
6.5
6.7
6.9
7.2
7.5
7.6
9
6.5
6.7
6.9
7.1
7.3
7.5
7.8
8.1
8.4
8.6
10
7.2
7.4
7.7
7.9
8.1
8.4
8.7
9.0
9.4
9.5
11
8.0
8.2
8.4
8.7
9.0
9.2
9.6
9.9
10.3 10.5
12
8.7
9.0
9.2
9.5
9.8
10.1 10.4 10.8 11.3 11.4
13
9.4
9.7
10.0 10.3 10.6 10.9 11.3 11.7 12.2 12.4
14
10.2 10.5 10.8 11.1 11.4 11.8 12.2 12.7 13.2 13.4
15
10.9 11.2 11.6 11.9 12.3 12.6 13.1 13.6 14.1 14.3
16
11.6 12.0 12.3 12.7 13.1 13.5 14.0 14.5 15.1 15.3
17
12.4 12.7 13.1 13.5 13.9 14.3 14.8 15.4 16.0 16.3
18
13.1 13.5 13.9 14.3 14.7 15.2 15.7 16.3 17.0 17.2
19
13.9 14.2 14.7 15.1 15.6 16.0 16.6 17.2 17.9 18.2
20
14.6 15.0 15.4 15.9 16.4 16.9 17.5 18.1 18.8 19.2

1.1
9.6

1.2
12.9

1.3
18.4

1.4
27.4

0.8
1.8
2.8
3.7
4.7
5.7
6.6
7.6
8.6
9.5
10.5
11.4
12.4
13.4
14.3
15.3
16.3
17.2
18.2
19.2

0.8
1.8
2.8
3.7
4.7
5.7
6.6
7.6
8.6
9.5
10.5
11.4
12.4
13.4
14.3
15.3
16.3
17.2
18.2
19.2

0.8
1.8
2.8
3.7
4.7
5.7
6.6
7.6
8.6
9.5
10.5
11.4
12.4
13.4
14.3
15.3
16.3
17.2
18.2
19.2

0.8
1.8
2.8
3.7
4.7
5.7
6.6
7.6
8.6
9.5
10.5
11.4
12.4
13.4
14.3
15.3
16.3
17.2
18.2
19.2

3.6.6 Extraction of sampling depth from semi-infinite phantom model of dysplastic
progression
Three different phantom geometries, simulating the progression from healthy tissue to
severe dysplasia, underwent DRS evaluation using both SDSs (374 and 730 µm). Figure 19
shows that the extracted µs’ for phantom 1 (blue line) was approximately 7 cm-1 at 630 nm, as
expected from the phantom generation protocol (Greening et al., 2014). As the higher scattering
(µs’ = 14 cm-1) layers proliferated upwards towards the probe tip (phantoms 2 and 3), an increase
in volume-averaged µs’ occurred for both SDSs, although more so for the shorter SDS, as
expected. For the shorter SDS, there was a significant increase in volume-averaged µs’ from
phantoms 1 to 2 and 2 to 3. However, for the longer SDS, there was only a significant increase in
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volume-averaged µs’ from phantoms 2 to 3. This indicates the 374 µm SDS is more sensitive to
scattering heterogeneities at upper layers compared to the 730 µm SDS.
This phenomenon is further quantified in Table 10 by the percent increase in volumeaveraged µs’ at 630 nm for Phantoms 1-3 for each SDS. The data indicates that the µs’ percent
increase for the 374 µm SDS is significantly greater compared to the 730 µm SDS. This is
because the shorter SDS has a decreased sampling depth, and therefore scattering is mostly
affected by more superficial heterogeneities, as seen in early dysplasia, compared to the longer
SDS. However, it is important to note that the 374 µm SDS still does not exclusively sample the
upper layers, as indicated by the fact that the volume-averaged µs’ of phantom 3 (300 µm thick
heterogeneity) is approximately 9 cm-1 rather than 14 cm-1 at the reference 630 nm. Additionally,
sampling depth of the 374 µm SDS at a µs’ of 14 cm-1 is ~400 µm, indicating a sampling depth
deeper than the 300 µm scattering heterogeneity. These results demonstrate the value of
including a shorter SDS for detection of more superficial scattering changes. The value of
including an additional longer SDS was shown in the following section describing in vivo results
from healthy human oral mucosa.
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Figure 19. The volume-averaged µs’ (a, b) increased as the proliferating
scattering heterogeneity moved upwards towards the phantom surface (going
from P1 to P3) showing a vertical line at 630 nm, in which percent increase in
volume-averaged µs’ was measured from. There was a significantly greater µs’
increase in these values for the 374 µm SDS compared to the 730 µm SDS,
indicating that the shorter SDS is more sensitive to superficial scattering changes
associated with early epithelial dysplasia.
Table 10. Paired t-test statistics for percent increases in µs’ (λ = 630 nm) for dysplasiamimicking phantom model
374 μm SDS (n=10)
730 μm SDS (n=10)
Phantom
Significance
P-Value
Comparison
(Y/N), α=0.01
Mean
Std. Dev. Mean
Std. Dev.
-4
P1 to P2 (%)
4.97
0.40
1.42
1.93
1.7x10
Y
P2 to P3 (%)
16.18
5.95
9.19
1.54
4.6x10-3 Y
P1 to P3 (%)
21.96
6.42
10.72
0.93
1.2x10-4 Y
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3.6.7 Collaboration with the Boston University Department of Biomedical Engineering: twolayer LUT improves the accuracy of tumor layer optical property extractions using SFDI
The following section was directly adapted from Syeda Tabassum, Vivian Pera and
Darren Roblyer from Boston University, with whom we provided tissue-simulating PDMS
phantoms for their experiments (Tabassum et al., 2018).
Experimental measurements were conducted to determine if the Gardner two-layer LUT
inversion algorithm improves the accuracy of tumor layer optical property extractions compared
to the Gardner homogeneous LUT. This accuracy test utilized the four two-layer phantoms
described in Section 3.5.5. Each of the two-layer phantoms used the same top (skin) layer. The
measured thickness of the skin layer was 310 μm at its center, which is within 0.8% of the skin
layer thickness defined in the MC simulations used to generate the Gardner two-layer LUT.
Absorption of the skin layer was 0.0936 mm−1 at 659 nm, which is within 2.52% of the MC
absorption parameter, and the μ0s value was 0.780 mm−1 at 659 nm, which is within 0.063% of
the MC value. For the tumor layer, four different pairs of optical properties were utilized,
spanning a range of optical properties observed in our prior work, in which we monitored
PC3/2G7 mouse xenografts over 45 days using SFDI (Tabassum et al., 2016). These pairs are
labeled as tumor 1 through tumor 4 in Figure 10. The optical property pairs, reported at 659 nm,
are as follows: for tumor 1: μa ¼ 0.0244 mm−1 and μ0 s ¼ 2.054 mm−1; tumor 2: μa ¼ 0.002
mm−1 and μ0s ¼ 2.314 mm−1; tumor 3: μa ¼ 0.0039 mm−1 and μ0s ¼ 0.714 mm−1; and tumor
4: μa ¼ 0.0301 mm−1 and μ0s ¼ 0.676 mm−1.
Each two-layer phantom was measured with SFDI, and the bottom (tumor) layer optical
properties were extracted using both the Gardner homogeneous and Gardner two-layer LUTs.
Since these phantoms have flat surfaces, no corrections for height or angle were implemented.
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The absolute differences between the measured and true μa for the tumor layer are shown in
Figures 10(a) and 10(b). The absolute differences between the measured and true μ0s for the
tumor layer are shown in Figures 5(c) and 5(d). In both cases, Figures 10(b) and 10(d)
recapitulates the data in Figures 10(a) and 10(c) but with a zoomed-in y-axis to allow
visualization of the small error values obtained for some phantoms. In the worst-case, the μa and
μ0 s extraction errors were 20.33% and 10.87% for the two-layer LUT.
In all cases, the error in tumor layer optical property extraction is substantially lower for
the two-layer LUT versus the homogeneous LUT. This effect is not as pronounced in μ0s for
tumors 3 and 4, as μ0s values in these tumors are very similar to that of the skin layer (μ0 s ¼
0.78 mm−1). Note that the decrease in error by the two-layer LUT is between 7 and 256 times
for μa and between 2 and 24 times for μ0s. Taken together, these results confirm that the twolayer LUT provides a better estimate of the true tumor layer optical properties than the
homogeneous LUT (Tabassum et al., 2018).
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Figure 20. Comparisons in bottom (tumor) layer optical property extraction errors
for the Gardner homogeneous and Gardner two-layer LUT inversion algorithms.
Diffuse reflectance measurements of four two-layer tissue-simulating optical
phantoms were made with SFDI, and both inversion models were used to extract
the bottom (tumor) layer optical properties (labeled as tumors 1 to 4). (a) The
absolute extraction error compared with the known tumor layer μa. (b) The same
data but with a zoomed-in y-axis so that small extraction errors can be visualized.
(c) Absolute errors in tumor layer μ0s extractions and (d) the same data with a
zoomed-in y-axis. Optical properties were measured at 659 nm (Tabassum et al.,
2018).
3.7 How-to guide: solid phantoms as tools for simulating epithelial structure
Presented in this section is a tutorial for constructing solid phantoms. These phantoms
can be used to simulate thin epithelial tissue 100’s of microns thick. Thin layers can be stacked
to mimic the geometry of layered epithelia, such as in the epidermis and dermis of skin. Different
types of scattering and absorbing agents can be added to the solid phantoms to mimic an array of
μs’ and μa. Furthermore, these solid optical phantoms can easily be molded into a variety of
thicker shapes and inclusions/heterogeneities can be added for various purposes. Therefore, these
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phantoms are a robust, multipurpose tool for a variety of imaging and spectroscopy applications.
3.7.1 Constructing the PDMS-based mix
The substrate material used to construct the following optical phantoms is
polydimethylsiloxane (PDMS), a thermoset polymer. PDMS-based phantoms have been used by
investigators for various purposes including epithelial tissue simulation (Greening et al., 2014;
Wang et al., 2011), retina-simulating phantoms (Fogli et al., 2014), aorta models (Schlicht et al.,
2013), and other soft tissues (Avigo et al., 2015) for various imaging purposes.
To construct these PDMS-based phantoms, an aliquot of PDMS elastomer base
(Sylgard® 184 Silicone Elastomer Base) is poured into a plastic mixing cup. Depending on the
application, less volume of elastomer base is needed for thinner layers (~150-300 μm) versus
slightly thicker layers (300+ μm). After dispensing the PDMS elastomer base, the scattering and
absorbing agents can be added. Scattering agents can be a variety of substances, such as TiO2 or
polystyrene microspheres. Absorbing agents can also be a variety of substances including dyes
and inks. The examples for this tutorial will use TiO2 (14021, Sigma Aldrich, USA) and watersoluble nigrosin (N4763, Sigma Aldrich, USA) as the scattering and absorbing agents,
respectively. Before adding the curing agent, it is important to thoroughly mix the elastomer base
and optical agents. Mixing can be done by hand or in an appropriate automated mixing machine.
Once mixed, the appropriate amount of curing agent (Sylgard® 184 Silicone Elastomer Curing
Agent) should be added to the mix. The amount of curing agent needed is a 1:10 mass-to-mass
ratio of curing agent to elastomer base (Greening et al., 2014). It is recommended to use a
reliable micropipette to add in the appropriate amount of curing agent to the mix. Immediately
following addition of curing agent, the curing process will begin. Therefore, it is imperative to
mix the curing agent into the PDMS elastomer base immediately either by hand or with an
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automated mixing machine. Some mixing machines contain a “degassing” feature, in which the
recovered mixed product is free of air bubbles. If mixing the elastomer base, curing agent, and
scattering and absorbing agents by hand, the resultant mix must be fully degassed using a
vacuum for at least 90-120 minutes. Furthermore, the PDMS must always be vacuumed to create
a spatially homogenous solution free of air bubbles after dispensing into a mold.
Curing PDMS at room temperature takes between 48-72 hours. Curing can be accelerated
by placing the fully mixed and degassed solution into an oven. Placing the mix inside an oven at
70°C will cure the mix in 2 hours. Furthermore, if needed, curing can be halted by placing the
mix in a sub-0°C freezer.
Figure 21 shows the process for creating bulk PDMS-based phantoms, including the
viscous, pre-cured PDMS elastomer base, the addition of TiO2 as the scattering agent and water
soluble nigrosin as the absorbing agent.

Figure 21. A demonstration of the process to create PDMS-based phantoms with
TiO2 and water-soluble nigrosin. The figure shows (a) PDMS elastomer base with
no mixed components, (b) TiO2 mixed in the PDMS elastomer base, and (c),
water-soluble nigrosin mixed in the PDMS elastomer base.
Since PDMS is a viscous polymer prior to curing into a permanent solid polymer, it can
be molded into a variety of shapes and sizes. Figure 22 shows an example of a PDMS-based
phantom, containing TiO2 and water-soluble nigrosin, molded into a cylinder 28 mm in diameter
and 50 mm in height. The cylinder had a μs’ of 4.75 cm-1 and μa of 0.25 cm-1 at a reference of
633 nm. One 6.35-diameter hole was drilled into the top of the phantom 30 mm deep. The drilled
184

hole was filled with PDMS-based phantom mix with a μs’ of 4.75 cm-1 and μa of 5.0 cm-1, so that
scattering was constant, and absorption was increased by a factor of 20. This demonstration
shows that heterogeneities or inclusions can be added to a solid-PDMS phantom to potentially
simulate a variety of tissue types for different imaging or spectroscopic applications.

Figure 22. PDMS-based phantoms molded into three-dimensional structures. The
figure shows (a) PDMS molded into the shape of a finger, (b) a PDMS optical
phantom with 5 mm-diameter holes drilled 5 cm deep for the addition of optical
inclusions, and (c) a block of PDMS containing TiO2 and water-soluble nigrosin
that can be used as a “semi-infinite” layer in which thin PDMS phantom layers
can be stacked.
3.7.2 Spin coating technique for creation of thin phantoms
In addition to using PDMS to create bulk tissue phantoms, thin phantoms, down to
approximately 100 μm or thinner, can also be constructed (Greening et al., 2014; Koschwanez et
al., 2009). These thin phantoms can be stacked to create semi-permanent multilayer phantoms.
These multilayer phantoms are semi-permanent because each individual layer is optically stable
over time, but each layer can be switched out for additional layers. This gives investigators the
freedom to mix and match stable layers of varying optical properties and thicknesses.
Optical properties of these PDMS-based phantoms are controlled with the addition of
scattering and absorbing agents. The scattering properties can be controlled by obtaining a LUT
showing μs’ as a function of scattering agent concentration, other empirical methods presented in
literature, or Mie Theory. The absorbing properties can be controlled by evaluating the μa of
dilute solutions of the absorbing agent using a spectrophotometer and Beer’s Law.
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Layer thickness is controlled using a custom spin coating technique. Immediately after
the PDMS-reagent mixture has completed the mixing and degassing steps outlined in the
previous section, a quarter-sized amount is transferred to an unmodified silicon wafer. These
wafers are 500 microns in depth, with a diameter of 100 millimeters. The wafer is then placed
within a spin coating machine and spun at an appropriate rotational speed (RPM) to yield the
desired layer thickness. For our purposes, the spin coater spins the silicon wafer at maximum
speed for 20 seconds, with a 2 second acceleration and deceleration period. Immediately after
curing, the still-viscous spun layer of PDMS is transferred to a 70°C oven where it is allowed to
complete the curing process for 2 hours. Several groups have used spin coating methods to
produce thin phantom layers and their specific target thicknesses can be found elsewhere
(Koschwanez et al., 2009; Greening et al., 2014).
For this tutorial, it is important to note the parameters that affect layer thickness using a
spin coater. First, maximum speed affects layer thickness. The faster the silicon wafer spins the
PDMS mix, the thinner the resultant layer. Second, duration of speed affects layer thickness. A
shorter spin duration increases layer thickness whereas a longer spin duration decreases layer
thickness. Third, the temperature of the PDMS mix prior to mixing affects resultant layer
thickness. Since PDMS is a thermoset, the higher the temperature prior to spinning, the thicker
the layer since the polymer will begin to resist mechanical forces throughout curing. A colder
pre-spun mix will result in thinner layers. Fourth, the post-spinning curing temperature will
affect thickness. Since the PDMS will not have fully cured after spinning, it will continue to
slightly settle and spread out post-spinning. Therefore, the higher the temperature post spinning,
the thicker the resultant layer. Fifth, additives to the PDMS mix will affect layer thickness. One
group has shown that adding in a type of alcohol results in thinner layers when holding all other
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variables constant (Koschwanez et al., 2009). Additionally, adding in varying amounts of
scattering and absorbing agents may affect resultant thickness, although this has not been
extensively investigated at this time. The next few factors are timing factors, since the curing
process is time sensitive. In all cases, increased time between steps results in thicker layers.
These factors include the time between mixing the curing agent with the elastomer base and
spinning with the spin coater, and the time between mixing with the spin coater and placing in
the oven to finalize the curing process.
The spin coating method for creating phantoms is extremely useful and important. It is,
for this process, what allows there to be multiple layer thicknesses to simulate different depths
within epithelial tissues. It also allows for a simple way of creating multi-layer phantoms to
quickly and easily vary a simulation of different depths within epithelial tissues by stacking a
pre-made, set number of individual thin phantoms (Greening et al., 2014).
Figure 23 shows the process of creating thin PDMS-based phantoms. The uncured
viscous PDMS-phantom mix, with μs’ of 4.75 cm-1 and μa of 0.25 cm-1 at a reference of 633 nm,
is poured onto a silicon wafer. The silicon wafer is placed into a spin coating machine which
spins the uncured PDMS at a user-specified speed. The uncured PDMS spreads out, becoming
thinner. The uncured, thinned PDMS-phantom is then placed in an oven to finish curing, and
afterwards a piece can be cut to various geometries. In this example, the resultant cured phantom
was 300 µm and approximately 2 cm2.
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Figure 23. The process of creating thin PDMS-based optical phantoms. The
figure shows the (a) silicon wafer with uncured the uncured PDMS mix (scale bar
=3 cm), (b) silicon wafer inside the spin coating machine, (c) uncured PDMS mix
after being spun down in the spin coating machine (scale bar =3 cm), and (d)
cured 300 µm thick phantom cut to a 2 cm2 square with μs’ of 4.75 cm-1 and μa of
0.25 cm-1 at a reference of 633 nm to simulate Caucasian epidermal tissue (scale
bar = 7.5 mm).
Figure 24 shows more examples of thin PDMS-based optical phantoms. Figure 24(a)
shows three 270 μm thick phantoms with increasing concentration of TiO2, corresponding to μs’
values of 4.6, 8.2, and 21.5 cm-1 and a μa of 0 cm-1 at 633 nm. Figure5(b) shows an image of a
large base phantom layer with μs’ and μa of 4.75 cm-1 and 0.25 cm-1 at 633 nm. One top of this
base layer are four optically heterogeneous 100 μm-thick PDMS-based phantoms with μs’ and μa
of 4.75 cm-1 and 5.00 cm-1 at 633 nm. To demonstrate the ability to create semi-permanent
multilayer phantoms, the four optical heterogeneous layers have either zero, one, two, or three
100 μm-thick layers that have identical optical properties to the base layer (μs’ = 4.75 cm-1 and μa
= 0.25 cm-1 at 633 nm). This demonstrates the ability of thin PDMS-based phantom layers to be
stacked in various arrangements to create multilayer phantoms with optical heterogeneities. In
this case, the optical heterogeneities had a 20x increase in absorption for demonstrative purposes,
although in real tissue, heterogeneities may not be as optically different (Greening et al., 2014;
Salomatina et al., 2006).
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Figure 24. This figure shows (a) three non-absorbing 270 µm thick phantom
layers, each approximately 1.5 cm2, with increasing µs’ (4.6, 8.2, and 21.5 cm-1)
due to increased concentrations of titanium dioxide (TiO2) and μa = 0 cm-1, and
(b) a 6 cm-diameter “semi-infinite” layer (μs’ = 4.75 cm-1, μa = 0.25 cm-1 at 633
nm) with various thin stacked phantoms on top. At each quadrant, there exists a
highly absorbing inclusion (μs’ = 4.75 cm-1, μa = 5.00 cm-1 at 633 nm) with either
0, 1, 2, or 3 overlying 100 μm thick layers with optical properties (μs’ = 4.75 cm-1,
μa = 0.25 cm-1 at 633 nm) matching that of the underlying “semi-infinite” layer.
3.8 Discussion
3.8.1 PDMS as a substrate material
We have demonstrated a reproducible method for creating thin PDMS-based phantoms
with tunable thickness and optical properties (reduced scattering and absorption coefficients) (de
Bruin et al., 2010; Saager et al., 2010; Pogue et al., 2006; Ayers et al., 2008; Sandell et al.,
2011; Liu et al., 2006; Bae et al., 2013). PDMS, a silicone based polymer, was chosen as the
substrate material due to its relatively long optical stability when compared to other commonly
used substrates (de Bruin et al., 2010; Pogue et al., 2006). Bruin et al. demonstrated that optical
properties of PDMS-based phantoms using TiO2 as a scattering agent remained stable over a six
month testing period (de Bruin et al., 2010). Pogue et al. reports that silicone-based phantoms
with TiO2 and various inks should have an optical stability of at least one year (Pogue et al.,
2006). Furthermore, PDMS is optically clear, easily moldable, and has a comparable refractive
index (1.4) to human tissue (de Bruin et al., 2010; Saager et al., 2010; Pogue et al., 2006).
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3.8.2 Spin coating to produce individual thin layers
We demonstrated an ability to create both thin phantom layers (between 115 and 880 μm)
and thick phantom layers (approximately 2.5 cm thick). Thick phantoms could be made at other
thicknesses as well by varying the volume dispensed into the ARE-100 conditioning mixer cup
(Intertronics, UK) mold.
To create thin phantom layers, a spin coating technique was used to spin partially cured
PDMS down to reproducible thicknesses as shown in Figure 11 (Bae et al., 2013; Koschwanez et
al., 2009). Koschwanez et al. have previously outlined a spin coating technique to create multilayered PDMS phantoms by spinning uncured PDMS over an already cured layer. However,
their thin phantoms ranged between 2 and 30 μm, much thinner than our intended range (100300 μm) for mimicking epithelial tissue thickness (Harris et al., 1992; Chang et al., 2012;
Guimarães et al., 2007; Rocha et al., 2010). Furthermore, our method allowed for thin layers to
be used interchangeably and non-permanently to rapidly test multiple configurations. In our
studies, the relationship between the maximum 20 second spin speed of the spin coater and the
resulting thickness of cured, individual PDMS layers containing varying amounts of TiO2 and
1% w/v nigrosin/EtOH can be seen in Figure 11. Spin speeds of 100 rpm produced phantoms
with an average thickness of 880 µm and standard deviation of 34 µm. Spin speeds of 1000 µm
produced phantoms with an average thickness of 115 µm and standard deviation of 4 µm. As
spin speed increased, thickness decreased, and standard deviation tended to decrease. For
researchers interested in using this technique, the following inverse equation (Eq. 3), based on
data presented here, can be used as a guideline to estimate the necessary spin speed [rpm] given a
desired thickness with relative accuracy,
𝑠 = 115,900 ∙ (𝑡 −0.9985 ) − 15.09

(3)
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where t is the desired thickness [µm] and s is the resulting spin speed [rpm]. The R2 value for
this equation is 0.988 for the data presented in this manuscript. This equation (Eq. 3) was
generated by the MATLAB curve fitting toolbox using a 2-term power model.
One consideration when using this spin coating technique is the potential non-uniformity
of absorbing and scattering agents within the PDMS material. Heterogeneities in these materials
may result at increasing radial distances due to the rotational acceleration of the spin coater
(Saager et al., 2010). This may also mean that thin phantoms of identical concentrations of
optical agents, but different thicknesses may have slightly different optical properties. Since
SFDI required thick phantoms (> 2.5 cm) for characterization, optical properties of thin layers
were not explicitly measured (Cuccia et al., 2009). However, from data presented in Figure 16
and 17, we are reasonably confident that thin layers have bulk scattering and absorbing
properties comparable to the thicker layers characterized by SFDI. To definitively validate thin
layer uniformity, methods capable of characterizing optical properties of thin layers, such as
integrating spheres and Inverse Adding-Doubling (IAD) methods, must be further explored
(Prahl et al., 1993; Pickering et al., 1993). Another limitation to this procedure was creating
phantoms with a lower limit of approximately 115 μm. While thinner layers could potentially be
produced using our spin coating technique, such thin layers were increasingly difficult to work
with by hand and could no longer be considered interchangeable with regards to creating
multilayered phantoms. Therefore, applications in need of phantoms thinner than 115 μm, such
as retinal imaging, may benefit from other spin coating techniques such as those presented by
Bae et al. or Koschwanez et al. that can produce much thinner layers (Bae et al., 2013; Chang et
al., 2012; Baxi et al., 2014).
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3.8.3 Alcohol-soluble nigrosin as an absorbing agent
The absorption coefficient (µa) of PDMS phantoms was manipulated by using alcoholsoluble nigrosin as the absorbing agent (Saager et al., 2010; Liu et al., 2006). A 1% w/v solution
of nigrosin/ethanol was prepared and added to phantoms at increasing concentrations as seen in
Figure 14. Figure 15 shows that µa was independent of TiO2 concentrations. However, µa was
shown to be wavelength dependent when using 1% w/v nigrosin/EtOH for the absorbing agent.
This can be seen in Figure 14 in the difference between the best fit curves for the 591 nm
(dashed) and 851 nm (dotted) wavelengths, respectively. As wavelength increased, µa tended to
decrease. This observation is comparable to results on similar phantoms created by Saager et al
(Saager et al., 2010). In addition, µa was strongly dependent on concentration of 1% w/v
nigrosin/EtOH as expected. Figure 14 shows that a more linear region exists between 1% w/v
nigrosin/EtOH concentrations from 0 to 7 µL/g PDMS elastomer base, corresponding to µa
values between approximately 0 and 0.9-1.2 cm-1 depending on the measured wavelengths.
Increases in µa began to level off for 1% w/v nigrosin/EtOH concentrations between 7 to 40 µL/g
PDMS elastomer base, corresponding to µa values between approximately 0.9-1.2 and 1.5 cm-1.
Just as in the case of the previous thickness-spin speed relationship (Eq. 3), a useful
inverse equation would be one that estimates the necessary concentration of 1% w/v
nigrosin/EtOH in PDMS given a desired µa. Because µa was shown to be dependent on both
absorbing concentration and wavelength, a simple inverse equation was not found. Instead, the
relationship between absorbing agent concentration and desired µa was modeled by a piecewise
function for each of the six studied wavelengths (591, 631, 659, 691, 731, and 851 nm). This set
of equations, generated by the MATLAB curve-fitting toolbox, was used to create the lookup
tables found in the appendix. However, it should be noted that these equations and corresponding
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lookup tables, generated from our limited sample size of 16 PDMS-based phantoms (Table 1),
should just be used as guidelines. Exact µa values cannot be accurately predicted due to our lack
of extensive validation testing so optical properties should always be independently validated.
One of the major drawbacks to using alcohol-soluble nigrosin as the absorber was its
hydrophilic nature. The alcohol-soluble nigrosin did not mix easily with the silicone base
material used to produce PDMS. To account for this, Bisaillon et al. and Bruin et al. both suggest
mixing hexane with PDMS (de Bruin et al., 2010; Bisaillon et al., 2008). However, Koschwanez
et al. suggested that adding hexane swells the PDMS substrate, and instead mixed tert-butyl
alcohol with PDMS (Koschwanez et al., 2009). Using a certain percent tert-butyl alcohol within
the PDMS substrate may aid in more efficient mixing of alcohol-soluble nigrosin and should be
explored in future studies. If this is to be done, however, new thickness-spin speed curves (see
Figure 11) would need to be generated between 100 and 1000 rpm for tert-butyl alcohol infused
PDMS (Koschwanez et al., 2009). However, our described procedure accounted for mixing
difficulties by thoroughly mixing 1% w/v nigrosin/EtOH in PDMS with a sonicator, vortex
mixer, and an ARE-100 conditioning mixer. Another limitation for the phantoms presented here
was a characteristic peak in absorption in the 870-930 nm range when using nigrosin-silicone
based tissue phantoms (Saager et al., 2010). Because our SFDI analysis only covered a
wavelength range up to 851 nm, this phenomenon was not observed. Therefore, for our purposes,
the procedure presented here to manipulate µa using alcohol-soluble nigrosin is sufficient.
Finally, other absorbing agents such as whole blood, inks, dyes, or fluorophores may be
investigated either as the single absorber or in combination with each other in the outlined
procedure for phantom construction (Saager et al., 2010; Pogue et al., 2006).
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3.8.4 Titanium dioxide as a scattering agent
The reduced scattering coefficient (µʹs) of PDMS phantoms was manipulated by using
titanium dioxide (TiO2) as the scattering agent (Saager et al., 2010). The µʹs of PDMS phantoms
was shown to be dependent on TiO2 concentration (Figure 12), wavelength (Figure 12), and 1%
w/v nigrosin/EtOH concentration (Figure 13). The dependence of µʹs on scattering agent
concentration and wavelength has been demonstrated in previous phantom studies (de Bruin et
al., 2010; Saager et al., 2010). Depending on the wavelength, Figure 12 shows that phantoms
were produced with reduced scattering coefficients between approximately 1 and 20 cm-1.
However, Figure 13 shows that as 1% w/v nigrosin/EtOH concentration increased, µʹs decreased
in phantoms with identical concentrations of TiO2 (Phantoms #1, 9-15 in Table 1). Furthermore,
the decline of µʹs due to increased concentration of 1% w/v nigrosin/EtOH was greater at lower
wavelengths (591 and 621 nm) when compared to higher wavelengths (731 and 851 nm).
Furthermore, in Figure 13, once a certain concentration of 1% w/v nigrosin/EtOH was reached
(around 7 µL/g), further changes in wavelength and concentration did not affect µʹs.
The roughly linear relationship between µʹs and absorbing agent concentration over the
tested wavelengths (Figure 13) implies there may exist an empirically determined correction
factor that could account for all variables (TiO2 concentration, wavelength, and 1% w/v
nigrosin/EtOH concentration) that affect µʹs. Thus, given a desired wavelength, µa, and µʹs, the
necessary TiO2 concentration was analytically determined. Therefore, for researchers interested
in manipulating µʹs within PDMS phantoms, the provided lookup tables can predict TiO2
concentration based on data presented in this paper. Of note, however, in Figure 13, the
phenomenon that increasing 1% w/v nigrosin/EtOH concentration reduced µʹs was only observed
in phantoms with minimal TiO2 concentration (0.001 g TiO2/g PDMS elastomer base). Further
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studies will need to be completed to validate the lookup tables presented here and determine
whether this phenomenon is prevalent in phantoms with much higher TiO2 concentrations, such
as 0.007 or 0.008 g TiO2/g PDMS elastomer base. It should also be noted that the lookup tables
assume a linear relationship in µʹs and TiO2 concentration beyond the tested limits (0.001 – 0.008
g/g). Further SFDI analysis will be needed to validate these values within the lookup table.
Finally, it is possible to expand this approach by using scattering agents other than TiO2.
Scattering materials such as polystyrene beads, silicon dioxide, aluminum oxide powders or
other types of microspheres have been successfully demonstrated by other investigators and
could potentially be applied using our spin coater approach (de Bruin et al., 2010; Pogue et al.,
2006; Kanick et al., 2012; Passos et al., 2005).
3.8.5 Multi-layered phantoms to simulate heterogeneities
Generally, the purpose of multi-layered phantoms is to introduce geometrical and optical
heterogeneities in phantoms to simulate the layered structure of epithelial tissue (de Bruin et al.,
2010; Pogue et al., 2006). A multi-layered phantom (Table 2, Phantom #18) with two thin layers
(200 µm) was compared to a control phantom (Table 2, Phantom #17) with identical
concentrations of optical agents. The µʹs and µa for the two phantoms were compared in Figure
16 and 17. Only slight differences were present between the two phantoms across the six
measured wavelengths. Figure 16, comparing µʹs, shows an average aggregate error of 7.7%.
Figure 17, comparing µa, shows an average aggregate error 10.9%. We believe these differences
were due to random error in dispensing the precise amounts of TiO2 and 1% w/v nigrosin/EtOH
solution rather than being due to air pockets between layers. This assumption was further
validated in Figure 18, which compares multi-layered phantoms to human epithelium using an
OCT B-scan technique. OCT instrumentation, operating at 1325 nm (outside the wavelength
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range of our SFDI equipment), was used for comparative purposes and was not meant to validate
optical properties of phantoms. The multi-layered phantom (Figure 18) shows no visible air
pockets between adjacent layers. These validations give us good reason to believe that creating
PDMS-based multi-layered phantoms using our procedure can serve as appropriate models of
various epithelium. In addition to providing evidence for the absence of air pockets, B-scans in
Figure 18 were used for visually comparing thicknesses of phantoms to several types of
epithelium (Higgins et al., 2014).
The comparative images shown in Figure 18 as well as the data from Figure 11 show that
the thickness of individual PDMS layers accurately modeled the thickness of several types of
human epithelium (skin from the finger or wrist and oral mucosa). In addition, we believe that
the phantom procedure presented here could potentially model the thickness of other epithelial
tissue types, such as tongue and gingivae (100-200 μm thick, cervical epithelium (180 μm thick),
and esophageal epithelium (250 μm thick) (Harris et al., 1992; Guimarães et al., 2007; Rocha et
al., 2010).
3.9 Conclusion
To design these phantoms, lookup tables (Tables 4-9) have been provided to guide
researchers in selecting the appropriate concentrations of scattering and absorbing agents (TiO2
and 1% w/v Nigrosin/EtOH). Thick or thin (between 115 and 880 µm) phantoms can be created
by either directly molding uncured PDMS or by using the described spin coating technique. Eq.
3 provides guidance in selecting an appropriate spin speed based on a desired phantom layer
thickness. Thick and thin layers can be combined to form multi-layered phantoms to simulate
optical heterogeneities seen in tissue (Figure 16-18). In addition, individual thin layers may be
used interchangeably to test multiple configurations (Saager et al., 2010). These PDMS-based
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tissue-simulating phantoms may be used by researchers as optically stable calibration devices for
various optical imaging techniques including, but not limited to, optical coherence tomography
(OCT), diffuse optical spectroscopic imaging (DOSI), endoscopy, or microendoscopy (de Bruin
et al., 2010; Saager et al., 2010; Cerussi et al., 2012; Pogue et al., 2006; Higgins et al., 2014).
Using the provided lookup tables, these phantoms have the potential to mimic the optical
properties of common types of epithelium including breast, skin, colon, oral, cervical, and
esophagus, among others (Sandell et al., 2011; Harris et al., 1992; Guimarães et al., 2007; Rocha
et al., 2010).
A semi-infinite phantom model was used to simulate dysplastic progression in the oral
mucosa (Figure 9) (Zhu et al., 2011; Speight, 2007; Warnakulasuriya et al., 2008). Results
confirmed that the longer 374 μm SDS was more sensitive to the scattering heterogeneity at
superficial layers (Figure 19), where epithelial dysplasia is known to have a profound effect on the
scattering properties in such layers (Collier et al., 2003; Clark et al., 2004; Arifler et al., 2003).
These experiments demonstrate the potential for monitoring scattering changes associated with
early epithelial dysplasia which is often confined above the basement membrane (Warnakulasuriya
et al., 2008; Zhu et al., 2011; Speight, 2007; Bouquot et al., 2006).
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Chapter 4 (Specific Aim 3): Sampling depth of a diffuse reflectance spectroscopy probe for
in vivo physiologic quantification of murine subcutaneous tumor allografts

4.1 Introduction
Diffuse reflectance spectroscopy (DRS) is a non-invasive, spectral biopsy technique that
is used to indirectly estimate tissue optical properties and differentiate tissue types (Valdés et al.,
2017; Baltussen et al., 2017). The fundamental tissue optical properties are reduced scattering
coefficient (μs’) and absorption coefficient (μa) (Novikova, 2017). The μs’ morphologically
depends on the size, density, and orientation of scattering particles in tissue, such as the cell
membrane, cell nuclei, mitochondria, lysosomes, and collagen fibers, among others (Sandell et
al., 2011; Arifler et al., 2007). In amelanotic tissues, the μa in the visible and near infrared
spectral range functionally depends on total hemoglobin concentration and tissue oxygen
saturation (Novikova, 2017). Changes in these fundamental optical properties have been shown
to occur in neoplastic and cancerous tissue because of angiogenesis, degradation of stromal
collagen, and altered morphology of epithelial cells (Arifler et al., 2007; Arifler et al., 2003;
Lister et al., 2012). Therefore, DRS has shown promise for early cancer diagnostics, tracking
tissue response to therapy, and in intraoperative surgical guidance (Yu et al., 2014; Valdés et al.,
2017; Baltussen et al., 2017; Spliethoff et al., 2016; Spliethoff et al., 2014; Lin et al., 2000; Hu
et al., 2016).
Spliethoff et al. used DRS to track changes in optical parameters over time in a mouse
xenograft model of hereditary breast cancer in response to cisplatin chemotherapy. They showed
that treated tumors had increased StO2 compared to non-treated tumors, and concluded that DRS
provided valuable functional tissue information that correlated well with tumor treatment
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response (Spliethoff et al., 2014). This group also evaluated their fiber-optic needle-based DRS
system on human lung cancer patients undergoing a diagnostic image-guided transthoracic
needle biopsy procedure, and concluded that spectroscopic guidance enabled more accurate
needle positioning for lung biopsies (Spliethoff et al., 2016). DRS has also been clinically
applied to neurosurgery, in which Lin et al. performed DRS measurements on in vitro brain
tumors and developed a discrimination algorithm, primarily based on scattering from white
matter, with a sensitivity and specificity of 96% and 93%, respectively (Lin et al., 2000).
Recently, Hu et al. used DRS to measure tissue hypoxia in a subcutaneous mouse xenograft
model of human pharynx squamous cell carcinoma treated with radiation and found that higher
doses of radiation yielded a quicker increase in tumor oxygenation (Hu et al., 2016).
DRS probes vary greatly in terms physical geometry and sampling depth depending on
the tissue-of-interest. Physical geometry can differ in terms of probe length, probe tip diameter,
number and type of integrated optical fibers, and degree of invasiveness. For example, most DRS
probes contact the tissue surface and are considered non-invasive but contact probes have limited
sampling depth. Some groups have overcome this sampling depth limitation by creating
minimally invasive, fiber-optic needle-based DRS systems (Spliethoff et al., 2014). However,
these systems sacrifice non-invasiveness and may induce bleeding at the tip of the needle,
potentially affecting accuracy when quantifying total hemoglobin content. In non-invasive,
contact-based DRS systems, sampling depth depends on source-detector separation (SDS), or the
distance between the optical fibers delivering and collecting light. In general, as SDS increases,
sampling depth increases-due to the increased overall path length travel of the remitted photons
at a cost of progressively decreasing signal-to-noise ratio (Kanick et al., 2009; Hennessy et al.,
2014; Hennessy et al., 2013). Thus, sampling depth can be fine-tuned to collect light primarily
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from specific tissue layers, such as epithelial, stromal, or subcutaneous tumor layers. Therefore, a
relationship between raw diffuse reflectance, μs’, μa, and sampling depth must be established for
each SDS channel.
Specifically, DRS can be used in subcutaneous murine tumors, which are used for a
variety of research purposes including investigating the effects of potential therapies (He, Tian,
Li, et al., 2015). The central research question in this paper is: How can a DRS probe be
optimally designed for evaluating tissue physiological parameters in subcutaneous murine
tumors? At present, there have been no studies simultaneously quantifying wavelength- and
SDS-dependent sampling depth in DRS probes with multiple channels to sample murine
subcutaneous tumor allografts. The present study fills this knowledge gap by elaborating on
methods to quantify wavelength-dependent sampling depth and demonstrating our capability to
quantify physiologically-relevant parameters such as total hemoglobin concentration (THC) and
tissue oxygen saturation (StO2), in subcutaneous murine tumors models. Experimental methods
presented here are scalable for a variety of application-specific constraints, such as using small
SDSs for endoscopically-deployable probes within the sub-diffuse regime, where the diffuse
approximation is limited (Kanick et al., 2014).
A DRS probe was designed to interrogate subcutaneous murine tumors at increasing
sampling depths and quantify the associated optical properties. The relationship between diffuse
reflectance, μs’, μa, and SDS was experimentally established by measuring a set of tissuesimulating calibration phantoms to create lookup tables (LUTs). Then, the LUT was used as an
inverse model to fit measured spectral data and extract optical properties (Greening, James, et
al., 2016; Greening, James, Powless, et al., 2015; Greening, Rajaram, et al., 2016). DRS data at
each SDS represents a weighted average of physiological parameters collected at increasing
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depths. Therefore, a one-layer inverse experimental model was chosen to quantity volumeaveraged, rather than layer-specific, physiological parameters without assuming precise
thickness of overlying skin layers (Sharma et al., 2013). The accuracy of the probe in extracting
optical properties was determined using a second set of hemoglobin-based tissue-simulating
phantoms. Following this, the relationship between sampling depth, μs’, μa, and SDS was
experimentally established by detecting an embedded, highly-absorbing, optical heterogeneity
within tissue-simulating phantoms at incremental distances. Finally, the DRS technique was
applied to a Balb/c murine allograft model of CT26 colon carcinoma as a model for
subcutaneous mouse tumors. The µs’, µa, THC, StO2, and sampling depths were compared for
normal and tumor tissue. The central hypothesis was that this probe would simultaneously
sample the overlying epithelial skin layer as well as the subcutaneous Balb/c-CT26 tumor and
accurately extract physiologically-relevant optical parameters from each.
4.2 Materials and methods
4.2.1 Instrumentation
The DRS probe (FiberTech Optica, Kitchener, ON, Canada) consists of a brass ferrule tip
6.35 mm in diameter and 50 mm in length (Figure 1). Five multimode optical fibers (NA = 0.22
± 0.02, high-OH for wavelength range 190-1200 nm) are arranged in a slit line along the tip of
the brass ferrule, with one fiber serving as the source fiber and the remaining four fibers serving
as the detector fibers. SDSs are 0.75, 2.00, 3.00, and 4.00 mm. These optical fibers were
included to sample into the subcutaneous murine tumor at increasing sampling depths The source
fiber, as well as the 2.00, 3.00, and 4.00 SDS fibers (FiberTech Optica, SUV400/440PI) consist
of a 400/440 μm ± 2% silica core/cladding with a 470 μm ± 5% polyimide jacket. The 0.75 mm
SDS fiber (FiberTech Optica, SUV200/220PI) consists of a 200/220 μm ± 2% silica
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core/cladding with a 245 μm ± 5% polyimide jacket.
The total length of the DRS probe is 1.00 m. The distal (common) end of the probe, is
0.67 m long, and fibers are secured within a 4.8 mm outer diameter black PVC coating monocoil.
The proximal (legs) end of the probe is 0.33 m in length, and each individual fiber is secured
within a 3.0 mm outer diameter black PVC monocoil terminating in Subminiature version A
(SMA) connectors, reinforced with strain relief, to be attached to the lamp or spectrometers.
A 20W tungsten-halogen lamp (Ocean Optics, HL-2000-HP) provided broadband light
(360-2400 nm) to the 400-μm core source fiber. One spectrometer (Ocean Optics,
USB2000+VIS-NIR-ES) with a Sony ILX511B 2048-element linear silicon CCD array collected
diffusely reflected light from the 0.75 and 2.00 mm SDSs. A second spectrometer (Ocean Optics,
FLAME-S) with a Sony ILX511B 2048-element linear silicon CCD array collected diffusely
reflected light from the 3.00 and 4.00 mm SDSs. The spectral resolution of the system (Eq. 1)
was calculated by
𝑅𝑎𝑛𝑔𝑒𝑠𝑝𝑒𝑐𝑡𝑟𝑎𝑙 (𝑛𝑚)
𝑅𝑠𝑝𝑒𝑐𝑡𝑟𝑎𝑙 (𝑛𝑚) = [
] × 𝑅𝑝𝑖𝑥𝑒𝑙 (𝑝𝑖𝑥𝑒𝑙𝑠)
𝐸𝑙𝑒𝑚𝑒𝑛𝑡𝑠𝑝𝑖𝑥𝑒𝑙 (𝑝𝑖𝑥𝑒𝑙𝑠)

(1)

where Rspectral is the spectral resolution in nm, Rangespectral is the spectral range which equaled
667 nm based on each spectrometer having a grating of 600 lines/nm, Elementspixel is the number
of pixel elements which equaled 2048, and Rpixel is the pixel resolution which equaled 6.5 pixels
based on a 50 μm diameter laser cut slit within the round SMA connector (Ocean Optics,
INTSMA-KIT). This resulted in a spectral resolution of 2.1 nm. No binning was performed.
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Figure 1. The diffuse reflectance spectroscopy probe showing (a) distal optics,
(b) dimenstions of the optical fibers within the probe tip, and (c) proximal optics
showing several legs of the DRS probe, spectrometers and lamp.
4.2.2 Animal model
The study was approved by the University of Arkansas Institutional Animal Care and Use
Committee (IACUC #18060). CT26 (ATCC®, CRL-2638TM), a murine colon carcinoma cell line
derived from the Balb/c mouse strain, was maintained in Roswell Park Memorial Institute
(RPMI)-1640 medium (ATCC®, 30-2001TM) supplemented with 10% fetal bovine serum
(ATCC®, 30-2020), 1% antibiotic antimycotic solution (Sigma-Aldrich, A5955-100ML), and
0.2% amphotericin B/gentamicin (Thermo Fisher Scientific, R015010). Third passage (P3) CT26
cells were used throughout the study (Castle et al., 2014).
Ten female Balb/c mice were (strain: 000651, The Jackson Laboratory, ME, USA) aged
nine weeks were housed in groups of three in three cages in the Small Animal Facility at the
University of Arkansas. The facility was maintained at 23°C ± 1°C and 40-60% humidity on a
12:12 hour light-dark cycle. Food (8640, Teklad) and water was provided ad libitum. All nine
mice acclimated for seven days after arrival prior to the study start. After one week of
acclimation, the left flanks of the 10-week old Balb/c mice were shaved, and Nair was applied
for one minute to locally remove hair. Then, 1x105 CT26 cells in sterile saline were injected
subcutaneously into the left flank (Zhang et al., 2013; Tongu et al., 2015; Malvicini et al., 2011).
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Tumor allografts grew until they reached a volume of 200 mm3, after which the tumor underwent
DRS measurements.
4.2.3 Tumor allograft geometry
After performing DRS measurements of Balb/c-CT26 tumor allografts at a volume of 200
± 50 mm3, mice were euthanized via cervical dislocation under 4.0% isoflurane and 1 L/min
oxygen. Tumors were dissected, placed in OCT and flash frozen in isopentane in liquid nitrogen,
and stored at -80°C for up to one week. Tumors cut into 6-μm sections using a cryostat (Leica
Biosystems CM1860) and stained with hematoxylin (VWR 100504-404) and eosin (VWR
10143-130) (H&E). H&E-stained tissue sections were imaged with a microscope (Nikon Eclipse
Ci) with a 4X/0.25 NA objective and field-of-view (FOV) of 2.9 x 2.2 mm. Tumors often
exceeded this FOV (i.e. a perfectly spherical tumor at a volume of 200 mm3 would have a
diameter of ~7.4 mm). Therefore, images were taken of the entire tumor cross section and
stitched together using a commercial panoramic image stitching software (Microsoft, Image
Composite Editor) (Figure 2). Thickness of the epidermis, dermis/hypodermis, and fascia were
calculated from H&E images calibrated to a 1951 USAF resolution test target (Thorlabs,
R1DS1P). All nine CT26 tumors were measured to determine average and standard deviation.
Calculating tissue thickness overlying the subcutaneous tumor was important to determine which
layers were sampled by each SDS of the DRS probe (Figure 2).
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Figure 2. The subcutanous Balb/c-CT26 colon tumor allograft showing (a) the
DRS probe in contact with the tumor (b) an H&E-stained transverse section of
tumor with overlying tissue layers (scale bar = 1 mm, E=epidermis, D=dermis,
F=fascia, T=tumor), and (c) a representation of light transport through the murine
subcutaneous tumor allograft at each of the four SDSs (0.75, 2.00, 3.00, and 4.00)
4.2.4 Optical phantoms
To establish a relationship between optical properties, diffuse reflectance, and sampling
depth in the LUT model, liquid calibration phantoms were generated with known µs’ and µa.
Calibration phantoms were constructed using distilled water as the solvent. The scattering agent
was 1.00 µm-diameter polystyrene microspheres (07310-15, Polysciences, USA) and the
associated µs’ was calculated using Mie theory. The absorbing agent was teal India ink (11BY,
Salis International, USA). The µa was calculated by measuring a diluted solution of teal India ink
in distilled water using a spectrophotometer (5102-00, PerkinElmer, USA) and the Beer-Lambert
Law (Greening, James, et al., 2016; Greening, Rajaram, et al., 2016; Greening, James and
Muldoon, 2015; Greening, James, Powless, et al., 2015).
A 5 x 3 (15 total) set of calibration phantoms was created, corresponding to five
scattering ranges and three absorbing ranges (Figure 3). Five of the 15 phantoms were
considered “scattering-only” and contained only polystyrene microspheres without India ink.
Distilled water and polystyrene microspheres were mixed inside 7 mL scintillation vials (66022300, VWR, USA) to yield a µs’ of 2.7, 3.8, 5.4, 7.6, and 10.9 cm-1 at a reference of 630 nm to
span a µs’ range of 2-15 cm-1 from 450-900 nm. The remaining ten calibration phantoms
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contained both polystyrene spheres and teal India Ink. Five of the 12 phantoms had a peak µa of
3.0 cm-1 at 632 cm-1 and the final five phantoms had a peak µa of 10 cm-1 at 632 cm-1. Thus,
calibration phantoms spanned a µs’ range of 2-15 cm-1 and a µa range of 0-10 cm-1 from 450-900
nm. These ranges span the optical property range of interest for subcutaneous Balb/c-CT26
tumor allografts (Sabino et al., 2016; Spliethoff et al., 2014; Honda et al., 2011).
To validate the relationship between optical properties and diffuse reflectance in the LUT
model, liquid validation phantoms were generated with known µs’ and µa. Using these validation
phantoms, accuracy of the LUT model could be established by comparing known µs’ and µa
(expected values) to the µs’ and µa generated by the LUT model (experimental). Validation
phantoms were constructed similar to calibration phantoms, but used bovine hemoglobin
(H2625, Sigma-Aldrich, USA) as the absorbing agent. Bovine hemoglobin was used to better
simulate biological tissue absorption.
A 3 x 3 (9 total) set of validation phantoms was created, corresponding to three scattering
ranges and three absorbing ranges (Figure 3). Polystyrene microspheres were added such that
phantoms yielded a µs’ of 5.2, 8.5, and 13.5 cm-1 at a reference of 630 nm to span a µs’ range of
4-19 cm-1 from 450-900 nm. Bovine hemoglobin was added such that phantoms yielded a µa of
0-1.8 cm-1, 0-3.6 cm-1, and 0-8.1 cm-1, respectively.
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Figure 3. Calibration phantoms were made with distilled water, polystyrene
microspheres, and teal India ink to span µs’ and µa ranges between (a) 2-15 cm-1
and (b) 0-10 cm-1, respectively, while validation phantoms were made with
distilled water, polystyrene microspheres, and bovine hemoglobin to span µs’ and
µa ranges between (c) 4-19 cm-1 and (d) 0-8 cm-1, respectively.
4.2.5 Lookup tables for diffuse reflectance
The DRS probe was placed in each liquid calibration phantom, so it was completely
submerged at 2 cm from the bottom of the 7 mL scintillation vial. Broadband DRS data (450-900
nm) were recorded at each SDS (0.75, 2.00, 3.00, and 4.00 mm) with integration times of 100,
200, 300, and 400 ms, respectively, to yield a signal-to-noise ratio (SNR) of at least 15 dB. Five
spectra were averaged for all measurements. Spectra were converted to absolute diffuse
reflectance values (Sharma et al., 2013) by calibrating with a Spectralon® 20% diffuse
reflectance standard (SRS-20-010, Labsphere, USA), which accounts for the spectral shape and
daily intensity fluctuations of the halogen lamp. Diffuse reflectance calibration (Eq. 2) was
calculated by
𝑅(𝜆) =

𝐼𝑠𝑎𝑚𝑝𝑙𝑒 (𝜆) − 𝐼𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 (𝜆)
[𝐼𝑠𝑡𝑑 (𝜆) − 𝐼𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 (𝜆)] × 100⁄𝑅𝑠𝑡𝑑

(2)

where R (  ) is absolute diffuse reflectance, I sample (  ) is the intensity of the raw, uncorrected
spectra from phantoms or tissue, I background (  ) is the inherent background noise (spectra
collected without excitation from the light source), I std (  ) is the spectral intensity of the
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Spectralon® 20% diffuse reflectance standard, and

100 Rstd accounts for the reflectance level

(20%) of the Spectralon® diffuse reflectance standard. All intensity measurements per SDS were
acquired with equal integration time.
LUTs were generated for each SDS by plotting absolute diffuse reflectance (R) against
µs’ and µa and then interpolating between raw data points to create a smooth mesh for µs’
between 4-12 cm-1 and µa between 0-8 cm-1 (Figure 4). This optical property range accounts for
all expected μs’ and μa in murine tissue in the wavelength range of interest (450-900 nm) (Sabino
et al., 2016).

Figure 4. (a-d) LUTs were created for each SDS (0.75, 2.00, 3.00, and 4.00 mm)
using diffuse reflectance spectra from calibration phantoms which were then (e-h)
interpolated to create a continuous mesh for µs’ values between 4-12 cm-1 and µa
values between 0-8 cm-1.
4.2.6 Validation of lookup table inverse model
Once LUTs were constructed (Figure 4), the accuracy of the LUTs needed to be
quantified. In other words, for a single spectrum, how closely do the experimental optical
properties (determined by the LUT model) match the expected optical properties?
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The DRS probe was placed in each liquid bovine Hb-based validation phantom, so it was
completely submerged 2 cm from the bottom of the 7 mL scintillation vial. Broadband DRS data
(450-900 nm) were recorded at each SDS (0.75, 2.00, 3.00, and 4.00 mm) with integration times
of 100, 200, 300, and 400 ms, respectively, to yield an SNR of at least 15 dB. Five spectra were
averaged for all measurements. Spectra were converted to absolute diffuse reflectance values by
calibrating with a Spectralon® 20% diffuse reflectance standard and background noise
subtraction as previously described.
Experimental μs’ and μa were calculated using the damped least-squares nonlinear fitting
method, appropriate for least squares curve fitting. This method will be henceforth referred to as
the LUT inverse model fit and was based on the constraining equation for μs’ (Eq. 3) and μa (Eq.
4). The constraining equation for μs’ is
𝜇𝑠′ (𝜆)

=

𝜇𝑠′ (𝜆0 )

𝜆 −𝐵
×[ ]
𝜆𝑜

(3)

where μs’(λ) is the reduced scattering coefficient, μs’(λ0) is the reduced scattering coefficient at a
reference of 630 nm, λ is all wavelengths, λ0 is 630 nm, and B is the scattering exponent, which
relates to the size of tissue scatterers; smaller values of B correspond to larger scatterer sizes
(Greening, James, et al., 2016; Zonios et al., 2008). Zonios et al. describes an in-depth method to
calculate spherical scatterer diameter based on B, which can range between 0.2 and 4.0 in tissue
(Zonios et al., 2008). On the other hand, the constraining equation for μa is
𝜇𝑎 (𝜆) = 𝐶 × 𝜇𝑎,𝑠𝑡𝑜𝑐𝑘 (𝜆)

(4)

where μa(λ) is the absorption coefficient, μa, stock(λ) is the absorption coefficient of the bovine-Hb
stock solution, and C is the volume fraction of bovine-Hb stock solution in the phantom. The μa
of the bovine-Hb stock solution was determined via a spectrophotometer and the Beer-Lambert
Law. These constraining equations required initial and boundary conditions, listed in Table 1.
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Bounds for μs’ at 630 nm were set based on the μs’ limits of the calibration phantoms used to
create the LUTs. Bounds for B were set to exceed values commonly observed (~0.9-1.2) in tissue
(Semeniak, 2017). Bounds for C were set to be the minimum and maximum values for volume
fraction (Greening et al., 2018). Initial conditions did not affect outcomes as long as they were
between the lower and upper bounds. Initial and boundary conditions were constant for all
validation phantoms and for all SDSs.
Table 1. Boundary conditions for quantifying optical properties of validation phantoms
Variable Lower
Upper
Bound
Bound
μs’ (λ0) 2.0 cm-1
15.0 cm-1
B
0.0
4.0
C
0.0%
100%
After initial conditions were set, the LUT inverse model fit performed up to 1x104
iterations until the sum of squares (2) was minimized (Sharma et al., 2013) between the fitted
reflectance and measured reflectance. All phantom DRS spectra underwent a final quality control
step. If 2 was greater than 5%, data was discarded (Figure 5).
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Figure 5. The LUT inverse model of diffuse reflectance fit is based on the
damped least-squares nonlinear fitting method, with the goal of outputting μs’ and
μa, as well as contributing parameters from the constraining equations such as
scattering exponent and absorber concentration.
Percent errors for μs’ and μa were calculated by comparing the expected optical properties
derived from Mie Theory and the Beer-Lambert Law to experimental optical properties derived
from the LUT inverse model fit. Average percent error was then calculated by averaging the
percent error at each wavelength (450-900 nm) for each validation phantom (9 phantoms).
Percent errors were always positive values; thus, overestimating and underestimating optical
properties produced positive errors that did not cancel out. The LUT was considered accurate
when average percent errors for μs’ and μa were each less than 10%, a standard cutoff across
literature (Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011; Greening,
James, et al., 2016; Greening, Rajaram, et al., 2016).
4.2.7 Optical properties from Balb/c-CT26 tumor allografts
After validation of the LUTs, spectra were collected from Balb/c-CT26 tumor allografts

222

200 ± 50 mm3 in diameter (n=9), as well as immediately adjacent tissue from the same mouse.
Mice were not anesthetized during data collection. The DRS probe was placed in direct contact
with the tissue. Broadband DRS data (450-900 nm) were recorded at each SDS (0.75, 2.00, 3.00,
and 4.00 mm) with integration times of 100, 200, 300, and 400 ms, respectively, to yield an SNR
of at least 15 dB. Five spectra were averaged for all measurements. Spectra were converted to
absolute diffuse reflectance values by calibrating with a Spectralon® 20% diffuse reflectance
standard and background noise subtraction as previously described.
The optical properties were quantified in a similar manner to validation phantoms, using
the LUT inverse model fit based on the damped least-squares nonlinear fitting method (Nichols
et al., 2012). Quantifying in vivo μs’ relied on the same constraining equation as validation
phantoms (Eq. 3). Next, assuming hemoglobin as the only in vivo absorber from 450-900 nm, the
constraining equation (Eq. 5) for μa was expressed as
𝜇𝑎,𝑖 (𝜆) = 𝑇𝐻𝐶 × [𝛼𝜀𝐻𝑏𝑂2 (𝜆) + (1 − 𝛼)𝜀𝐻𝑏 (𝜆)]

(5)

where, μa,i is the initial tissue absorption coefficient, THC is the total hemoglobin concentration
in tissue, α is the tissue oxygen saturation (StO2), and 𝜀𝐻𝑏𝑂2 (𝜆) and 𝜀𝐻𝑏 (𝜆) are the extinction
coefficients of oxyhemoglobin and deoxyhemoglobin, respectively. Next, the final version of the
constraining equation for μa (Eq. 6) incorporated the standard pigment-packaging correction
factor, described in depth by Rajaram et al. (Rajaram, Gopal, et al., 2010). The corrected
absorption equation is expressed as
𝜇𝑎,𝑓 (𝜆) = 𝜇𝑎,𝑖 (𝜆) × [

1 − 𝑒 −2∙𝜇𝑎,𝑏𝑙(𝜆)∙𝑟𝑣𝑒𝑠𝑠
]
2 ∙ 𝜇𝑎,𝑏𝑙 (𝜆) ∙ 𝑟𝑣𝑒𝑠𝑠

(6)

where μa,f is the final tissue absorption coefficient, μa,i is the initial absorption coefficient, μa,bl is
the absorption coefficient of whole blood assuming a hemoglobin concentration of 150 mg/mL,
and rvess is the average blood vessel radius in the sampled tissue. Including the pigment223

packaging correction factor accounts for hemoglobin in tissue being confined to blood vessels,
which is a small fraction of the total volume sampled by light. This phenomenon differs from the
homogenous tissue-simulating phantoms. However, like the homogenous tissue-simulating
phantoms, the constraining equations for in vivo measurements of Balb/c-CT26 allografts
required initial and boundary conditions, listed in Table 2. Bounds for μs’ at 630 nm were set
based on the μs’ limits of the calibration phantoms used to create the LUTs. Bounds for B were
set to exceed values commonly observed (~0.9-1.2) in tissue (Semeniak, 2017). Bounds for THC
were set such that the maximum could not exceed the hemoglobin concentration found in whole
blood (150 mg/mL). Bounds for StO2 were set such that the maximum could not exceed the StO2
found in fully oxygenated tissue (100%). For rvess, average capillary radius is approximately 2.5
μm (Potter et al., 1983), whereas average arteriole radius is approximately 10-15 μm (Burrows et
al., 1981). Bounds for rvess were set to significantly exceed these averages. Initial conditions
(Figure 5) did not affect outcomes as long as they were between the lower and upper bounds.
Initial and boundary conditions were constant for all in vivo measurements and for all SDSs.
Table 2. Boundary conditions for quantifying optical properties of Balb/c-CT26 tissue
Variable Lower
Upper
Bound
Bound
μs’ (λ0) 2.0 cm-1
15.0 cm-1
B
0.0
4.0
THC
0 mg/mL
150 mg/mL
StO2
0.0%
100%
rvess
0 μm
100 μm
After initial conditions were set, the LUT inverse model fit performed up to 1x104
iterations until the sum of squares (2) was minimized between the fitted reflectance and
measured reflectance. Using the constraining equations for in vivo tissue, μs’ at 630 nm, THC,
and StO2 were quantified as a function of tissue type (normal vs. tumor) and SDS. Optical
properties were compared between normal and tumor tissue for each SDS. The significance
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threshold was set at 0.05. All in vivo DRS spectra underwent a final quality control step. If 2
was greater than 5%, data was discarded (Figure 5). Artifacts due to mouse movement during
data collection could potentially cause a high 2 between the fitted reflectance and measured
reflectance. Significance of optical properties between tissue type (healthy and tumor) and SDS
(0.75, 2.00, 3.00, 4.00) was determined using two-way mixed ANOVA. The significance level
was set at 0.05.
4.2.8 Sampling depth of DRS probe into tissue
The next goal was to quantify sampling depth for each SDS as a function of μs’ and μa. In
other words, once μs’ and μa have been quantified via the LUT inverse model, at what depth into
tissue are these optical properties being measured?
To quantify sampling depth, a 5 x 3 (15 total) set of calibration phantoms were
constructed (Greening, James, et al., 2016). Each of these phantoms was placed into a 5 mL
beaker (Figure 6) with a highly absorbing (μa > 100 cm-1) black phantom layer, made with
(poly)-dimethylsiloxane (PDMS) and black India ink at the bottom. It was assumed that any
photon contacting this layer would be attenuated. The μa of the black layer was calculated using
a spectrophotometer and the Beer-Lambert Law. Additionally, the black layer contained no
scattering agent. Contributions from specular reflection at the interface between the black layer
and calibration phantoms were negligible (data not shown) since there is a minimal mismatch
between the PDMS and liquid phantoms (Greening, James, et al., 2016; Hennessy et al., 2014).
The probe was placed in direct contact with the black layer (Figure 6(a-d)). Using a
mechanical translation stage equipped with a micrometer scale (LNR25M, Thorlabs, USA), the
probe was raised from the black layer in 50 μm increments from 0 to 3 mm. DRS measurements,
from 450-900 nm, were taken at each 50 μm step at each SDS of 0.75, 2.00, 3.00, and 4.00 mm
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at integration times of 100, 200, 300, and 400 ms, respectively, to yield an SNR of at least 15 dB.
Since the optical properties of the calibration phantoms were known, a relationship was
established between μs’, μa, and reflectance at various sampling depths. As the probe increased in
distance from the black layer, reflectance increased, then leveled (Figure 6(e)). At each
wavelength, the probe was most sensitive to changes in optical properties when 50% of photons
reached the black layer (Figure 6(f)). When this process was repeated at each wavelength, a
relationship between sampling depth and wavelength was established (Figure 6 (g)). Therefore,
sampling depth(λ) was defined at the most sensitive 50-μm increment.
Three-dimensional plots were generated for each SDS by plotting sampling depth (D)
against µs’ and µa and then interpolating between raw data points to create a smooth mesh for µs’
between 4-12 cm-1 and µa between 0-8 cm-1. This optical property range accounts for all
expected μs’ and μa in murine tissue in the wavelength range of interest (450-900 nm). Once
optical properties were calculated using the LUT inverse model, sampling depth was quantified.
Significance of sampling depth between tissue type (healthy and tumor) and SDS (0.75, 2.00,
3.00, 4.00) was determined using two-way mixed ANOVA. The significance level was set at
0.05.
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Figure 6. Sampling depth was quantified by (a-d) taking DRS measurements of
calibration phantoms at 50 μm increments between 0-3 mm from a highly
absorbing (μa > 100 cm-1) phantom layer. (e) Reflectance (R) increased as
distance between the probe and black layer increased, shown for calibration
phantom #7 at the 3.00 mm SDS as an example. (f) Sampling depth (D) was
defined when the SDS is most sensitive to the black layer, which occurs when
50% of photons reach the black layer. (g) Sampling depth (D) was then quantified
at the 50 μm increment at each wavelength.
4.3 Results
4.3.1 Tumor allograft geometry by tissue type
Tumors were dissected, cut into 6 μm sections, and H&E stained. Three primary tissue
types were visualized above the subcutaneous tumor (Figure 7): the epidermis,
dermis/hypodermis, and fascia. In female Balb/c-CT26 tumor allografts (n=9), the epidermis was
0.22 ± 0.05 mm thick, the base of the dermis was 0.71 ± 0.11 mm from the surface, and the base
of the fascia was 1.00 ± 0.15 mm from the surface.
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Figure 7. To acquire optical properties from the subcutaneous tumor, broadband
light from the DRS probe needed to penetrate past the fascia, located 1.00 ± 0.15
mm from the surface. Values are mean ± SD. (scale bar = 1 mm)
4.3.2 Validation of lookup table inverse model
The reflectance from each validation phantom at each SDS, with known μs’ and μa, was
plotted against the LUT created from the calibration phantoms (Figure 8). Percent errors were
acceptable if less than 10% for both μs’ and μa.

Figure 8. Reflectance from bovine Hb-based validation phantoms (red) was
plotted against the LUTs (grayscale grid) for each SDS of a) 0.75 mm, b) 2.00
mm, c) 3.00 mm, and d) 4.00 mm.
Average percent errors for μs’ were 2.9%, 4.7%, 2.2%, and 2.8% for the 0.75, 2.00, 3.00,
and 4.00 mm SDSs, respectively. Average percent errors for μa were 9.1%, 9.6%, 9.6%, and
9.2% for the 0.75, 2.00, 3.00, and 4.00 mm SDSs, respectively. Thus, all percent errors were
below 10% (Figure 9).
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Figure 9. Percent errors for comparing experimental optical properties (from
LUT inverse model fit) and expected (known) optical properties were below 10%
for all SDS of (a,e) 0.75 mm, (b,f) 2.00 mm, (c,g) 3.00 mm, and (d,h) 4.00 mm.
The LUT inverse model fit more accurately extracted (a-d) μs’ (percent errors <
5%) compared to (e-h) μa. Black dots represent raw data. Red lines indicate a
perfect fit with 0% error. Gray background represents the acceptable 10% error.
4.3.3 Sampling depth in Balb/c-CT26 allografts
Following DRS measurements of calibration phantoms overlying a highly absorbing
PDMS layer, three-dimensional plots were generated for each SDS by plotting sampling depth
(D) against µs’ and µa and then interpolating between raw data points to create a smooth mesh.
Sampling depths were valid for µs’ between 4-12 cm-1 and µa between 0-8 cm-1 (Figure 10).
Lowest sampling depth occurred at highest optical properties (μs’ = 12 cm-1, μa = 8 cm-1) and
highest sampling depth occurred at lowest optical properties (μs’ = 4 cm-1, μa = 0 cm-1). Based on
this, sampling depths ranged between 0.37 to 1.10 mm, 0.72 to 1.76 mm, 0.92 to 2.08 mm, and
1.16 to 2.25 mm for the 0.75, 2.00, 3.00, and 4.00 mm SDSs, respectively, indicating sampling
depth increased as SDS increased. Subcutaneous tumors were located 1.00 ± 0.15 mm or deeper
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below the skin surface; thus, broadband light from the DRS probe needed to penetrate at least
1.15 mm into tissue to sample tumor optical properties. With regards to the colormap in Figure
10, red coloring indicates sampling depth ≤ 1.15 mm, which was the average thickness, plus one
standard deviation, of the overlying skin and fascia of the subcutaneous Balb/c-CT26 tumor.
Yellow coloring indicates sampling depth between 1.15 and 1.45 mm, with peak yellow
occurring at 1.30 mm, which was the average thickness, plus two standard deviations. Green
coloring indicates sampling depth ≥ 1.45 mm, which was the average thickness plus three
standard deviations. Thus, yellow and green coloring represent optical properties in which tumor
tissue was sampled.

Figure 10. Raw sampling depth data (a-d) was plotted for each SDS and then (eh) interpolated into a mesh. Sampling depth increased as SDS increased.
4.3.4 Balb/c-CT26 allograft wavelength-dependent optical properties
Next, DRS measurements were collected from Balb/c-CT26 tumor allografts (n=9) 200 ±
50 mm3 in diameter, as well as immediately adjacent normal flank tissue from the same mouse.
The LUT inverse model fit analyzed the spectra to output μs’(λ) and μa(λ) (Figure 11). Based on
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the relationship between μs’, μa, and sampling depth (Figure 10), sampling depth was quantified
as a function of wavelength. In general, as SDS increased, μs’(λ) decreased, μa(λ) increased, and
sampling depth increased for both normal and tumor tissue.

Figure 11. Average optical properties and sampling depth for (a-c) normal Balb/c
flank tissue and (d-f) subcutaneous Balb/c-CT26 tumor allografts showing (a, d)
μs’, (b, e) μa, and (c, f) sampling depth. As SDS increased, μs’ decreased, μa
increased, and sampling depth increased for both tissue types. Values are mean ±
SD.
4.3.5 Balb/c-Ct26 allograft DRS-derived physiological parameters
After comparing wavelength-dependent optical properties as a function of SDS, key
physiological optical parameters were extracted and compared for normal and tumor tissue
(Figure 12).
The μs’ at 630 nm decreased as SDS increased (Figure 12(a)), as observed in Figure 11.
For the 0.75, 3.00, and 4.00 mm SDSs, differences in μs’ were insignificant between normal and
tumor tissue. In the 2.00 mm SDS, μs’ was significantly lower in tumor tissue (p=0.02) compared
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to normal tissue, but only by 0.49 cm-1.
The THC, measured in mg/mL, increased as SDS increased (Figure 12(b)). This was also
indicated by the observed increased μa(λ) magnitude observed in Figure 11. For the 0.75, 2.00,
and 4.00 mm SDSs, differences in THC were insignificant between normal and tumor tissue. In
the 3.00 mm SDS, THC was significantly lower in normal tissue (p=0.03) compared to tumor
tissue, but only by 0.64 mg/mL. The THC rose from approximately 1.4 mg/mL in the 0.75 mm
SDS to approximately 6.8 mg/mL in the 4.00 mm SDS for both tissue types.
The StO2 remained constant as SDS increased in normal tissue (Figure 12(c)). However,
StO2 decreased as SDS increased in tumor tissue, indicating increasing hypoxia at increased
depths within the tumor microenvironment. The StO2 quantified by the short 0.75 mm SDS was
significantly higher (p<0.01) than the StO2 quantified by all longer SDSs. Furthermore, there
was no significant difference in StO2 between normal and tumor tissue in the 0.75 mm SDS.
However, tumor tissue expressed significantly decreased StO2 compared to normal tissue for
SDSs of 2.00, 3.00, and 4.00 mm.
In Figure 12(d), sampling depth was quantified at the first Q-band of hemoglobin at 542
nm, where the lowest sampling depth would occur. In normal tissue, sampling depth was
0.66±0.04, 1.22±0.11, 1.55±0.12, and 1.64±0.12 mm at 542 nm for the 0.75, 2.00, 3.00, and 4.00
mm SDSs, respectively. In tumor tissue, sampling depth was 0.66±0.03, 1.30±0.09, 1.49±0.14,
and 1.65±0.05 mm at 542 nm for the 0.75, 2.00, 3.00, and 4.00 mm SDSs, respectively. There
was no significant difference (p > 0.05) comparing sampling depth in normal vs. tumor tissue.
For both normal and tumor tissue, sampling depth increased significantly (p<0.01) at longer
SDSs of 2.00, 3.00, and 4.00 mm compared to the shorter 0.75 mm SDS.
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Figure 12. Average (a) μs’ at 630 nm, (b) THC, (c), StO2, and (d) sampling depth
for normal (dark gray) and tumor (light gray) tissue. The μs’ was comparable
between normal and tumor tissue and decreased as SDS increased. The THC was
comparable between normal and tumor tissue and increased as SDS increased.
The StO2 in tumor tissue was significantly decreased compared to normal tissue
for SDSs longer than 0.75 mm. Additionally, StO2 decreased as SDS decreased.
The sampling depth was comparable between normal and tumor tissue and
increased as SDS increased. Values are mean ± SD. Significance is indicated by
*(p<0.05).
4.4 Discussion
A diffuse reflectance spectroscopy (DRS) probe was designed to acquire optical
properties of subcutaneous murine tumor allografts and was applied specifically in Balb/c-CT26
colon tumor allografts. In this paper, a complete validation of the DRS probe in this context was
presented. Raw data from DRS is reflectance intensity as a function of wavelength. This paper
explicitly describes a method to post-process raw spectra into the associated optical properties,
µs’ and µa, physiological perfusion parameters including THC and StO2, and sampling depth
(Hennessy et al., 2014; Rajaram et al., 2008). The central hypothesis was that this DRS probe
would simultaneously sample the overlying epithelial skin layer as well as the subcutaneous
tumor allograft by including multiple discrete source-detector separations (SDSs) and extract
optical parameters from increasing depths (He, Tian and He, 2015; Hennessy et al., 2014). DRS
data at each SDS represents a weighted average of physiological parameters collected from
increasing sampling depths. In the female Balb/c-CT26 colon tumor allograft model, the skin,
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consisting of the epidermis, dermis, and hypodermis was 0.71 ± 0.11 mm thick, and the
underlying fascia resulted in 1.00 ± 0.15 mm of total tissue above the underlying subcutaneous
tumor. These values are expected to vary based on mouse strain, subcutaneous tumor location,
sex, and age, and should be independently confirmed by investigators performing similar studies
(Azzi et al., 2005; Calabro et al., 2011; Sabino et al., 2016). Thus, the DRS probe needed to
sufficiently sample beyond the 1.00 mm skin layer and into the subcutaneous tumor.
A lookup-table (LUT)-based inverse model, an established method, was chosen as the
method to relate diffuse reflectance with µs’ and µa (Rajaram et al., 2008; Greening, James,
Powless, et al., 2015; Greening, James, et al., 2016; Nichols et al., 2012). Other methods exist to
perform this task such as Monte Carlo-based simulations (Hennessy et al., 2014; Hennessy et al.,
2013; Zhong et al., 2014), but the LUT-based inverse model was chosen because it is based on
experimental values that necessarily account for our specific system response (Nichols et al.,
2012). To generate a LUT, a set of calibration phantoms with known optical properties was used.
As of the current report, the LUTs for each SDS are valid for µs’ between 4-12 cm-1 at 630 nm
and for µa between 0-8 cm-1. This optical property range effectively encompasses expected
optical properties found in murine skin and subcutaneous tumors between 450-900 nm (Sabino et
al., 2016). This wavelength range was chosen because of the absorption properties of
hemoglobin, with specific absorption peaks (Q-bands) at 542 and 576 nm that indicate THC and
StO2 and negligible absorption (µa < 0.5 cm-1 for both oxygenated and deoxygenated hemoglobin
in whole blood) between 600-900 nm (Prahl, 2015). Therefore, reflectance in the 600-900 nm
wavelength range necessarily indicates µs’ (Sharma et al., 2013). It is common in literature to
report µs’ at a reference of 630 nm, so this convention was used here (Sharma et al., 2013;
Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Hennessy et al., 2015).

234

Since the LUTs were generated with dye-based calibration phantoms, a set of bovine
hemoglobin-based phantoms, which more closely simulate physiological conditions, with known
optical properties was used to validate the LUTs (Greening, James, et al., 2016). Within the LUT
optical property range, it was shown that average percent errors for extracting µs’ and µa were
below 10% for all SDSs, indicating it is reasonable to assume that measured tissue optical
properties and physiological perfusion metrics are accurate within 10%. Average percent errors
below 10% are considered acceptable and are comparable to many other DRS studies
(Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011). However, it was not
uncommon for percent errors in several experimental optical property observations to exceed
10% (Figure 9). Despite this, there was no relationship between percent error and magnitude of
µs’ and µa, indicating that while some in vivo measurements of murine tissue may indeed exceed
10%, on average the percent errors will be within 10% regardless of magnitude of µs’ and µa.
Additionally, percent errors did not significantly change with respect to SDS. Since SDS is
related to sampling depth (Hennessy et al., 2014), this indicates that measuring optical properties
of deeper tumor tissue was no less accurate than measuring optical properties of shallower skin
tissue. It should be noted that average percent errors for extracting µa were greater (~9%)
compared to extracting µs’ (~3%), a common observation in existing literature (Rajaram, Aramil,
et al., 2010). Finally, since LUT validation was performed with bovine hemoglobin-based
phantoms, it was extraneous to perform additional validation via Monte Carlo simulations.
Once the relationship between diffuse reflectance, µs’ and µa was established and
validated, the same set of calibration phantoms was used to establish a relationship between
sampling depth, µs’ and µa. As of the current report, the sampling depth relationship for each
SDS are valid for µs’ between 4-12 cm-1 at 630 nm and for µa between 0-8 cm-1. We employed a
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method to quantify sampling depth similar to that pioneered by Hennessey et al. (Hennessy et al.,
2014), in which sampling depth as a function of wavelength was quantified based on the depth at
which the SDS was most sensitive to an optical heterogeneity (Figure 6). It is important to note
that, even at lower and higher depths, the probe was still sensitive to the optical heterogeneity
(Figure 6(f)), similar to other studies (Hennessy et al., 2014). This shows that stating the probe
has a single sampling depth at specific optical properties is an oversimplification. Instead, the
depth sampled by our DRS probe represents a wide range, a phenomenon described explicitly by
Kanick et al. (Kanick et al., 2009). However, for simplicity, we report sampling depth as a single
value at which the SDS was most sensitive to the heterogeneity. Figure 10 shows that sampling
depth increased with increasing SDS, and decreased with increasing µs’ and µa, as expected
(Hennessy et al., 2014; Kanick et al., 2009).
There was a decrease in sampling depth at the Soret band (< 500 nm) and Q-bands (542
and 576 nm) of hemoglobin. It is these peaks that most heavily influence extracted THC and
StO2 in the LUT inverse model. Thus, even though sampling depth is higher at longer
wavelengths, we explicitly report sampling depth at the first Q-band of hemoglobin, where
sampling depth is lowest in our wavelength range (450-900 nm). From Figure 12(d), we can
conclude that the 0.75 mm SDS only samples the skin layer since its sampling depth was
0.66±0.04 mm and 0.66±0.03 mm for normal and tumor tissue, respectively, shallower than the
1.00 ± 0.15 mm normal tissue above the subcutaneous tumor. Further evidence for the 0.75 mm
SDS sampling only the overlying skin layer is shown from Figure 12(a-c), in which there were
insignificant differences between normal vs. tumor tissue with respect to µs’, THC, and StO2.
The tumor begins to be sampled at the 2.00, 3.00, and 4.00 mm SDSs, indicated by the sampling
depths at the first Q-band to be 1.30±0.09, 1.49±0.14, and 1.65±0.05 mm, respectively. As such,
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since the subcutaneous tumor is relatively hypoxic (Shay et al., 2014), there was a significant
difference in StO2 between normal and tumor tissue at these sampling depths (Figure 12(c)).
Furthermore, in tumor tissue, StO2 decreased steadily from 44±11% to 22±7% as SDS increased.
It is important to note that the observed decreasing StO2 with increasing sampling depth does not
necessarily indicate the tumor was more hypoxic at increased depths but is most likely due to
more overall tumor tissue contributing to the volume-averaged physiological parameters. It is
common for DRS-derived StO2 of keratinized epithelia, such as the skin, to be much less than
100% (Spliethoff et al., 2014). DRS studies reporting in non-keratinized epithelia tend to extract
much higher StO2 values upwards of 95% (Greening, James, et al., 2016). Additionally, the StO2
presented in this study does not necessarily correlate to arterial oxygen saturation, which would
be more accurately measured using pulse oximetry (Bashkatov et al., 2014). Interestingly, µs’
and THC were mostly comparable between normal and tumor tissue, indicating StO2 may be a
key physiological parameter to evaluate murine tissue health via DRS, a sentiment held by other
research groups (Spliethoff et al., 2014; Spliethoff et al., 2016; Sircan-Kucuksayan et al., 2015).
Figures 11 and 12 show that increasing sampling depth resulted in decreased µs’ and
increased µa in both normal and tumor tissue. In the skin, scattering from the epidermis (0 to 0.22
mm) is primarily caused by keratin, a filamentous protein, as well as cell nuclei and lipid
membranes. In the dermis and hypodermis, (0.22 to 0.71 mm) scattering is primarily caused by
collagen, which accounts for approximately 25% of the dermal volume, other cellular
constituents (Lister et al., 2012; Arifler et al., 2007; Arifler et al., 2003), and lipids confined to
adipocytes in the hypodermis. In the superficial fascia (0.71 to 1.00 mm), an areolar connective
tissue (Arifler et al., 2007; Kumka et al., 2012), scattering is primarily caused by collagenous,
elastic, and reticular fibers. Finally, scattering in the CT26 cell layer (an epithelial cell type) is
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caused by cellular constituents. Measurements in similar tissue in literature have suggested that
epithelial tumors have lower light scattering (Collier et al., 2003) compared to skin, whose
scattering properties are dominated by the dermis (Lister et al., 2012), although a direct
comparison of µs’ between subcutaneous CT26 allografts and skin has not been exclusively
studied. The µs’ presented here were comparable to other studies (Sabino et al., 2016). On the
other hand, increased µa, associated with increased THC, increased with sampling depth. The
epidermis contains no blood vessels, which are situated in deeper dermal layers (Sabino et al.,
2016). In Balb/c mice, which are albino, hemoglobin is the only significant absorber. It is
important to note that the observed increasing THC with increasing sampling depth does not
necessarily indicate higher THC in the tumor but is most likely due to reduced contribution of
the epidermis to the volume-averaged optical properties of the subcutaneous tumor model. The
µa and THC presented here were comparable to other studies (Lister et al., 2012; Rajaram,
Reichenberg, et al., 2010; Bremmer et al., 2011; Sabino et al., 2016).
This work has several limitations. First, contact-based, non-invasive DRS cannot sample
into the center of a subcutaneous tumor 200 ± 50 mm3 in diameter. Sampling into the tumor
center may be difficult even for small tumors, since even at the 4.00 mm SDS, sampling depth
only reached 1.65±0.05 mm Therefore, considering the spatial heterogeneity of the tumor
microenvironment (Yuan, 2016), DRS may not provide representative data for the entire tumor.
Spliethoff et al. overcame this limitation by using a minimally-invasive biopsy needle with
integrated optical fibers for intratumoral DRS measurements in subcutaneous murine xenografts
(Spliethoff et al., 2014). Secondly, extracted optical properties are volume-averaged, meaning
that fine spatial resolution of µs’ and µa is lost (Kanick et al., 2009; Saager et al., 2011).
Moreover, even at long SDSs designed to sample deeper into the subcutaneous tumor allograft,
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extracted optical properties are a volume-averaged measurement of both tumor and skin. To
overcome this limitation, the 0.75 mm SDS was integrated into the DRS probe design to
simultaneously and exclusively sample overlying skin. This way, fluctuations in optical
properties and physiological parameters over time could be attributed to either changes in the
tumor itself, or changes in the skin, and assumptions could be limited. Saager et al. mitigated this
volume-average limitation by implementing a depth-resolved quantification based on a two-layer
Monte Carlo model (Saager et al., 2011). Additionally, due to the thin nature of skin, we expect
overall optical contributions on tumor physiological parameters to be relatively small (Muldoon
et al., 2012). Finally, future work must correlate DRS-derived perfusion metrics with
immunohistochemical analysis. For example, pimonidazole is a dye that stains for hypoxia
(Aguilera et al., 2014), and can be used to correlate end-point hypoxic fraction of tumor sections
with in-vivo StO2 measurements via DRS.
4.5 Conclusion
Diffuse reflectance spectroscopy is a non-invasive spectral biopsy tool that has shown
promise in early cancer diagnostics, tracking tissue response to therapy, and in intraoperative
surgical guidance. This paper provides an outline for a general method for quantifying tissue
optical properties, as well as physiologically relevant perfusion parameters, such as hemoglobin
concentration and tissue oxygen saturation, that can be used by investigators hoping to
implement diffuse reflectance spectroscopy for cancer research. Experimental methods presented
here are scalable for smaller probe sizes (within the sub-diffuse regime) for endoscopicallydeployable spectroscopy probes, where the diffuse approximation is limited.
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Chapter 5 (Specific Aim 3): Effects of isoflurane anesthesia on physiological parameters in
murine tumor allografts measured via diffuse reflectance spectroscopy

5.1 Introduction
Diffuse reflectance spectroscopy (DRS) is a non-invasive method which can be used to
quantify volumetric total hemoglobin concentration (THC), tissue oxygen saturation (StO2), and
tissue scattering at or within accessible tissue sites (Rajaram et al., 2010; Glennie et al., 2015;
Yu et al., 2014; Glennie et al., 2014; Chin et al., 2017; Fong et al., 2017; Greening, James and
Muldoon, 2015; Greening et al., 2016; Hennessy et al., 2014; Karsten et al., 2013). This
technique has been adapted for studies of tumor perfusion and response to therapy, since THC
and StO2 can be used to differentiate therapeutic responders from non-responders over the course
of treatment (Yu et al., 2017; Thong et al., 2017; Schaafsma et al., 2015). DRS is widely used in
murine studies in which subcutaneous or orthotopic tumor models are treated with anti-cancer
agents or radiation therapy and tumor perfusion is monitored longitudinally over time (Turley et
al., 2012; Spliethoff et al., 2014; Hu et al., 2016; Vishwanath, Klein, et al., 2009; Palmer et al.,
2009). For example, Turley et al. used a handheld DRS probe to show that Bevacizumab, an antiVEGF monoclonal antibody, decreased oxyhemoglobin (THC * StO2) in melanoma tumor
xenografts over a 7-day study (Turley et al., 2012). Spliethoff et al. used DRS to show that
cisplatin, a chemotherapy drug, caused an increase in tumor StO2 in an orthotopic model of
mammary tumors over a 7-day study (Spliethoff et al., 2014). Finally, Hu et al. used DRS to
show that oxygenation kinetics of pharynx squamous cell carcinoma xenografts changed prior to
tumor volume changes in response to radiation therapy (Hu et al., 2016). These studies indicate
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that DRS provides clinically relevant, quantitative, and functional information that can be used to
monitor tumor response to various types of chemotherapy, radiation therapy, or immunotherapy.
Anesthesia is typically used in murine studies because it reduces the animals’ stress,
enables easy manipulation of the mice, allows for injections of cancer cells and anti-cancer
agents, and allows for accompanying surgical procedures. Anesthetic agents used in mouse
studies can be delivered via inhalational (isoflurane or sevoflurane) or injected (pentobarbital or
ketamine/xylazine) routes (Gargiulo et al., 2012). According to the American Veterinary
Medical Association (AVMA), the Institute for Laboratory Animal Research (ILAR), and the
Cornell University Institutional Animal Care and Use Committee (IACUC), the most common
and recommended anesthesia technique for mice is inhaled isoflurane, a halogenated anesthetic
gas supplemented with either 21% (i.e. room air equivalent) or 100% oxygen (O2) (Gargiulo et
al., 2012; Leary et al., 2013; Bliss, 2017). The minimum alveolar concentration (MAC), which is
the anesthesia required to prevent movement in response to surgical stimuli in 50% of subjects, is
1.4% for mice under isoflurane anesthesia (Gargiulo et al., 2012). Therefore, the most common
practice in DRS studies is placing mice in an induction chamber where anesthesia is quickly
induced at 3.0-5.0% isoflurane, and then transferred to a nose cone where anesthesia is
maintained at 1.5-3.0% isoflurane, with a constant gas flow rate of 1 L/min (Leung et al., 2015;
Spliethoff et al., 2014; Turley et al., 2012; Hu et al., 2016; Vishwanath, Klein, et al., 2009;
Gargiulo et al., 2012; Wang et al., 2004; Vishwanath, Yuan, et al., 2009; Guoqiang et al., 2005).
Isoflurane is a respiratory and myocardial depressant, which causes increased partial pressure of
carbon dioxide and bicarbonate levels in arterial blood (Cesarovic et al., 2010; Thal et al., 2007).
Thus, even in the presence of O2 delivery via nose cone, isoflurane results in tissue O2
desaturation, which may be a confounding variable when studying tissue perfusion of
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subcutaneous murine models in response to therapy. Additionally, some therapies, such as
chemotherapy or immunotherapy, depend on adequate tissue perfusion and O2 saturation to be
effective (Ueda et al., 2013). DRS can quantify these perfusion metrics and help understand if
limitations exist for emerging cancer therapies (Huang et al., 2013). However, there have been
no studies analyzing the effects of isoflurane anesthesia on DRS-derived physiological
parameters of murine tissue.
The present study fills this knowledge gap by monitoring DRS-derived physiological
parameters of murine tissue while mice were under various anesthesia conditions. Physiological
parameters studied include THC, StO2, tissue oxyhemoglobin (HbO2), and reduced scattering
coefficient (μs’). It should be noted that DRS quantifies average StO2 sampled by light, rather
than arterial oxygen saturation (SaO2), venous oxygen saturation (SvO2), or peripheral oxygen
saturation (SpO2) (Teng et al., 2008; Sircan-Kucuksayan et al., 2015). StO2 linearly correlates
with the average of SaO2 and SvO2; thus, StO2 values are significantly lower than SaO2 (Hueber
et al., 2001). HbO2 is the product of THC and StO2, and describes the concentration of O2-bound
hemoglobin in circulation (Chung et al., 2010; Lee et al., 2007). This study was divided into four
aims: 1) examine the effects of isoflurane anesthesia on DRS-derived physiological parameters
of normal immunocompetent mouse tissue, 2) determine optimal anesthetic conditions for
performing DRS while adhering to AVMA and IACUC standards (Gargiulo et al., 2012; Bliss,
2017; Leary et al., 2013), 3) characterize the time-dependent response of physiological
parameters while maintaining mice on 1.5% isoflurane after induction with either 1.5% or 4.0%
isoflurane, and 4) validate findings in a subcutaneous murine allograft model of colon
carcinoma. An allograft model of colon carcinoma was chosen because they are well-established
models in literature but are understudied regarding DRS. For the first aim, physiological
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parameters were quantified after manipulating two variables including metabolic gas type (O2 vs.
medical air) and isoflurane concentration (1.5% to 4.0%). For the second aim, optimal anesthetic
conditions were determined based on least significant differences between control (noanesthesia) and experimental groups. For the third aim, mice were anesthetically induced with
either 4.0% isoflurane for one minute or 1.5% isoflurane for four minutes. Following induction,
mice were transferred to a nose cone and maintained on 1.5% isoflurane for 15 minutes to
determine how initial induction conditions affect physiological properties over time.
Physiological parameters were monitored via DRS every minute. Finally, for the fourth aim, an
allograft model of murine colon carcinoma was used to demonstrate expected changes in DRSderived tumor physiological parameters during isoflurane anesthesia.
The central hypothesis was that DRS can accurately monitor physiological changes
associated with isoflurane anesthesia. Specially, isoflurane anesthesia was expected to yield
experimentally-induced low StO2 and HbO2, but insignificant changes in THC and μs’, for both
normal and subcutaneous tumor sites. Optimal anesthesia conditions were expected to occur at
the lowest tested isoflurane concentration (1.5%) with 100% O2. Furthermore, StO2 and HbO2
were expected to change over time in response to anesthesia. This work aims to guide
investigators in eliminating, limiting, or managing anesthesia-induced physiological changes in
DRS studies in mouse models.
5.2 Materials and methods
5.2.1 Murine models
The study was approved by the University of Arkansas Institutional Animal Care and Use
Committee (IACUC #18060). Fifteen female Balb/c mice (strain: 000651, The Jackson
Laboratory, ME, USA) aged nine weeks were purchased. Balb/c mice were housed in groups of

248

three in five cages at 23°C ± 1°C and 50% ± 10% humidity on a 12:12 hour light-dark cycle.
Food (8640, Teklad) and water was provided ad libitum. All 15 mice acclimated for seven days,
including daily handling (2 minutes) for adaptation to future measurements, after arrival prior to
the start of the study. After one week of acclimation, left flanks of the 10-week old Balb/c mice
were shaved and Nair depilatory was applied for one minute to locally remove fur.
5.2.2 Cell line for allograft model of colon carcinoma
Five of the 15 Balb/c mice were randomly selected for tumor allotransplantation. CT26
(ATCC®, CRL-2638TM), a colon carcinoma cell line derived from the Balb/c mouse strain, was
maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (ATCC®, 30-2001TM)
supplemented with 10% fetal bovine serum (ATCC®, 30-2020), 1% antibiotic antimycotic
solution (Sigma-Aldrich, A5955-100ML), and 0.2% amphotericin B/gentamicin (Thermo Fisher
Scientific, R015010) at 37°C and 5% CO2. CT26 cells were brought to the third passage (P3).
Then, 1x105 CT26 cells in sterile saline were injected subcutaneously into the left flank. Tumor
allografts grew until they reached a volume of 100 mm3, measured via 𝑉 = (𝐿 ∙ 𝑊 2 )/2, which
took 14.4 ± 2.2 days, upon which tumor underwent DRS measurements. Then, tumor allografts
continued to grow until they reached 500 mm3, approximately 18.1 ± 1.2 days following
implantation, upon which additional DRS measurements were taken to compare physiological
parameters at different tumor sizes in response to isoflurane anesthesia. For controls, adjacent
healthy flank tissue was measured.
5.2.3 Diffuse reflectance spectroscopy instrumentation
The custom, handheld DRS probe (FiberTech Optica, Kitchener, ON, Canada) was used
in direct contact with tissue to perform all spectroscopy measurements. The brass probe tip is
cylindrical with a diameter of 6.35 mm. The probe includes a 400 μm-core source fiber
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(FiberTech Optica, SUV400/440PI, 0.22 ± 0.02 NA) which delivers broadband light (450-900
nm) from a 20W tungsten-halogen lamp (Ocean Optics, HL-2000 HP) into tissue, and an
adjacent 400-μm core detector fiber (FiberTech Optica, SUV400/440PI, 0.22 ± 0.02 NA) which
transfers diffusely reflected light to a spectrometer (Ocean Optics, FLAME-S) with an optical
resolution of 2.1 nm. The center-to-center source-detector separation (SDS) between these two
optical fibers was 3.00 mm. All DRS measurements were performed in a dark environment.
The four physiological parameters were quantified by inputting raw DRS spectra into an
experimental lookup-table (LUT)-based post-processing software with a priori values for
oxygenated and deoxygenated hemoglobin extinction coefficients (Greening et al., 2016; Prahl,
2015; Greening, James, Powless, et al., 2015). The software performed an iterative model fit,
based on a standard damped least-squares nonlinear fitting method, on raw DRS data to quantify
THC, StO2, HbO2, and μs’ (Greening et al., 2016). Additionally, the chi-squared (Χ2) value
indicated goodness-of-fit between the model fit and raw DRS data; for this study, if Χ2 values
exceeded 1.0, data was rejected and re-acquired as this was likely due to user-induced movement
artifacts during data collection (i.e. discarding data taken with small air gaps between probe and
skin). Finally, the software is based on a fitting range (i.e. boundary conditions) for all four
physiological parameters, as shown in table 1. Lower and upper bounds were set to encompass a
wide range of potential physiological parameters in murine skin and tumor tissue (Sabino et al.,
2016; Prahl, 1999). The wavelength range used to fit the data was between 450 to 900 nm.
Table 1. Boundary conditions for quantifying in vivo physiological parameters
Physiological
Lower
Upper
parameter
Bound
Bound
THC
0 mg/mL
150 mg/mL
StO2
0%
100%
HbO2
0 mg/mL
150 mg/mL
12
μs’ (750 nm)
3 cm-1
m-1
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5.2.4 Controlling for confounding variables in mouse diffuse reflectance spectroscopy
Positioning of the mice during DRS measurements could potentially affect results by
changing venous blood distribution. Therefore, for DRS measurements of mice under isoflurane
anesthesia, mice were placed in the prone position. For DRS measurements of non-anesthetized
mice, mice sat in the operator’s hand. Thus, the tumor and adjacent healthy skin were identically
oriented during measurements in both anesthesia and non-anesthesia cases.
Next, the method of restraining non-anesthetized animals during measurements could
affect results by increasing stress leading to altered hemodynamic and tissue blood volume levels
(Sikora et al., 2016; Zhao et al., 2011). Mice were restrained by holding the base of the tail
between index and middle fingers and allowing the mouse to rest in the palm, or, for the
anesthesia conditions, in the prone position with a nose cone delivering isoflurane and metabolic
gas. Stress was accounted for in two ways. First, all mice were handled daily for 2 minutes
during the 7-day acclimation period to allow the mouse to adapt to DRS measurement
procedures and provide reproducible results (Zhao et al., 2011). Additionally, mouse respiration
rate was monitored during experiments. During DRS measurements of anesthetized animals,
respiration rate was monitored visually by an operator not performing measurements. Safe
respiration rate under anesthesia is 55-70 breaths per minute (Ewald et al., 2011). During DRS
measurements of non-anesthetized animals, breath rate was not to exceed 150 breaths per minute
(BPM) or a 10% increase from baseline prior to handling (Ewald et al., 2011). If BPM did not
fall within these stress-related criteria, DRS measurements were not taken.
Finally, previous research has shown that absorption due to THC and StO2 decreases with
both increasing probe-tissue pressure and time since the probe may physically compress blood
out of the tissue site and impede the sampled tissue site from receiving replacement oxygenated
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blood (Lim et al., 2011). Although probe-pressure effects were not directly measured in this
study, probe-pressure effects have been shown to be nearly negligible (< 5% error) within a
range of probe-skin pressures between 9 to 152 mN/mm2 (1.3 to 22.0 PSI) using a similar 6.35
mm-diameter DRS probe in short (< 2 s) contact durations. Normal probe-skin pressure tends to
be less than 9 mN/mm2, and, for our setup, a contact time less than 1 s, justifying the non-use of
an integrated pressure sensor (Lim et al., 2011).
5.2.5 Effect of isoflurane concentration on physiological tissue parameters
The aim of this experiment was to examine the effect of inhaled isoflurane anesthesia
physiological parameters of murine tissue, measured by DRS, and determine optimal anesthetic
conditions for DRS.
The normal, exposed left flank of Balb/c mice (n=10) underwent DRS with varying
anesthesia conditions. The control group received no anesthesia. Subsequent groups received
isoflurane anesthesia (Henry Schein Animal Health, 1169567762) using a tabletop laboratory
animal anesthesia system (VWR, 89012-492). Metabolic gas was varied between pure O2 (100%
O2, Airgas, OX USP200) and medical air (21% O2, Airgas, AI USP200), with a constant flow
rate of 1 L/min. Isoflurane concentration was varied between 1.5%, 2.0%, 3.0%, and 4.0%. Mice
were induced and maintained on the same isoflurane concentration. Concentrations below 1.5%
were not tested because such concentrations would be below the MAC value (1.4%) for
isoflurane in mice (Gargiulo et al., 2012). Isoflurane concentrations above 4.0% were not tested
since higher values are usually only used for isoflurane-induced euthanasia according to AVMA
(Leary et al., 2013). Furthermore, investigators generally do not exceed 4.0% isoflurane during
anesthetic induction (Turley et al., 2012; Spliethoff et al., 2014; Hu et al., 2016; Vishwanath,
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Klein, et al., 2009; Gargiulo et al., 2012; Leung et al., 2015; Wang et al., 2004; Vishwanath,
Yuan, et al., 2009; Guoqiang et al., 2005).
Mice were placed in a 2L induction chamber with an input connected to the isofluranegas mix and output connected to a disposable charcoal filter (VWR, 89012-608) housed in an
externally ventilating chemical fume hood. Mice were anesthetically induced until they had no
pedal reflex (firm toe pinch). Mice were then transferred to a second independent anesthesia
circuit consisting of a 9 mm-diameter nose cone with an input connected to the isoflurane-gas
mix and output connected to a disposable charcoal filter. To maintain body temperature, mice
were placed on a water-based warming pad (Stryker, #TP12E) controlled by a warming pump
(Stryker, #TP700) set to 42°C (107°F), as recommended by the Cornell University IACUC
(Bliss, 2017).
The DRS probe was placed in direct contact with the exposed skin of the left flank. DRS
measurements were taken with an integration time of 75 ms, and the probe was in direct contact
with skin for less than 1 s to mitigate probe-pressure effects. Ten DRS measurements were
averaged over the course of 30 seconds per mouse, with the probe being completely removed
from the skin between each data take. Total time under anesthesia was less than 5 minutes in all
cases. Paired t-tests were used to compare groups since each mouse was subject to all groups.
Figure 1 shows the experimental setup.
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Figure 1. Balb/c mice in experimental groups underwent isoflurane induction for
less than 3 minutes, depending on concentration (1.5%, 2.0%, 3.0%, or 4.0%),
using either 1 L/min of 100% or 21% O2 (a). Then, mice underwent less than 30
seconds of 10 consecutive DRS measurements on healthy tissue of the exposed
left flank in either control (b), or experimental (1.5%, 2.0%, 3.0%, or 4.0%
isoflurane) groups (c). During maintenance, mice were maintained on a warming
pad.
5.2.6 Temporal effects of isoflurane anesthesia on physiological tissue parameters
The aim of this experiment was to characterize the time-dependent physiological
parameter response while maintaining the mouse on 1.5% isoflurane after isoflurane induction.
DRS measurements were taken on left flank of conscious mice (n=10) every minute for
five minutes with no isoflurane anesthesia as a baseline. Mice were restrained within the palm of
the hand gently holding the tail, held no more than three inches above the work surface.
Then, mice were placed into the 2L induction chamber supplied with either 4.0%
isoflurane for one minute or 1.5% isoflurane for four minutes with 1 L/min O2. No DRS
measurements occurred during induction. Mice were then transferred to a nose cone and
maintained on 1.5% isoflurane and 1 L/min O2 for 15 minutes, with DRS measurements taken
every minute. A maximum of 15 minutes was chosen since it takes approximately 10-15 minutes
for mice to fully respond to a change in isoflurane concentration (Ewald et al., 2011). Therefore,
to control for intergroup and intragroup variation, DRS measurements must occur only after the
mouse has presumably fully responded to such change. Throughout DRS measurements under
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anesthesia, mice were maintained on a water-based warming pad (Stryker, #TP12E) controlled
by a warming pump (Stryker, #TP700) set to 42°C (107°F).
Following 15 minutes of isoflurane maintenance, mice were removed from anesthesia
and DRS measurements were taken every minute for 5 minutes. DRS measurements were taken
with an integration time of 75 ms. Figure 2 visualizes the experimental set-up.

Figure 2. Conscious Balb/c mice underwent DRS for 5 minutes. Then, mice were
anesthetically induced for 1 or 4 minutes with 4.0% or 1.5% isoflurane (Iso),
respectively, and 1 L/min O2. Following induction, mice were transferred to a
nose cone and underwent DRS for 15 minutes at 1.5% isoflurane and 1 L/min O2.
Finally, mice were removed from the nose cone and the left flank underwent DRS
for 5 minutes.
For each mouse, physiological parameters (THC, StO2, HbO2, and μs’) were normalized
to the highest value over the 25-minute data acquisition period. Then, normalized values of all
mice were averaged as a function of time. Both normalized and non-normalized data are
presented.
5.2.7 Physiological parameters of CT26 colon carcinoma allografts
A second cohort of Balb/c mice (n=5) with CT26 murine colon carcinoma allografts
underwent DRS as a representative model of subcutaneous tumor allografts. Measurements with
(1.5% isoflurane and 1 L/min O2) and without anesthesia were performed on allografts at
volumes of 100 mm3 and 500 mm3 and an immediately adjacent normal site. Mice were placed
in the 2L induction chamber (1.5% isoflurane and 1 L/min O2) until loss of pedal reflex and
transferred to the nose cone. Ten DRS measurements were averaged per site at an integration
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time of 75 ms per spectra to minimize motion artifacts. Figure 3 visualizes the experimental setup.

Figure 3. DRS was performed on Balb/c mouse (10 weeks old) to quantify
physiological parameters (THC, StO2, HbO2, and μs’) in subcutaneous CT26
tumor allografts at a volume of 100 mm3 (b, e), 500 mm3 (c, f), and adjacent
normal tissue (a, d) both with (d, e, f) and without isoflurane anesthesia (a, b, c).
Anesthesia was constant at 1.5% isoflurane and 1 L/min O2.
5.3 Results
5.3.1 Effect of isoflurane concentration on physiological tissue parameters
The left flank of Balb/c mice (n=10) underwent DRS measurements while varying
isoflurane concentration between 0.0% (control, no anesthesia) and 4.0%, and varying metabolic
gas between 21% O2 and 100% O2.
For THC (Figure 4a), there were no significant differences between using O2 or air.
However, there was a significant decrease in THC compared to control as isoflurane exceeds
2.0% (p < 0.01). At 4.0% isoflurane, THC dropped to 68% (p < 0.01) and 67% (p < 0.01)
compared to the control in O2 and air, respectively.
For StO2 (Figure 14b), there were no significant differences between using O2 or air,
although average values for StO2 tended to be higher when using O2. Unlike THC, StO2
decreases rapidly, even at the minimum 1.5% isoflurane. For example, at 1.5% isoflurane with
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air, StO2 decreased to 87% (p = 0.028) compared to the control. StO2 continued to decrease
within both O2 and air groups (p < 0.01) up to 3.0% isoflurane. Then, between 3.0% and 4.0%
isoflurane, StO2 stabilized to ~8-15% compared to the control.
For HbO2 (Figure 14c), despite there being no significant differences between using O2 or
air for THC and StO2, there was a significant difference in HbO2 between using O2 and air at
1.5% isoflurane (p = 0.04), suggesting that O2 is the preferred metabolic gas compared to air
with regards to DRS-derived physiological parameters. Most notably, there were significant
differences between using 1.5% isoflurane and the control for both O2 (88%, p = 0.043) and air
(69%, p < 0.01) groups. This finding suggests that even at the lowest isoflurane concentration
(1.5%) above the MAC value (1.4%) for mice, DRS-derived HbO2 values were affected.
For μs’ (Figure 14d), there were no significant differences between using O2 or air.
Additionally, μs’ was unaffected by changes in isoflurane concentration. These findings suggest
that all anesthesia conditions affect at least one of the tested physiological parameters. However,
1.5% isoflurane and 1 L/min O2 most closely mimicked ideal no-anesthesia conditions.
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Figure 4. Physiological parameters of THC (a), StO2 (b), HbO2 (c), and μs’ (d) of
the normal left flank of Balb/c mice (n=10) was compared for isoflurane
concentration (1.5% to 4.0%) and either 100% O2 (dark gray) or 21% O2 (light
gray). THC (a) and StO2 (b) were only affected by isoflurane concentration. HbO2
(c) was affected by both isoflurane concentration and metabolic gas. Finally, μs’
(d) was unaffected by increases in isoflurane concentration and metabolic gas.
Even at low isoflurane concentrations (1.5%), physiological parameters were
affected. Based on these results, O2 is the preferred metabolic gas over air, and
1.5% isoflurane is most appropriate when applicable. Control indicates
measurements from non-anesthetized mice. Values are means ± SD. Significance
is indicated by *(p<0.05) and ** (p<0.01).
5.3.2 Temporal effects of isoflurane anesthesia on physiological tissue parameters
DRS measurements were taken on Balb/c mice (n=10) every minute for five minutes with
no isoflurane anesthesia as a baseline. During these five minutes, all physiological parameters
remained stable. After one or four minutes with 4.0% or 1.5% isoflurane, respectively, and 1
L/min O2, mice were transferred to a nose cone with 1.5% isoflurane and 1 L/min O2.
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For both 4.0% and 1.5% isoflurane induction condition, THC (Figure 5a) decreased from
approximately 3.7 mg/mL to 2.8-3.2 mg/mL and remained relatively stable throughout the 15minute duration. During the 5-minute recovery period, THC showed a slight rise to
approximately 3.4 mg/mL. For StO2, on the other hand (Figure 5b), the induction period resulted
in a decrease from approximately 50% to 31% and 7% for the 1.5% and 4.0% isoflurane
induction conditions, respectively. For the 4.0% isoflurane condition, StO2 increased over time
during the maintenance period, but not dramatically, having reached a final value of just 11% at
the end of 15 minutes. On the other hand, for the 1.5% isoflurane condition, StO2 continued to
decrease to 51% for 6 months, then rose back to 22% at the end of 15 minutes, indicating that, as
expected, physiological changes occur more slowly in mice anesthetized with 1.5% isoflurane.
Similarly, HbO2 (Figure 5c), as anticipated, demonstrated similar trends to StO2.
Finally, μs’ (Figure 4d) was unaffected by isoflurane anesthesia. Following maintenance
with 1.5% isoflurane and 1 L/min O2, mice were removed from isoflurane for a “recovery”
period and DRS data was collected for an additional five minutes. Mice generally regained
consciousness within one minute and full movement within two minutes, after which mice were
gently restrained in the palm of the hand with the tail held secure between index and middle
finger no more than three inches above the work surface. THC, StO2, and HbO2 increased within
the five minutes; however, none reached 100% of the baseline values within the five-minute
recovery period. On the other hand, μs’ remained constant during the 5 minutes of recovery.
From these experiments, physiological parameters were affected by anesthetic induction
with both 1.5% and 4.0% isoflurane. It cannot be assumed, once 1.5% isoflurane maintenance
begins, that physiological parameters are representative. THC, StO2, and HbO2 did not recover to

259

the baseline values by the end of 15 minutes, nor did these physiological parameters fully
recover after the five-minute recovery period.

Figure 5. Temporal effects of 1.5% and 4.0% isoflurane anesthesia induction on
physiological parameters of THC (a), StO2 (b), HbO2 (c), and μs’ (d) of the
normal left flank of Balb/c mice (n=10). The μs’ (d) was unaffected by induction,
maintenance, and recovery periods. Other physiological parameters all showed an
initial decrease after induction, with a slight increase by the end of the 15-minute
maintenance period, but not back to baseline values. Based on these results, it is
clear than any isoflurane induction concentration influences DRS-derived
physiological parameters. Values are means ± SD.
5.3.3 Physiological parameters of CT26 colon carcinoma allografts
Colon carcinoma murine CT26 allografts in Balb/c mice at volumes of 100 mm3 and 500
mm3 were compared with adjacent normal tissue with (1.5% isoflurane and 1 L/min O2) and
without isoflurane anesthesia to quantify physiological parameters (Figure 6). All mice were
induced with 1.5% isoflurane for four minutes to avoid the effects of 4.0% isoflurane seen in
Figure 4.
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For adjacent tissue locations (no tumor), there was significant reduction in physiological
parameters for the anesthesia condition compared to the no anesthesia condition for THC (p <
0.01), StO2 (p = 0.04), and HbO2 (p = 0.02). However, overall trends within the anesthesia and
no anesthesia groups were similar, with insignificant reductions in physiological parameters
when using 1.5% isoflurane and 1 L/min O2. Additionally, as tumor size increased, StO2 and
HbO2 decreased while THC increased and μs’ remained constant. Further comparisons across
and within groups were visually expressed in Figure 6.

Figure 6. Comparison of the physiological parameters, THC, StO2, HbO2, and μs’
of subcutaneous CT26 tumor allografts and adjacent normal tissue both with
(light gray) and without (dark gray) isoflurane anesthesia. Similar to previous
findings, THC, StO2, and HbO2 were reduced when comparing the no-anesthesia
and 1.5% isoflurane conditions in adjacent normal tissue. Results demonstrate that
isoflurane anesthesia causes experimentally-reduced HbO2 values, and that StO2
and HbO2 decreased with increasing allograft tumor volumes, whereas THC
increased and μs’ remained constant. Values are means ± SD. Significance is
indicated by *(p<0.05) and ** (p<0.01).
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5.4 Discussion
Isoflurane anesthesia is a known respiratory and myocardial depressant, causing
increased serum carbon dioxide and bicarbonate levels, and decreased arterial pressure. Despite
this, isoflurane is commonly applied as an anesthetic agent in studies investigating volumetric
perfusion of murine tissue, which is the aim of many DRS-based studies. To better understand
the effects of isoflurane anesthesia on DRS-derived physiological parameters, the present study
monitored murine THC, StO2, HbO2, and μs’ using DRS under various anesthesia conditions.
Understanding the effects of isoflurane anesthesia on these tissue physiological parameters will
help guide investigators in DRS experimental design.
In this study, increasing isoflurane concentration significantly decreased THC, StO2, and
HbO2 while having no effect on µs’ (Figs. 4-6). Of all four DRS-derived physiological
parameters, StO2 was most influenced by changes in isoflurane concentration. Furthermore,
using 100% O2, rather than 21% O2, resulted in closer approximation to no-anesthesia controls
(Figure 4), a trend echoed by Gerling et al. who showed that supplying 100% O2 led to increased
StO2 (Gerling et al., 2014). Because of this, 100% O2 was used throughout the remainder of the
study.
In Figure 4b, StO2 did not decrease (50% to 48%, p = 0.32) when comparing the noanesthesia control to the 1.5% isoflurane condition. However, StO2 drastically decreased from
48% to 6% when increasing isoflurane from 1.5% to 4.0% in normal tissue. StO2 values of ~6%
have been observed in similar spectroscopy studies of mice tissue during anesthesia (Spliethoff
et al., 2014). StO2 linearly correlates with the average of SaO2 and SvO2; thus, StO2 values are
significantly lower than SaO2 (Hueber et al., 2001), which can be measured via pulse oximetry
(Al-Samir et al., 2016). Decreased StO2 is primarily caused by isoflurane-induced decreased
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mean arterial blood pressure (MAP) (Oshita et al., 1989). Szczesny et al. measured MAP of mice
under increasing isoflurane concentrations, and showed that MAP decreased from 80 mmHg to
below 40 mmHg as isoflurane concentration was increased from 1.0% to 4.0% (Szczesny et al.,
2004). Constantinides et al. echoed this trend, showing that MAP decreased from 85 mmHg to
73 mmHg when increasing isoflurane concentration from 1.0% to 2.0% with 100% O2.
Additionally, this research showed that MAP decreased from 92 mmHg to 84 mmHg when
decreasing O2 from 100% to 21% with 1.5% isoflurane (Constantinides et al., 2012).
To our knowledge, no other studies report StO2 (as low as 6% in Figure 14b) at high
(4.0%) concentrations of isoflurane, since many studies state they DRS acquisition during
isoflurane maintenance of 1.5%. However, this statement paints an incomplete picture. This
report is important because the most common anesthetic practice in DRS studies is placing mice
in an induction chamber where anesthesia is induced at ~4.0% isoflurane (Gargiulo et al., 2012).
This isoflurane concentration can have long-lasting effects on blood physiology, even when mice
are transferred to a nose cone where isoflurane is maintained at 1.5% (Figure 5). Therefore, we
show that isoflurane induction, not just maintenance, highly affects DRS-derived StO2 (Figure
5). We recommend 1.5% isoflurane with 100% O2 for both induction and maintenance, despite
increased time to loss of pedal reflex.
Of note are conflicting results from a study by Farzam et al. In this study, mice were
anesthetized and maintained on 3.5% and 2.0% isoflurane, respectively, and StO2 values were
~75% in orthotopic renal cell carcinoma tumors (Farzam et al., 2017), a stark increase from our
StO2 of 22% at 2.0% isoflurane (Figure 4b). However, this study analyzed an orthotopic, rather
than subcutaneous, tumor model of a different cell line. In a more comparable study, Rajaram et
al. reported StO2 values near 30% under similar isoflurane conditions (1.5%) and wavelength
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ranges (350 to 850 nm) of murine skin at a comparable SDS (2.5 mm) (Rajaram et al., 2015).
The wavelength range used to fit data and SDS are paramount when comparing between studies.
Unlike hemodynamic physiological parameters, the µs’ was unaffected by changes in
isoflurane concentration and O2 levels. Tissue scattering is primarily caused by local density of
lipid membranes from cellular tissues, mitochondria, lysosomes, and collagenous tissue like the
skin (Jacques, 2013), which was the primary tissue type interrogated in this experiment. These
scattering structures are unaffected by isoflurane conditions, resulting in stable µs’.
Based on these results, isoflurane anesthesia should be carefully considered when
performing DRS studies to quantify THC, StO2, and HbO2; however, some invasive and
minimally invasive studies cannot eliminate the anesthesia use. For example, Spliethoff et al.
used a 21G optical needle probe to perform deep intratumoral DRS measurements to overcome
sampling depth limitations with mice under anesthesia (Spliethoff et al., 2014). Westerkamp et
al. performed postmortem DRS on liver tissue following hepatectomy (Westerkamp et al., 2015).
Finally, Palmer et al. performed DRS on 4T1 mammary tumor allografts while concurrently
measuring the partial pressure of O2 using an OxyLite sensor, which required anesthesia (Palmer
et al., 2009). Thus, it is not always applicable to perform live DRS with no anesthesia; 100% O2
with minimal isoflurane (1.5%) is recommended in these cases. Using a minimum of 1.5%
isoflurane for induction over a four-minute period also drastically decreased StO2 and HbO2,
although changes were slower to occur compared to 4.0% isoflurane induction (Figure 5). If
anesthesia is needed when measuring in vivo physiological parameters via DRS, it may be more
representative to slowly induce anesthesia with 1.5% isoflurane rather than rapidly inducing
anesthesia with 4.0% isoflurane and lowering concentration for anesthesia maintenance.
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Finally, THC, StO2, HbO2, and μs’ of Balb/c-CT26 colon tumor were measured via DRS.
Figure 6a indicates that increased tumor volume correlates to increased THC. Across Figs. 4-6,
we report THC of 2.8 to 4.0 mg/mL in normal tissue and 4.0 to 4.8 mg/mL in subcutaneous
CT26 tumor allografts under 1.5% isoflurane anesthesia, comparable to a study by Spliethoff et
al (Spliethoff et al., 2014) in similar conditions. Increased tumor THC is due to increased tumor
microvasculature coupled with increased ratio of deoxyhemoglobin to oxyhemoglobin. This
trend of increased tumor THC is well known (Quincy Brown et al., 2009; Wang et al., 2009).
Figure 16b shows that StO2 of tumors with volumes of 500 mm3 was ~14%, both with and
without 1.5% isoflurane. This low StO2 value is similar to a study by Spliethoff et al., which
reported slightly lower StO2 values of 2-6% in larger mammary xenograft tumors (up to 800
mm3) using 1.5% isoflurane anesthesia (Spliethoff et al., 2014). Rich et al. reported similar StO2
values of 5-15% in head and neck cancer xenograft tumors, measured using photoacoustic
imaging (Rich et al., 2016). Finally, Rajaram et al. reported DRS-derived StO2 around 20% for
mammary xenografts at 1.5% isoflurane anesthesia (Rajaram et al., 2015). The Rajaram study
also reported a ~1.5x decrease in StO2 of 100 mm3 mammary tumor xenografts compared to
normal tissue, whereas this present study reports a ~1.6x decrease (Figure 6b) in StO2 of 100
mm3 colon tumor allografts compared to normal tissue. The comparable StO2 values in these
studies lend support to our results. HbO2 in Figure 6c demonstrates similar trends as StO2. In
Figure 6d, µs’ was unaffected by tumor size and isoflurane, similar to Figs. 4 and 5.
Additionally, in tumors, there were insignificant decreases in THC, StO2, and HbO2 when
using 1.5% isoflurane compared to a no-anesthesia control, suggesting it may be appropriate to
monitor percent changes in physiological parameters over time. In longitudinal treatment studies,
accompanying non-endpoint procedures such as chemotherapy, radiation therapy,
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immunotherapy, or other treatment or observation procedures requiring anesthesia should ideally
be performed after DRS measurements have concluded.
One limitation of this study is the focus on non-invasive DRS of readily accessible
murine tissue, such as skin and subcutaneous tumor allografts, which only requires contact
between the probe and skin directly overlying the tumor. Additionally, DRS was the only
technique used to quantify THC, StO2, HbO2, and μs’ and cannot provide insights into tumor
vascular heterogeneity (Kwong et al., 2016; Greening et al., 2016; Valdés et al., 2016; Mourant
et al., 2014). Other optical techniques exist to quantify these parameters including diffuse optical
imaging (DOI) (Kwong et al., 2016), hyperspectral imaging (Hendargo et al., 2015), and near
infrared spectroscopy (NIRS), which extends the wavelength range of DRS into the near infrared
to quantify additional endogenous chromophores such as fat and water (Kawaguchi et al., 2017;
Chen et al., 2015; Kondepati et al., 2008; Spliethoff et al., 2014). For example, DOI combined
with magnetic resonance imaging can differentiate tumors with low and high vascular
heterogeneity, and hyperspectral imaging can quantify vascular O2 supply and blood flow in
rodent models. These spectral and imaging techniques would benefit from an in-depth analysis at
how anesthetic drugs affect results. Next, DRS-derived physiological parameters were only
quantified in response to isoflurane anesthesia. Despite being the most common type of
anesthetic used in DRS-based mouse studies, other anesthesia drugs exist including sevoflurane,
Pentobarbital, and ketamine/xylazine (Gargiulo et al., 2012). Finally, further tests with additional
cell lines for murine subcutaneous allografts or xenografts will generalize results. An allograft
model of colon carcinoma (Balb/c-CT26) was chosen because they are well-established models
in literature but are understudied regarding DRS. Results compare well with other
allograft/xenograft tumors in terms of physiological parameters (THC, StO2, HbO2, and μs’).
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The findings presented here suggest that DRS is a valid tool to dynamically monitor
changes in physiological parameters. These findings indicate that DRS has the potential to help
investigators understand if limitations exist for certain cancer therapies that directly depend on
tumor O2 consumption and help guide investigators in managing anesthesia-induced
physiological changes in DRS studies of murine subcutaneous tumor allografts. Future studies
analyzing DRS-derived physiological parameters in response to these drugs will increase the
generalization of our findings.
5.5 Conclusion
Diffuse reflectance spectroscopy can be effectively used to monitor dynamic fluctuations
in tissue physiological parameters, such as total hemoglobin concentration, tissue oxygen
saturation, oxyhemoglobin, and tissue scattering, and is an attractive tool for monitoring tumor
response to therapy. Additionally, diffuse reflectance spectroscopy has the potential to help
investigators understand if limitations exist for certain cancer therapies, such as chemotherapy or
PDT, that directly depend on oxygen consumption and well-perfused tumors. Investigators using
this tool should understand the dynamic effects of isoflurane concentration on resulting
physiologic values. We show that isoflurane induction, not just maintenance, highly affect
hemodynamic parameters. Alternative methods to diffuse reflectance spectroscopy, such as pulse
oximetry, should be considered when monitoring arterial, rather than tissue, oxygen saturation,
during anesthesia.
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Chapter 6 (Specific Aim 3): Quantification of subcutaneous murine colon carcinoma
tumors in response to chemotherapy and macrophage-targeted immunotherapy measured
using diffuse reflectance spectroscopy

6.1 Introduction
Colorectal cancer (CRC) is the fourth most common cancer in the United States,
accounting for 140,000 new cases and 50,000 deaths in 2018 (Siegel et al., 2018). Until recently,
patients with locally advanced CRC (high-risk stage II and stage III tumors) were treated via
surgery followed by postoperative (adjuvant) chemotherapy. Adjuvant chemotherapy was given
to ensure remaining cancer cells at tumor margins were eliminated after surgery (Jeon et al.,
2011; Wolmark et al., 1999; de Gramont et al., 2000; Andre et al., 2003). Patients with stage IV
CRC may also receive chemotherapy, but only for palliative, rather than curative, measures
(Ronnekleiv-Kelly et al., 2011). For early stage CRC patients, treatment options include
polypectomy or local excision without chemotherapy or radiotherapy. Polypectomy is the
removal of polyps during diagnostic colonoscopy (Horiuchi et al., 2014), whereas local excision
is the removal of small tumors and a portion of healthy surrounding tissue during colonoscopy
(Althumairi et al., 2015).
In recent years, the addition of preoperative (neoadjuvant) chemotherapy for locally
advanced CRC has become clinically accepted in recent years after success in esophageal(2002)
and gastric cancers (Cunningham et al., 2006), and a series of clinical studies by the
Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy (FOxTROT)
Collaborative Group (Group, 2012). The goals of neoadjuvant chemotherapy include achieving
complete eradication of cancer cells or pathological complete response (pCR) prior to surgery,
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reducing intraoperative tumor cell shedding during surgery, and decreasing local recurrence rates
(Van Cutsem et al., 2013; Zhou et al., 2013; Ludmir et al., 2017). In a feasibility phase trial by
the FOxTROT Collaborative Group, 150 patients with locally advanced CRC were given a
combination of chemotherapy drugs either in the neoadjuvant or adjuvant setting. Patients
receiving neoadjuvant chemotherapy experienced significant tumor downstaging and regression,
and the FOxTROT Collaborative Group is currently conducting a further Phase III trial (Group,
2012).
At present, in locally advanced colon cancer, neoadjuvant chemotherapy is generally
given to patients in 2-12 two-week cycles over 4-24 weeks (Cercek et al., 2014). After assessing
tumor therapeutic response after 4-6 cycles of neoadjuvant chemotherapy using techniques such
as endorectal ultrasound (Cercek et al., 2014), CT, PET-CT, or MRI (or a combination of these
techniques), patients with locally advanced disease either receive additional neoadjuvant
chemotherapy cycles or proceed to surgery. Surgery is followed by 9-12 two-week cycles of
adjuvant chemotherapy over 18-24 weeks (Zhou et al., 2013; Cheeseman et al., 2008; HabrGama et al., 2010). In both the neoadjuvant and adjuvant settings, the current chemotherapy
regimen is FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin and
oxaliplatin (Jeon et al., 2011; Carrato, 2008). Variations of this type of chemotherapy have been
a fixture in colorectal cancer treatment since the 1960’s and have been optimized since (Sharp et
al., 1962; Nadler et al., 1964).
Although there has been a steady reduction in CRC incidence and mortality since the
1970’s, primarily attributed to reduction in preventable risk factors, advances in early detection
(Miles et al., 2015), nationwide screening initiatives (Siegel et al., 2018; Levin, 2016; Bénard et
al., 2018; Issa et al., 2017), and continued optimization of neoadjuvant and adjuvant
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chemotherapy regimens (Zhou et al., 2013), current treatment standards and management of
CRC remains problematic (Van Cutsem et al., 2013). Problems with standard CRC treatment
include low 5-year survival rate (~10%) for patients presenting with metastatic CRC (mCRC)
(Lynch et al., 2016), non-specificity for the genetic and biological heterogeneity of CRC
(Blanco-Calvo et al., 2015), potential for multi-year treatment (Van Cutsem et al., 2013), high
recurrence rates (30-40%) of locally advanced disease even after successful therapy and curative
surgery (A. S. Walker et al., 2014), and chemoresistance (He et al., 2017; Hammond et al., 2016;
Zhang et al., 2017). Therefore, investigators are exploring new therapeutic techniques to
overcome these barriers. One broad technique that has gained clinical traction is immunotherapy.
Immunotherapy is an emerging technique to treat CRC by stimulating or enhancing a
patient’s immune system to combat cancer cells without the cytotoxic drawbacks of
chemotherapy (Boland et al., 2017). Current immunotherapy techniques for CRC treatment
include monoclonal antibody therapy, adoptive cell transfer (ACT) therapy, cancer vaccines and
cell therapy (Lynch et al., 2016). Among the many types of immunotherapy strategies,
monoclonal antibody therapy has gained the most clinical traction for treating CRC in recent
years (Noguchi et al., 2013). This systematic review discusses current monoclonal antibody
immunotherapy, which is divided into antibodies targeting either immune checkpoints or
cytokines. Treatments discussed are either approved by the U.S. Food and Drug Administration
(FDA), in clinical trials in humans, or in pre-clinical trials in animals. Finally, this review
discusses emerging methods (optical and non-optical) to monitor tumor response to
immunotherapy treatments in CRC patients.
6.2 Immune checkpoints in colorectal cancer
Immune checkpoints are any set of ligand-mediated inhibitory pathways that keep the

276

immune system in check and maintain homeostasis by regulating the duration and amplitude of
immune responses (Pardoll, 2012; Lee et al., 2016). Several immune checkpoints have been used
as immunotherapeutic targets in CRC, including cytotoxic T-lymphocyte antigen-4 (CTLA4),
programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), tumor
necrosis factor receptor (TNRF) superfamily member 9 (TNFRSF9 or CD137), and TNFRSF7
(or CD27) (Pardoll, 2012; Lynch et al., 2016). Table 1 lists these CRC immune checkpoints that
have been targeted by immunotherapy drugs and whether they are immunosuppressive or illicit a
positive immune response.
Table 1. Immune checkpoints targeted for immunotherapy in colorectal cancer
Immune response
Positive (anti-tumor)
Suppressive (pro-tumor)

Immune checkpoint
CD28/B7
CD137/CD137L
CD27/CD70
CTLA4/B7
PD-1/PD-L1

6.2.1 CTLA4
CTLA4, and its homolog, CD28, are cell surface receptors found on CD4+ cells (helper
T-cells) and CD8+ cells (cytotoxic T-cells) (Lynch et al., 2016). The ligands for CTLA4 and
CD28 are the B7 proteins, B7-1 (CD80) and B7-2 (CD86), which are produced by antigen
presenting cells (APCs) (Lynch et al., 2016). B7 ligands are upregulated and presented on the
cell surface by APCs when the APCs encounter and acquire non-self-antigens (Buchbinder et al.,
2016). When T-cells detect B7, along with major histocompatibility complex loaded with
cognate peptide, competitive binding ensues between CD28/B7 and CTLA4/B7 to maintain Tcell homeostasis. CD28/B7 binding initiates immune stimulation by increasing T-cell
proliferation whereas CTLA4/B7 binding initiates immunosuppression by competitively
reducing signaling of the CD28/B7 complex (Beyersdorf et al., 2015; Seidel et al., 2018). Then,
CTLA4 reduces the probability of future CD28/B7 binding by removing B7 proteins from the
277

APC surface via trans-endocytosis (Qureshi et al., 2011). Thus, CTLA4/B7 interaction is
involved in immune tolerance and immunosuppression, a hallmark of cancer (Passardi et al.,
2017). Monoclonal antibodies targeting and blocking the CTLA4 immune checkpoint pathway
results in increased CD28/B7-dependent clonal expansion of T-cells and has shown promising
clinical benefits (Sun et al., 2016).
6.2.2 PD-1
PD-1 is a well-studied immune checkpoint, with its primary function to suppress the
immune response to regulate tolerance and autoimmunity (Riley, 2009; Valentini et al., 2018;
Keir et al., 2006). PD-1 is a cell surface receptor found on CD4+ cells, CD8+ cells, B-cells,
natural killer (NK) cells, myeloid-derived cells, and macrophages (Valentini et al., 2018; Sundar
et al., 2015). The primary function of PD-1 is to suppress the immune response (Riley, 2009).
The ligands for PD-1 are the B7 proteins, B7-H1 (PD-L1) and B7-DC (PD-L2). PD-L2 is
produced by APCs. PD-L1 is expressed by T-cells, B-cells, dendritic cells (DCs), and
macrophages and is upregulated by many pro-tumor cytokines such as IL-4, IL-10 VEGF, and
TNF-α produced by infiltrating immune cells (Riley, 2009; Wang et al., 2017; Dong et al., 2017;
Sundar et al., 2015). Additionally, PD-L1 is directly expressed by many types of cancer cell,
including CRC and is associated with poor prognosis (O'Neil et al., 2017). PD-1/PD-L1 binding
results in T-cell apoptosis and reduced IL-2 (an anti-tumor cytokine) production (Valentini et al.,
2018). Thus, PD-1 and PD-L1 are active targets in CRC immunotherapy research with the goal
of introducing monoclonal antibodies to block PD-1/PD-L1 binding and improve the anti-tumor
immune response (Lynch et al., 2016).
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6.2.3 CD137
CD137 is a cell surface receptor expressed on activated T-cells, NK cells, and DCs (Segal
et al., 2017). Its primary ligand is CD137L which is expressed on APCs including DCs, activated
B-cells, and macrophages. Binding of CD137L to CD137 promotes an immune response through
T-cell activation and proliferation (Wang et al., 2008). Thus, CD137/CD137L binding promotes
polarization towards an anti-tumor environment. A study by Dimberg et al. showed a
significantly lower CD137L concentration in CRC tissue compared to normal tissue., but similar
concentrations of CD137 (Dimberg et al., 2006).
6.2.4 CD27
CD27 is part of the TNFR family cell surface receptor expressed on NK cells, B-cells,
and naïve CD4+ and CD8+ cells. After activation, T-cells upregulate CD27. Its ligand is CD70,
which is expressed, after activation, by activated DCs, B-cells, T-cells, and NK cells.(van de Ven
et al., 2015) CD27/CD70 binding results in proliferation of CD4+ and CD8+ cells, promoting an
anti-tumor environment. Therefore, agonistic antibodies for CD27, antibodies that target and
activate receptor, have been developed to enhance this response and are currently in clinical
trials for CRC (van de Ven et al., 2015).
6.3 Immune checkpoint inhibition immunotherapy
6.3.1 FDA-approved drugs
FDA-approved CRC immunotherapy drugs for immune checkpoint inhibition include
Nivolumab and Pembrolizumab.
Nivolumab is an immunoglobulin immune checkpoint inhibitor that binds to PD-1
receptors, blocking PD-1 activation and resulting in T-cell activation and immune response
(Sundar et al., 2015). Nivolumab was granted accelerated approval by the FDA in 2017
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following an ongoing, multicenter Phase II trial (NCT02060188) (Overman et al., 2017), funded
by Bristol-Myers Squibb, that indicated Nivolumab was effective for CRC patients with deficient
DNA mismatch repair (dMMR)/microsatellite instability high (MSI-H) disease (Smith et al.,
2018). dMMR/MSI-H CRC makes up approximately 12-15% of cases and is phenotypically
characterized by a high quantify of tumor infiltrating lymphocytes (TILs), prevalence in the right
side of the colon (proximal colon), and poor differentiation (Kawakami et al., 2015). The
approval of Nivolumab was particularly important since standard FOLFOX-based chemotherapy
has limited benefit for dMMR/MSI-H CRC patients (Kawakami et al., 2015). There are currently
39 ongoing clinical trials further exploring Nivolumab as either stand alone or combinatorial
treatment for CRC.
Pembrolizumab is an IgG4-k monoclonal antibody that inhibits PD-1 binding with PD-L1
and PD-L2. This results in an upregulated immune response against CRC cells (O'Neil et al.,
2017). Pembrolizumab was granted accelerated approval by the FDA in 2017 as a second-line
treatment for either unresectable, dMMR, or MSI-H CRC following multiple Phase II and III
clinical trials (Diaz et al., 2017; Le et al., 2016). There are currently 52 ongoing clinical trials
further exploring Pembrolizumab as either stand alone or combinatorial treatment for CRC.
6.3.2 Clinical studies
Immune checkpoint immunotherapy drugs for CRC that are currently undergoing clinical
trials include Urelumab, Varlilumab, and Ipilimumab.
Urelumab is a monoclonal antibody that targets CD137 and activates CD137-expressing
T-cells and NK cells, resulting in a positive immune response against cancer cells. Urelumab was
developed by Bristol-Myers Squibb and is undergoing a Phase I/II clinical trial (NCT01471210)
for melanoma, B-cell non-Hodgkin’s lymphoma, and solid tumors, including 10 patients with
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CRC. The objectives for this ongoing study include safety, tolerability, pharmacokinetics, and
immunogenicity (Segal et al., 2017).
Varlilumab is an agonistic (activating) anti-CD27 monoclonal antibody that binds to
CD27, mimicking the CD70 ligand, and eliciting proliferation of CD4+ and CD8+ cells.
Following a Phase I study with 10 CRC tumors (Burris et al., 2017), Varlilumab is currently
undergoing a Phase II clinical trial (NCT02335918) in combination with the FDA-approved
Nivolumab for several types of solid tumors, including CRC. The primary outcome measure is
the objective response rate (ORR).
Ipilimumab is a receptor antagonistic for CTLA4 (Selby et al., 2016) and was FDA
approved in 2011 for treating melanoma (Specenier, 2016). Ipilimumab is currently undergoing
multiple Phase I and Phase II clinical trials (12 active trials) for CRC (Toh et al., 2016),
including microsatellite-stable (MSS), mCRC (NCT03271047), and dMMR/MSI-H CRC
(NCT03350126), with no published results yet at the time of this writing.
Additionally, a major area of clinical research in CRC is combinatorial therapy using one
or more FDA-approved drugs. For example, there are currently 37 active clinical trials using
FDA-approved Pembrolizumab in combination with experimental drugs or other FDA-approved
drugs to treat CRC.
6.3.3 Pre-clinical studies
In a subcutaneous allograft model of murine CRC, mice were treated with a combination
of anti-mouse CTLA4, and the chemotherapy agents ixabepilone, paclitaxel, gemcitabine, or
etoposide (Jure-Kunkel et al., 2013). CRC allografts showed reduced tumor growth rate in mice
treated with anti-mouse CTLA4 alone, and further reduction in growth rate in combination
treatment groups. 50% and 70% of mice displayed complete tumor regression after treatment
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with anti-CTLA4 and either ixabepilone or paclitaxel, respectively. Additionally, activated Tcells in the TME significantly increased in response to therapy (Jure-Kunkel et al., 2013).
Although immune checkpoint inhibition was successful in this subcutaneous murine model of
CRC, some groups prefer to implement orthotopic models since they better represent the tumor
immune environment.
Zhao et al. established an orthotopic mouse model for CRC using endoscopy-guided
microinjection of CT26 cells into the colon wall, and compared this to standard subcutaneous
allograft models of CRC (Zhao et al., 2017). Mice were treated with a combination of immune
checkpoint inhibitors, anti-mouse PD1 and anti-mouse CLTA4, 1 day after tumor implantation.
They found that orthotopic models were more sensitive to this checkpoint inhibition compared to
subcutaneous tumor models; in fact, tumors failed to grow in treated orthotopic models, while
tumor growth only slowed in subcutaneous models, confirming an earlier study by Leach et al
(Leach et al., 1996). Although subcutaneous models are easier to establish and represent a
“worst-case scenario” in that the TME is highly immunosuppressive, orthotopic CRC mouse
models better represent the human TME based on infiltration of immune cells (Zhao et al.,
2017).
6.3.4 Conclusion
Immune checkpoint inhibition is a promising approach for CRC treatment (Jenkins et al.,
2018), with several FDA-approved drugs already on the market and many more in clinical trials.
Although immune checkpoint inhibition has shown success in treating CRC, the biggest
challenge for investigators is identifying which patients may or not respond before treatment
initiation (Jenkins et al., 2018) and overcoming tumor cell resistance to this immunotherapy (Lee
et al., 2016). Jenkins et al. provides a comprehensive review of tumor cell resistance to immune
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checkpoint inhibition (Jenkins et al., 2018). This heterogeneous patient response to immune
checkpoint inhibition is a strikingly similar problem to identifying responders vs. non-responders
for standard first-line neoadjuvant chemotherapy in CRC (Tsuji et al., 2012). The current stateof-the-art is to biopsy the tumor during colonoscopy and determine expression levels of markers
such as a PD-L1 using immunohistochemistry (IHC). Patients overexpressing the target
biomarker, such as PD-LI, are considered the best candidates for that immunotherapy (Patel et
al., 2015). In the future, investigators are looking into identifying other biomarkers and
personalized gene-expression signatures to identify candidates most likely to respond to immune
checkpoint inhibition (B. Li et al., 2017; Tsuji et al., 2012; Dunne et al., 2017; Guinney et al.,
2015; Kather et al., 2018).
6.4 Cytokines in colorectal cancer
Cytokines are small cell-signaling proteins, produced by immune cells (Akdis et al.,
2016), that are involved in myriad pathways in CRC (West et al., 2015). Chemokines, members
of a family of cytokines able to induce cellular chemotaxis, are also involved in CRC pathways
(Itatani et al., 2016). Thus, cytokines and chemokines, and their receptors, make attractive
targets for CRC therapy, although pre-clinical and clinical research currently lags other discussed
CRC immunotherapy techniques (Lynch et al., 2016; Akram et al., 2016). Development of
cytokine-targeted immunotherapy can potentially be used as stand-alone treatment or, more
likely, combinatorial treatment with either chemotherapy, radiotherapy, or other immunotherapy
techniques to normalize the CRC tumor microenvironment (TME) (Klampfer, 2011).
Multiple immune cells in the TME release cytokines and chemokines including tumorassociated macrophages (TAMs), monocytes, neutrophils, cancer-associated fibroblasts (CAFs),
dendritic cells, T-cells, NK cells, myeloid-derived suppressor cells (MDSCs), and mast cells
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(Lynch et al., 2016; Mager et al., 2016). Table 1 shows an up-to-date snapshot of cytokines and
chemokines involved in CRC, many of whose roles are under active investigation. Included in
this table are interleukins and growth factors, which are types of cytokines (Itatani et al., 2016;
Mager et al., 2016; Landskron et al., 2014; Klampfer, 2011; Ohlsson et al., 2016; Setrerrahmane
et al., 2017; Allen et al., 2018; Manzat Saplacan et al., 2017; Yuan et al., 2015; Mira et al.,
2017; Wang et al., 2016; Liu et al., 2016). Chemokines and cytokines not listed may represent a
research gap with regards to CRC. Several of these cytokines and chemokines have gained
traction as effective immunotherapy targets for the treatment of CRC.
Table 2. Cytokines and chemokines involved in human CRC pathogenesis
Interleukins
Growth Factors
Chemokines
Pro-Tumor

IL-1β
IL-4
IL-6
IL-8
IL-11

IL-17
IL-17A
IL-22
IL-23
IL-33

VEGF
TNF-α
EGF
HGF

FGF
PDGF
CSF1

Dual Role/
Controversial

IL-1
IL-9

IL-10
IL-21

TGF-β
TGF-β1

TNF
CSF2

Anti-Tumor

IL-2
IL-12
IL-15

IL-17F
IL-18

IFN-γ

CXCL1
CXCL2
CXCL5
CXCL8
CXCL12
CXLC9
CXCL17
CXCL10
CCL3
CCL4

CCL2
CCL15
CCL20
CX3CL1
CCL5
CCL21
CCL24
CCL19

6.5 Cytokine-targeted immunotherapy
6.5.1 FDA-approved drugs
All current FDA-approved cytokine-targeted immunotherapy drugs for CRC either target
vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), or epidermal growth
factor (EGF) receptors (EGFR). Cytokine-targeted immunotherapy drugs targeting either VEGF
or VEGFR include bevacizumab, aflibercept, and regorafenib. Drugs targeting EGRF include
cetuximab and panitumumab. All five FDA-approved drugs primarily benefit mCRC patients,
although many clinical trials are ongoing for other CRC subtypes in both neoadjuvant and
adjuvant settings.
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6.5.2 Anti-vascular endothelial growth factors (anti-VEGFs)
Bevacizumab is a monoclonal antibody VEGF-inhibitor, preventing tumor blood vessel
growth. The FDA approved bevacizumab as first line treatment for mCRC in 2004 (Strickler et
al., 2012) and in 2006 for second-line treatment of mCRC in combination with FOLFOX4
(Cohen et al., 2007), making it the first anti-VEGF drug for CRC. A phase III clinical trial by
Eastern Cooperative Oncology Group (ECOG) tested bevacizumab’s efficacy and safety in
combination with FOLFOX4 (Giantonio et al., 2007). Patients treated with the combination
therapy saw a longer median overall survival of 12.9 months with a 22.2% response rate
compared to an overall survival of 10.8 months and an 8.6% response rate for patients receiving
standalone FOLFOX4 chemotherapy (Giantonio et al., 2007). Additional studies have confirmed
the benefits of bevacizumab in treating mCRC (Hurwitz et al., 2004; Saltz et al., 2008; Ilic et al.,
2016).
Six years later in 2012, aflibercept, an antiangiogenic VEGF inhibitor, was approved by
the FDA as a second-line treatment for mCRC in combination with the FOLFIRI chemotherapy
regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) (Stewart et al., 2012).
Aflibercept is meant to be used for mCRC patients who failed to respond to previous FOLFOXbased chemotherapy (Van Cutsem et al., 2012). In a phase III clinical trial (NCT00561470), the
addition of aflibercept to FOLFIRI improved overall median survival from 12.1 to 13.5 months
and progression-free survival from 4.7 to 6.9 months for stage IV mCRC patients (Van Cutsem
et al., 2012). In an update to this same phase III clinical trial, published in 2014, investigators
found that overall survival increased by 0.8 months for mCRC patients with no prior
bevacizumab treatment and 1.5 months for patients with no prior bevacizumab treatment
(Tabernero et al., 2014).
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Regorafenib is an oral kinase inhibitor that targets oncogenic and angiogenic kinases to
inhibit VEGFR activation, resulting in inhibition of tumor cell proliferation and angiogenesis
(Dhillon, 2018). In 2012, the FDA granted approval for regorafenib to treat mCRC patients
based on the CORRECT phase III clinical trial (NCT01103323). The median overall survival
was 6.4 months in patients who received regorafenib monotherapy and 5.0 months in patients
who received placebo. This study did, however, note adverse events in 93% of regorafenibtreated patients (Grothey et al., 2013). In 2015, the CONCUR phase III clinical (NCT01584830)
became the second trial to demonstrate overall survival benefits of regorafenib (8.8 months) vs.
placebo (6.3 months) for mCRC patients (Li et al., 2015).
6.5.3 Anti-epidermal growth factor receptors (anti-EGFRs)
In 2004, the FDA approved the monoclonal antibody, cetuximab, to treat advanced CRC
patients who have failed standard chemotherapy (Saltz et al., 2007; Mesia et al., 2016; Hubbard
et al., 2013; Cunningham et al., 2004). Cetuximab targets the ligand-binding domain of EGFR,
resulting in reduced tumor growth and differentiation (Lenz, 2007). A clinical trial conducted by
the North Central Cancer Treatment Group (NCCTG) N0147 compared the use of FOLFIRI with
and without cetuximab in stage III CRC patients with both wild-type KRAS and mutant KRAS.
Combination treatment with cetuximab plus FOLFIRI showed that 5-year disease-free survival,
overall survival, and time to recurrence in patients with wild-type KRAS improved from 64% to
83% (p=0.10), 76% to 87% (p=0.21), and 67% to 86% (p=0.09), respectively (Huang et al.,
2014). Based in part on this study, as well as the CEGOG trial,(Ocvirk et al., 2010) the FDA
approved cetuximab in 2012 as a first-line treatment in KRAS-/EGFR+ mCRC in combination
with FOLFIRI.

286

In 2017, panitumumab, another EGFR inhibitor, was granted FDA approval to treat
mCRC patients with wild-type RAS as a first-line treatment in combination with FOLFOX
(Douillard et al., 2014; Price et al., 2014). A study by Leone et al. used panitumumab in
combination with capecitabine plus oxaliplatin (XELOX) to study its efficacy in patients with
liver only mCRC. Out of the forty-six patients, the objective response rate was 54% with two
patients with complete responses and 23 with a partial response. The medial overall survival rate
was observed to be 21.9 months with a median progression-free survival of 8.5 months. Overall,
the combination of panitumumab with XELOX (P-XELOX) yield a high response for patients
with liver only mCRC (Leone et al., 2013).
6.5.4 Clinical studies
One pathway currently being studied is the IL-6/STAT3 pathway. IL-6 binds to the IL-6
receptor (IL-6R), activating the signal transducer and activator of transcription 3 (STAT3)
signaling pathway. This pathway induces transcription of various genes involved in
differentiation and proliferation and reduces CD4+ immune responses (Kitamura et al., 2017). In
a phase I/II clinical trial, CRC patients with advanced solid tumors, along with other cancer
patients, received IL-6 neutralizing antibodies at increasing doses. Although investigators
showed increased tumor hemoglobin in response to IL-6 neutralization, colorectal tumors had a
low response rate measured via RECIST criteria. Although this study indicate that stand-alone
IL-6 inhibition was inadequate for advanced CRC solid tumors, investigation of IL-6/STAT3
modulation is worth further exploration (Angevin et al., 2014).
IL-10 is also being explored as an immunotherapy target. A future spotlight will be on a
collaborative industry-academic phase I clinical trial, which has enrolled 350 patients with
various solid tumors including CRC. In this study, AM0010, a PEGylated human IL-10, will be
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self-administered subcutaneously in four monthly cycles, either as a monotherapy or with
chemotherapy, to test the safety, toxicity, maximum tolerated dose, anti-tumor activity, and
pharmacokinetics of this cytokine-targeted immunotherapy (Bauer et al., 2014). In addition to IL
pathways, nimotuzumab (NCT00972465), a monoclonal antibody targeting EGFR, and
imalumab (NCT02448810), a monoclonal antibody targeting macrophage inhibitory factor
(MIF), are undergoing clinical trials for CRC (Xu et al., 2016; Mahalingam et al., 2015).
6.5.5 Pre-clinical studies
The effect of modulating cytokines and chemokines in the human CRC TME is mostly
hypothesized and has not yet been rigorously tested in clinical trials. Most CRC cytokine
modulation research, besides the aforementioned interleukins, exists in the pre-clinical and basic
biology realms.
Two chemokine receptors, C-C chemokine receptor type 1 (CCR1) and chemokine C-C
motif receptor-like 2 (CCRL2), have been recently implicated in aiding in liver metastasis
(Akram et al., 2016), the primary cause of death for CRC patients (Valderrama-Trevino et al.,
2017). Ligands for CCR1 and CCRL2 are the chemokines CCL3, CCL5, CCL7, and CCL23, and
are suggested as potential targets for cytokine-targeted immunotherapy (Akram et al., 2016).
CCL2 and CCL24 were also found to be highly elevated (>100-fold) in CRC liver metastases
compared to healthy adjacent liver tissue, implying that these chemokines could also be targets
for cytokine-targeted immunotherapy (Cheadle et al., 2007).
Chemokine neutralization, especially of CCL2, has gained traction in both CRC and
non-CRC studies of mice (Chun et al., 2015). CRC, independent of subtype (Lim et al., 2016;
Becht et al., 2016), recruits circulating monocytes via chemotaxis to the TME primarily through
the release of CCL2, also known as monocyte chemoattractant protein-1 (MCP1), a highly
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elevated chemokine in CRC (Marech et al., 2016; Lim et al., 2016; Becht et al., 2016; Chun et
al., 2015). In the TME, monocytes differentiate into TAMs, partially as a result of CCL2. TAMs,
the most abundant immune cell in the TME, also have the most substantial and pervasive effect
of any immune cell in the TME (Erreni et al., 2011; Allavena et al., 2008; Chen et al., 2005;
Marech et al., 2016). In CRC, TAMs have been shown to have both anti-tumor and pro-tumor
functions, depending on whether they are polarized more towards an M1 (classical) or M2
(alternative) phenotype and their physical location within the tumor (Marech et al., 2016). Protumor functions of alternatively activated M2-polarized TAMs include tumor growth,
angiogenesis, immunosuppression, and matrix remodeling (Liu et al., 2015). Additionally, CCL2
binding to its receptor, CCR2, on endothelial cells increases vascular permeability and metastatic
risk (Lim et al., 2016). Thus, targeting CCL2 to reduce M2-polarized, pro-tumor TAMs is an
attractive ongoing cytokine-targeted immunotherapy strategy in pre-clinical settings. In mouse
models, CCL2 blockade has resulted in reduced neovascularization and tumor size of
orthotopic colon tumors in Balb/c mice, suggesting that CCL2 may be a promising target for
treating colitis-associated colon cancer (Popivanova et al., 2009). Additionally, anti-CCL2
immunotherapy prolonged survival in C57BL/6 mice with GL261 glioma (Zhu et al., 2011), and
reduced TAM infiltration in FVB/N mice with MCF-7 breast cancer (Svensson et al., 2015).
However, few cytokine-targeted immunotherapy techniques have been tested for efficacy in
human CRC, although oral N-acetyl-L-cysteine (NAC) co-administered with mesalamine, an
anti-inflammatory, has benefitted ulcerative colitis patients, attributed in part to the downregulation of CCL2 and IL-8 (Guijarro et al., 2008). In summary, many investigators now
believe that CCL2-neutralizing immunotherapy will play an important role in early-stage CRC
treatment in future clinical studies (Chun et al., 2015).
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Besides CCL2, other cytokines and chemokines have been explored. For example,
blocking the pro-angiogenic and pro-tumor chemokine ligand 1 (CXCL1), whose gene is also
known as growth-regulated oncogene-α, using an anti-CXCL1 neutralizing antibody inhibited
tumor growth and angiogenesis in a mouse xenograft model of human CRC (Wang et al.,
2006). Blockade of IL-1β reduced tumor formation in a mouse model of colitis-associated CRC
(Wang et al., 2014). TNF blockade reduced CRC carcinogenesis in an AOM/DSS (colitisinduced) mouse model (Popivanova et al., 2008). On the other hand, the addition of IL-15, which
has anti-tumor effects in CRC (Table 3), was shown to increase the therapeutic effects of antiPD-L1 and anti-CTLA4 treatment in a CT26 colon carcinoma mouse model (Yu et al., 2010).
The overarching current hypothesis is that cytokine-targeted immunotherapy, especially the
blockade of pro-tumor cytokines in CRC, may enhance tumor therapeutic response in CRC
tumors treated with chemotherapy, radiation, or approved checkpoint inhibitors (Mager et al.,
2016).
6.5.6 Conclusion
Cytokine-targeted immunotherapy research lags other discussed CRC immunotherapy
methods, although further investigation is justified. The biggest challenge facing this type of
therapy is determining which pharmacokinetic and pharmacodynamic variables are important
navigating cytokine pathways while decreasing systemic toxicity in CRC patients. Additionally,
the FDA approved drugs, cetuximab and panitumumab are ineffective in patients with RAS
mutations (~23% of stage IV CRC patients). (sirisena, the pattern of KRAS mutations in
metastatic, bmc res notes) Overall, cytokine therapies will likely be most effective in
combination with other immunotherapies or chemo- and/or radiotherapy (Lynch et al., 2016).
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6.6 Assessing tumor therapeutic response
In addition to new CRC therapies being investigated, an important branch of CRC
research is development of clinically-translatable methods to rapidly assess whether a therapy
regimen is effective on a per patient basis (Berger et al., 2017; Roblyer et al., 2011). Rapid
assessment of therapy can prevent unnecessary chemotherapy in both responders and nonresponders (Granata et al., 2015). Currently, tumors are assessed based on the widely accepted
Response Evaluation Criteria in Solid Tumors (RECIST) criteria, which grades tumors as, from
most desirable to least desirable, complete responders, partial responders, stable disease, or
progressive disease (Eisenhauer et al., 2009; Wahl et al., 2009; Chung et al., 2012). The overall
goal of assessing tumor therapeutic response is adjusting treatment if necessary, avoiding surgery
and reducing morbidity (A.S. Walker et al., 2014). The standards for monitoring tumor
therapeutic response to neoadjuvant therapy (chemotherapy, radiation, and/or immunotherapy)
using RECIST are digital rectal examination (DRE), rigid proctoscopy, biopsy,
carcinoembryonic antigen (CEA) level, and a radiological technique such as CT (A.S. Walker et
al., 2014), PET-CT (Petersen et al., 2014), MRI (Van Cutsem et al., 2016), or DiffusionWeighted (DW)-MRI (A.S. Walker et al., 2014). However, following neoadjuvant treatment
initiation, assessing tumor response does not occur for approximately two months (Habr-Gama et
al., 2010; Van Cutsem et al., 2016). Additionally, for patients showing evidence of partial or
complete response after these two months of neoadjuvant treatment, they must wait an additional
1-2 months for follow-up as part of the “Wait and Watch Protocol” (A.S. Walker et al., 2014).
Finally, studies have shown that current radiological techniques are insufficient to identify
responders with positive predictive values less than 50% (Kekelidze et al., 2013). However,
several research groups are investigating optical and imaging methods to rapidly assess
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therapeutic response on a scale of days or weeks, rather than months.
Optical methods to monitor CRC tumor therapeutic response use light to acquire relevant
clinical information. Since the CRC screening, diagnostic, and, in some cases, therapeutic
standard (in early CRC stages only) is colonoscopy, investigators are aiming to create minimallyinvasive endoscopy-compatible techniques. Techniques currently being evaluated, mostly in preclinical laboratory settings, for use in CRC include nonlinear optical imaging, fluorescencebased endoscopy, and diffuse reflectance spectroscopy.
6.6.1 Nonlinear optical imaging
Nonlinear optical imaging has been used to image freshly resected advanced rectal
adenocarcinoma sections of patients who had received neoadjuvant radiochemotherapy. This ex
vivo, label-free imaging method combined second harmonic generation (SHG) and two-photon
excited fluorescence (TPEF) and showed that SHG microscopy could determine degree of
fibrosis post-neoadjuvant chemoradiotherapy (L. H. Li et al., 2017). Therefore, this method
could potentially direct ideal operating time. Although this study was performed ex vivo, future
miniaturization of nonlinear optical microscopy techniques as an endoscopic method has
important applications in early preoperative tumor evaluation and clinical disease management.
In fact, miniaturization of similar techniques have been performed in in vivo rat colon tissue.
A flexible multiphoton microendoscope, with a 3 mm outer diameter and 4 cm rigid
length, has recently been developed by investigators out of Cornell University. This multiphoton
microendoscope, the first of its kind, uses a resonant-nonresonant raster scanner to acquire en
face images of unstained rat colon tissue at a field-of-view of 115 μm x 115 μm (Brown et al.,
2012). Potential clinical advantages of this research include diagnostic optical biopsy and realtime histopathological assessment of CRC tumor response to neoadjuvant chemotherapy and
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antibody immunotherapy.
6.6.2 Fluorescence-based endoscopy
Fluorescence-based endoscopy is a new approach imaging modality that integrates a
colonoscopy with optical imaging. This technique is a “robust method for early detection of CRC
owing to its intrinsic coupling of detection with the underlying molecular-level pathology of the
disease”. With the use of molecular imaging, this type of optical system can detect variations in
tissues unlike other system that only detect changes in structure (Sakuma et al., 2015).
In a study by Mitsunaga et al., they developed a “rapid fluorescent detection method”
using a “topically applied enzymatically activatable probe (gGlu-HMRG)” to detect the γglutamyltranspeptidase (GGT) enzyme during a colonoscopy. Expression of GGT was higher in
mouse models with CRC than those without. Five minutes after topical administration, gGluHMRG fluorescent lesions were detected using fluorescent microscopy. Based on these results,
the use of gGlu-HMRG can improve detection of colitis-associated colon cancer (CAC) with a
“higher target to background ratio” compared to conventional white light colonoscopy
(Mitsunaga et al., 2013).
In a human study by Watanabe et al., used the PINPOINT® Endoscopic Fluorescence
Imaging System intraoperatively to identify tumor sites using indocyanine green during
laparoscopic surgery. Using this system, surgeons saw a tumor visibility rate of 93.8%. No
adverse effects were observed during these procedures. As a result, this study provided evidence
that the PINPOINT® system was able to identify colorectal tumors without adverse effects
(Watanabe et al., 2017).
Fluorescence-based endoscopy techniques are not only used for tumor detection, but they
can also monitor tumor response to various therapies. Sakuma et al., used fluorescence-based
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endoscopic imaging to investigate TF-antigen detection in CRC tumors during chemotherapy.
With the use of a nanobeacon and fluorescence labeled (FL) endoscopy signals, they found that
the tumors were above the signal threshold indicating a cancerous abnormality. After
chemotherapy treatment with 4-paclitaxel, no tumors were detected through FL endoscopy.
Based on these results, this type of imaging modality can be used to observe tumor response
during chemotherapy (Sakuma et al., 2015).
6.6.3 Diffuse reflectance spectroscopy
Diffuse reflectance spectroscopy (DRS) is a non-invasive or minimally-invasive
technique that uses a small probe to deliver broadband light to tissue and collect the diffusely
reflected light with a spectrometer (G.J. Greening et al., 2018; Greening et al., 2016; Dadgar et
al., 2018). DRS can provide relevant clinical information such as total hemoglobin content,
tissue oxygen saturation, oxy- and deoxyhemoglobin, lipid and water content, and tissue
scattering properties, and can thus be applied to monitoring tumor response to therapy (G.J.
Greening et al., 2018; Spliethoff et al., 2014).
DRS has recently been used in an ex vivo study of resected human colon tissue to
differentiate tissue type with an overall accuracy of 95%. The investigators hope to eventually
apply this technology in an in vivo setting for real-time guidance during CRC surgery (Baltussen
et al., 2017). DRS has also been integrated into a fiber-optic biopsy needle to assess functional
tissue properties in an in vivo study of lung cancer patients (Spliethoff et al., 2016). This same
research group also used their DRS system to monitor tumor response to chemotherapy in a
murine subcutaneous mammary tumor model. The investigators found that tumors showed an
increase in lipid content and tissue oxygen saturation after just 2 days of treatment, and believe
this technology can someday help optimize personalized cancer treatments (Spliethoff et al.,
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2014). Next, Schols et al. used DRS in open colorectal surgery to detect mesenteric arteries in
real-time to reduce interoperative risk of iatrogenic surgery (Schols et al., 2015). One of primary
limitations with optical methods, such as DRS, is poor light sampling into highly scattering
tissues. However, it’s been shown that, at the optical properties found in colorectal tissue
(Carneiro et al., 2018), DRS sampling depth is greater than 0.5 mm at 630 nm at source-detector
separations (< 1 mm) compatible with the biopsy port of standard colonoscopes (G.J. Greening et
al., 2018).
As of yet, DRS applied to CRC is in its infancy; it has only been applied to monitor
tumor therapeutic response to chemotherapy in mouse models, although investigators believe
DRS technology can be used to quantify volumetric tumor perfusion in response to
immunotherapies, which can eventually help guide clinicians in identifying potential responders
and non-responders during early therapy (G.J. Greening et al., 2018).
6.7 Introduction to study
Colorectal cancer (CRC) is estimated to account for 140,050 new cancer cases annually
in the United States, making it the 4th most common cancer type overall (behind breast, lung, and
prostate), and resulting in 50,630 annual deaths (Siegel et al., 2016). Tumor stage is determined
using the MRI-based tumor, node, and metastasis (TNM) Staging System, which guides CRC
treatment (Ferrari et al., 2015; Dienstmann et al., 2017). Locally-advanced CRC (stages II-III),
which account for approximately 20% of cases, describes cancer that has spread from the site of
the primary tumor to surrounding tissue or lymph nodes, but has not metastasized (Landmann et
al., 2005; Ferrari et al., 2015; Dienstmann et al., 2017). The standard of treatment for locallyadvanced CRC is neoadjuvant chemoradiotherapy (CRT) using 5-fluorouracil (5-FU), followed
by total mesorectal excision (TME) surgery (Boland et al., 2014). Following neoadjuvant CRT,
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biopsies are examined to determine pathologic response. Ideally, patients will exhibit pathologic
complete response (pCR), defined as the absence of residual cancer cells in histological
examination, since achieving pCR reduces distal recurrence risk (Ferrari et al., 2015). For
example, the 5-year distal-metastases-free survival is significantly greater (89%) for patients
achieving pCR compared to those who don’t (75%). However, pCR is achieved in less than 30%
of cases, resulting in distal recurrence rates of 25%, which is the primary cause of CRC-related
death (Ferrari et al., 2015). An emerging strategy known as immunotherapy, or
immunomodulation therapy, has gained clinical momentum in recent years to aid neoadjuvant
CRT in reducing pre-operative tumor burden and recurrence risk (Lynch et al., 2016; Yuan et al.,
2015; Sanchez-Castanon et al., 2016).
Immunotherapy in CRC is a broad neoadjuvant therapy approach, with most strategies
aimed at modulating the host immune system to inhibit checkpoints of pro-tumor pathways to
increase the tumor’s sensitivity to chemotherapy (Lynch et al., 2016). One specific
immunotherapy strategy is the blockade of CCL2/MCP-1 (monocyte chemoattractant protein-1),
an elevated cytokine during CRC progression which recruits monocytes to the tumor
microenvironment (Chun et al., 2015). Monocytes differentiate into tumor-associated
macrophages (TAMs), which have pro-tumor functions in CRC (Erreni et al., 2011; Li et al.,
2016; Guo et al., 2016; Zhang et al., 2016; Kaler et al., 2009; Popovic et al., 2007; Herbeuval et
al., 2004; Guo et al., 2013; Zou et al., 2017; Barbera-Guillem et al., 2002), although some
conflicting studies have reported anti-tumor functions of TAMs at tumor margins (Funada et al.,
2003; Sugita et al., 2002; Forssell et al., 2007; Zhou et al., 2010). Pro-tumor functions of TAMs
include direct secretion of angiogenic growth factors (GFs) leading to an increase in vascular
endothelial growth factor (VEGF) (Burmeister et al., 2017; Erreni et al., 2011; Barbera-Guillem
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et al., 2002), as well as ECM-degrading matrix metalloproteases (MMPs) which allow for tumor
expansion and release of ECM-sequestered angiogenic GFs (Erreni et al., 2011; Guo et al.,
2013). Thus, CCL2-mediated TAM infiltration is linked to increased inflammation, angiogenesis
and tumorigenesis (Guo et al., 2016; McClellan et al., 2012). Additionally, CCL2 has been
linked to other pro-tumor/immunosuppressive functions such as inducing myeloid-derived
suppressor cell (MDSC) accumulation and promoting STAT-mediated T-cell suppression of
polymorphonuclear (PMN)-MDSCs (Chun et al., 2015). Therefore, anti-CCL2 immunotherapy
has the potential to reduce tumor burden and recurrence risk.
Recent research has explored CCL2 blockade as an immunotherapy strategy in mouse
models of various cancers. Popivanova et al. showed that CCL2 blockade reduced
neovascularization and colon tumor size in Balb/c mice (Popivanova et al., 2009). Zhu et al.
showed that administration of anti-CCL2 in combination with temozolomide chemotherapy to
C57BL/6 mice with GL261 glioma significantly prolonged survival (Zhu et al., 2011). Svensson
et al. demonstrated that CCL2 blockade in FVB/N mice with MCF-7 breast cancer decreased
TAM infiltration and reduced estrogen-stimulated cancer growth (Svensson et al., 2015). Kirk et
al. showed that delivering anti-CCL2 in combination with docetaxel chemotherapy to SCID mice
with C4-2B prostate adenocarcinoma inhibited tumor progression (Kirk et al., 2013). Finally,
Zhang et al. demonstrated that TAMs directly contribute to 5-FU chemoresistance in CRC, and
concluded that TAM pathways (such as CCL2) were potential immunotherapy targets to increase
efficacy of 5-FU chemotherapy (Zhang et al., 2016). However, no studies have combined
chemotherapy with CCL2 blockade in a mouse model of CRC.
The present study uses anti-CCL2 as a neoadjuvant immunotherapy strategy (Singh et al.,
2014), combined with standard 5-FU chemotherapy, in Balb/c mice with subcutaneous CT26

297

colon carcinoma allografts. Female Balb/c mice were injected with CT26 tumor cells in the left
flank, and then given the control vehicle, isotype control antibody, anti-CCL2 immunotherapy,
5-FU chemotherapy, or combination therapy (five groups). Combination therapy was expected to
alter CRC tumor perfusion due to effects of chemotherapy and CCL2-mediated effects on TAMs.
Therefore, during the study, tumor perfusion was longitudinally measured via non-invasive
diffuse reflectance spectroscopy (DRS), a non-invasive, probe-based technique which can
quantify perfusion metrics such as tissue hemoglobin content (THC), tissue oxygen saturation
(StO2), and oxyhemoglobin (HbO2), as well as the reduced scattering coefficient (μs’). DRS
measurements were then correlated to end-point immunohistochemistry (IHC) analysis of
hypoxia (pimonidazole), angiogenesis (CD105), tumor-associated macrophage (TAM)
polarization (CD80, CD68, and CD206), proliferation (Ki67), and apoptosis (CC3). This study
forms two major hypotheses: 1) CCL2 blockade in the tumor microenvironment as an
immunotherapy strategy will increase sensitivity of CT26 tumors to 5-FU chemotherapy,
quantified by tumor size, DRS perfusion metrics, IHC analysis, and CCL2 ELISA and 2)
changes in tumor perfusion will precede measurable changes in tumor size. Confirmation of
these hypotheses may indicate that DRS could potentially be used to monitor early tumor
response to combinatorial immunotherapy and chemotherapy.
6.8 Materials and methods
6.9.1 Cell line
CT26 (ATCC®, CRL-2638TM), a murine colon carcinoma cell line derived from the
Balb/c mouse strain, was maintained in Roswell Park Memorial Institute (RPMI)-1640 medium
(ATCC®, 30-2001TM) supplemented with 10% fetal bovine serum (ATCC®, 30-2020), 1%
antibiotic antimycotic solution (Sigma-Alrich, A5955-100ML), and 0.2% amphotericin
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B/gentamicin (Thermo Fisher Scientific, R015010). CT26 cells were brought to the third passage
(P3).
6.8.2 Animal model
The study was approved by the University of Arkansas Institutional Animal Care and Use
Committee (IACUC #17072). Eight-week-old female Balb/c mice (n=125) were obtained from
The Jackson Laboratory (Bar Harbor, ME, USA). Upon arrival to the Small Animal Facility at
the University of Arkansas, mice were housed in groups of three at 23°C ± 1°C and 50% ± 10%
humidity with a 12:12-hour light-dark cycle and had access to water and standard rodent food ad
libitum. Mice were weighed daily upon arrival. Mice underwent 2 weeks of environmental
acclimation, including daily handling (2 minutes per mouse) for stress adaptation to future
handling during measurements. After 2 weeks, the hair on the injection site (left flank) of the
now 10-week old Balb/c mice was removed via shaving and NairTM, and then cleaned, prior to
injection with CT26 cells. Then, the mice underwent subcutaneous (SQ) injection of 1x105 CT26
cells into the shaved and depilated left flank (Figure 1). Tumors were allowed to grow until they
reached 75 ± 5 mm3 (day 0), as measured via 𝑉 = (𝐿 ∙ 𝑊 2 )/2, which took an average of 14 ± 4
days.

Figure 1. Balb/c mice were the model organization for the studies presented here.
CT26 cells were injected subcutaneously into the left flank to form colon tumor
allografts. Image of mouse and syringe sourced from the Library of Science
Medical Figures, which are free to share, copy, and redistribute under Create
Commons License BY-NC-SA 4.0.
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6.8.3 Anesthesia protocol
Mice were anesthetized with isoflurane (ISO) and 1 L/min oxygen (O2) for various
procedures throughout the study. Procedures included shaving and nairing of left flank, SQ CT26
cell injection, intraperitoneal (IP) injection of therapy/control, IP injection of pimonidazole, and
tumor vivisection and euthanasia. Mice undergoing DRS measurements were not anesthetized
since isoflurane can depress StO2 and HbO2 (Gage J. Greening et al., 2018). All mice were
physically maintained on a water-based warming pad (Stryker, #TP700) controlled by a warming
pump (Stryker, Kalamazoo, MI, #TP12E) set to 42°C. Table 3 lists the isoflurane concentration
for induction and maintenance for each procedure as well as approximate anesthesia time for
each.
Table 3. Isoflurane anesthesia specifications per procedure with 1 L/min O2
Procedure
SQ Injection of CT26 Cells
IP Injection of Therapy/Control
IP Injection of Pimonidazole
Tumor Vivisection and Euthanasia

[ISO]
(Induction)
3.0%
3.0%
2.0%
4.0%

Time
(min)
2
2
2
1

[ISO]
(Maintenance)
2.0%
2.0%
2.0%
4.0%

Time
(min)
2
1
1
5

6.8.4 Control and experimental groups
For analysis of early tumor therapeutic response, 62 female Balb/c mice were randomly
divided into five groups of up to 15 mice once the CT26-tumors reached 75 mm3 (Figure 2). The
first group (control, n=15) received saline injections for vehicle control. The second group
(n=13) received isotype antibody control. The third group (n=10) received immunotherapy but
no chemotherapy. The fourth group (n=12) received chemotherapy but no immunotherapy. The
fifth group (n=12) received a combination of both chemotherapy and immunotherapy. For each
group of mice, mice were euthanized on either day 1 (n=5), day 3 (n=5), or day 7 (n=5) for endpoint immunohistochemical and ELISA analysis. Table 4 and Figure 2 shows the breakdown of
control and experimental groups.
300

Table 4. Breakdown of control and experimental groups
Group

Sample Size

Saline Control

1
2
3
4
5
Total

15
13
10
11
12
61

X

Isotype Control

Anti-CCL2
Immunotherapy

5-FU
Chemotherapy

X
X
X

X
X

Figure 2. For analysis of early tumor therapeutic response, 62 female Balb/c mice
were randomly divided into five groups of up to 15 mice once the CT26-tumors
reached 75 mm3. Then, mice were subject to either one of five therapies: saline
control, isotype (antibody) control, anti-CCL2 antibody immunotherapy, 5-FU
chemotherapy, or a combination of immunotherapy and chemotherapy. Tumors
then underwent daily DRS measurements. Image of mouse, syringe and
antibodies sourced from the Library of Science Medical Figures, which are free
to share, copy, and redistribute under Create Commons License BY-NC-SA 4.0.
6.8.5 Chemotherapy
5-Fluorouracil (5-FU), purchased from Sigma-Aldrich (St. Louis, MO, USA), is an
antitumor chemotherapy agent that induces p53-dependent apoptosis and decreases proliferation
(Balmer et al., 2014). 5-FU powder (Sigma Aldrich, #F6627-10G) was diluted in DMSO at 40
mg/mL and stored at -20°C for a maximum of two months before injection. A second dilution of
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5-FU/DMSO was then created in sterile saline (VWR, Radnor, PA, #89167-774) to bring the 5FU concentration to 20 mg/mL. On the day of 5-FU injection, aliquots of 20 mg/mL 5FU+DMSO in sterile saline were further diluted to 3 mg/mL 5-FU/saline in sterile
microcentrifuge tubes (VWR, #20170-038), and brought to 37.3°C. Using a 28G insulin syringe
(VWR, #BD329410), mice in groups 4 and 5 received daily intraperitoneal (IP) administration of
5-FU at a concentration of 15 mg/kg/dose (Wu et al., 2016) starting at day 0 (tumor = 75 mm3)
until day 6 (140 mg/kg/week). This resulted in an average injection of 300 µg 5-FU in 100 µL
vehicle, based on average mouse weight of approximately 20 g at time of injection.
A daily 5-FU dosage of 15 mg/kg was chosen to approximate average 5-FU dosage in
humans. In the standard FOLFOX6 CRC chemotherapy treatment, 5-FU is given every 2 weeks
at 2.4 g/m2, and repeated in 4-6 courses in the neoadjuvant settings (Fang et al., 2016). The
average body surface area (BSA) in cancer patients is approximately 1.8 m2 (Sacco et al., 2010)
and the average body weight of adult humans in North America is approximately 80 kg (Walpole
et al., 2012). Based on FDA guidelines, to convert human dose (mg/m2) to mouse dose (mg/kg),
the human dose is multiplied by 12.3 and divided by 3 (Nair et al., 2016). Based on this
information, 5-FU dose in mice can be solved as shown in Equation 1.
[

2,400 𝑚𝑔 5𝐹𝑈
1.8 𝑚2
12.3 𝑂𝑛𝑒 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
𝑚𝑔 5𝐹𝑈
]
∙
[
]∙[
]∙[
] = 15.8
2
𝑚 ∙ 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
80 𝑘𝑔
3
14 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒𝑠
𝑘𝑔

(1)

6.8.6 Immunotherapy
Anti-CCL2 (2H5), purchased from Bio X Cell (West Lebanon, NH, USA), is a
monoclonal antibody that neutralizes murine CCL2 (monocyte chemoattractant protein-1), and
has been demonstrated as an in vivo immunotherapy agent (Singh et al., 2014; Palframan et al.,
2001). Anti-CCL2 (Bio X Cell, 2H5, #BE0185) was shipped at 7.4 mg/mL in PBS and stored at
4°C for a maximum of two months before injection. On the day of anti-CCL2 injection, aliquots
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of 7.4 mg/mL anti-CCL2/PBS solution were diluted with sterile saline (VWR, #89167-774) to 1
mg/mL anti-CCL2/saline in sterile microcentrifuge tubes (VWR, #20170-038), and brought to
37.3°C. Using a 28G insulin syringe (VWR, #BD329410), mice in groups 3 and 5 received IP
administration of anti-CCL2 at a concentration of 4.0 mg/kg/dose (Zhu et al., 2011; Singh et al.,
2014) given every other day on days 0 (tumor = 75 mm3), 2, 4, and 6 (16 mg/kg/week). This
resulted in an average injection of 80 µg anti-CCL2 (2H5) in 100 µL vehicle, based on average
mouse weight of 20 g at time of injection. The isotype control antibody, polyclonal Armenian
hamster IgG (Bio X Cell, #BE0091), was made in an identical manner to anti-CCL2 and mice
were dosed at the same concentration, schedule, and method.
6.8.7 Diffuse reflectance spectroscopy
The purpose of DRS was to non-invasively quantify in vivo THC, StO2, and HbO2, and
μs’ of subcutaneous CT26 tumors (Figure 3).
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Figure 3. DRS can quantify StO2, THC, and μs’. The HbO2 can be calculated by
the product of StO2 and THC. Thus, DRS can be used as a metric to determine
low (blue) vs. high (red) oxygenation and low (less vessels) vs. high (more
vessels) hemoglobin content. Image of cell sourced from the Library of Science
Medical Figures by somersault1824, which are free to share, copy, and redistribute
under Create Commons License BY-NC-SA 4.0.

6.8.7.1 Diffuse reflectance spectroscopy probe
This probe was described in Chapter 4. The DRS probe (FiberTech Optica, Kitchener,
ON, Canada) was 1.0 m in total length, with the split position located 0.67 m from the common
(distal) end. Five individual optical fibers (one source and four detectors) were integrated within
the distal brass ferrule (6.35 mm diameter x 50 mm long). All fibers were arranged linearly in a
slit line, resulting in source-detector separations (SDS) of 0.75, 2.00, 3.00, and 4.00 mm. Each
optical fiber consisted of a high-OH silica core, a silica cladding, and polyimide jacket optimized
for a wavelength range of 190-1200 nm, which exceeded the desired wavelength range of 450750 nm used in this study. The source fiber, as well as the 2.00, 3.00, and 4.00 SDS fibers
(FiberTech Optica, SUV400/440PI) consisted of a 400/440 ± μm ± 2% silica core/cladding with
a 470 μm ± 5% polyimide jacket. The 0.75 mm SDS fiber (FiberTech Optica, SUV200/220PI)
consisted of a 200/220 μm ± 2% silica core/cladding with a 245 μm ± 5% polyimide jacket.

304

These optical fibers were included to sample into the subcutaneous murine CT26 tumor at
multiple sampling depths to quantify THC, StO2, and HbO2, and μs’.
Probe sheathing consisted of black PVC coated monocoil (4.8 mm OD, 0.67 length) at
the common end and black PVC furcation tubing (3.0 mm OD, 0.33 length) for the individual
legs originating at the breakout joint. The five individual optical fibers within the furcation
tubing terminated at standard SMA connectors, reinforced with strain relief.
6.8.7.2 Diffuse reflectance spectroscopy instrumentation
A 20W tungsten-halogen lamp (Ocean Optics, HL-2000-HP) provided broadband light
(360-2400 nm) to the 400 μm core source fiber. A spectrometer (Ocean Optics, FLAME-S) with
a Sony ILX511B linear silicon CCD array (2,048 pixel elements) collected diffusely reflected
light from the 2 and 3 mm SDSs. The spectrometer had a grating of 600 lines/mm and grating
spectral range of 667 nm. Next, the spectrometer was fit with a 50 μm diameter laser cut slit
within the round SMA connector (Ocean Optics, INTSMA-KIT), yielding a pixel resolution of
6.5 pixels. This resulted in an optical resolution of 2.1 nm, as calculated from Equation 2.
𝑂𝑝𝑡𝑖𝑐𝑎𝑙 𝑅𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 (𝑛𝑚) = [

𝑆𝑝𝑒𝑐𝑡𝑟𝑎𝑙 𝑅𝑎𝑛𝑔𝑒 (𝑛𝑚)
] ∙ [𝑃𝑖𝑥𝑒𝑙 𝑅𝑒𝑠. (𝑝𝑖𝑥𝑒𝑙𝑠)]
𝑃𝑖𝑥𝑒𝑙 𝐸𝑙𝑒𝑚𝑒𝑛𝑡𝑠 (𝑝𝑖𝑥𝑒𝑙𝑠)

(2)

6.8.7.3 Diffuse reflectance spectroscopy measurements
All mice (n=62) underwent DRS measurements starting at day 0 (tumor = 75 mm3) prior
to therapy or control. The hair on the skin at the tumor site was removed via shaving and NairTM,
and then cleaned, 24 hours prior to the first DRS measurement. In this study, only the 3.00 mm
SDS was used. The 3.00 mm SDS provided an optimal balance of signal-to-noise (> 15 dB),
appropriate in vivo integration time (75 ms), and wavelength-dependent sampling depth (~1.3 to
2.1 mm).
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In the early response groups (Table 2, n=75), DRS measurements were taken daily on
days 0-7, whereas in the survival groups (Table 2, n=50), DRS measurements were taken on days
0-7, 10, 15, 20, and then in increments of 10 days thereafter until humane end-point euthanasia
criteria. Additionally, a final DRS measurement was taken immediately prior to euthanasia in the
survival groups.
In all cases, the DRS probe was placed on the tumor site such that the linear arrangement
of optical fibers were collinear with the long axis of the tumor (cranial to caudal direction).
Tumor sites for DRS measurements were kept consistent throughout the study by marking the
skin with histopathology ink off the collinear axis. Data was acquired using custom LabVIEW
software. The user placed the probe on the tumor site of non-anesthetized mice while spectra
were collected via a foot pedal control. For each tumor, at least 10 DRS measurements were
acquired at an integration time of 75 ms. Day-to-day fluctuations in light source intensity were
controlled for by calibration with a Spectralon® 20% diffuse reflectance standard. Daily
spectrometer dark noise was subtracted from each spectra.
Each DRS measurement resulted in a value for THC, StO2, HbO2, μs’(630 nm) and a chisquare (Χ2) value. THC, StO2, HbO2, μs’(630 nm) were quantified by inputting raw DRS spectra
into custom lookup-table (LUT)-based MATLAB software with a priori values for oxygenated
and deoxygenated hemoglobin extinction coefficients (Prahl, 2015; Greening et al., 2016;
Greening et al., 2015). The software performed an iterative model fit (1x104 iterations) to the
raw DRS data to quantify THC, StO2, HbO2, μs’(630 nm). The Χ2 value indicated goodness-offit between the model fit and raw DRS data; high Χ2 values usually implied specular reflection
due to user movement. Therefore, if Χ2 of a spectra exceeded 10, data was discarded. THC, StO2,
HbO2, and μs’(630 nm) values (≥10) were averaged to yield a daily result. At the conclusion of
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study (either after day 7 or at humane end-point euthanasia criteria), histopathology ink was used
to indicate probe location and orientation for spatial correlation with IHC.
6.8.8 Diffuse reflectance spectroscopy and tumor volume statistics
The primary data set consisted of five metrics: tumor size, StO2, THC, HbO2, and μs’
(630 nm), henceforth just referred to as μs’, which are presented as raw scores and as normalized
scores. Comparing raw scores allows seeing the range of values that should be expected for each
metric. Comparing normalized scores allows us to see how metrics increase or decrease from
each tumor’s baseline measurement. The data set consisted of observations on 61 subjects
divided between 5 treatments, as shown in Table 4. Each subject was assessed at Day 0 and
subsequently for one, three, or seven successive days according to the third (approximately) of
the sample to which the mouse had been assigned, respectively. On each of the days on which
each subject was assessed, the assessments were expressed in 5 raw score metrics and in 5
normalized metrics. This resulted in a data set consisting of 16 subjects who were assessed only
on the first day after the baseline, 23 who were assessed on each of the three days following the
baseline, and 22 who were assessed on each of the seven days following the baseline. Three sets
of analyses were conducted on these data. Each will be described below along with statistical
procedures used to conduct the analyses.
6.8.8.1 Comparisons of days 1, 3, and 7 to Day 0 within treatment by metric
These analyses compared subjects’ scores at Days 1, 3, and 7 to their scores at Day 0,
within each of the 5 treatments. Since the scores at Day 0 and at each of the other 3 days
referenced the identical subjects, a repeated measures ANOVA analysis was required. The
normality of the residual error scores for the raw and normalized metrics was tested using the
Shapiro-Wilk test. Due to the large sample size, the rule of thumb of .90 or higher for the
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Shapiro-Wilk test statistic (W) was used as the indicator of adequate normality in the error
distribution. The W for the error residuals exceeded .90 for both the raw and normalized scores in
8 of the 10 cases, as shown in Table 5. The W statistic for the residual for the normalized HbO2
score was within .006 of .90, which is close enough to .90 to avert any concern about any
problematic effect of its slight departure from normality.
Table 5. Breakdown of control and experimental groups
Shapiro-Wilk
Error Measure
Statistic
df
Residual for Tumor Size (Raw)
.925
296
Residual for StO2 (Raw)
.992
296
Residual for THC (Raw)
.992
296
Residual for HbO2 (Raw)
.988
296
Residual for μs’ (Raw)
.956
296
Residual for Tumor Size (Normalized)
.906
297
Residual for StO2 (Normalized)
.934
297
Residual for THC (Normalized)
.913
297
Residual for HbO2 (Normalized)
.894
297
Residual for μs’ (Normalized)
.794
297

p
<.001
.111
.113
.017
<.001
<.001
<.001
<.001
<.001
<.001

The Šídák post-hoc test was used to adjust for multiple comparisons. The Šídák post-hoc
test is a conservative test (Kim, 2015) assumes independence of all measurements, meaning that
measurements have no connection to other measurements chances of happening. The Šídák posthoc test protects against type 1 errors but is sensitive to type 2 errors (Lee et al., 2018). A type 1
error is the rejection of the null hypothesis (false positive) whereas a type 2 error is the failure to
reject a false null hypothesis (false negative) (Banerjee et al., 2009). In these experiments, it was
imperative to protect against type 1 errors. Additionally, the Šídák post-hoc test was appropriate
since we operated under the universal null hypothesis assumption that all tests would not be
significant (Armstrong, 2014). The normalized μs’ scores manifested a much larger departure
from normality, necessitating the use of the nonparametric Wilcoxon Signed Rank test to assess
the differences between Day 0 and Days 1, 3, and 7 within each of the 5 treatments.
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6.8.8.2 Comparisons of treatments for days 1, 3, and 7, within metrics
These analyses compared subjects’ scores between the 5 treatments at Days 1, 3, and 7,
within each of the 5 metrics. Since the scores on each treatment and on each of the 3 days
referenced the identical subjects, a repeated measures analysis methodology was required. Since
the necessary pairwise comparisons were derived from the same repeated measures ANOVA as
was used for the first set of comparisons described above, the residual error scores were
identical, as were the results of the Shapiro-Wilk tests for departures from normality. Again, the
Šídák post-hoc test was used to adjust for multiple comparisons. Additionally, the normalized μs’
scores were the only ones that manifested a serious departure from normality, necessitating the
use of the nonparametric Wilcoxon Signed Rank test, this time for comparing all pairs of
treatments on the normalized metric 5 scores within Days 1, 3, and 7.
6.8.8.3 Correlations between normalized metrics within treatments
These analyses computed the Pearson product-moment correlations between each pair of
normalized metric scores within each of the five treatments. Shapiro-Wilk tests for normality
were conducted for scores on all five normalized metrics within each treatment. Correlations
between any pair of metrics within a treatment where one or both of the metrics had ShapiroWilk values below .88 were recomputed using the nonparametric Spearman’s rho correlation.
6.8.9 Immunohistochemistry
Mice from each of the five groups (Table 4) were further divided into three cohorts (up to
n=5) based on end-point IHC analysis. Tumors were vivisected immediately prior to euthanasia
via cervical dislocation on day 1, 3, or 7 for IHC analysis. Tumors were resected following the
final DRS measurement.
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Tumors were oriented within the cryomolds (VWR, #25608-916) such that the cutting
face would be coplanar to the light path from the DRS measurements. The cryomold was filled
with optimal cutting temperature (OCT, VWR, #25608-930) and flash frozen in isopentane
(VWR, #AA19387-AP) chilled in liquid nitrogen at -75°C for 15 seconds. Tissue was then
stored at -80°C until sectioning. Tumors were longitudinally sectioned on Superfrost® Plus
microslides (VWR, #48311-703) in 5 μm sections using a cryostat (Leica, #CM1860) at -25°C,
which were then stored permanently at -80°C. Tumor tissue was stained for hypoxia, TAMpolarization, proliferation, apoptosis, and hematoxylin and eosin (H&E).
6.8.9.1 Tumor-associated macrophages
Next, tumor sections were stained to quantify TAM count and M1-M2 polarization
(Barros et al., 2013). Tumors were stained for CD68 (pan-macrophage), CD80 (M1 TAM
marker), and CD206 (M2 TAM marker) (Peng et al., 2017). Cells were considered M1-polarized
TAMs if they expressed both CD68 and CD80 and M2-polarized TAMs if they expressed both
CD68 and CD206. Cells expressing all markers were considered non-polarized TAMs and cells
stained with only CD80 or CD206 were not considered TAMs (Barros et al., 2013). For each
tumor, two 5 μm tissue sections were stained for TAM analysis.
Upon removal from -80°C, slides were fixed in 0°C acetone (VWR, #BDH1101-4LP) for
10 minutes. Slides were blocked with sterile, 4% goat serum, 0.5% bovine serum albumin (BSA)
(Sigma-Aldrich, #A9647-10G), 0.1% NaN3, 0.05% Triton-X, and 0.05% Tween-20 in PBS for 2
hours at room temperature. Tumor sections were then stained with a cocktail of anti-CD80
Brilliant Violet 421 (BioLegend, #104725), anti-CD68 Alexa Fluor 488 (BioLegend, #137012),
and anti-CD206 Alexa Fluor 594 (BioLegend, #141726) at dilutions of 1:20, 1:100, and 1:125,
respectively, and stored in a PBS-humidified incubator for 90 minutes at room temperature.
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Slides were washed 3x with PBS-t between major steps. Slides were mounted with FluoromountG (VWR, #100241-847) and permanently stored at 4°C in the dark.
Slides were imaged with a upright microscope (Nikon, Eclipse Ni-U), 20X/0.50NA
objective lens (Nikon, CFI Plan Fluor 20X), monochrome digital camera (Nikon, DS-Qi1Mc),
and PC-based camera control unit (Nikon, DS-U3). The anti-CD80, anti-CD68, and anti-CD206
stains were imaged with DAPI (Chroma Technology, 49000), FITC (Chroma Technology,
SP101), and Texas Red (Chroma Technology, 41004) filter sets, respectively, at an integration
time of 100 ms and gain of 1x. For each tumor, two 5 μm thick tissue sections were stained. Five
high-powered fields-of-view (0.21 x 0.15 mm) were taken for each of the two sections for a total
of 10 TAM FOVs per tumor. Cells per FOV were counted based on a previously published
protocol. All counts were made blinded to DRS data. Total immune cells were counted over the
10 FOVs to calculate TAM count and polarization. A more in-depth look at tumor-associated
macrophages, including the precise staining procedure, is as follows:
6.9 Tumor-associated macrophages
Tumor-associated macrophages (TAMs) are the most abundant immune cells in the tumor
microenvironment (TME) in most cancers (Noy and Pollard, 2014), and also have the most
substantial and pervasive effect of any immune cell in the TME (Allavena et al., 2008; Erreni et
al., 2011; Chen et al., 2005; Marech et al., 2016). TAMs have been shown to have both antitumor and pro-tumor functions, depending on whether they are polarized more towards an M1
(classical) or M2 (alternative) phenotype (Chen et al., 2005), respectively, and their physical
location within a tumor (Marech et al., 2016). In reality, M1 and M2 TAMs are the extremes of a
continuum of intermediate cells which may have both anti-tumor and pro-tumor functions. Broad
anti-tumor functions of classically activated M1-polarized TAMs include inflammation and
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immune response (Sugita et al., 2002; Funada et al., 2003; Zhou et al., 2010). On the other hand,
pro-tumor functions of alternatively activated M2-polarized TAMs include tumor growth,
angiogenesis, immunosuppression, and matrix remodeling (Liu and Cao, 2015). In most cancers,
TAMs are skewed more towards the pro-tumor M2-phenotype (Yang and Zhang, 2017);
therefore, TAMs have gained clinical momentum as immunotherapy targets for cancer. Currently,
there are over 30 clinical trials targeting TAMs; strategies include reducing monocyte
recruitment to the tumor and reprogramming M2-TAMs to M1-TAMs. Yang and Zhang provide a
comprehensive review of TAM immunotherapy strategies (Yang and Zhang, 2017). Still many
other groups are actively investigating TAMs in the basic science and pre-clinical realms
(Cassetta et al., 2016; He et al., 2017; Jarosz-Biej et al., 2018; Suarez-Lopez et al., 2018).
However, TAMs in some cancers, like colorectal cancer (CRC), simultaneously have both
detrimental and beneficial effects on the patient (Zhong et al., 2018).
The dual-role of TAMs in CRC has yet to be fully understood. It has recently been shown
that macrophages induce resistance to fluorouracil-based chemotherapy, and that this TAMinduced resistance may contribute to the poor chemotherapy response in some CRC patients
(Zhang et al., 2008; Zhang et al., 2016). Currently, a gap in colon cancer research is how therapy
affects TAMs in the colorectal TME, and, in turn, how altering TAM population and polarization
affects tumor therapeutic response. Therefore, this immunohistochemistry staining protocol was
developed to stain for TAMs in murine subcutaneous colon tumor allografts, although this
protocol can be used for other murine tissue. In this article, Balb/c mice were subcutaneously
injected in the left flank with CT26 murine colon carcinoma cells. Tumors grew until they
reached 75 mm3. Following three days of additional tumor growth, untreated tumors were
dissected, flash-frozen in isopentane and liquid nitrogen, and stored at -80 °C until
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cryosectioning, and then sectioned at a thickness of 5 μm. The scope of this article is on
macrophage immunohistochemistry of murine tumors, not on the tumor model itself. Therefore,
this protocol can be readily modified to stain any murine tissue in allograft, xenograft, or
orthotopic tumor models.
This direct immunohistochemistry staining method uses three primary-conjugated
macrophage antibodies: anti-CD68, anti-CD80, and anti-CD206. CD68 is a pan-macrophage
surface marker (Gordon et al., 2014), CD80 is a cell surface marker for M1-type macrophages
(Zhou et al., 2017), and CD206 is a cell surface marker for M2-type macrophages (Kigerl et al.,
2009). CD68, CD80, and CD206 are markers for other cell types as well but were chosen such
that (CD68+/CD80+)-cells were considered M1-TAMs, (CD68+/CD206+)-cells were considered
M2-TAMs, and (CD80+/CD206+)-cells were considered dendritic cells (DCs). Cells expressing
all macrophage surface markers were considered to have a mixed M1-M2 phenotype (Figure 4).
With this simple and reproducible method, we are able to accurately stain for M1 and M2
macrophages. To ensure long-term relevancy and usability of this protocol, this work also
provides an easy-to-follow mathematical analysis of antibody concentrations so that readers can
easily modify and optimize this protocol for their specific test system. This work is relevant for
investigators developing and/or testing TAM-targeting cancer immunotherapies in mice.
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Figure 4. A double stain technique was used to distinguish M1- and M2polarized macrophages. CD68+/CD80+ cells were considered M1 TAMs and
CD68+/CD206+ cells were considered M2 TAMs. Additionally,
CD68+/CD80+/CD206+ TAMs were considered to have a mixed phenotype.
6.10.1 Materials and reagents
A. Consumables
1. Paper towel
2. Aluminum foil
3. Coverslip
4. 10 μl sterile universal Fit S3 polymer pipette tips (VWR, catalog number: 89140-160)
5. 100 μl sterile universal Fit S3 polymer pipette tips (VWR, catalog number: 89140-162)
6. 1,000 μl sterile universal Fit S3 polymer pipette tips (VWR, catalog number: 89217-468)
7. SuperSpinTM microcentrifuge tubes (VWR, catalog number: 20170-038)
8. EasyDipTM slide staining rack (VWR, catalog number: CA87000-132)
9. Superfrost® plus micro slide (VWR, catalog number: 48311-703)
10. VistaVisionTM cover glasses, No. 1, 22 x 50 mm (VWR, catalog number: 16004-314)
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B. Animal
1. Balb/c mice (aged 10 weeks)
C. Antibodies
1. Brilliant Violet 421TM anti-mouse CD80 [stock solution concentration: 100 μg/ml,
staining concentration: 5 μg/ml (1:20), storage temperature: 2-8 °C undiluted, shelf-life:
~3 years (lot-specific)] (BioLegend, catalog number: 104725)
2. Alexa Fluor® 488 anti-mouse CD68 [stock solution concentration: 500 μg/ml, staining
concentration: 5 μg/ml (1:100), used at 5 μg/ml, storage temperature: 2-8 °C undiluted,
shelf-life: ~3 years (lot-specific)]) (BioLegend, catalog number: 137012)
3. Alexa Fluor® 594 anti-mouse CD206 [stock solution concentration: 500 μg/ml, staining
concentration: 4 μg/ml (1:125), storage temperature: 2-8 °C undiluted, shelf-life: ~3 years
(lot-specific)] (BioLegend, catalog number: 141726)
D. Reagents
1. Acetone (storage temperature: -20 °C, shelf-life: 4 years) (VWR, catalog number:
BDH1101-4LP)
2. Phosphate-buffered saline (PBS), 1x without Calcium and Magnesium (storage
temperature: 2-8 °C, shelf-life: 3 years) (VWR, catalog number: 45000-446)
3. TritonTM X-100 (storage temperature: room temperature, shelf-life: 2 years) (Sigma
Aldrich, catalog number: X100-100ML)
4. Tween® 20 (storage temperature: room temperature, shelf-life: 3 years) (Sigma-Aldrich,
catalog number: P9416-100mL)
5. Goat serum (storage temperature: -20 °C, shelf-life: 2 years) (Sigma-Aldrich, catalog
number: G9023-10ML)
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6. Sodium azide (NaN3) (storage temperature: room temperature) (Sigma-Aldrich, catalog
number: S2002-25G)
Note: This compound is toxic (GHS06), a health hazard (GHS08), and an environmental
hazard (GHS09). It should be handled with protective clothing in a certified fume hood
and disposed of at an approved waste disposal site per institutional regulations
7. Bovine serum albumin (BSA) (storage temperature: 2-8 °C, shelf-life: 1 year) (SigmaAldrich, catalog number: A8806-5G)
8. Universal antibody dilution buffer (storage temperature: room temperature, shelf-life: 2
years) (Sigma-Aldrich, catalog number: U3510-100ML)
9. Isopentane (storage temperature: room temperature, shelf-life: 2 years) (VWR, catalog
number: AA19387-AP)
10. Liquid nitrogen (Airgas, catalog number: NI NF180LT22)
11. Quick-dry nail polish
12. Fluoromount-G® slide mounting medium (storage temperature: room temperature, shelflife: 15 months) (VWR, catalog number: 100241-874)
13. Macrophage antibody cocktail (see Recipes)
14. Blocking solution (see Recipes)
15. PBS-T washing solution (see Recipes)
6.9.2 Equipment
1. Tweezer
2. 0.5-10 μl ergonomic high performance single-channel mechanical pipettor (VWR,
catalog number: 89079-962)
3. 10-100 μl ergonomic high performance single-channel mechanical pipettor (VWR,
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catalog number: 89079-968)
4. 100-1,000 μl ergonomic high performance single-channel mechanical pipettor (VWR,
catalog number 89079-974)
5. Linear pipettor stand (VWR, catalog number: 40000-272)
6. 80-Place storage system (VWR, catalog number: 30128-282)
7. EasyDipTM slide staining jars, white (VWR, catalog number: CA87000-126)
8. Low temperature organic liquid filled thermometer (VWR, catalog number: 89062-908)
9. SlideTrayTM 20 slide humidity chamber with black lid (VWR, catalog number: 102097504)
10. Laboratory bench and table protector with leakproof and moisture barrier (VWR, catalog
number: 89126-790)
11. -20 °C and -80 °C freezers
12. Water bath (VWR, catalog number: 89501-464)
13. Upright microscope (Nikon, model: Eclipse Ni-U)
14. Monochrome digital camera (Nikon, model: DS-Qi1Mc)
15. PC-based camera control unit (Nikon, model: DS-U3)
16. SOLA Light Engine® fluorescent lamp (Lumencor, catalog number: SOLA SM 6-LCRSB)
17. DAPI filter set (Chroma Technology, catalog number: 49000)
18. FITC filter set (Chroma Technology, catalog number: SP101)
19. Texas red filter set (Chroma Technology, catalog number: 41004)
20. Objective lens, 20x/0.50NA (Nikon, catalog number: CFI Plan Fluor 20X)
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6.9.3 Software
1. NIS-Elements F Ver4.60.00 for 64bit edition (Nikon,
https://www.nikoninstruments.com/Products/Software)
2. ImageJ bundled with 64-bit Java 1.8.0_112 (National Institutes of Health and the
Laboratory for Optical Computational Instrumentation,
https://imagej.nih.gov/ij/download.html)
6.9.4 Procedure
The scope of this section is on macrophage immunohistochemistry of murine tumors, not
on the tumor model itself; however, the tumor model is briefly described here. Five Balb/c mice
(aged 10 weeks) were subcutaneously injected with 1 x 105 CT26 cells (passage 3) in sterile
saline into the left flank until the tumors reached a volume of 75 mm3 (Greening et al., 2018a
and 2018b). Three days after reaching this volume, the five untreated mice were euthanized, and
the tumor was dissected for TAM analysis (Figure 5). This staining and imaging procedure
works best with flash frozen tumors. Therefore, upon dissection, tumors were placed in a
cryomold and covered completely in optimal cutting temperature (OCT). The cryomold with
OCT and tumor was flash frozen in isopentane chilled in liquid nitrogen at -75 °C to -77 °C for
at least 15 s and stored permanently in -80 °C until sectioning. The tumor was sectioned at 5 μm,
although sections up to 10 μm are acceptable. Once sectioned, slides were stored for up to one
month at -80 °C before staining. All antibody solutions and stained slides were handled in
darkness.
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Figure 5. Murine colon tumor allografts were (a) dissected and flash frozen.
Tumors were (b) sectioned at 5 μm thickness (H&E shown for clarity, yellow box
not to scale). Tumor sections were (c) stained for TAMs and imaged with a 20x
objective at 10 regions of interest (ROI) along the section. Scale bar = 30 µm.
Images enhanced for publication.
A. Preparing slides for staining (20 min)
Note: Keep at least 90 ml of acetone stored at -20 °C for at least 1 h prior to start of
procedure.
1. Remove 5 μm-thick slides from -80 °C.
2. Place all slides in -20 °C.
3. Keep the acetone for 20 min at -20 °C.
4. Prepare macrophage antibody cocktail (see Recipes).
5. Set out four EasyDipTM slide staining jars.
6. Fill 3 staining jars with 90 ml of room temperature sterile PBS-T (see Recipes).
7. Remove blocking solution aliquots (see Recipes) from 4 °C and set in 80-Place Storage
System at room temperature.
8. 20 min after Step A3, remove acetone from -20 °C.
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9. Fill final staining jar with 90 ml of -20 °C acetone.
10. Place low-temperature thermometer in 1st staining jar with acetone.
B. Fixation with acetone (10 min)
1. When the acetone reaches -3 °C, remove slides from -20 °C.
2. Place slides (up to 12) in the EasyDipTM slide staining rack.
3. Place the staining rack (with slides) in cold acetone for 10 min.
4. Remove from acetone and air dry for 5 s.
C. Wash with PBS-T (#1) (5 min)
1. Place the staining rack in PBS-T (2nd staining jar) for 2 min.
2. Dip the staining rack in PBS-T for 1 min such that each “dip” is 3 s (20 total dips).
3. Swirl staining rack inside slide staining jar for 1 min such that each “swirl” is 1 s (60 total
swirls).
4. Keep staining rack in PBS-T unmoving for an additional 1 min.
D. Adding blocking solution (2 h)
1. Remove staining rack from PBS-T (2nd staining jar).
2. Remove 3 slides from the staining rack.
3. Keep the other slides (if there are more than 3) in the staining rack and place back in
PBS-T.
4. Using a paper towel, dry the area around the tissue sections without touching the tissue
sections. Note: A hydrophobic barrier PAP pen may be used to keep reagents localized
on the tissue specimen but is not required.
5. Add 50-100 μl (depending on size of tissue section) blocking solution to each tissue
section.
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6. Place slides (with blocking solution) in a dark humidified chamber at room temperature.
7. Repeat Steps D1-D6 for additional slides.
8. Incubate in the dark humidified chamber at room temperature for 60 min.
9. Reapply 50-100 μl blocking solution to each tissue section.
10. Incubate in the dark humidified chamber at room temperature for 60 min.
E. Adding macrophage antibody cocktail (2 h)
Note: The following steps must be performed in a dark room.
1. Remove macrophage antibody cocktail from 4 °C and remove aluminum foil.
2. Remove 1 slide from the dark humidified chamber.
3. Using a paper towel, dry the area around the tissue sections without touching the tissue
sections.
4. Add 100 μl of macrophage antibody cocktail to each tissue section.
5. Place slide with macrophage antibody cocktail in a dark humidified chamber.
6. Repeat Steps E2-E5 for additional slides.
7. Incubate in the dark humidified chamber at room temperature for 2 h.
F. Wash with PBS-T (#2) (5 min)
Note: The following steps must be performed in a dark room.
1. Remove the dark humidified chamber from 4 °C.
2. Place all slides back in staining rack.
3. Place the staining rack in PBS-T (3rd staining jar) for 2 min.
4. Dip the staining rack in PBS-T for 1 min such that each “dip” is 3 s (20 total dips).
5. Swirl staining rack inside slide staining jar for 1 min such that each “swirl” is 1 s (60 total
swirls).
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6. Keep staining rack in PBS-T unmoving for an additional 1 min.
G. Wash with PBS-T (#3) (5 min)
Note: The following steps must be performed in a dark room.
1. Place the staining rack in PBS-T (4th staining jar) for 2 min.
2. Dip the staining rack in PBS-T for 1 min such that each “dip” is 3 s (20 total dips).
3. Swirl staining rack inside slide staining jar for 1 min such that each “swirl” is 1 s (60 total
swirls).
4. Keep staining rack in PBS-T unmoving for an additional 1 min.
H. Mounting slides
Note: The following steps must be performed in a dark room.
1. Remove staining rack from PBS-T (4th staining jar).
2. Set all slides face-up on paper towel.
3. Using a paper towel, dry the area around the tissue sections without touching the tissue
sections.
4. Add 1-2 drops of Fluoromount-G® Slide Mounting Medium to each tissue section.
5. Gently place 22 x 50 mm coverslip on each slide.
6. Using tweezers, gently press out air bubbles.
7. Wipe off any excess mounting medium.
8. Let slides sit for 5 min.
9. Apply quick-dry nail polish along the edges of the coverslip. Ensure edges are completely
covered to prevent drying out of slides.
10. Leave slides to dry for 1 h.
11. Store slides permanently in the dark at 4 °C.
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6.9.5 Data analysis
A. Imaging
1. Remove slides from 4 °C, but keep in the dark.
2. Place slide under a microscope.
3. Turn on fluorescent lamp, microscope, and camera.
4. Open imaging software.
5. Change the fast focus to 1,280 x 1,024 no binning.
6. Change the quality capture to 1,280 x 1,024 no binning.
7. Set the exposure to 100 ms.
8. Set the gain to 1x.
9. Switch to the 20x objective.
10. Use the DAPI filter and bring the CD80+ cells into focus.
11. Image the CD80-stained cells.
Note: In the 5 μm thick slide, some cells may be in-focus while others are out-of-focus.
Starting 1 μm beneath the tissue surface, adjust the z-axis travel 1 μm between each step
and take at least 4 images of the same location in the x-y plane (Figure 6).
12. Without moving tissue location, switch to the FITC filter and bring the CD68+ cells into
focus.
13. Image the CD68-stained cells.
Note: See the note under step A11 (Image the CD80-stained cells).
14. Without moving tissue location, use the Texas Red filter and bring the CD206+ cells into
focus.
15. Image the CD206-stained cells.
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Note: See the note under step A11 (Image the CD80-stained cells).
16. Switch to a new tissue location and repeat Steps A10-15.
17. Acquire images from the desired amount of tissue locations.
Note: In this study, 10 regions-of-interests (ROI) per tumor were imaged (image area =
31,100 μm2).

Figure 6. Multiple images in varying z-axis depths of the same x-y location may
be needed for accurate TAM counting. Notice the red-circled cell starts in-focus
at (A) and is out-of-focus at (D). Alternatively, notice the yellow-circled cells
start off out-of-focus at (A) and are in-focus at (D). Each image (A-D) represents
a 1 μm step along the z axis. Scale bars = 40 µm. 20x/0.50NA objective used for
each image. Images enhanced for publication.
Note: This part of the protocol may be modified depending on tissue section thickness
and desired accuracy when quantifying image-based cell counts.
B. TAM counting and polarization
1. Count CD68+ cells in each ROI.
2. Count CD80+ cells in each ROI.
3. Count CD206+ cells in each ROI.
4. Determine the number of CD68+/CD80+ cells in each ROI. These are M1-polarized
TAMs.
5. Determine the number of CD68+/CD206+ cells in each ROI. These are M2-polarized
TAMs.
6. Determine the number of CD68+/CD80+/CD206+ cells in each ROI. These are TAMs
with a mixed M1/M2 phenotype (Figure 7).
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Figure 7. Image of several TAMs imaged with DAPI (for CD80+), FITC (for
CD68+), and Texas Red (for CD206+) filter sets. The composite image (ImageJ)
shows a TAM with an M2 phenotype and a TAM with a mixed M1-M2
phenotype. Scale bars = 30 µm. 20x/0.50NA objective used for each image.
7. If desired, determine the number of CD80+/CD206+ cells in each ROI. There are dendritic
cells.
8. Calculate the average number of M1 TAMs (included TAMs with mixed phenotype) per
image area.
𝑇𝐴𝑀𝑀1 = (𝐶𝐷68+ /𝐶𝐷80+ 𝑐𝑒𝑙𝑙𝑠) + (𝐶𝐷68+ /𝐶𝐷80+ /𝐶𝐷206+ 𝑐𝑒𝑙𝑙𝑠)
9. Calculate the average number of M2 TAMs (including TAMs with mixed phenotype) per
image area.
𝑇𝐴𝑀𝑀2 = (𝐶𝐷68+ /𝐶𝐷206+ 𝑐𝑒𝑙𝑙𝑠) + (𝐶𝐷68+ /𝐶𝐷80+ /𝐶𝐷206+ 𝑐𝑒𝑙𝑙𝑠)
10. Calculate average M1/M2 ratio per mouse (Figure 8).
𝑇𝐴𝑀𝑀1
𝑇𝐴𝑀𝑟𝑎𝑡𝑖𝑜 = (
)
𝑇𝐴𝑀𝑀2
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Figure 8. TAMs in subcutaneous murine colon tumor allografts. In untreated
Balb/c-CT26 tumors, 3 days after the tumor reaches a volume of 75 mm3, there is
a significant difference (P < 0.01) between the number of M1 (58.8 ± 18.7
cells/mm2) and M2 TAMs (127.5 ± 34.2 cells/mm2) in the tumor, resulting in an
M1/M2 ratio of 46.1%.
6.9.6 Notes on procedure
This protocol can be modified to include nuclear staining. Figure 9 shows a Balb/c-CT26
subcutaneous colon tumor allograft tissue section stained with DAPI and CD206 only.
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Figure 9. This staining procedure can be modified to include nuclear stains. Here,
an untreated Balb/c-CT26 subcutaneous colon tumor allograft tissue section was
co-stained with DAPI and Alexa Fluor® 594 anti-mouse CD206. Scale bars = 100
μm. 20x/0.50NA objective used for each image.
A limitation of this staining protocol is the absence of a reliable stain for DCs. In addition
to being a commonly used pan-macrophage marker (Gordon et al., 2014), CD68 can also stain
for DCs at low levels in some tissues such as the lung (Yu et al., 2016, Figure 1). To control for
the possibility of DCs, this protocol may be modified to include a panel of DC-specific markers
for murine non-lymphoid tissues on adjacent tissue sections (Yu et al., 2016).
The following calculations aid in reproducibility of results and modification of the
protocol for specific test systems. Stock antibody concentrations and amount of antibodies per
vial are accurate up to the publication of this article and are subject to change based on
manufacturer lot specifications. The desired dilution from stock were experimentally-determined
in lab for the Balb/c-CT26 murine subcutaneous allograft model and may be different per
specific test system. The volume of macrophage antibody cocktail represents the total volume of
diluted antibody mix placed on the tissue section via micropipette before incubation at room
temperature for 2 h. The average area of our tissue sections was ~50 mm2. Thus, we recommend
a macrophage antibody cocktail volume per tissue section area of ~2 μl/mm2 (100 μl total per
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section).
The following calculations determine the volume of concentrated stock antibody to add to
the macrophage antibody cocktail, and how many trials can be performed with these settings.
1. Brilliant Violet 421TM anti-mouse CD80
Table 6. Constants for Brilliant Violet 421TM anti-mouse CD80 stain
Stock Antibody Concentration*
100 μg/ml
Desired Dilution from Stock*
1:20
Amount of Antibodies per Vial*
100 μg
Volume of Macrophage Antibody Cocktail per Tissue Section**
100 μl
* Values subject to change based on manufacturer specifications and recommendations
** Value depends on size of tissue section

Table 7. Calculations for Brilliant Violet 421TM anti-mouse CD80 stain
Desired Volume of Stock per Trial
Desired Antibody Amount per Trial
Desired Antibody Concentration in
Macrophage Antibody Cocktail
Trials per Vial of Antibodies

100 𝜇𝑙
1
] ∙ [ ] = 5 𝜇𝑙
1
20
100 𝜇𝑙
1
100 𝜇𝑔
1 𝑚𝑙
[
]∙[ ]∙[
]∙[
] = 0.5 𝜇𝑔
1
20
𝑚𝑙
1000 𝜇𝑙
1
100 𝜇𝑔
[ ]∙[
] = 5 𝜇𝑔/𝑚𝑙
20
1 𝑚𝑙
100 𝜇𝑔
1
[
]∙[
] = 200
1
0.5 𝜇𝑔
[

2. Alexa Fluor® 488 anti-mouse CD68
Table 8. Constants for Alexa Fluor® 488 anti-mouse CD68 stain
Stock Antibody Concentration*
500 μg/ml
Desired Dilution from Stock*
1:100
Amount of Antibodies per Vial*
100 μg
Volume of Macrophage Antibody Cocktail per Tissue Section**
100 μl
* Values subject to change based on manufacturer specifications and recommendations
** Value depends on size of tissue section

Table 9. Calculations for Alexa Fluor® 488 anti-mouse CD68 stain
Desired Volume of Stock per Trial
Desired Antibody Amount per Trial
Desired Antibody Concentration in Macrophage
Antibody Cocktail
Trials per Vial of Antibodies

100 𝜇𝑙
1
]∙[
] = 1 𝜇𝑙
1
100
100 𝜇𝑙
1
500 𝜇𝑔
1 𝑚𝑙
[
]∙[
]∙[
]∙[
] = 0.5 𝜇𝑔
1
100
𝑚𝑙
1000 𝜇𝑙
1
500 𝜇𝑔
[
]∙[
] = 5 𝜇𝑔/𝑚𝑙
100
1 𝑚𝑙
100 𝜇𝑔
1
[
]∙[
] = 200
1
0.5 𝜇𝑔
[
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3. Alexa Fluor® 594 anti-mouse CD206
Table 10. Constants for Alexa Fluor® 594 anti-mouse CD206 stain
Stock Antibody Concentration*
500 μg/ml
Desired Dilution from Stock*
1:125
Amount of Antibodies per Vial*
100 μg
Volume of Macrophage Antibody Cocktail per Tissue Section**
100 μl
* Values subject to change based on manufacturer specifications and recommendations
** Value depends on size of tissue section

Table 11. Calculations for Alexa Fluor® 594 anti-mouse CD206 stain
Desired Volume of Stock per Trial
Desired Antibody Amount per Trial
Desired Antibody Concentration in
Macrophage Antibody Cocktail
Trials per Vial of Antibodies

100 𝜇𝑙
1
]∙[
] = 0.8 𝜇𝑙
1
125
100 𝜇𝑙
1
500 𝜇𝑔
1 𝑚𝑙
[
]∙[
]∙[
]∙[
] = 0.4 𝜇𝑔
1
125
𝑚𝑙
1000 𝜇𝑙
1
500 𝜇𝑔
[
]∙[
] = 4 𝜇𝑔/𝑚𝑙
125
1 𝑚𝑙
100 𝜇𝑔
1
[
]∙[
] = 250
1
0.4 𝜇𝑔
[

6.9.7 Recipes
1. Macrophage antibody cocktail
Note: The following steps must be prepared in the dark.
a. Determine the number of tissue sections to be stained
b. Add 100 μl of universal antibody dilution buffer, per number of tissue sections, to
microcentrifuge tube
Note: This volume of 100 μl/section can be changed based on the size of the specific
tissue section. More than one microcentrifuge tube may be used if staining multiple
tissue sections requiring > 1 ml.
c. Add Brilliant Violet 421TM anti-mouse CD80 to universal antibody dilution buffer at
5 μg/ml (i.e., 1:20 dilution from 100 μg/ml stock)
d. Add Alexa Fluor® 488 anti-mouse CD68 to universal antibody dilution buffer at 5
μg/ml (i.e., 1:100 dilution from 500 μg/ml stock)
e. Add Alexa Fluor® 594 anti-mouse CD206 to universal antibody dilution buffer at 4
μg/ml (i.e., 1:125 dilution from 500 μg/ml stock)
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f. Gently and sufficiently pipette up and down to mix the macrophage antibody cocktail
g. Wrap microcentrifuge tubes with macrophage antibody cocktail with aluminum foil
and store at 4 °C until ready for use
2. Blocking solution
a. Bring sterile PBS to 37 °C in a water bath
b. Bring goat serum to room temperature
Note: The following steps must be prepared in a certified biological safety cabinet.
c. Add 4% (v/v) of goat serum to PBS
d. Add 0.5% (w/v) BSA to PBS
e. Add 0.1% (w/v) NaN3 to PBS
f. Perform sterile vacuum filtration of the blocking solution
g. Add 0.1% (v/v) TritonTM X-100 to PBS
h. Add 0.05% (v/v) Tween® 20 to PBS
i. Shake solution vigorously until TritonTM X-100 and Tween® 20 have dispersed
Note: If needed, solution can be placed in a 37 °C water bath for 5-10 min to aid
dispersion.
j. Aliquot blocking solution into sterile microcentrifuge tubes
k. Store blocking solution at 4 °C (can be stored for up to 2 months)
3. PBS-T washing solution
a. Bring sterile PBS to 37 °C in a water bath
Note: The following steps must be prepared in a certified biological safety cabinet.
b. Add 0.2% (v/v) of Tween® 20 to PBS (1 ml)
c. Shake solution vigorously until TritonTM X-100 and Tween® 20 have dispersed

330

Note: If needed, solution can be placed in a 37 °C water bath to aid dispersion.
d. Store PBS-T washing solution at room temperature
6.10 Results
6.11.1 Repeated measures analysis of studied metrics
Figure 10 shows representative images of Balb/c-CT26 tumor size over the 7-day time
course as a function of treatment regimen. After the final DRS measurement, tumors were
dissected, and mice were euthanized.

Figure 10. Tumor size of Balb/c-CT26 colon tumor allografts over time in
response to controls and therapies
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Figure 11. Raw (non-normalized) tumor size per day per treatment group. For
statistical analysis, see Table 12

Figure 12. Raw (non-normalized) StO2 per day per treatment group. For
statistical analysis, see Table 12
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Figure 13. Raw (non-normalized) THC per day per treatment group. For
statistical analysis, see Table 12

Figure 14. Raw (non-normalized) HbO2 per day per treatment group. For
statistical analysis, see Table 12
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Figure 15. Raw (non-normalized) μs’ per day per treatment group. For statistical
analysis, see Table 12
Table 12. Comparisons to day 0 within treatment, within metric, raw values
Treatment

Raw
Metric

Tumor size

StO2

Control:
Saline

THC

HbO2

μs’

Control:
Isotype

Tumor size
StO2

Pairwise
Comparisons
(I) Day

0

0

0

0

0

0
0

95% Confidence Interval
for Differenced
Lower
Upper
Bound
Bound
-83.285
28.356

Std. Error

Sig.d

(J) Day

Mean
Difference
(I-J)

1

-27.465

17.707

.974

3

-108.425a,*

19.797

<.001

-170.834

-46.016

7

-607.873a,*

25.041

<.001

-686.815

-528.931

1

.008

.031

1.000

-.089

.105

3

-.005a

.034

1.000

-.113

.103

7

.035a

.043

1.000

-.102

.172

1

.020

.106

1.000

-.316

.355

3

-.225a

.119

.822

-.600

.150

7

.009a

.150

1.000

-.465

.483

1

.017

.087

1.000

-.257

.291

3

-.086a

.097

1.000

-.392

.221

7

.097a

.123

1.000

-.290

.485

1

.048

.118

1.000

-.325

.420

3

.409a

.132

.059

-.007

.826

7
1

.286a

.167

.924

-.240

.813

-38.337a,c

19.020

.724

-98.298

21.624

3

-147.328a,*,c

21.790

<.001

-216.022

-78.634

7

-611.757a,*,c

36.832

<.001

-727.871

-495.643

1

.042a,c

.033

.998

-.062

.146

334

Table 12. Comparisons to day 0 within treatment, within metric, raw values (cont.)
Treatment

Raw
Metric

StO2

THC

Pairwise
Comparisons
(I) Day
0

0

Control:
Isotype
HbO2

μs’

Tumor size

StO2

ImmunoTherapy

THC

HbO2

μs’

Tumor size

StO2

0

0

0

0

0

0

0

0

0

ChemoTherapy
THC

HbO2
μs’

0

0
0

95% Confidence Interval
for Differenced
Lower
Upper
Bound
Bound
-.088
.150

Std. Error

Sig.d

(J) Day

Mean
Difference
(I-J)

3

.031a,c

.038

1.000

7

-.041a,c

.064

1.000

-.242

.160

1

.128a,c

.114

1.000

-.232

.488

3

-.143a,c

.131

1.000

-.555

.270

7

-.053a,c

.221

1.000

-.750

.644

1

.145a,c

.093

.974

-.150

.439

3

.045a,c

.107

1.000

-.292

.383

7

-.064a,c

.181

1.000

-.634

.506

1

.126

a,c

.127

1.000

-.275

.526

3

.066a,c

.145

1.000

-.392

.525

7

.663a,c

.246

.191

-.112

1.437

1

-34.807a,c

21.686

.962

-103.173

33.559

3

-84.687a,*,c

21.686

.003

-153.053

-16.321

7

-463.176a,*,c

26.560

.000

-546.907

-379.445

1

.010a,c

.038

1.000

-.108

.128

3

.050a,c

.038

.996

-.068

.169

7

-.011a,c

.046

1.000

-.156

.134

1

.092a,c

.130

1.000

-.319

.502

3

.141a,c

.130

1.000

-.270

.552

7

-.521a,*,c

.160

.035

-1.024

-.018

1

.043a,c

.107

1.000

-.293

.379

3

.146a,c

.107

.995

-.190

.482

7

-.174a,c

.130

.997

-.585

.237

1

.193a,c

.145

.997

-.263

.650

3

.339a,c

.145

.434

-.118

.795

7

.604a,*,c

.177

.021

.045

1.163

1

-20.716

22.280

1.000

-90.955

49.524

3

-107.261a,*

22.644

<.001

-178.646

-35.876

7

-186.511a,*

26.805

<.001

-271.013

-102.008

1

-.020

.039

1.000

-.141

.102

3

.040a

.039

1.000

-.084

.164

7

-.031a

.046

1.000

-.177

.115

1

-.255

.134

.813

-.677

.167

3

-.192a

.136

.992

-.621

.237

7

-.005a

.161

1.000

-.512

.503

1

-.088

.109

1.000

-.433

.257

3

.059a

.111

1.000

-.291

.410

7

-.060a

.132

1.000

-.476

.355

1

.183

.149

.999

-.285

.652
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Table 12. Comparisons to day 0 within treatment, within metric, raw values (cont.)
Treatment
ChemoTherapy

Raw
Metric

(I) Day

μs’

0

Tumor size

0

StO2

ComboTherapy

Pairwise
Comparisons

THC

HbO2

μs’

0

0

0

0

Std. Error

Sig.d

(J) Day

Mean
Difference
(I-J)

3

.014a

.151

1.000

7

-.049a

.179

1.000

1

-14.134

19.797

3

-53.994a

23.214

7

-99.300a,*

1

95% Confidence Interval
for Differenced
Lower
Upper
Bound
Bound
-.463
.490
-.613

.515

1.000

-76.544

48.275

.446

-127.175

19.188

27.997

.013

-187.561

-11.040

-.032

.034

1.000

-.140

.076

3

-.030a

.040

1.000

-.156

.097

7

-.026a

.049

1.000

-.178

.127

1

.130

.119

1.000

-.244

.505

3

-.081a

.139

1.000

-.520

.359

7

-.256a

.168

.979

-.786

.274

1

-.050

.097

1.000

-.356

.257

3

-.094a

.114

1.000

-.454

.265

7

-.121a

.138

1.000

-.554

.313

1

-.122

.132

1.000

-.538

.295

3

.096a

.155

1.000

-.392

.584

7

.484a

.187

.248

-.105

1.073

Based on estimated marginal means
*. The mean difference is significant at the .05 level.
a. An estimate of the modified population marginal mean (J).
c. An estimate of the modified population marginal mean (I).
d. Adjustment for multiple comparisons: Sidak.
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Figure 16. Normalized tumor size per day per treatment group. For statistical
analysis, see Table 13

Figure 17. Normalized StO2 per day per treatment group. For statistical analysis,
see Table 13

Figure 18. Normalized StO2 per day per treatment group. For statistical analysis,
see Table 13
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Figure 19. Normalized HbO2 per day per treatment group. For statistical analysis,
see Table 13

Figure 20. Normalized μs’ per day per treatment group. For statistical analysis,
see Table 13
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Table 13. Comparisons to day 0 within treatment, within metric, normalized values
Treatment

Normalized
Metric

Tumor size

StO2

Control:
Saline

THC

HbO2

μs’

Tumor size

StO2

Control:
Isotype

THC

HbO2

μs’

Tumor size

ImmunoTherapy

StO2

THC

Pairwise
Comparisons
(I) Day

0

0

0

0

0

0

0

0

0

0

0

0

0

95% Confidence Interval
for Differenced
Lower
Upper
Bound
Bound
-1.112
.363

Std. Error

Sig.d

(J) Day

Mean
Difference
(I-J)

1

-.375

.234

.962

3

-1.448a,*

.262

<.001

-2.272

-.623

7

-8.020a,*

.331

<.001

-9.063

-6.976

1

-.058

.109

1.000

-.403

.287

3

.100a

.122

1.000

-.286

.486

7

.250a

.155

.960

-.238

.738

1

.003

.053

1.000

-.163

.168

3

-.070a

.059

.999

-.255

.115

7

-.039

a

.074

1.000

-.273

.195

1

-.049

.139

1.000

-.486

.388

3

.039a

.155

1.000

-.450

.527

7

.221a

.196

1.000

-.397

.839

1

.003

.037

1.000

-.114

.120

3

.111

.042

.208

-.020

.242

7

.032

.053

1.000

-.134

.198

1

-.486a,c

.251

.790

-1.279

.306

3

-1.863a,*,c

.288

<.001

-2.771

-.955

7

-7.735a,*,c

.487

<.001

-9.270

-6.201

1

.078a,c

.118

1.000

-.293

.448

3

.220a,c

.135

.953

-.205

.645

7

.270a,c

.228

.999

-.448

.988

1

.052a,c

.056

1.000

-.126

.230

3

-.029a,c

.065

1.000

-.233

.175

7

-.001a,c

.109

1.000

-.345

.343

1

.114a,c

.149

1.000

-.355

.583

3

.208a,c

.171

.999

-.329

.746

7

.299a,c

.288

1.000

-.609

1.208

1

.029a,c

.040

1.000

-.097

.155

3

.055a,c

.046

.999

-.089

.199

7

.252a,*,c

.077

.036

.008

.496

1

-.444a,c

.287

.975

-1.347

.460

3

-1.090a,*,c

.287

.005

-1.993

-.186

7

-5.741a,*,c

.351

<.001

-6.848

-4.635

1

.021a,c

.134

1.000

-.402

.443

3

.185a,c

.134

.994

-.237

.608

7

-.020a,c

.164

1.000

-.538

.497

1

.031a,c

.064

1.000

-.171

.234

3

.048a,c

.064

1.000

-.154

.251

7

-.195a,c

.079

.325

-.444

.053
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Table 13. Comparisons to day 0 within treatment, within metric, normalized values (cont.)
Treatment

Normalized
Metric

HbO2

Pairwise
Comparisons
(I) Day

0

ImmunoTherapy
μs’

Tumor size

StO2

ChemoTherapy

THC

HbO2

μs’

Tumor size

StO2

ComboTherapy

THC

HbO2

μs’

0

0

0

0

0

0

0

0

0

0

0

95% Confidence Interval
for Differenced
Lower
Upper
Bound
Bound
-.504
.566

Std. Error

Sig.d

(J) Day

Mean
Difference
(I-J)

1

.031a,c

.170

1.000

3

.205a,c

.170

.999

-.330

.740

7

-.282a,c

.208

.996

-.938

.373

1

.046a,c

.046

1.000

-.098

.189

3

.082a,c

.046

.876

-.061

.226

7

.139a,c

.056

.320

-.037

.315

1

-.280

.294

1.000

-1.208

.648

3

-1.467a,*

.299

<.001

-2.411

-.524

7

-2.453a,*

.354

<.001

-3.570

-1.336

1

-.169

.138

.999

-.604

.265

3

.041a

.140

1.000

-.400

.482

7

-.301a

.166

.872

-.823

.222

1

-.137

.066

.669

-.346

.071

3

-.160a

.067

.402

-.372

.052

7

-.056a

.080

1.000

-.307

.195

1

-.371

.174

.626

-.920

.179

3

-.118a

.177

1.000

-.676

.441

7

-.361a

.210

.920

-1.023

.300

1

.043

.047

1.000

-.104

.191

3

-.029a

.048

1.000

-.179

.121

7

-.035a

.056

1.000

-.212

.143

1

-.183

.262

1.000

-1.007

.642

3

-.447a

.293

.978

-1.369

.475

7

-1.225a,*

.370

.030

-2.391

-.058

1

-.243

.122

.748

-.629

.143

3

-.108a

.137

1.000

-.539

.323

7

-.253a

.173

.988

-.799

.293

1

.048

.059

1.000

-.137

.233

3

.102a

.066

.974

-.105

.309

7

-.083a

.083

1.000

-.345

.178

1

-.179

.155

1.000

-.668

.309

3

-.134a

.173

1.000

-.680

.412

7

-.371a

.219

.932

-1.062

.320

1

-.040

.042

1.000

-.171

.091

3

.053a

.047

1.000

-.094

.200

7

.038a

.059

1.000

-.147

.224

Based on estimated marginal means
*. The mean difference is significant at the .05 level.
a. An estimate of the modified population marginal mean (J).
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c. An estimate of the modified population marginal mean (I).
d. Adjustment for multiple comparisons: Sidak.

Figure 21. Comparison of treatments for days 1, 3, and 7 for raw (nonnormalized) tumor size. For statistical analysis, see Table 14

Figure 22. Comparison of treatments for days 1, 3, and 7 for raw (nonnormalized) StO2. For statistical analysis, see Table 14
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Figure 23. Comparison of treatments for days 1, 3, and 7 for raw (nonnormalized) THC. For statistical analysis, see Table 14

Figure 24. Comparison of treatments for days 1, 3, and 7 for raw (nonnormalized) HbO2. For statistical analysis, see Table 14
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Figure 25. Comparison of treatments for days 1, 3, and 7 for raw (nonnormalized) μs’. For statistical analysis, see Table 14
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Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values
Day

Raw
Metric

Pairwise Comparisons
(I) Treatment

Control: Saline

Tumor
size

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

StO2

Control: Isotype

Immunotherapy
1

Chemotherapy

Control: Saline

THC

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

HbO2
Control: Isotype

Immunotherapy

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-67.086
36.781

Std.
Error

Sig.d

(J) Treatment

Mean
Difference
(I-J)

Control: Isotype

-15.152a

18.375

.995

Immunotherapy

-9.930a

19.797

1.000

-65.881

46.021

Chemotherapy

5.771

20.124

1.000

-51.105

62.647

Combo-therapy

11.748

18.781

.999

-41.332

64.828

Immunotherapy

5.222a,b

20.397

1.000

-52.425

62.869

Chemotherapy

20.924b

20.714

.977

-37.621

79.469

Combo-therapy

26.901b

19.412

.839

-27.964

81.765

Chemotherapy

15.702b

21.985

.998

-46.435

77.838

b

20.763

.971

-37.003

80.360

Combo-therapy

21.678

Combo-therapy

5.977

21.075

1.000

-53.588

65.541

Control: Isotype

.021

.032

.999

-.069

.111

Immunotherapy

.115

.034

.009

.018

.212

Chemotherapy

.120

.035

.007

.021

.219

Combo-therapy

.087

.033

.078

-.005

.179

Immunotherapy

.094

.035

.077

-.005

.194

Chemotherapy

.099

.036

.060

-.002

.201

Combo-therapy

.066

.034

.406

-.029

.161

Chemotherapy

.005

.038

1.000

-.103

.112

Combo-therapy

-.028

.036

.996

-.130

.073

Combo-therapy
Control: Isotype

-.033
.570a,*

.037
.110

.989
<.001

-.136
.258

.070
.882

Immunotherapy

.350a,*

.119

.035

.014

.686

Chemotherapy

.384*

.121

.017

.042

.725

Combo-therapy

.419*

.113

.003

.100

.737

Immunotherapy

-.220a,b

.122

.533

-.567

.126

Chemotherapy

-.187b

.124

.765

-.538

.165

Combo-therapy

-.151b

.117

.886

-.481

.178

Chemotherapy

.034b

.132

1.000

-.339

.407

Combo-therapy

.069b

.125

1.000

-.284

.421

Combo-therapy

.035

.127

1.000

-.323

.393

Control: Isotype

.236a

.090

.092

-.019

.491

Immunotherapy

.392a,*

.097

.001

.117

.667

Chemotherapy

.408*

.099

.001

.129

.687

Combo-therapy

.339*

.092

.003

.078

.600

Immunotherapy

.156a,b

.100

.723

-.127

.439

Chemotherapy

.172b

.102

.620

-.116

.460

Combo-therapy

.103b

.095

.963

-.166

.373

Chemotherapy

.016b

.108

1.000

-.289

.321

Combo-therapy

-.053b

.102

1.000

-.341

.235
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Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values (cont.)
Day

Raw
Metric
HbO2

Pairwise Comparisons
(I) Treatment

(J) Treatment

Chemotherapy

Combo-therapy

-.069

.104

.999

Control: Isotype

-.083a

.123

.999

-.430

.264

Immunotherapy

.044a

.132

1.000

-.330

.417

Chemotherapy

.271

.134

.365

-.108

.651

Combo-therapy

-.151

.125

.925

-.506

.203

Immunotherapy

.127a,b

.136

.987

-.258

.512

Chemotherapy

.355b

.138

.104

-.036

.745

Combo-therapy

-.068b

.130

1.000

-.435

.298

Chemotherapy

.228

b

.147

.728

-.187

.642

Combo-therapy

-.195b

.139

.825

-.587

.196

Combo-therapy

-.423*

.141

.029

-.820

-.025

Control: Isotype

-43.183a,b

23.002

.471

-108.192

21.826

Immunotherapy

21.150a,b

21.686

.982

-40.141

82.441

Chemotherapy

.186a,b

22.354

1.000

-62.992

63.364

Combo-therapy

52.849a,b

24.043

.254

-15.103

120.802

Immunotherapy

64.333a,b

23.002

.055

-.676

129.342

Chemotherapy

43.369a,b

23.632

.504

-23.421

110.160

Combo-therapy

96.033a,b,*

25.236

.002

24.709

167.356

Chemotherapy

-20.964a,b

22.354

.986

-84.142

42.214

Combo-therapy

31.699a,b

24.043

.876

-36.253

99.652

Combo-therapy

52.663a,b

24.647

.290

-16.995

122.322

Control: Isotype

.024a,b

.040

1.000

-.089

.136

Immunotherapy

.169a,b,*

.038

<.001

.063

.275

Chemotherapy

.193a,b,*

.039

<.001

.083

.302

Combo-therapy

.103a,b

.042

.132

-.015

.221

Immunotherapy

.146a,b,*

.040

.003

.033

.258

Chemotherapy

.169a,b,*

.041

<.001

.054

.285

Combo-therapy

.080a,b

.044

.517

-.044

.203

Chemotherapy

.024a,b

.039

1.000

-.086

.133

Combo-therapy

-.066a,b

.042

.701

-.184

.052

Combo-therapy

-.090a,b

.043

.312

-.210

.031

Control: Isotype

.544a,b,*

.138

.001

.153

.934

Immunotherapy

.644a,b,*

.130

<.001

.276

1.012

Chemotherapy

.691a,b,*

.134

<.001

.312

1.070

Combo-therapy

.452a,b,*

.144

.020

.044

.860

Immunotherapy

.100a,b

.138

.998

-.290

.490

Chemotherapy

.147a,b

.142

.972

-.254

.548

Combo-therapy

-.092a,b

.152

1.000

-.520

.336

Chemotherapy

.047a,b

.134

1.000

-.332

.426

Control: Saline

1

μs’

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

Tumor
size

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline
3
StO2

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-.361
.224

Mean
Difference
(I-J)

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline
THC
Control: Isotype
Immunotherapy
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Std.
Error

Sig.d

Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values (cont.)
Day

Raw
Metric
THC

Pairwise Comparisons
(I) Treatment

(J) Treatment

Immunotherapy

Combo-therapy

-.192a,b

.144

.871

Chemotherapy

Combo-therapy

-.239a,b

.148

.680

-.657

.179

Control: Isotype

.239a,b

.113

.303

-.080

.558

Immunotherapy

.598a,b,*

.107

<.001

.296

.899

Chemotherapy

.658a,b,*

.110

<.001

.348

.968

Combo-therapy

.397a,b,*

.118

.009

.063

.731

Immunotherapy

.358a,b,*

.113

.017

.039

.678

Chemotherapy

.419a,b,*

.116

.004

.091

.747

Combo-therapy

.158

a,b

.124

.898

-.192

.508

Chemotherapy

.060a,b

.110

1.000

-.250

.371

Combo-therapy

-.201a,b

.118

.614

-.534

.133

Combo-therapy

-.261a,b

.121

.279

-.603

.081

Control: Isotype

-.504a,b,*

.153

.012

-.938

-.070

Immunotherapy

-.172a,b

.145

.931

-.581

.237

Chemotherapy

-.259a,b

.149

.582

-.681

.162

Combo-therapy

-.295a,b

.160

.502

-.748

.158

Immunotherapy

.332a,b

.153

.276

-.102

.765

Chemotherapy

.245a,b

.158

.729

-.201

.690

Combo-therapy

.209a,b

.168

.912

-.267

.685

Chemotherapy

-.087a,b

.149

1.000

-.509

.335

Combo-therapy

-.123a,b

.160

.997

-.576

.331

Combo-therapy

-.036a,b

.164

1.000

-.501

.429

Control: Isotype

-8.164a,b

40.571

1.000

-122.829

106.502

Immunotherapy

142.108a,b,*

30.669

<.001

55.429

228.787

Chemotherapy

420.385a,b,*

30.669

<.001

333.706

507.064

Combo-therapy

506.990a,b,*

32.529

<.001

415.053

598.927

Immunotherapy

150.272a,b,*

40.571

.003

35.607

264.938

Chemotherapy

428.548a,b,*

40.571

<.001

313.883

543.214

Combo-therapy

515.154a,b,*

41.995

<.001

396.464

633.844

Chemotherapy

278.276a,b,*

30.669

<.001

191.597

364.955

Combo-therapy

364.882a,b,*

32.529

<.001

272.945

456.819

Combo-therapy

86.606a,b

32.529

.080

-5.331

178.543

Control: Isotype

-.089a,b

.070

.899

-.288

.109

Immunotherapy

.067a,b

.053

.902

-.083

.217

Chemotherapy

.082a,b

.053

.740

-.069

.232

Combo-therapy

.067a,b

.056

.934

-.093

.226

Immunotherapy

.157a,b

.070

.239

-.042

.355

Chemotherapy

.171a,b

.070

.147

-.028

.369

Combo-therapy

.156a,b

.073

.286

-.050

.362

Control: Saline

HbO2

Control: Isotype

Immunotherapy
3

Chemotherapy

Control: Saline

μs’

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

Tumor
size

Control: Isotype

Immunotherapy

7

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-.600
.216

Mean
Difference
(I-J)

Chemotherapy

Control: Saline
StO2
Control: Isotype
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Std.
Error

Sig.d

Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values (cont.)
Day

Raw
Metric

StO2

Pairwise Comparisons
(I) Treatment
Immunotherapy
Chemotherapy

Control: Saline

THC

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline
7
HbO2

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

μs’

Control: Isotype

Immunotherapy
Chemotherapy

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-.136
.164

Std.
Error

Sig.d

(J) Treatment

Mean
Difference
(I-J)

Chemotherapy

.014a,b

.053

1.000

Combo-therapy

-.001a,b

.056

1.000

-.160

Combo-therapy

-.015a,b

.056

1.000

-.174

.144

Control: Isotype

.400a,b

.244

.659

-.289

1.089

Immunotherapy

-.252a,b

.184

.851

-.772

.269

Chemotherapy

.644a,b,*

.184

.006

.124

1.165

Combo-therapy

.043a,b

.195

1.000

-.509

.595

Immunotherapy

-.652a,b

.244

.077

-1.340

.037

Chemotherapy

.244

a,b

.244

.978

-.444

.933

Combo-therapy

-.357a,b

.252

.822

-1.070

.356

Chemotherapy

.896a,b,*

.184

<.001

.375

1.416

Combo-therapy

.295a,b

.195

.759

-.257

.847

Combo-therapy

-.601a,b,*

.195

.023

-1.153

-.049

Control: Isotype

-.053a,b

.199

1.000

-.617

.510

Immunotherapy

.095a,b

.151

.999

-.331

.520

Chemotherapy

.355a,b

.151

.177

-.071

.781

Combo-therapy

.188a,b

.160

.937

-.264

.639

Immunotherapy

.148a,b

.199

.998

-.415

.711

Chemotherapy

.409a,b

.199

.345

-.155

.972

Combo-therapy

.241a,b

.206

.939

-.342

.824

Chemotherapy

.260a,b

.151

.590

-.165

.686

Combo-therapy

.093a,b

.160

1.000

-.359

.545

Combo-therapy

-.168a,b

.160

.970

-.619

.284

Control: Isotype

.216a,b

.271

.996

-.550

.981

Immunotherapy

.216a,b

.205

.968

-.362

.795

Chemotherapy

-.199a,b

.205

.982

-.778

.379

Combo-therapy

.216a,b

.217

.979

-.397

.830

Immunotherapy

.001a,b

.271

1.000

-.765

.766

Chemotherapy

-.415a,b

.271

.742

-1.180

.350

Combo-therapy

.001a,b

.280

1.000

-.791

.793

Chemotherapy

-.416a,b

.205

.359

-.994

.163

Combo-therapy

-6.000E5a,b
.415a,b

.217

1.000

-.614

.613

.217

.443

-.198

1.029

Combo-therapy

*. The mean difference is significant at the .05 level.
a. An estimate of the modified population marginal mean (J).
c. An estimate of the modified population marginal mean (I).
d. Adjustment for multiple comparisons: Sidak.
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.159

Figure 26. Comparison of treatments for days 1, 3, and 7 for normalized tumor
size. For statistical analysis, see Table 15

Figure 27. Comparison of treatments for days 1, 3, and 7 for normalized StO2.
For statistical analysis, see Table 15
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Figure 28. Comparison of treatments for days 1, 3, and 7 for normalized THC.
For statistical analysis, see Table 15

Figure 29. Comparison of treatments for days 1, 3, and 7 for normalized HbO2.
For statistical analysis, see Table 15
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Figure 30. Comparison of treatments for days 1, 3, and 7 for normalized μs’. For
statistical analysis, see Table 15
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values
Day

Norm.
Metric

Pairwise Comparisons
(I) Treatment

Control: Saline

Tumor
size

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

StO2

Control: Isotype

Immunotherapy
1

Chemotherapy

Control: Saline

THC

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

HbO2
Control: Isotype

Immunotherapy

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-.798
.575

Std.
Error

Sig.d

(J) Treatment

Mean
Difference
(I-J)

Control: Isotype

-.112a

.243

1.000

Immunotherapy

-.069a

.262

1.000

-.808

.670

Chemotherapy

.095

.266

1.000

-.657

.847

Combo-therapy

.192

.248

.997

-.509

.894

Immunotherapy

.042a,b

.270

1.000

-.719

.804

Chemotherapy

.207b

.274

.998

-.567

.980

Combo-therapy

.304b

.257

.934

-.421

1.029

Chemotherapy

.164b

.291

1.000

-.657

.985

Combo-therapy

.261

b

.274

.985

-.514

1.037

Combo-therapy

.097

.279

1.000

-.690

.884

Control: Isotype

.135a

.114

.931

-.186

.456

Immunotherapy

.078a

.122

.999

-.268

.424

Chemotherapy

-.112

.124

.990

-.463

.240

Combo-therapy

-.186

.116

.693

-.514

.143

Immunotherapy

-.057a,b

.126

1.000

-.413

.299

Chemotherapy

-.247b

.128

.432

-.609

.115

Combo-therapy

-.321b

.120

.077

-.660

.018

Chemotherapy

-.190b

.136

.832

-.574

.194

Combo-therapy

-.264b

.128

.341

-.627

.099

Combo-therapy

-.074

.130

1.000

-.442

.294

Control: Isotype

.049a

.055

.990

-.105

.203

Immunotherapy

.029a

.059

1.000

-.137

.194

Chemotherapy

-.140

.060

.179

-.309

.028

Combo-therapy

.045

.056

.996

-.112

.203

Immunotherapy

-.021a,b

.061

1.000

-.192

.150

Chemotherapy

-.190b,*

.061

.022

-.363

-.016

Combo-therapy

-.004b

.058

1.000

-.167

.159

Chemotherapy

-.169b

.065

.098

-.353

.016

Combo-therapy

.017b

.062

1.000

-.157

.191

Combo-therapy

.185*

.063

.033

.009

.362

Control: Isotype

.163a

.144

.949

-.243

.570

Immunotherapy

.080a

.155

1.000

-.358

.518

Chemotherapy

-.322

.157

.350

-.767

.123

Combo-therapy

-.130

.147

.991

-.546

.285

Immunotherapy

-.083a,b

.160

1.000

-.534

.368

Chemotherapy

-.485b,*

.162

.030

-.943

-.027

Combo-therapy

-.294b

.152

.429

-.723

.136

Chemotherapy

-.402b

.172

.186

-.888

.084

Combo-therapy

-.211b

.162

.887

-.670

.249
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values
(cont.)
Day

Norm.
Metric
HbO2

Pairwise Comparisons
(I) Treatment
Chemotherapy

Control: Saline

1

μs’

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

Tumor
size

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline
3
StO2

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline
THC
Control: Isotype

(J) Treatment

Mean
Difference
(I-J)

Std.
Error

Sig.d

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-.275
.657

Combo-therapy

.191

.165

.941

Control: Isotype

.026a

.039

.999

-.083

.135

Immunotherapy

.043a

.042

.974

-.075

.160

Chemotherapy

.040

.042

.985

-.079

.160

Combo-therapy

-.043

.040

.961

-.155

.069

Immunotherapy

.017a,b

.043

1.000

-.104

.138

Chemotherapy

.014b

.044

1.000

-.109

.138

Combo-therapy

-.069

b

.041

.620

-.184

.046

Chemotherapy

-.002b

.046

1.000

-.133

.128

Combo-therapy

-.086b

.044

.405

-.209

.038

Combo-therapy

-.083

.044

.467

-.209

.042

Control: Isotype

-.415a,b

.304

.851

-1.274

.444

Immunotherapy

.358a,b

.287

.909

-.452

1.168

Chemotherapy

-.020a,b

.295

1.000

-.855

.815

Combo-therapy

1.001a,b,*

.304

.011

.141

1.860

Immunotherapy

.773a,b

.304

.110

-.086

1.632

Chemotherapy

.396a,b

.312

.901

-.487

1.278

Combo-therapy

1.416a,b,*

.320

<.001

.510

2.321

Chemotherapy

-.378a,b

.295

.896

-1.213

.457

Combo-therapy

.642a,b

.304

.304

-.217

1.502

Combo-therapy

1.020a,b,*

.312

.012

.138

1.903

Control: Isotype

.120a,b

.142

.994

-.282

.522

Immunotherapy

.085a,b

.134

.999

-.294

.464

Chemotherapy

-.059a,b

.138

1.000

-.450

.331

Combo-therapy

-.208a,b

.142

.791

-.610

.194

Immunotherapy

-.035a,b

.142

1.000

-.436

.367

Chemotherapy

-.179a,b

.146

.918

-.592

.234

Combo-therapy

-.328a,b

.150

.260

-.752

.096

Chemotherapy

-.145a,b

.138

.970

-.535

.246

Combo-therapy

-.293a,b

.142

.336

-.695

.108

Combo-therapy

-.149a,b

.146

.975

-.562

.264

Control: Isotype

.040a,b

.068

1.000

-.152

.233

Immunotherapy

.118a,b

.064

.505

-.064

.300

Chemotherapy

-.090a,b

.066

.855

-.277

.097

Combo-therapy

.172a,b

.068

.118

-.021

.365

Immunotherapy

.078a,b

.068

.948

-.115

.270

Chemotherapy

-.130a,b

.070

.484

-.329

.068

Combo-therapy

.131a,b

.072

.512

-.072

.335
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values
(cont.)
Day

Norm.
Metric

THC

Pairwise Comparisons
(I) Treatment
Immunotherapy
Chemotherapy

Control: Saline

HbO2

Control: Isotype

Immunotherapy

3

Chemotherapy

Control: Saline

μs’

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

Tumor
size
7

Control: Isotype

Immunotherapy
Chemotherapy

StO2

Control: Saline

Control: Isotype

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-.396
-.021

Std.
Error

Sig.d

(J) Treatment

Mean
Difference
(I-J)

Chemotherapy

-.208a,b,*

.066

.019

Combo-therapy

.054a,b

.068

.997

-.139

.247

Combo-therapy

.262a,b,*

.070

.002

.064

.460

Control: Isotype

.170a,b

.180

.986

-.339

.678

Immunotherapy

.166a,b

.170

.981

-.314

.646

Chemotherapy

-.157a,b

.175

.990

-.651

.338

Combo-therapy

-.173a,b

.180

.984

-.681

.336

Immunotherapy

-.003

a,b

.180

1.000

-.512

.505

Chemotherapy

-.326a,b

.185

.562

-.849

.197

Combo-therapy

-.342a,b

.190

.529

-.878

.194

Chemotherapy

-.323a,b

.175

.497

-.817

.172

Combo-therapy

-.339a,b

.180

.467

-.848

.170

Combo-therapy

-.016a,b

.185

1.000

-.539

.506

Control: Isotype

-.056a,b

.048

.943

-.193

.081

Immunotherapy

-.028a,b

.046

1.000

-.157

.101

Chemotherapy

-.140a,b,*

.047

.032

-.273

-.007

Combo-therapy

-.058a,b

.048

.929

-.195

.079

Immunotherapy

.027a,b

.048

1.000

-.109

.164

Chemotherapy

-.084a,b

.050

.619

-.225

.056

Combo-therapy

-.002a,b

.051

1.000

-.146

.142

Chemotherapy

-.112a,b

.047

.170

-.244

.021

Combo-therapy

-.030a,b

.048

1.000

-.166

.107

Combo-therapy

.082a,b

.050

.652

-.058

.223

Control: Isotype

.284a,b

.536

1.000

-1.231

1.800

Immunotherapy

2.278a,b,*

.405

<.001

1.133

3.424

Chemotherapy

5.566a,b,*

.405

<.001

4.421

6.712

Combo-therapy

6.795a,b,*

.430

<.001

5.580

8.010

Immunotherapy

1.994a,b,*

.536

.002

.479

3.509

Chemotherapy

5.282a,b,*

.536

<.001

3.767

6.797

Combo-therapy

6.511a,b,*

.555

<.001

4.942

8.079

Chemotherapy

3.288a,b,*

.405

<.001

2.143

4.434

Combo-therapy

4.517a,b,*

.430

<.001

3.302

5.731

Combo-therapy

1.228a,b,*

.430

.046

.013

2.443

Control: Isotype

.020a,b

.251

1.000

-.689

.729

Immunotherapy

-.270a,b

.190

.816

-.806

.266

Chemotherapy

-.550a,b,*

.190

.040

-1.086

-.014

Combo-therapy

-.503a,b

.201

.124

-1.071

.066

Immunotherapy

-.290a,b

.251

.942

-.999

.419
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values
(cont.)
Day

Norm.
Metric

Pairwise Comparisons
(I) Treatment
Control: Isotype

StO2

Immunotherapy
Chemotherapy

Control: Saline

THC

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

7

HbO2

Control: Isotype

Immunotherapy
Chemotherapy

Control: Saline

μs’

Control: Isotype

Immunotherapy
Chemotherapy

95% Confidence
Interval for Differenced
Lower
Upper
Bound
Bound
-1.279
.138

Std.
Error

Sig.d

(J) Treatment

Mean
Difference
(I-J)

Chemotherapy

-.570a,b

.251

.214

Combo-therapy

-.523a,b

.260

.370

-1.257

.211

Chemotherapy

-.280a,b

.190

.780

-.816

.256

Combo-therapy

-.233a,b

.201

.943

-.801

.336

Combo-therapy

.048a,b

.201

1.000

-.521

.616

Control: Isotype

.038a,b

.120

1.000

-.302

.378

Immunotherapy

-.156a,b

.091

.602

-.413

.101

Chemotherapy

-.017

a,b

.091

1.000

-.274

.240

Combo-therapy

-.044a,b

.097

1.000

-.317

.229

Immunotherapy

-.194a,b

.120

.681

-.534

.146

Chemotherapy

-.055a,b

.120

1.000

-.395

.285

Combo-therapy

-.082a,b

.125

.999

-.434

.270

Chemotherapy

.139a,b

.091

.744

-.118

.396

Combo-therapy

.112a,b

.097

.942

-.161

.385

Combo-therapy

-.027a,b

.097

1.000

-.300

.245

Control: Isotype

.078a,b

.318

1.000

-.819

.976

Immunotherapy

-.503a,b

.240

.315

-1.182

.175

Chemotherapy

-.582a,b

.240

.149

-1.261

.096

Combo-therapy

-.592a,b

.255

.190

-1.311

.127

Immunotherapy

-.582a,b

.318

.507

-1.479

.316

Chemotherapy

-.661a,b

.318

.324

-1.558

.236

Combo-therapy

-.670a,b

.329

.352

-1.599

.258

Chemotherapy

-.079a,b

.240

1.000

-.758

.599

Combo-therapy

-.089a,b

.255

1.000

-.808

.631

Combo-therapy

-.010a,b

.255

1.000

-.729

.710

Control: Isotype

.220a,b

.085

.101

-.021

.461

Immunotherapy

.107a,b

.065

.649

-.076

.289

Chemotherapy

-.067a,b

.065

.973

-.249

.116

Combo-therapy

.006a,b

.068

1.000

-.187

.200

Immunotherapy

-.113a,b

.085

.873

-.354

.128

Chemotherapy

-.287a,b,*

.085

.009

-.528

-.045

Combo-therapy

-.214a,b

.088

.152

-.463

.036

Chemotherapy

-.173a,b

.065

.074

-.356

.009

Combo-therapy

-.100a,b

.068

.787

-.294

.093

Combo-therapy

.073a,b

.068

.966

-.120

.266

*. The mean difference is significant at the .05 level.
a. An estimate of the modified population marginal mean (J).
c. An estimate of the modified population marginal mean (I).
d. Adjustment for multiple comparisons: Sidak.
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6.11.2 Correlation of spectroscopy-derived data

Figure 31. Correlations of normalized spectroscopy-dervied data. For statistical
analysis on Pearson (parametric) and Spearman (non-parametric) correlations and
significance, see Tables 16-30
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Table 16. Test of normality for saline control group
Tumor size
StO2
THC
HbO2
μs’

Shapiro-Wilk
Statistic
70
70
70
70
70

Statistic
.771
.890
.925
.880
.968

Statistic
.000
.000
.000
.000
.066

Table 17. Pearson correlation (parametric) of normalized metrics for saline control group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
-.344**
.003
70

THC
.116
.340
70
-.280*
.019
70

HbO2
-.298*
.012
70
.894**
.000
70
.168
.164
70

μs’
-.074
.545
70
.232
.053
70
-.162
.180
70
.172
.155
70

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
Red shading = excluded significant correlation due to normality violation
Table 18. Spearman correlation (non-parametric) of normalized metrics for saline control group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
-.363**
.002
70

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
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THC
.195
.106
70
-.451**
.000
70

HbO2
-.312**
.009
70
.840**
.000
70
.002
.987
70

μs’
-.287*
.016
70
.311**
.009
70
-.241*
.044
70
.153
.205
70

Table 19. Test of normality for isotype control group
Tumor size
StO2
THC
HbO2
μs’

Shapiro-Wilk
Statistic
51
51
51
51
51

Statistic
.728
.948
.916
.905
.902

Statistic
.000
.026
.002
.001
.001

Table 20. Pearson correlation (parametric) of normalized metrics for isotype control group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
-.302*
.031
51

THC
.128
.370
51
-.092
.521
51

HbO2
-.280*
.047
51
.936**
<.001
51
.252
.074
51

μs’
-.657**
.000
51
.141
.322
51
-.059
.683
51
.141
.323
51

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
Red shading = excluded significant correlation due to normality violation
Table 21. Spearman correlation (non-parametric) of normalized metrics for isotype control group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
-.484**
<.001
51

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
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THC
-.184
.196
51
-.009
.950
51

HbO2
-.516**
<.001
51
.923**
.000
51
.304*
.030
51

μs’
-.624**
<.001
51
.211
.137
51
.099
.489
51
.249
.078
51

Table 22. Test of normality for immunotherapy-treated group
Tumor size
StO2
THC
HbO2
μs’

Shapiro-Wilk
Statistic
60
60
60
60
60

Statistic
.789
.974
.890
.887
.974

Statistic
.000
.240
.000
.000
.226

Table 23. Pearson correlation (parametric) of normalized metrics for immunotherapy-treated
group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
.076
.565
60

THC
.542**
.000
60
.552**
<.001
60

HbO2
.327*
.011
60
.915**
<.001
60
.825**
<.001
60

μs’
-.390**
.002
60
-.078
.554
60
-.315*
.014
60
-.247
.057
60

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
Red shading = excluded significant correlation due to normality violation
Table 24. Spearman correlation (non-parametric) of normalized metrics for immunotherapytreated group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
-.058
.660
60

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
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THC
.282*
.029
60
.502**
.000
60

HbO2
.014
.916
60
.929**
.000
60
.717**
.000
60

μs’
-.502**
<.001
60
.039
.767
60
-.027
.841
60
-.016
.905
60

Table 25. Test of normality for chemotherapy-treated group
Tumor size
StO2
THC
HbO2
μs’

Shapiro-Wilk
Statistic
60
60
60
60
60

Statistic
.799
.934
.929
.837
.967

Statistic
.000
.003
.002
.000
.100

Table 26. Pearson correlation (parametric) of normalized metrics for chemotherapy-treated
group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
.294*
.023
60

THC
.192
.141
60
.400**
.002
60

HbO2
.275*
.033
60
.926**
.000
60
.693**
.000
60

μs’
.261*
.044
60
-.207
.112
60
.006
.964
60
-.150
.254
60

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
Red shading = excluded significant correlation due to normality violation
Table 27. Spearman correlation (non-parametric) of normalized metrics for chemotherapytreated group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
.203
.120
60

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance

359

THC
.267*
.040
60
.297*
.021
60

HbO2
.215
.100
60
.912**
<.001
60
.601**
<.001
60

μs’
.302*
.019
60
-.214
.100
60
.048
.714
60
-.165
.208
60

Table 28. Test of normality for combination therapy-treated group
Tumor size
StO2
THC
HbO2
μs’

Shapiro-Wilk
Statistic
56
56
56
56
56

Statistic
.930
.906
.609
.909
.601

Statistic
.003
.000
.000
.000
.000

Table 29. Pearson correlation (parametric) of normalized metrics for combination therapytreated group
Tumor size

StO2

THC

HbO2

StO2
-.012
.927
56

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

THC
.219
.105
56
.364**
.006
56

HbO2
-.036
.793
56
.970**
.000
56
.470**
.000
56

μs’
.377**
.004
56
.404**
.002
56
.622**
.000
56
.345**
.009
56

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
Red shading = excluded significant correlation due to normality violation
Table 30. Spearman correlation (non-parametric) of normalized metrics for combination therapytreated group
Tumor size

StO2

THC

HbO2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

StO2
-.100
.464
56

THC
-.137
.315
56
.199
.142
56

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Green shading = significance
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HbO2
-.125
.357
56
.936**
.000
56
.425**
.001
56

μs’
.319*
.017
56
.189
.163
56
-.311*
.020
56
.059
.663
56

6.11.3 Tumor associated macrophages
In our macrophage staining, we were able to stain for two different cell types: M1 and
M2 macrophages using a triple staining procedure, which reduces the possibly of the common
problem of including dendritic cells when counting macrophages. In general, M1 macrophages
are considered anti-tumor and M2 macrophages are considered pro-tumor, although this is an
oversimplification. M1 macrophages are counted if stained with both CD68 and CD80, whereas
M2 macrophages are counted if stained with both CD68 and CD206. In a comparison between
the isotype control and immunotherapy groups (Fig. 32), on both day 3 and day 7, the M1/M2
ratio in the isotype control group is elevated, as expected based on a reduction in the number of
M2-polarized pro-tumor macrophages. The literature shows that an increase in the M1/M2 ratio
is a positive prognostic indicator of cancer-specific survival (Edin et al., 2012).
Specifically, on day 3, the M1/M2 ratio for the isotype control and immunotherapy
groups are 45.1% ± 18.4% and 52.2% ± 14.2% (p = 0.28). On day 7, the M1/M2 ratio for the
isotype control and immunotherapy groups are 29.5% ± 6.5% and 43.6% ± 16.1% (p = 0.13).
These results, although insignificant, seem to indicate an increase in the M1/M2 ratio in tumors
treated with anti-CCL2 immunotherapy. However, both groups show a decrease in the M1/M2
ratio over time. For example, in the isotype control group, M1/M2 ratio decreases from 45.1% ±
18.4% to 29.5% ± 6.5% (p = 0.14). In the anti-CCL2 immunotherapy group, M1/M2 ratio
decreases from 52.2% ± 14.2% to 43.6% ± 16.1% (p = 0.28). Note that the decrease is more
significant for the control group.
In the isotype control treatment group (i.e. mice treated with isotype antibodies as a
control for anti-CCL2 immunotherapy), more and more M2 macrophages infiltrate the tumor
over time, lowering the M1/M2 ratio significantly. In the immunotherapy group, there is a slight
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but insignificant decrease in the M1/M2 ratio, potentially indicating that our anti-CCL2
immunotherapy is working to reduce monocyte infiltration as expected. Work in this area is
ongoing and research will be needed in correlating M1/M2 ratios to HbO2 values among
treatment groups. We expect that a decrease in M2 macrophages, coupled with chemotherapy,
will increase survival in mice compared to chemotherapy alone, although the precise interplay
between TAMs and DRS-derived HbO2 remains to be determined.

Figure 32. In both the isotype control (dark gray) and anti-CCL2 immunotherapy
treated groups (light gray), the M1/M2 ratio decreased over time, although the
M1/M2 ratio decreased more in the isotype control group. On both days 3 and 7,
the M1/M2 is elevated in the immunotherapy-treated group, albeit insignificantly.
An increase in the M1/M2 ratio has been shown to be a positive prognostic
indicator of cancer-specific survival (Edin et al., 2012).
6.11 Discussion
In this study, Balb/c mice were subcutaneously injected with murine CT26 colon
carcinoma cells in the left flank. Tumors were allowed to grow until they reached 75 mm3. Once
the tumor reached 75 mm3, mice underwent intraperitoneal treatment with either saline control,
isotype control, anti-CCL2 neutralizing antibody immunotherapy, 5-FU chemotherapy, or a
combination of anti-CCL2 immunotherapy and 5-FU chemotherapy for up to 7 days.
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A two-way ANOVA with repeated measures was used to assess both the comparisons of
treatments for days 1, 3, and 7 within metrics and comparisons to day 0 within treatment and within
metrics. The normality of the residual error scores for the raw and normalized metrics was tested using
the Shapiro-Wilk test. The Wilcoxon Signed Rank test was used to assess the differences between Day 0
and Days 1, 3, and 7 within each of the 5 treatments and for comparing all pairs of treatments on Days 1,
3, and 7 for any metrics in which normality failed (W < 0.9). These analyses computed the Pearson

product-moment correlations between each pair of normalized metric scores within each of the
five treatments. Shapiro-Wilk tests for normality were conducted for scores on all five
normalized metrics within each treatment. Correlations between any pair of metrics within a
treatment where one or both of the metrics had Shapiro-Wilk values below .88 were recomputed
using the nonparametric Spearman’s rho correlation.
The first topic of discussion is the effect of treatment on tumor size. Tumor size is the
most common metric to assess response to anticancer therapy. Tumors were measured daily with
external calipers. By the end of 7 days, tumors grew to 682 ± 85 mm3 (128% growth per day),
690 ± 119 mm3 (125% growth per day), 540 ± 82 mm3 (96% growth per day), 262 ± 131 mm3
(49% growth per day), and 175 ± 26 mm3 (32% growth per day) for the saline control, isotype
control, immunotherapy, chemotherapy, and combination groups, respectively (Figure 10, 11 and
16). Tables 12 and 14 shows the statistics for raw tumor size; however; tables 13 and 15, which
shows statistics for normalized tumor size, is perhaps more important since growth is normalized
to the tumor size at day 0. This allows for comparisons between mice that may have had different
initial tumor sizes of 74 or 77 mm3, for example. In all groups except for the combination
therapy group, tumor size had significantly increased by day 3 (Table 13). In the combination
therapy group, tumor size had significantly increased by day 7 (Table 13). So, it is noteworthy
that tumors from all treatment groups experienced tumor growth. At day 3, tumors treated with
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combination therapy (anti-CCL2 + 5-FU) showed significantly reduced tumor growth compared
to saline control (p=0.011), isotype control (<0.001), and chemotherapy (p=0.012) groups. By
day 7, all groups showed significantly different tumor growth rates, expect for the saline and
isotype control groups (p=1.000), as expected. By day 7, combination therapy proved just
slightly better than chemotherapy alone (p=0.046) with regards to tumor growth. Based on this
data alone, it would appear that both immunotherapy and chemotherapy slowed tumor growth,
albeit chemotherapy being more successful. A combination of the two treatments slowed tumor
growth even further. One surprising result indicated that, according to Pearson correlations,
tumor size significantly, albeit weakly, correlated with μs’ (Figure 31(a), Tables 18, 21, 24, 27,
and 30) in all treatment groups. There was a negative correlation of μs’ vs. tumor size for the
saline control (R=-0.287, p=0.016), isotype control (R=-0.624, p<0.001), and immunotherapy
groups (R=-0.502, p<0.001), and a positive correlation of μs’ vs. tumor size for the chemotherapy
(R=-0.302, p=0.019) and combination treatment groups (R=0.319, p=0.017). However, the small
R values give reason to question the importance of these results. Additionally, Wang et al. found
that chemotherapy-treated breast cancer xenografts had reduced tumor cell density and
proliferating cell density (Wang et al., 2013), which would theoretically lead to a negative
correlation of μs’ vs. tumor size (Su et al., 2015) in chemotherapy-treated mice, rather than the
small positive correlation seen in our study. A potential confounding variable in this situation
could be the skin layer overlying the tumor in this subcutaneous tumor model. It is reasonable to
assume that, in larger tumors, the skin is stretched. Since chemotherapy and combination therapy
treated mice had reduced tumor growth, it may be reasonable to assume that the skin was less
stretched, although this was not explicitly tested. If this was the case, light from the DRS probe
could potentially interact with the skin layer less in (Rajaram, Gopal, et al., 2010) the control
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groups compared to treatment groups. Skin has a higher scattering coefficient due to its collagen
content (Lister et al., 2012; Zonios et al., 2008) compared to a tumor (Cerussi et al., 2006;
Spliethoff et al., 2014; Su et al., 2015), so “stretching” of the skin in a subcutaneous model could
certain affect measured μs’. Some groups have solved this issue by creating a fiber-optic needle
that penetrates the skin layer to sample μs’ at the center of allograft or xenograft tumors
(Spliethoff et al., 2014). Interestingly, tumor size negatively and significantly correlated with
StO2 and HbO2 (Figure 31(c, d), Tables 18, 21, 24, 27, and 30) in only the saline control (R=0.363 and -0.312, p=0.002 and p=0.009) and isotype control groups (R=-0.484 and -0.516,
p<0.001 and p<0.001), but not the treatment groups. This indicates that in control groups, as
tumor size increases, StO2 and HbO2 decreases, indicating a more hypoxic tumor
microenvironment with tumor growth. Furthermore, tumor hypoxia, as seen in the control tumors
here, have been linked to tumor progression (Vaupel et al., 2006), which is what these results
indicate. Spectroscopically-derived StO2 and HbO2 (StO2 * THC) have been shown to be
correlated with tumor hypoxic fraction, validated with pimonidazole, an established hypoxia
biomarker (Dadgar et al., 2018). These studies by Dadgar et al. showed that DRS-based
measurements of StO2 and HbO2 can indirectly and non-invasively quantify tumor hypoxia
(Dadgar et al., 2018). Although there was a correlation between tumor size and HbO2 in control
tumors in this study, other groups have shown that hypoxia cannot be predicted by tumor size
alone (Walsh et al., 2014), which perhaps partially explains why there was no correlation
between tumor size and HbO2 in experimental treatment groups. There were no correlations
between tumor size and THC, except in the immunotherapy group (R=0.282, p=0.029). Although
tumor size did correlate with many DRS-based metrics, it should be noted that volumetric
measurements of allograft or xenograft tumors via external calipers is highly affected by error.
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More accurate ways of measuring tumor size include micro-computed tomography (microCT)
(Jensen et al., 2008).
The next topic of discussion is the effect of treatment on the DRS-derived perfusion
metrics, StO2, THC, and HbO2. StO2 is the tissue oxygen saturation, which is a metric of
assessing oxygen saturation, and is defined as the oxygen saturation averaged over the arteriovenous network (Christen et al., 2014). Optical methods quantifying StO2, including DRS and
near-infrared spectroscopy (NIRS), has already made its way to the clinic, where it is currently
being used to noninvasively alert clinicians of peripheral hypoperfusion and tissue hypoxia at the
patient bedside (Epstein et al., 2014). THC is the volume-averaged total hemoglobin, given as a
concentration, of the tissue sampled by spectroscopic methods (G.J. Greening et al., 2018;
Rajaram, Gopal, et al., 2010). HbO2 is simply the amount of oxygenated hemoglobin from the
total hemoglobin content and is mathematically a simple product of StO2 and THC (Quincy
Brown et al., 2009; G.J. Greening et al., 2018). Raw values for volume-averaged StO2 ranged
from 3% to 63% (Figure 12). These StO2 values are comparable to other spectroscopy-based
cancer studies (G.J. Greening et al., 2018; G. J. Greening et al., 2018; Palmer et al., 2009;
Spliethoff et al., 2014). It is important to note that these raw values are lower than what is
expected of arterial oxygen saturation (SaO2), which is typically between 96% to 98% measured
via pulse oximetry (Collins et al., 2015). Raw values for volume-averaged THC ranged between
1.54 mg/mL to 3.42 mg/mL (Figure 13), corresponding to blood volume fractions of 0.95% to
2.28%, based on the well-established assumption that the concentration of hemoglobin in whole
blood is 150 mg/mL (Prahl, 1999). These THC/blood volume fraction values are comparable to
other spectroscopy-based cancer studies (Rajaram, Gopal, et al., 2010; Spliethoff et al., 2014).
Based on these comparisons to literature, it was reasonable to assume that HbO2 values were as
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expected, although studies explicitly reporting spectroscopy-derived HbO2 are uncommon. Raw
values for volume-averaged HbO2 ranged between 0.05 mg/mL to 1.79 mg/mL (Figure 14).
Tables 12 and 14 shows the statistics for raw StO2, THC, and HbO2; however; tables 13
and 15, which shows statistics for normalized StO2, THC, and HbO2, is perhaps more important
since these metrics are normalized to the value at day 0. This allows for comparisons between
mice that may have had different initial StO2, THC, and HbO2 values. Within each treatment,
neither StO2, THC, and HbO2 significantly changed from baseline (Figures 17-19). However,
there were several noteworthy trends that may show significance with increased sample power.
By day 7, StO2 and HbO2 in the saline control group decreased to 75% ± 5% and 78% ±
6% of baseline values, respectively, whereas THC barely increased to 104% ± 6% of baseline
values, although all changes were insignificant (Figure 27-29). Similarly, by day 7, StO2 and
HbO2 in the isotype control group decreased to 73% ± 21% and 70% ± 10% of baseline values,
respectively, whereas THC remained at exactly that of baseline values (100% ± 15%), although
all changes were insignificant (Figure 27-29). In the immunotherapy group, by day 7, StO2 and
HbO2 increased to 102% ± 28% and 128% ± 56% of baseline values, respectively, whereas THC
increased to 120% ± 26% of baseline values, although all changes were insignificant (Figure 2729). It is worth noting that there was a large increase in standard deviation of the
immunotherapy-treatment group compared to the isotype control group, indicating variability in
treatment effect within subjects. In the chemotherapy group, by day 7, StO2 and HbO2 increased
to 130% ± 37% and 136% ± 44% of baseline values, respectively, whereas THC increased to
106% ± 15% of baseline values, although all changes were insignificant (Figure 27-29). Again,
standard deviations were much greater compared to the saline control group. Finally, in the
combination-treatment group, by day 7, StO2 and HbO2 increased to 125% ± 22% and 137% ±
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31% of baseline values, respectively, whereas THC barely increased to 108% ± 7% of baseline
values, although again all changes were insignificant (Figure 27-29). Another noteworthy find
was the oxyhemoglobin flare on day 1 in the chemotherapy-treatment group (144% ± 62%
compared to day 0 baseline) (Figure 29). Although there was a high standard deviation with no
significance, three mice had tumors had HbO2 flares that doubled compared to baseline (213%,
230%, and 257%) and 6 of 11 mice experience HbO2 flares in the chemotherapy-treatment
group. However, subject-to-subject variability was high. In the future, the DRS-derived HbO2
metric will be correlated to survival. For example, the question can be asked: do these mice with
tumors that experience an increase in HbO2 one day post-chemotherapy have increased survival
compared to those that experience no HbO2 flare or a decreased HbO2 flare? In 2011, Roblyer et
al. found that an HbO2 flare one day post-treatment correlated with increased neoadjuvant
chemotherapy response in human breast cancer patients (Roblyer et al., 2011). This is important
because many patients receiving neoadjuvant chemotherapy do not achieve any measurable
response while undergoing toxic chemotherapy. Thus, optical spectroscopy techniques such as
DRS may be beneficial in evaluating a patient’s (or mouse) early response to therapy, and, if it
has been shown to correlate with survival, can guide clinicians in deciding whether to continue
with treatment, switch treatments, or proceed more quickly to surgery to reduce unnecessary
toxic side effects (Roblyer et al., 2011; A.S. Walker et al., 2014). This indicates that DRS may
be useful as a future complimentary tool to monitor early tumor therapeutic response in colon
cancer. Next, at 7 days post-treatment, HbO2, a marker currently being explored as a functional
prognostic cancer marker, trended to increase in immunotherapy, chemotherapy, and
combination therapy groups compared to their appropriate controls (p=0.315, 0.149, and 0.190).
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StO2 correlated with THC in the saline control, immunotherapy-treatment group, and
chemotherapy-treatment groups, while not correlating with THC in the isotype control and
combination-treatment groups (Figure 31). However, the author cautions to not look too deeply
into these significant results. Since the change in THC over the 7-day treatment period was
insignificant for all treatment groups and lacked any relevant or interesting trends, it can be
concluded that, in this study, THC did not change in response to treatment. Therefore, any
significance in the correlation between StO2 and THC is likely a false positive due to lowpowered data (Figure 31). There was always a necessary significant correlation between StO2
and HbO2 since these metrics are mathematically related.
While StO2, and HbO2 are often used as an indicator of tissue/tumor health, it has been
suggested that these metrics can fail as reliable indicators in certain circumstances (Boas et al.,
2011). For example, StO2 alone cannot detect differences in oxygen delivery or utilization
between tumors of different treatment groups or even within a single treatment group.
Furthermore, in breast cancer, StO2 alone values measured via optical techniques can fail to
distinguish malignant from non-malignant lesions (Boas et al., 2011). However, by combining
several metrics such as StO2, THC, HbO2, and μs’, along with anatomical tumor size measured
via external calipers, DRS may be able to overcome this limitation. Although not explicitly
studied in these experiments, DRS can also provide data on scattering exponent, average blood
vessel radius, fat content and water content (Rajaram et al., 2016; Rajaram et al., 2015; Rajaram,
Reichenberg, et al., 2010; Spliethoff et al., 2016; Spliethoff et al., 2014). However, since these
studies indicated no changes in THC or μs’ in response to therapy, or in response to simple tumor
growth in control animals, and since HbO2 values are determined in part by StO2, it’s possible
DRS may be limited in providing reliable information to clinicians making vital decisions in
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managing their patients’ therapy regimens. DRS combined with other imaging techniques such
as high-resolution microendoscopy (Parikh et al., 2014), or spectroscopic techniques such as
Raman spectroscopy (Jenkins et al., 2016) or hyperspectral imaging (Awan et al., 2018) may be
more valuable than single-modality DRS.
6.12 Conclusion
Colorectal cancer is still one of the most prominent cancer types within the United States.
Although current treatment standards (neoadjuvant therapy, surgery, and adjuvant therapy) treat
a wide spectrum of cancer patients, recurrence, patient heterogeneity, toxicity, and poor survival
rate remain problematic. Therefore, research into antibody-based immunotherapies in both
clinical and pre-clinical settings is highly active. Clinical research into immune checkpoint
inhibitors is more mature than cytokine-targeted immunotherapy. At present, cytokine-targeted
immunotherapy is limited to anti-VEGF, anti-VEGFR, and anti-EGFR therapies for mCRC
patients, although there is a growing interest in interleukin and chemokine therapies in both preclinical and early clinical trials. Additionally, monitoring CRC tumor response is a major
problem, and investigators are continuing to engineer optical methods to improve the state-ofthe-art. One of the biggest emerging challenges for immunotherapy in CRC is elucidating the
genomic biomarkers for identifying patients likely to be responders or non-responders for certain
immunotherapy regimens and monitoring response in real-time (Kather et al., 2018). In this
study, DRS probe was applied to subcutaneous murine colon tumors undergoing either antibody
immunotherapy or standard 5-fluorouracil chemotherapy. Mice treated with a combination of
these therapies showed reduced tumor growth compared to saline control, isotype control,
immunotherapy, and chemotherapy groups 7 days post-treatment. Additionally, at 7 days posttreatment, oxyhemoglobin, a marker currently being explored as a functional prognostic cancer
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marker, trended to increase in immunotherapy, chemotherapy, and combination therapy groups
compared to controls. Also of interest, an oxyhemoglobin flare was shown in tumors treated with
chemotherapy, indicating that DRS may be useful as a complimentary tool to monitor early
tumor therapeutic response in colon cancer. However, subject-to-subject variability was high and
studies correlating survival to early oxyhemoglobin flares are suggested. Additionally, singlemodality DRS may be limited in providing clinicians reliable clinical information, and it is
suggested to combine DRS with other endoscopically-compatible imaging or spectroscopic
methods. Finally, ongoing research in the Muldoon laboratory at the University of Arkansas is
analyzing the correlation of DRS-derived metrics with TAMs in the tumor microenvironment,
which will provide valuable microscopic information about how immunotherapy and
chemotherapy affect immune cell populations.
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Chapter 7: Conclusion

Colorectal cancer is the 4th most common and 2nd deadliest cancer. Problems exist with
predicting which patients will respond best to certain therapy regimens. Diffuse reflectance
spectroscopy has been suggested as a candidate to optically monitor a patient’s early response to
therapy and has been received favorably in experimentally managing other cancers such as breast
and skin. In this dissertation, two diffuse reflectance spectroscopy probes were designed: one with
a combined high-resolution microendoscopy modality, and one that was optimized for acquiring
data from subcutaneous murine tumors.
For Specific Aim 1, our objective was to Develop and validate a quantitative hybrid
imaging and spectroscopy microendoscope to monitor dysplastic progression within epithelial
tissues. Co-registration of both techniques is important because this technique can be potentially
used to not only detect dysplasia using two different modalities, but also to monitor personalized
response of sub-surface dysplastic lesions to anti-tumor therapy at multiple source-detector
separations. Our central hypothesis was that High-resolution microendoscopy and DRS can be
combined within a single optical probe to co-register image and spectral data of in vivo epithelia.
With this multimodal system, epithelial morphological data can be correlated with quantitative
spectroscopy data of the subsurface microenvironment, including associated optical properties.
This multimodal microendoscopy approach encompasses both structural and spectroscopic
reporters of perfusion within the tissue microenvironment and can potentially be used to monitor
tumor response to therapy. This hybrid imaging and spectroscopy platform may be capable of
collecting a wealth of information about the structural and functional properties of tissue at various
imaging sites in ex vivo and in vivo models. The potential of this technique to be coupled to the
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biopsy port of a conventional endoscope makes further clinical translation and complimentary
optical biopsy in the oral cavity and other epithelial tissues feasible. For both probes, percent errors
for estimating tissue optical properties (reduced scattering coefficient and absorption coefficient)
were less than 5% and 10%, respectively.
For Specific Aim 2, our objective was to demonstrate a method for producing thin phantom
layers with tunable optical properties using poly(dimethylsiloxane) (PDMS) as a substrate material
at six discrete wavelengths (591, 631, 659, 691, 731, and 851 nm) at varying concentrations of
titanium dioxide and nigrosin. Our central hypothesis was that thin, PDMS-based optical phantoms
can accurately simulate the geometry and optical properties of target epithelia and can be used to
tst the sensitivity of various imaging and spectroscopy equipment to heterogeneities. From the
presented data, we provide lookup tables to determine appropriate concentrations of scattering and
absorbing agents to be used in the design of PDMS-based phantoms with specific optical
coefficients. In addition, heterogeneous phantoms, mimicking the layered features of certain tissue
types, may be fabricated from multiple stacked layers, each with custom optical properties. These
thin, tunable PDMS optical phantoms can simulate many tissue types and have broad imaging
calibration applications in endoscopy, diffuse optical spectroscopic imaging (DOSI), or optical
coherence tomography (OCT), among others.
For Specific Aim 3, our objectives were to (1) Design a DRS probe with four SDSs (0.75,
2.00, 3.00, and 4.00 mm) to interrogate increasing tissue volumes between 450-900 nm. The goal
was to quantify percent errors in extracting μa and μs’, and to quantify sampling depth into
subcutaneous Balb/c-CT26 colon tumor allografts. Using an optical phantom-based experimental
method, lookup-tables were constructed relating μa, μs’, diffuse reflectance, and sampling depth.
(2) Examine whether blockade of monocyte recruitment via anti-CCL2 (macrophage
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chemoattractant protein-1) leads to enhanced sensitivity of 5-FU (5-fluorouracil) therapy in a
CT26-Balb/c mouse model of CRC, and whether this effect can be quantified via DRS. The
oxyhemoglobin flare has not been quantified after combinatorial chemotherapy and
immunotherapy, and furthermore, has not been quantified in colon cancer tumors. Can DRS be
used to quantify the therapy-induced oxyhemoglobin flare in a mouse model of colon cancer?
The central hypothesis is that tumors treated with immunotherapy will have increased tumor
therapeutic response to chemotherapy, as measured via tumor size and DRS-derived metrics.
This work shows that the DRS probe can accurately extract optical properties, and the resultant
physiological parameters such as total hemoglobin concentration and tissue oxygen saturation,
from sufficient depth within subcutaneous Balb/c-CT26 colon tumor allografts. Methods
described here can be generalized for other murine tumor models. The diffuse reflectance
spectroscopy probe was applied to subcutaneous murine colon tumors (n=61) undergoing either
antibody immunotherapy or standard 5-fluorouracil chemotherapy. Mice treated with a
combination of these therapies showed reduced tumor growth compared to saline control, isotype
control, immunotherapy, and chemotherapy groups (p<0.001, <0.001, <0.001, and 0.046,
respectively) 7 days post-treatment. Additionally, at 7 days post-treatment, oxyhemoglobin, a
marker currently being explored as a functional prognostic cancer marker, trended to increase in
immunotherapy, chemotherapy, and combination therapy groups compared to controls (p=0.315,
0.149, and 0.190). Also of interest, an oxyhemoglobin flare (average increase of 1.44x from
baseline, p=0.03 compared to controls) was shown in tumors treated with chemotherapy,
indicating that diffuse reflectance spectroscopy may be useful as a complimentary tool to
monitor early tumor therapeutic response in colon cancer. There were no differences observed
for total hemoglobin content, reduced scattering coefficient, scattering exponent, or blood vessel
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radius. However, subject-to-subject variability was high and studies correlating survival to early
oxyhemoglobin flares are suggested. In this study, 5-fluorouracil (5-FU) was chosen as the
chemotherapy agent. Fluorouracil-based chemotherapy, especially 5-FU, has been a staple in
CRC treatment for nearly 60 years. For example, the FOLFOX chemotherapy regimen for colon
and colorectal cancer (CRC) consists of 5-FU, leucovorin, and oxaliplatin. Besides FOLFOX,
there are three other first-line treatments for CRC including FOLFIRI, FOLFOXIRI, and
XELOX. FOLFIRI consists of 5-FU, leucovorin, and irinotecan hydrochloride. FOLFOXIRI
consists of 5-FU, leucovorin, oxaliplatin, and hydrochloride. XELOX is slightly different in that
it consists of oxaliplatin and capecitabine. Thus, in three of four common first-line treatments, 5FU is the common drug. To simplify study design, 5-FU was chosen as the only chemotherapy
agent. It would also be interesting to perform this same study using oxaliplatin as the primary
chemotherapy agent, since it is also used in three of four first-line treatments. In the body, 5-FU
is converted to fluorodeoxyuridine monophosphate (FdUMP). FdUMP forms a complex with
thymidylate synthase (TS), an enzyme that catalyzes deoxyuridine monophosphate (dUMP)
to deoxythymidine monophosphate (dTMP), which is a DNA monomer and key for DNA
replication. Thus, 5-FU-mediated depletion of dTMP results in cytotoxicity and apoptosis in the
rapidly growing cells in CRC (Zhang et al., 2008). However, there are several remaining
questions.
The Tromberg group recently found that neoadjuvant chemotherapy causes an early (1day post treatment initiation) flare in tumor oxyhemoglobin (HbO2) in breast cancer patients that
eventually show increased survival. Alternatively, breast cancer patients with tumors that did not
have an early HbO2 had decreased survival. Why is this? What are the biological mechanisms
contributing to this early chemotherapy-derived HbO2 flare? Can this HbO2 be observed in other
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tumors, including in murine xenograft and allograft models? The HbO2 flare hasn’t widely been
discussed in animal models. Can optical methods such as diffuse reflectance spectroscopy be
used to accurately monitor the HbO2? Is the correlation of early HbO2 flares with positive
neoadjuvant chemotherapy response universal to other cancers besides breast cancer? How will
early knowledge of tumor HbO2 lead to improved therapy management? Many of these questions
are currently open-ended and hot topics of research. These questions could be future avenues of
research that the present dissertation work will help lead to. Thus, it is important to discuss what
is currently known about these questions, what doors this dissertation research has closed, and
what doors this dissertation research has opened.
First, discussion will focus on the biological origin of the HbO2 flare. There are two
current hypotheses in the field. First, it is possible that chemotherapy induction decreases cancer
cellular metabolism leading to a decrease in the conversion of oxyhemoglobin to
deoxyhemoglobin. Second, it is possible that chemotherapy induction increases perfusion to
tissue. For the first hypothesis, HbO2 is formed when oxygen (O2) binds to heme, the ironcontaining compound of hemoglobin in red blood cells. During gas exchange, HbO2 forms in
pulmonary capillaries and is transported to the rest of the body, where O2 serves as the final
electron acceptor during oxidative phosphorylation. As a brief review, oxidative phosphorylation
is the primary cellular metabolism pathway in which O2 is the final electron acceptor to produce
adenosine triphosphate (ATP), the organic chemical that provides energy to most cellular
processes. Thus, how does chemotherapy induction decrease cancer cellular metabolism and the
conversion of oxyhemoglobin to deoxyhemoglobin? From the perspective of 5-FU, it is possible
that the FdUMP-TS complex causes a decrease in cellular metabolism since TS is a known
regulator of several critical cellular metabolic pathways (Chu et al., 1996). However, since the
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Tromberg group reported the HbO2 in patients treated with a variety of different
chemotherapy/immunotherapy drugs instead of 5-FU, including doxorubicin, cyclophosphamide,
paclitaxel, carboplatin, trastuzumab, and bevacizumab, other mechanisms may be responsible
(Tromberg et al., 2017; Roblyer et al., 2011). A 2016 study shows that chemotherapy increases
the risk of metabolic syndrome in patients with breast cancer (Bicakli et al., 2016). However,
exact biological mechanisms are unknown. A 2018 study by Gorini et al. stated that, “Many
cancer therapies produce toxic side effects whose molecular mechanisms await full elucidation.”
On interesting hypothesis is that because chemotherapy and radiation (including 5-FU) are
known to increase intracellular reactive oxygen species (ROS) (Focaccetti et al., 2015), the ROS
can lead to a mitochondrial imbalance of the normally tightly-regulated ROS production and
detoxification, leading to a shift towards glycolysis (Warburg effect) and impaired oxidative
phosphorylation (Liemburg-Apers et al., 2015), even in the presence of oxyhemoglobin (Liberti
et al., 2016). In brief review, the Warburg effect is the phenomenon of tumor cells favoring
glycolysis for their energy demands, even when there is enough oxygen for oxidative
phosphorylation. If indeed the assumption is true that chemotherapy can lead to further shifts
away from oxidative phosphorylation, this would support the hypothesis that cancer therapy can
lead to a decrease in the conversion of oxyhemoglobin to deoxyhemoglobin, resulting in an
HbO2 flare (Tromberg et al., 2017; Roblyer et al., 2011), although it is unclear how this would
correlate with increased survival. The Tromberg group also notes that a drop in
deoxyhemoglobin, as well as oxyhemoglobin, should accompany a decrease in metabolism
(Roblyer et al., 2011), although no changes in total hemoglobin (THC) were observed in our
study. For the second hypothesis that chemotherapy induction increases perfusion to tumor
tissue, it is suggested that ROS triggers downstream activation of HIF-1 transcription factor,

394

which progresses both angiogenesis and the metabolic switch to glycolysis (Constans et al.,
2011). Additionally, chemotherapy induction can cause an acute inflammatory response (Feng et
al., 2017; Lian et al., 2017). Acute inflammatory response is marked by increased vascular
permeability and vessel dilation over the course of hours to several days, potentially contributing
to the increased HbO2 observed in our group and the Tromberg group. However, based on this
hypothesis, it would have been expected to observe an increase in tumor THC as well, something
that was observed in the Tromberg group but not in the present study. However, it is entirely
possibly that tumor THC changes were masked by the overlying skin layer or inability to sample
the entire tumor or intra-tumoral heterogeneities. Many previous studies have shown that clinical
outcome has a positive correlation with serum inflammatory biomarkers such as IL-1, IL-6, and
TNF-α (Roblyer et al., 2011). Forward studies can take several directions. First, switching from a
subcutaneous model of colon cancer to a chemically-induced orthotopic model of colon cancer
with a smaller probe compatible with the biopsy port of small animal colonoscopes may
elucidate possible differences in both THC and HbO2 in treated vs. control tumors. Furthermore,
further thin-film phantom studies are needed to elucidate DRS sensitivity to THC-based
heterogeneities.
This leads back into Specific Aim 2 in which there is a critical need to simulate
epithelium-like structures in the field of biomedical optics (Greening et al., 2014). The phantoms
created in Specific Aim 2 can mimic simple squamous epithelium in terms of the geometry and
optical properties. Therefore, it would be of interest to combine study design from Specific Aims
2 and 3 to test various DRS probes in monitoring a THC-based, rather than StO2-based, HbO2
flare. Small (~100 μm) geometrical heterogeneities could be created, both at the surface and subsurface levels, with varying concentrations of hemoglobin-simulating absorbing agent to
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elucidate DRS sensitivity to THC changes. Coupling this with measuring in vivo changes in
tissues with known inflammation may provide more evidence for DRS in the clinical
management of inflammatory-based diseases such as CRC.
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Chapter 8: Appendix
Protocols and Methodology
Creating PDMS Phantoms
1. Place a THINKY cup on the scale and zero out the weight of the THINKY cup.
2. Dispense desired weight of Sylgard® 184 Silicone Elastomer Base into a THINKY cup.
a. For making thin phantoms, dispense between 6.5-7.0 grams of elastomer base.
3. Record, to the nearest hundredth, the amount of Sylgard® 184 Silicone Elastomer Base
dispensed.
4. Open the MATLAB program called PDMSphantom.m.
5. Run the program.
6. Type a reference wavelength. For most purposes, type “621”.
7. Type the desired reduced scattering coefficient (cm-1) at this reference wavelength.
8. Type the desired layer thickness (μm). If you are making a thick phantom, just type in any
number.
9. Type in the measured weight of the PDMS elastomer base from step 3.
10. The output parameters will be displayed in the Command Window.
11. Weigh out an appropriate amount of titanium dioxide in a weigh boat and dispense into the
THINKY cup containing the PDMS elastomer base.
12. Place the mixture inside the tan plastic THINKY cup holder.
13. Weigh the tan plastic THINKY cup holder.
14. Put the cup holder containing the THINKY cup in the THINKY machine.
15. Manually adjust the wheel so that the indicator is the same weight as measured in step 14.
16. Run the mixture through two cycles (8 total minutes) of the THINKY machine.
17. Using a micropipette, dispense the appropriate amount of curing agent inside the mixture.
18. Repeat steps 14-17.
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19. For creation of thin phantoms, follow the following steps:
a. Begin a timer upon removal of the final mixture from the THINKY machine.
b. After exactly 1 minute from removal, place the THINKY cup onto plastic petri dish
and place in the oven at 70ºC for exactly 3 minutes.
c. Remove from the oven. Exactly 1 minute after removal, dispense the PDMS mixture
onto a silicone wafer in the Spin Coater.
d. Run the Spin Coater on the desired settings.
e. After completion, remove the silicone wafer from the Spin Coater and immediately
place in the oven at 70ºC for 2 hours.
f. Remove the silicon wafer from the over after 2 hours of curing at 70°C.
20. For creation of thick phantoms or phantoms in a mold, follow the following steps:
a. Remove the mixture from the THINKY machine.
b. Poor mixture into desired mold.
c. Place mold into vacuum chamber.
d. Ensure that the downstream vacuum tubes in the fume hood are clamped off with
surgical clamps such that the only path is from the vacuum to the vacuum chamber.
e. Plug in the vacuum.
f. Turn the knob on the vacuum so that air is getting sucked out. If you are unsure, you
should start seeing bubbles appear at the top of the PDMS mixture between 1-5
minutes.
g. Leave the phantom in the vacuum chamber for 1 hour.
h. Slowly let air back into the vacuum chamber.
i. Remove mold from vacuum chamber.
j. Place mold in the oven for 2 hours at 70°C to complete the curing process.
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SCS Spincoat G3P-8
1. Turn on the power in the back of the machine.
2. Turn on the vacuum pump.
3. Turn on the air valve. This will activate the main menu screen.
4. Change to channel 10 on the Spincoat G3P-8.
5. Click Mode on the control panel to get to the settings menu.
6. Scroll through the steps until you reach Step 0. Set the Ramp to 0, the RPM to 0, and the Dwell
to 0.
7. Scroll through the steps until you reach Step 1. Set the Ramp to 0, the RPM to 0, and the Dwell
to 1.
8. Scroll through the steps until you reach Step 2. Set the Ramp to 4, the RPM to any desired
value, and the Dwell to 20.
9. Scroll through the steps until you reach Step 3. Set the Ramp to 4, the RPM to 0, and the Dwell
to 1.
10. Scroll through the steps until you reach Step 5. Set the Ramp to 0, the RPM to 0, and the Dwell
to 0.
11. Click Enter to save the settings.
12. Click Mode on the control panel to get back to the home screen.
13. Place the large circular white chuck onto the Spincoat G3P-8.
14. Test run the spin coater to make sure everything is working.
15. If everything is working, turn off the vacuum and air pump for now until the spin coater is
ready to be used.
16. Place a silicone wafer on the chuck.
17. Close the lid.
18. Run
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Creating Multi-Layered Phantoms
1. Remove the silicon wafer from the over after 2 hours of curing at 70°C.
2. Put on latex or nitrile gloves.
3. Without scratching the silicon wafer, peel off the PDMS layer. If all steps were followed
completely, the layer should peel off fairly easily.
Note: If you make a phantom layer that is 200 microns or thinner, peeling the layer off the
silicon wafer will be difficult, but possible. Some tearing, especially at first, is expected.
4. Lay the layer as flat as possible on a clean surface, such as in the petri dish.
5. With a disposable scalpel or razor blade, cut a square approximately 1.5 x 1.5 centimeters.
6. Place this square layer over another layer using tweezers. Be careful not to squeeze the layer
too hard.
7. After the application of one layer on top of another layer, you must place the entire system in
a vacuum chamber.
8. Use the vacuum chamber to vacuum the system so that the single layer can adhere to the base
layer underneath. Vacuum for at least 40 minutes or until there are no air bubbles between
phantom layers
9. Once there are no air bubbles between layer interfaces, continue adding more layers and
vacuuming until the multi-layered phantom is complete.
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Software Implementation for the DRSME
Downloading Software for Dual-Camera System in LabVIEW
Note that software and firmware versions listed in this protocol will likely have been updated
since the time of this publication.
1. Obtain 2 Point Grey monochrome Flea3 USB cameras (model number FL3-U3-13S2M-CS)
2. Go to the following URL: https://www.ptgrey.com/support/downloads
3. Login
4. Product Families: Flea3
5. Camera Models: FL3-U3-32S2M-CS
6. Operating System: Windows 7 64bit
7. Search
8. Click “Software”
9. Download FlyCapture 2.9.3.11 SDK - Windows (64-bit) — 02/15/2016 - 251.1416MB under
the heading of Latest FlyCapture2 Full SDK
10. Click “Install” → Next → Check “I accept the terms in the License Agreement” → Next →
Next
11. Enter the appropriate full name, organization, and email.
12. Check “Anyone who uses this computer”
13. Check “Automatically register with PGR via the internet” → Next → Next
14. Click “Complete”
15. Check “I will use USB Cameras” and then check “Install PGRUSBCam – Point Grey USB
Camera Driver” and then uncheck “Install USBPro – Point Grey USB Interface Driver” →
Next
16. Check “Click to Confirm”
17. Check “FlyCapture 2 will manage processor idle states”
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18. Check “The installer will register the DirectShow dlls” → Next → Install → Finish
19. Go to the following URL: https://www.ptgrey.com/support/downloads
20. Login
21. Camera Family: Flea3
22. Model Number: FL3-U3-13S2M-CS
23. Operating System: Windows 7 x64
24. Search
25. Click “Firmware”
26. Download “Flea3 USB3 2.7.3.0 Firmware”
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Creating Dual-Camera System in LabVIEW
1. Connect both Flea3 cameras to the computer
2. Open FlyCapture: Start menu → type “Point Grey FlyCap2” → Click “Point Grey FlyCap2”
3. Open the UpdatorGUI utility: Start menu → type “UpdatorGUI3” → Click “UpdatorGUI3”
4. Select one of the cameras
5. Click “Open” to select the firmware file (C:\Program Files (x86)\Point Grey Research\Flea3
USB3 2.7.3.0 Firmware\fl3-u3-2.07.3-00.ez2)
6. Click “Update”
7. Repeat steps 36-38 for the second camera (make sure you wait for the update to finish on the
first camera before proceeding to the second camera)
8. Download National Instruments’ Vision Acquisition Software
9. Extract all the files to C:\Program Files (x86)\National Instruments
10. Once installation of “NI Vision Acquisition Software February 2014” has finished, open the
Driver Control GUI: Start menu → type “DriverContolGUI” → Click “DriverControlGUI”
11. Click the “USB” tab (loading may take a few moments)
12. Select “Point Grey USB3 Vision Camera”
13. Select “Third-Party Drivers” → then select the driver that is listed under the menu
(“NI: niu3vk.inf
1.1.0.49152”)
14. Click “Install Driver”
15. Repeat steps 42-46 for the second camera
16. Both cameras will now be listed as “NI-IMAQdx USB3 Vision Device”
17. Start → Type “MAX” → Click “NI MAX” (Make a shortcut for this on the desktop)
18. On the Configuration Tree, click “My System” → “Devices and Interfaces”
19. Both cameras will be listed as “Point Grey Research Flea3 FL3-U3-32S2M
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Using Cameras in FlyCapture
1. Open the “DriverControl GUI.”
2. Navigate to the USB tab.
3. Locate one of the “NI-IMAQdx USB3 Vision Device” devices and highlight it.
4. On the right, select “Point Grey Drivers.”
5. In the drop down menu, click “USB Camera (Signed) 2.6.3.0”
6. Click “Install Driver”
7. The device will now be listed as “Point Grey USB3 Vision Camera”
8. Exit the DriverControlGUI.
9. Open FlyCapture.
10. Highlight the camera.
11. Click “Configure Selected” in the lower right corner.
12. Click “Advanced Camera Settings” in the menu on the left.
13. Under “Memory Channel,” select “Default”
14. Click “Restore” and then save.
15. Do this for the other camera and both will revert back to their original settings.
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Running Spectrometer in LabVIEW
1. Go to http://www.oceanoptics.com/Technical/softwaredownloads.asp
2. Navigate to the OmniDriver+SPAM Windows Version (32-bit) – The current version is 2.37.
3. Click the “Windows Version (32-bit)” link to run the installer.
4. Run the Installer.
5. Select English as the language.
6. Select the “Redistributable version (for end-users)”
7. Select the Installation Directory (you shouldn’t have to change this), but if you do it should be
C:\Program Files (x86)\Ocean Optics\OmniDriverSPAM.
8. Check Yes for “Install VCREDIST silently” → Next
9. Finish the installation.
10. Visit the following link to set up an introductory LabVIEW GUI to run the USB2000+VISNIR-ES spectrometer with LabVIEW: https://www.youtube.com/watch?v=tT5C43D3rRA
11. Note: The spectrometer will not run with LabVIEW and SpectraSuite at the same time.
12. Note: To access the Wrapper library that contains all the LabVIEW sub-vi’s for the
spectrometer, navigate to C:\Program Files (x86)\Ocean
Optics\OmniDriverSPAM\labview\win32\Version8.5 and then click “Wrapper.llb”
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Arduino IDE and Libraries
1. Go to http://arduino.cc/en/main/software
2. Download Arduino 1.0.5 by clicking the link titled “Windows Installer”
3. Open the Installer.
4. Install the Arduino software.
5. Go to https://learn.adafruit.com/adafruit-motor-shield-v2-for-arduino/install-software
6. Click the green box that is titled “Download latest Adafruit Motor Shield V2 Library”
7. Navigate to C:\Program Files (x86)\Arduino\libraries
8. Create a new folder titled “Adafruit_Motorshield”
9. Open the contents of the downloaded .zip file
10. Copy all the material in the downloaded .zip file
11. Paste all the material from the .zip file to the “Adafruit_Motorshield” folder created in step 8.
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LabVIEW Interface for Arduino (LIFA)
1. Go to http://www.ni.com/download/ni-visa-5.4.1/4626/en/
2. Click the link for NI Downloader: NIVISA541full_downloader.exe (634.78 MB)
3. Open the downloaded folder → Run
4. Save the application (.exe) file to C:\Program Files (x86)\National Instruments\LabVIEW
2012
5. The National Instruments Downloader will begin the N-VISA download (this may take several
minutes).
6. When the download is complete, click “Open”
7. Click OK to the prompt.
8. In the “Unzip to folder:” box, copy “C:\National Instruments Downloads\NI-VISA\5.4.1”
9. Check “Override files without prompting”
10. Check “When done unzipping open: . \setup.exe”
11. Click “Unzip.” A blue progress bar will appear.
12. Once complete, click “Yes,” allowing the program to make changes on the computer.
13. Next → when prompted for a Destination Directory, copy “C:\Program Files (x86)\National
Instruments\” into the box (without the quotation marks) → Next → Next → Next
14. Check “I accept the above 2 License Agreement(s)” → Next → Next
15. NI-VISA 5.4.1 will now be installing. This will take several minutes.
16. Once the installation is complete, restart the computer.
17. Go to http://jki.net/vipm
18. Download the free version of VI Package Manager.
19. Open the Installer.
20. Install VI Package Manager.
21. Open VI Package Manager.
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22. Browse to “LabVIEW Interface for Arduino” – Version 2.2.0.79
23. Highlight the “LabVIEW Interface for Arduino” section.
24. Click the “Install Package(s)” button.
25. Accept the terms and conditions.
26. After a few moments, a confirmation window will appear. Click “Finish.”
27. Plug in the Arduino Uno R3 to the computer.
28. Navigate to C:\Program Files (x86)\Arduino and click “arduino.exe”
29. The Arduino IDE will open.
30. Click File → Open, and browse to LIFA_Base.ino found in C:\Program Files (x86)\National
Instruments\LabVIEW 2012\vi.lib\LabVIEW Interface for Arduino\Firmware\LIFA_Base
31. Click LIFA_Base.ino
32. Click Tools → Board → Arduino Uno
33. Determine the COM port that corresponds to the Arduino by opening Device Manager and
expanding “Ports (COM and LPT)”
34. Go back to the Arduino IDE
35. Click Tools → Serial Port → COMx (x is to be determined from step 17)
36. Click the “Upload” button.
37. If uploaded successfully, the firmware necessary to use the LabVIEW Interface for Arduino
(LIFA) will be successfully installed.
38. Close the Arduino IDE.
39. Open LabVIEW 2012.
40. Go to the Block Diagram
41. Right-click → Search → Type “Arduino” → Place an “Init” and “Close” function onto the
block diagram. Place the “Init” function somewhere on the left and the “Close” function
somewhere on the right.
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42. Right-click → Executive control → While Loop → Place the while loop in between (not
surrounding) the “Init” and “Close” function.
43. On the “Init” function, right-click “VISA-resource” → Create → Constant → change to COMx
(Determine the COM correct port that corresponds to the Arduino by opening Device Manager
and expanding “Ports (COM and LPT)”)
44. On the “Init” function, right-click “Baud Rate (115200)” → Create → Constant → change the
constant to 115200.
45. On the “Init” function, right-click “Board Type (Uno)” → Create → Constant → change to
Uno
46. On the “Init” function, right-click “Connection Type (USB/Serial)” → Create → Constant →
change to USB/Serial
47. Right-click → Search → Type “Arduino” → Digital Write Pin (place inside while loop).
48. Right-click → Search → Type “Arduino” → Set Digital Pin Mode (place inside while loop to
the left of the icon you placed in step 8).
49. From “Init,” connect “Arduino Resource” to “Arduino Research” on “Set Digital Pin Mode”
50. From “Init,” connect “error out” to “error in” on “Set Digital Pin Mode”
51. From “Set Digital Pin Mode,” connect “Arduino Resource” to “Arduino Research” on “Digital
Write Pin”
52. From “Set Digital Pin Mode,” connect “error out” to “error in” on “Digital Write Pin”
53. From “Digital Write Pin,” connect “Arduino Resource” to “Arduino Research” on “Close”
54. From “Digital Write Pin,” connect “error out” to “error in” on “Close”
55. Create a control on the Digital I/O Pin on “Set Digital Pin Mode” and change to 13 in the front
panel.
56. Create a constant on the Pin Mode on “Set Digital Pin Mode” and change to Output
57. From the Digital I/O Pin on “Digital Write Pin,” run a wire to the wire that is connected to the
Digital I/O Pin control created in step 17.
58. Go to the Front Panel.
59. Right-click → LED → Round LED → place in Front Panel
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60. Once this is place, move to the block diagram and place the LED icon (Boolean) inside the
while loop.
61. Right-click the LED icon in the block diagram → Change to Control
62. Right-click → Search → Type “Boolean to” → click “Boolean To (0,1) <<Conversion>> →
click “Boolean To (0,1)”
63. Connect the output of the LED to the input of the Boolean converter and the output of the
Boolean converter to the input of the “Digital Write Pin” input called “Value”
64. In the block diagram, click the icon that says “Clean Up Diagram”
65. Save the VI as “LIFA_Verification_Test.vi”
Reference Page 1 (Installing LIFA from VI Package Manager – Steps 17-26):
http://digital.ni.com/public.nsf/allkb/A20FBBD36820669086257886004D5F4D
Reference Page 2 (Installing LIFA Firmware onto Arduino Uno – Steps 27 – 37):
http://digital.ni.com/public.nsf/allkb/8C07747189606D148625789C005C2DD6?

66. Load the correct firmware onto the Arduino by completing steps 27-36 of Section 8.
67. Exit the Arduino IDE then go back to the front panel on LabVIEW.
68. Click the “run” arrow on the front panel.
69. Turn the LED on and off. If the on-board LED on the Arduino blinks, then LabVIEW is
successfully communicating with the Arduino.
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Stepper Motor Control with LabVIEW
1. Purchase the EasyDriver Stepper Motor Driver from Sparkfun:
https://www.sparkfun.com/products/10267
2. Solder connector pins on all the pins.
3. Plug the EasyDriver into a breadboard (across the middle ridge).
4. Run a jumper wire from “STEP” to the Arduino pin 2.
5. Run a jumper wire from “DIR” to the Arduino pin 3.
6. Run a jumper wire from “GND” (next to “STEP”) to the Arduino GND pin.
7. In the top left of the EasyDriver PCB, you will see 4 pins in a row (2 “A” pins and 2 “B” pins).
Going from A to B, connect the wires of the stepper motor in the following order: Grey, Green,
Yellow, Red.
8. Plug in the 9.6V, 300mA wall wart to the top right of the EasyDriver PCB (GND and M+).
9. Flash the Arduino with the LIFA_Base firmware (steps 27-37 of section 8).
10. Open LabVIEW → Help → Find Examples → Search → Type “Arduino” → Open “Arduino
Stepper Motor.vi”
11. Open the Block Diagram.
12. On the “Init” terminal, create constants for the following parameters: VISA resource, Baud
Rate, Board Type, and Connection Type.
13. Keep the Baud Rate at 115200.
14. Change the VISA resource to whatever COM port your Arduino is using.
15. Open the Front Panel.
16. Set the “Set Speed” to around 400, “# of Steps to Move” to 1600 (one full rotation), “Set
Acceleration” to 0, the “Stepper #” to 1.
17. Click Run.
18. Finally, click “Start Stepping.” If everything worked properly, the stepper motor should make
one counter clockwise rotation in 4 seconds (1600/400).
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Cell Culture
Equipment and Materials
Item

Distributor

Item Number

CT26.WT Colon Carcinoma Cells

ATCC

CRL-2638

Gloves

VWR

89038-270

Laboratory Bench and Table Protector

VWR

89126-790

KimWipes

VWR

470224-038

95% Reagent Ethanol

VWR

BDH1156-4LP

100% Isopropyl Alcohol

VWR

MK303206

10% Bleach

VWR

89501-620

RPMI-1640 Medium

VWR

71002-878

Fetal Bovine Serum (FBS)

ATCC

30-2020

Antibiotic Antimycotic Solution (Pen/Strep)

Sigma-Aldrich

A5955-100ML

Amphotericin B (AmpB)/Gentamicin (GM)

Thermo Fisher

R01510

Dulbecco’s Phosphate Buffered Saline

VWR

45000-434

Trypsin-EDTA Solution, 1X

VWR

VWRL0154-0100

Dimethyl Sulfoxide (DMSO)

VWR

97063-136

Sterile Saline (0.9% NaCl)

VWR

S5825

T75 Vented Cell culture Flask (Sterile)

VWR

10861-650

Nalgene Rapid-Flow Filter Units, 500 mL

VWR

16211-054

5 mL Serological Pipet Tip

VWR

89130-896

10 mL Serological Pipet Tip

VWR

89130-898

25 mL Serological Pipet Tip

VWR

89130-900
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Pipetting Device

VWR

53498-001

Variable Volume Pipettors

VWR

75788-458

Universal Shelf Clip for 3 Pipettors

VWR

40000-272

10 µL Pipette Tips (Sterile-Aerosol)

VWR

89174-520

100 µL Pipette Tips (Sterile-Aerosol)

VWR

10126-388

1000 µL Pipette Tip (Sterile-Aerosol)

VWR

89174-530

1000 µL Pipette Tip (Non-Sterile)

VWR

83007-384

15 mL Conical-Bottom Centrifuge Tubes

VWR

89039-666

50 mL Conical-Bottom Centrifuge Tubes

VWR

89039-658

Water Bath

VWR

89501-464

Parafilm M, Bemis

VWR

52858-076

Nalgene Cryo 1°C “Mr. Frosty” Container

VWR

55710-200

Cryogenic Vials, 2 mL, externally threaded

VWR

66021-978

Microcentrifuge Tube

VWR

20170-038
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Making RPMI-FBS Complete Growth Media

Step 1: Preparation and Storage of Solutions
1. Aliquot 100 mL of Pen/Strep into twenty 15 mL centrifuge tubes (5 mL each)
2. Store 20 aliquots of 5 mL Pen/Strep at -20°C
3. Store AmpB/GM (10 x 1 mL) at -20°C
4. Aliquot 500 mL of FBS into ten 50 mL centrifuge tubes (50 mL each)
5. Store 10 aliquots of 50 mL FBS at -20°C
6. Store base RPMI media at 4°C. Label

Step 2: Preparation
1. Obtain the following supplies and spray into the hood
a. 50 mL Fetal bovine serum (FBS)
b. 5 mL Antibiotic Antimycotic Solution (Pen/Strep)
c. 1 mL Amphotericin B (AmpB)/Gentamicin (GM)
d. One (1) Base Media
e. Twelve (12) 50 mL centrifuge tubes (2 for waste and 10 for media)
f. Three (3) 25 mL serological pipette tips
g. Two (2) 5 mL serological pipette tip
h. One (1) Rapid-Flow Filter Unit (“hourglass bottles”)

Step 3: Making and Filtering Media
1. Dispense 56 mL of base media into the two (2) 50 mL conical vials
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2. Put 50 mL of FBS directly into the base media bottle
3. Put 5 mL of Antibiotic Antimycotic (Pen/Strep) into base media bottle
4. Put 1 mL of AmpB/GM directly into the base media bottle
5. Attach the aspiration tube to the filter bottle
6. Dispense approximately 20 mL of media into the filter bottle
7. Push down the foot pedal
8. Wait for 20 mL of media to dispense to the bottom of the filter bottle
9. Slowly pour in the rest of the media while continuing to push down foot pedal
10. Wait for all media to dispense to the bottom
11. Release the foot pedal
12. Detach the aspiration tube

Step 4: Aliquoting and Storing Media
1. Unscrew the top of the filter bottle and throw away in Biohazard trash.
2. Aliquot the 500 mL media into ten (10) 50 mL centrifuge tubes
3. Remove complete media solutions from the hood
4. Clean hood thoroughly with 70% EtOH
5. Wrap Parafilm around the caps of the 50 mL centrifuge tubes
6. Place 50 mL centrifuge tubes with media at 4°C
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Feeding CT26 Cells

Step 1: Preparation
1. Place cell culture media in the 37.3°C water bath and wait 30 minutes
2. Clean hood with 70% EtOH

Step 2: Checking Cell Health
1. Spray gloves with 70% EtOH and rub hands together thoroughly
2. Remove tissue culture flask from incubator
3. Visually inspect the flask for mold or cloudiness
4. Set the flask on the microscope platform and turn lamp on
5. Focus the cells
6. Move the flask around above the objective to spot check for contamination
7. Spray the flask (but not the cap) with 70% EtOH, holding the bottle 12 inches away
8. Set flask it in the middle of the hood
9. Place all necessary serological pipettes in the left side of the hood
10. Obtain the 50 mL centrifuge tube with 37.3°C culture media
11. Spray in the 50 mL centrifuge tube with culture media into the hood
12. Obtain one (1) 50 mL centrifuge tube for waste
13. Loosen all caps slightly
14. Fully open the cap of the 50 mL waste tube
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Step 3: Media Dispensing
1. Unscrew lid on tissue culture flask
2. Put the pipette tip in the corner of the flask and remove old media
3. Dispense old media into the 50 mL waste tube
4. Screw the lid back onto the tissue culture flask
5. Set the flask down in the hood

Step 4: Media Addition
1. Obtain 15 mL of media
2. Unscrew the cap of the tissue culture flask
3. Dispense 15 mL of media into the flask without introducing bubbles
4. Gently swirl liquid around in the bottom of the flask
5. Place flask in incubator until next feeding or passaging
6. Clean everything appropriately
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Passaging CT26 Cells

Step 1: Preparation
1. Place cell culture media in the 37.3°C water bath.
2. Place PBS in the 37.3°C water bath
3. Place 0.25% Trypsin-EDTA in the 37.3°C water bath
4. Wait 30 minutes
5. Clean hood with 70% EtOH

Step 2: Checking Cell Health
1. Spray gloves with 70% EtOH and rub hands together
2. Remove tissue culture flask from incubator
3. Visually inspect the flask for mold or cloudiness
4. Set the flask on the microscope platform and turn lamp on
5. Focus the cells
6. Move the flask around above the objective to spot check for contamination
7. Spray the flask (but not the cap) with 70% EtOH, holding the bottle 12 inches away
8. Set flask it in the middle of the hood
9. Place all necessary serological pipettes in the left side of the hood
10. Obtain the 50 mL centrifuge tube with 37.3°C culture media
11. Spray in the 50 mL centrifuge tube with culture media into the hood
12. Obtain two (2) 50 mL centrifuge tube for waste
13. Obtain one (1) 15 mL centrifuge tube for centrifuging
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14. Loosen all caps slightly

Step 3: Media Dispensing
1. Unscrew lid on tissue culture flask
2. Put the pipette tip in the corner of the flask and remove old media
3. Dispense old media into the 50 mL waste tube
4. Screw the lid back onto the tissue culture flask
5. Set the flask down in the hood

Step 4: PBS Rinse
1. Obtain 10 mL of PBS
2. Unscrew lid on tissue culture flask
3. Dispense the PBS in the tissue culture flask
4. Screw lid back on tissue culture flask
5. Gently swirl flask with a rocking motion for 20 seconds
6. Unscrew lid on tissue culture flask
7. Remove PBS
8. Screw lid back on tissue culture flask
9. Dispense PBS in 50 mL waste tube

Step 5: Trypsin Re-Suspension
1. Unscrew lid on tissue culture flask
2. Obtain 5 mL of Trypsin-EDTA
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3. Dispense the trypsin in the tissue culture flask
4. Screw lid back on tissue culture flask
5. Gently swirl flask with a rocking motion for 30 seconds
6. Put the flask in the incubator for 3 minutes
7. Remove flask from incubator
8. Tap flask to break up cells from the bottom
9. Place flask underneath the inverted microscope to ensure that cells are detaching
10. Put tissue culture flask back in hood

Step 6: Media Addition #1
1. Obtain 4 mL of media
2. Unscrew lid on tissue culture flask
3. Dispense 4 mL of media into the flask (with the trypsin – total 9 mL)
4. Gently swirl flask with a rocking motion for 20 seconds

Step 7: Transfer to Centrifuge Tube
1. Obtain a 15 mL centrifuge tube
2. Remove all liquid from the tissue culture flask
3. Dispense the liquid (9 mL) into the 15 mL centrifuge tube
4. Set 15 mL centrifuge tube aside

Step 8: Media Rinse
1. Obtain 4 mL of media
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2. Dispense 4 mL of media into the “empty” tissue culture flask
3. Gently swirl flask with a rocking motion for 10 seconds
4. Remove 4 mL of media
5. Dispense the 4 mL of media into the centrifuge tube (total volume of 13 mL)

Step 9: Centrifuging Cells #1
1. Obtain the 15 mL centrifuge tube with 13 mL liquid
2. Place the 15 mL centrifuge tube in the centrifuge
3. Place the appropriate counter balance
4. Spin the tubes at 200 RCF for 5 minutes at 4°C
5. Without disturbing the pellet, place the 15 mL centrifuge tube back in the hood

Step 10: Dispensing of Supernatant #1
1. Unscrew the cap of the centrifuge tube
2. Remove supernatant (media/Trypsin-EDTA), leaving the pellet intact
3. Screw the cap gently back on the tube

Step 11: Media Addition #2
1. Obtain 10 mL of media
2. Unscrew the cap of the centrifuge tube
3. Dispense 10 mL of media into the tube (10 mL total)
4. Pipette up and down to mix cells
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Step 12: Counting Cells
1. Dispense 80 μL of media into a microcentrifuge tube
2. Dispense 20 μL of cells in media to the microcentrifuge tube
3. Mix the tube well
4. Obtain the hemacytometer
5. Load both chambers by pipetting the suspension under the cover slip
6. Place the hemacytometer on the microscope platform
7. View the first chamber
8. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes.
9. Total the cell count from the first 5 boxes
10. View the second chamber
11. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes
12. Total the cell count from the second 5 boxes

Step 13: Plating New Cells
1. Obtain one (1) new T75 tissue culture flask.
2. Fill the tissue culture flask with 15 mL of media
3. Place the required cell/media volume into the tissue culture flask
4. Screw lid back on tissue culture flask
5. Gently swirl flask with a rocking motion for 10 seconds
6. Place tissue culture flask quickly in the incubator
7. Clean everything appropriately
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Freezing CT26 Cells

Step 1: Preparing Freezing Container
1. Obtain an empty (no cryovials) Mr. Frosty Freezing Container from the -80°C freezer
2. Set on a paper towel
3. Unscrew the cap

Step 2: Complete Passaging Steps
1. Complete either a P1, P2, or a P3 passage (see the appropriate protocol)
2. Place DMSO in 37.3° water bath

Step 3: Preparation for Freezing
1. Obtain DMSO (50 µL required aliquot per freeze vial)
2. Obtain the desired number of cryo-vials for storage
3. Label the cryo-vials with date, initials, cell type, number of cells, and passage number
4. Slightly unscrew the caps of the cryo-vials so they are loose

Step 4: Creating Freeze Media
1. Dispense the appropriate amount of media into each cryo-vial
2. Obtain the centrifuge tube (with media and cells)
3. Dispense the appropriate amount of cells/media into each cryo-vial
4. Dispense the 50 µL DMSO into each cryo-vial
5. Cap the cryo-vials
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6. Gently mix
7. Place cryo-vials into Mr. Frosty container
8. Ensure Mr. Frosty has at least 1 inch of 100% isopropyl alcohol and refill as necessary
9. Place Mr. Frosty container in -80°C freezer for 12 hours
10. After 12 hours, remove Mr. Frosty container
11. Transfer cryo-vials to liquid nitrogen dewar
12. Clean everything appropriately
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Thawing CT26 Cells

Step 1: Preparation
1. Place cell culture media in the 37.3°C water bath.
2. Place PBS in the 37.3°C water bath
3. Place 0.25% Trypsin-EDTA in the 37.3°C water bath
4. Wait 30 minutes
5. Clean hood with 70% EtOH
6. Obtain a 50 mL centrifuge tube for liquid waste storage
7. Obtain one T75 tissue culture flask and spray it into the hood.

Step 2: Preparing T75 Flask
1. Label T75 flask with initials, date, CT26, P#, and 5x105
2. Loosen cap on the empty T75 flask
3. Dispense 14 mL of cell culture media into the T75 flask

Step 3: Preparing Cells
1. Remove the cryovial with cells from liquid nitrogen Dewar
2. Bring cryovial with cells to the 37.3°C warm water bath
3. Thaw the cells in the water bath without submerging the cryovial lid
4. When a small chunk of ice remains inside, remove from the water bath
5. Wipe the vial with 70% EtOH on a Kimwipe. Do not directly spray the vial
6. Place the cryovial vial into the hood
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7. Loosen cap on cell vial

Step 4: Plating Cells in T75 Flask
1. Fill the tissue culture flask with contents of the thawed cryovial
2. Screw caps gently back on tissue culture flask
3. Gently swirl flask with a rocking motion for 30 seconds
4. Place tissue culture flask quickly in the incubator
5. Clean everything appropriately

Step 5: Feeding Cells
1. Feed cells within 24 hours (see the appropriate protocol)
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Aliquoting CT26 Cells in Sterile Saline for Injection

Step 1: Preparation
1. Place cell culture media in the 37.3°C water bath.
2. Place dPBS in the 37.3°C water bath
3. Place saline in the 37.3°C water bath
4. Place 0.25% Trypsin-EDTA in the 37.3°C water bath
5. Wait 30 minutes
6. Clean hood with 70% EtOH
7. Obtain a small bucket of ice and set aside in freezer

Step 2: Checking Cell Health
1. Spray gloves with 70% EtOH and rub hands together
2. Remove tissue culture flask from incubator
3. Visually inspect the flask for mold or cloudiness
4. Set the flask on the microscope platform and turn lamp on
5. Focus the cells
6. Move the flask around above the objective to spot check for contamination
7. Spray the flask (but not the cap) with 70% EtOH, holding the bottle 12 inches away
8. Set flask it in the middle of the hood
9. Place all necessary serological pipettes in the left side of the hood
10. Obtain the 50 mL centrifuge tube with 37.3°C culture media
11. Spray in the 50 mL centrifuge tube with culture media into the hood
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12. Obtain two (2) 50 mL centrifuge tube for waste
13. Obtain one (1) 15 mL centrifuge tube for centrifuging
14. Loosen all caps slightly

Step 3: Media Dispensing
1. Unscrew lid on tissue culture flask
2. Put the pipette tip in the corner of the flask and remove old media
3. Dispense old media into the 50 mL waste tube
4. Screw the lid back onto the tissue culture flask
5. Set the flask down in the hood

Step 4: PBS Rinse
1. Obtain 10 mL of PBS
2. Unscrew lid on tissue culture flask
3. Dispense the PBS in the tissue culture flask
4. Screw lid back on tissue culture flask
5. Gently swirl flask with a rocking motion for 20 seconds
6. Unscrew lid on tissue culture flask
7. Remove PBS
8. Screw lid back on tissue culture flask
9. Dispense PBS in 50 mL waste tube
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Step 5: Trypsin Re-Suspension
1. Unscrew lid on tissue culture flask
2. Obtain 5 mL of Trypsin-EDTA
3. Dispense the trypsin in the tissue culture flask
4. Screw lid back on tissue culture flask
5. Gently swirl flask with a rocking motion for 30 seconds
6. Put the flask in the incubator for 3 minutes
7. Remove flask from incubator
8. Tap flask to break up cells from the bottom
9. Place flask underneath the inverted microscope to ensure that cells are detaching
10. Put tissue culture flask back in hood

Step 6: Media Addition #1
1. Obtain 4 mL of media
2. Unscrew lid on tissue culture flask
3. Dispense 4 mL of media into the flask (with the trypsin – total 9 mL)
4. Gently swirl flask with a rocking motion for 20 seconds

Step 7: Transfer to Centrifuge Tube
1. Obtain a 15 mL centrifuge tube
2. Remove all liquid from the tissue culture flask
3. Dispense the liquid (9 mL) into the 15 mL centrifuge tube
4. Set 15 mL centrifuge tube aside
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Step 8: Media Rinse
1. Obtain 4 mL of media
2. Dispense 4 mL of media into the “empty” tissue culture flask
3. Gently swirl flask with a rocking motion for 10 seconds
4. Remove 4 mL of media
5. Dispense the 4 mL of media into the centrifuge tube (total volume of 13 mL)

Step 9: Centrifuging Cells #1
1. Obtain the 15 mL centrifuge tube with 13 mL liquid
2. Place the 15 mL centrifuge tube in the centrifuge
3. Place the appropriate counter balance
4. Spin the tubes at 200 RCF for 5 minutes at 4°C
5. Without disturbing the pellet, place the 15 mL centrifuge tube back in the hood

Step 10: Dispensing of Supernatant #1
1. Unscrew the cap of the centrifuge tube
2. Remove supernatant (media/Trypsin-EDTA), leaving the pellet intact
3. Screw the cap gently back on the tube

Step 11: Saline Addition #1
1. Obtain 10 mL of saline
2. Unscrew the cap of the centrifuge tube
3. Dispense 10 mL of saline into the tube (10 mL total)
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4. Pipette up and down to mix cells

Step 12: Counting Cells
1. Dispense 80 μL of media into a microcentrifuge tube
2. Dispense 20 μL of cells in saline to the microcentrifuge tube
3. Mix the tube well
4. Obtain the hemacytometer
5. Load both chambers by pipetting the suspension under the cover slip
6. Place the hemacytometer on the microscope platform
7. View the first chamber
8. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes.
9. Total the cell count from the first 5 boxes
10. View the second chamber
11. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes
12. Total the cell count from the second 5 boxes

Step 13: Centrifuging Cells #2
1. Put the 15 mL centrifuge tube with cells into the centrifuge
2. Place the appropriate counter balance
3. Spin the tubes at 200 RCF for 5 minutes at 4°C
4. Without disturbing the pellet, place the 15 mL centrifuge tube back in the hood
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Step 14: Dispensing of Supernatant #2
4. Unscrew the cap of the centrifuge tube
5. Remove supernatant (sterile saline), leaving the pellet intact
Screw the cap gently back on the tube

Step 15: Saline Addition #2
1. Obtain appropriate volume of warm sterile saline
2. Dispense appropriate volume of saline into the tube
3. Slowly pipette up and down to mix cells

Step 16: Aliquot Cells into Microcentrifuge Tubes
1. Obtain desired number of sterile microcentrifuge tubes
2. Pipette 1x105 CT26 cells/sterile saline into each microcentrifuge tube
3. Cap tubes
4. Label tubes with CT26
5. Place tubes on ice (pre-prepared from earlier step)
6. Clean everything appropriately
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Subcutaneous Injection of CT26 Cells into Balb/c Mice
Equipment and Materials
Item

Distributor

Item Number

Gloves

VWR

89038-270

KimWipes

VWR

470224-038

Distilled Water

Walmart

009594226

Sterile Saline (0.9% NaCl)

VWR

S5825

95% Reagent Ethanol

VWR

BDH1156-4LP

10% Bleach

VWR

89501-620

28G U-100 BD Micro-Fine IV Syringe

VWR

BD329410

Microcentrifuge Tubes

VWR

20170-038

Alcohol Swab

VWR

BD326859

Water Bath

VWR

89501-464

Ear Punch, Scissor Style

VWR

10806-292

Aluminum Dissecting Pan

Carolina

629210

Lab Coat (Men’s)

VWR

10141-300

Lab Coat (Women’s)

VWR

10141-316

Analytical Balance

VWR

10159-998

Eye Gel

CVS

332692

Warm Water Pump

Global Medical

TP700

Warm Water Pump Pad

Kent Scientific

TPZ-0510EA

Valved In-Line Hose Barb Coupling Body

Fresh Water Systems

42100

Non-Valved In-Line Hose Barb Coupling

Fresh Water Systems

40900
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Rodent Trimmer Set

Braintree Scientific

CLP-9990 1201

Nair Hair Remover Lotion

Walmart

000287746
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Subcutaneous Injection of CT26 Cells into Balb/c Mice

Step 1: Preparation
1. Clean all surfaces with 70% EtOH
2. Set out the metal dissection pan
3. Set up the anesthesia cart (see appropriate instructions)
4. Turn on the hot water pump pad at least 30 minutes before the first injection
5. Obtain necessary amount of 28G needles
6. Obtain microcentrifuge tubes with aliquot of 1x105 CT26 cells in sterile saline in ice
7. Draw up entire aliquot (150 μL) of 1x105 CT26 cells in sterile saline
8. Get rid of any air bubbles in the needle

Step 2: Anesthetizing Mouse
1. Let mice become aware of presence for 30 seconds
2. Remove mouse from cage
3. Place the mouse in the mouse-isoflurane chamber
4. Secure the lid on the mouse-isoflurane chamber
5. Anesthetize mouse
6. Remove mouse without grabbing the tail
7. Place the mouse on the nosecone
8. Put eye drop gel in the mouse’s eyes
9. Ensure the mouse is on the nose cone for 30 seconds before proceeding
10. Ear punch the mouse appropriately
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11. Shave the tumor cell injection site

Step 3: Subcutaneous Injection into Flank
1. Hold the 28G needle at a 5-10° angle
2. Place the needle 5 mm away from the spine at the level of the thigh
3. Stretch the skin taught with the left hand
4. Insert the needle so that it goes just underneath the skin at the upper thigh
5. Lift the needle up to test that you have good skin penetration
6. Inject slowly
7. Withdraw needle
8. Remove mouse from anesthesia
9. Warm mouse up with your hand
10. Place the mouse back in its cage once it’s awake
11. Clean everything appropriately
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Treatment Preparation
Equipment and Materials
Item

Distributor

Item Number

5-Fluorouracil

Sigma-Aldrich

F6627-1G

CCL2 (MCP-1) Monoclonal Antibody (2H5)

Bio X Cell

BE0185-A005MG

CCL2 (MCP-1) Isotype Control

Bio X Cell

BE0091-A005MG

15 mL Conical-Bottom Centrifuge Tubes

VWR

89039-666

Dimethyl Sulfoxide (DMSO)

VWR

97063-136

Microcentrifuge Tubes

VWR

20170-038

80-Place Storage System

VWR

30128-276

Sterile Saline (0.9% NaCl)

VWR

101320-574

Gloves

VWR

89038-270

KimWipes

VWR

470224-038

Variable Volume Pipettors

VWR

75788-458

Universal Shelf Clip for 3 Pipettors

VWR

40000-272

10 µL Pipette Tips (Sterile-Aerosol)

VWR

89174-520

10 µL Pipette Tips (Sterile)

VWR

89368-970

100 µL Pipette Tips (Sterile-Aerosol)

VWR

10126-388

100 µL Pipette Tips (Sterile)

VWR

89140-162

1000 µL Pipette Tip (Sterile-Aerosol)

VWR

89174-530

1000 µL Pipette Tip (Sterile)

VWR

83007-380
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Preparation of 5-Fluorouracil Chemotherapy

Quantity per Container

1g

Dose Schedule

Daily

Dose per Day

15 mg/kg/day

5-FU per Injection (15 g to 30 g mouse)

0.225 – 0.450 mg

5-FU per Injection in Microcentrifuge Tube

1 mg

Injections (cohort 1)

2

Injections (cohort 2)

4

Injections (cohort 3)

7

Injection Method

Intraperitoneal

Step 1: Making 5-FU
1. Determine the number of injections you want to make
2. Prepare the biosafety cabinet
3. Obtain container of 5-FU and spray into hood
4. Obtain a 50 mL centrifuge tube
5. Label the 50 mL centrifuge tube with 40 mg/mL 5-FU/DMSO, initials, and date
6. Dispense 25 mL DMSO into 50 mL centrifuge tube
7. Dispense entire bottle (1 g) of 5-FU into 50 mL centrifuge tube
8. Remove solution from the hood
9. Vortex for 30 minutes at room temperature or until completely dissolved
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Step 2: Pre-Preparation of 5-FU
1. Obtain a 15 mL centrifuge tube
2. Dispense 5 mL of 40 mg/mL 5-FU/DMSO into 15 mL centrifuge tube
3. Dispense 5 mL of sterile saline into 15 mL centrifuge tube
4. Label the 15 mL centrifuge tube with 20 mg/mL 5-FU/Saline
5. Remove solution from the hood
6. Vortex for 1 minute or until completely dissolved
7. Store both solutions permanently at -20°C

Step 3: Preparing 5-FU for Injection
1. Obtain normal sterile saline
2. Remove 20 mg/mL 5-FU/Saline from -20°C
3. Obtain desired amount of 1.5 mL microcentrifuge tubes
4. Sterilize microcentrifuge tubes in autoclave
5. Place 23 μL of 20 mg/mL 5-FU/Saline in microcentrifuge tubes
6. Place 130 μL of saline in each tube to get a 3 mg/mL concentration of 5-FU/saline
7. Place 20 mg/mL 5-FU/Saline solution back in -20°C
8. Store aliquots at -20°C

Calculations:
1. Minimum Daily Dose of 5-FU per Mouse (15 g mouse)
[

15 𝑚𝑔
1 𝑘𝑔
]∙[
] ∙ [15 𝑔] = 0.225 𝑚𝑔
𝑘𝑔
1000 𝑔

2. Maximum Daily Dose of 5-FU per Mouse (30 g mouse)
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[

15 𝑚𝑔
1 𝑘𝑔
]∙[
] ∙ [30 𝑔] = 0.450 𝑚𝑔
𝑘𝑔
1000 𝑔

3. Total Number of 5-FU Injections
[2 𝑔𝑟𝑜𝑢𝑝𝑠] ∙ [

5 𝑚𝑖𝑐𝑒
2 𝑖𝑛𝑗𝑒𝑐𝑡.
4 𝑖𝑛𝑗𝑒𝑐𝑡.
7 𝑖𝑛𝑗𝑒𝑐𝑡.
] ∙ [(
)+(
)+(
)]
𝑐𝑜ℎ𝑜𝑟𝑡 ∙ 𝑔𝑟𝑜𝑢𝑝
𝑐𝑜ℎ𝑜𝑟𝑡 1
𝑐𝑜ℎ𝑜𝑟𝑡 2
𝑐𝑜ℎ𝑜𝑟𝑡 3
= 130 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠

4. Total 5-FU used:
[130 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠] ∙ [

0.450 𝑚𝑔
] = 58.5 𝑚𝑔
𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛

5. DMSO Measurement for 40 mg/mL 5-FU/DMSO Storage Solution
𝑉𝐷𝑀𝑆𝑂 = [

1 𝑚𝐿
] ∙ [𝑥 𝑚𝑔] = 25 𝑚𝐿
40 𝑚𝑔

6. Recovering 0.450 mg of 5-FU (for a 30 g mouse) per Microcentrifuge Tube
[

1 𝑚𝐿
1000 𝜇𝐿
] ∙ [0.450 𝑚𝑔 5𝐹𝑈] ∙ [
] = 22.5 𝜇𝐿
20 𝑚𝑔 5𝐹𝑈
1 𝑚𝐿

7. Required Saline per 5-FU Aliquot
𝑉𝑇𝑜𝑡𝑎𝑙 (𝜇𝐿) = [

20 𝑚𝑔 5𝐹𝑈 23 𝜇𝐿
1 𝑚𝐿
]∙[
]∙[
] = 153 𝜇𝐿
1 𝑚𝐿
1
3 𝑚𝑔 5𝐹𝑈

𝑉𝑎𝑙𝑖𝑞𝑢𝑜𝑡 (𝜇𝐿) = 23 𝜇𝐿
𝑉𝑆𝑎𝑙𝑖𝑛𝑒 (𝜇𝐿) = 𝑉𝑇𝑜𝑡𝑎𝑙 (𝜇𝐿) − 𝑉𝑎𝑙𝑖𝑞𝑢𝑜𝑡 (𝜇𝐿) = 130 𝜇𝐿
8. Required Volume of 3 mg/mL 5-FU/saline Per Mouse
[

1 𝑚𝐿 𝑠𝑎𝑙𝑖𝑛𝑒 1000 𝜇𝐿 15 𝑚𝑔 5𝐹𝑈
1 𝑘𝑔
]∙[
]∙[
]∙[
] ∙ 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑀𝑜𝑢𝑠𝑒 (𝑔)
3 𝑚𝑔 5𝐹𝑈
1 𝑚𝐿
𝑘𝑔
1000 𝑔
= 𝑥 𝜇𝐿 5𝐹𝑈/𝑠𝑎𝑙𝑖𝑛𝑒

Justification for 5-FU Dosage in Mice
5-FU Chemotherapy in Humans
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▪

2,400 mg/m2 given during treatment – repeated every 2 weeks

▪

Body surface area (BSA) is the unit in humans
2,400 𝑚𝑔 5𝐹𝑈

5FU Dose (based on Body Surface Area) in Humans: [𝑚2 ∙2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒]
1.6 𝑚2

Average Ratio of Body Surface Area to Weight in Humans: [ 60 𝑘𝑔 ]
Standard Human-to-Mouse FDA Conversion Factor: [

12.3
3

]

Conversion of Human BSA-based Dosage to Mouse Weight-based Dosage:
2,400 𝑚𝑔 5𝐹𝑈
1.6 𝑚2
12.3
1 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
𝒎𝒈 𝟓𝑭𝑼
𝒎𝒈 𝟓𝑭𝑼
[ 2
]∙[
]∙[
]∙[
] = 𝟏𝟖. 𝟕
≈ 𝟏𝟓
𝑚 ∙ 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
60 𝑘𝑔
3
14 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒𝑠
𝒌𝒈
𝒌𝒈
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Preparation of anti-CCL2 Immunotherapy

Quantity per Container

5 mg

Dose Schedule

Every Other Day (0, 2, 4, 6)

Dose per Day

4 mg/kg/day

Anti-CCL2 per Injection (15 g to 30 g mouse)

60 – 120 μg

Injections (cohort 1)

1

Injections (cohort 2)

2

Injections (cohort 3)

4

Injection Method

Intraperitoneal (I.P.)

Step 1: Making Anti-CCL2 (or Isotype Control)
1. Determine number of injections you want to make
2. Obtain desired amount of 1.5 mL microcentrifuge tubes
3. Sterilize microcentrifuge tubes in autoclave
4. Prepare the biosafety cabinet
5. Obtain stock anti-CCL2 solution
6. Obtain normal sterile saline
7. Spray everything into biosafety hood
8. Label tubes with initials, date, and 150 μg anti-CCL2/Saline
9. Aliquot 20 μL (150 μg anti-CCL2 protein) of stock anti-CCL2 into each tube
10. Aliquot 106 µL sterile saline into each tube to create a 1.2 mg/mL anti-CCL2/saline solution
11. Place anti-CCL2 stock solution back in 4°C fridge
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12. Place 1.2 mg/mL anti-CCL2 solutions back in 4°C fridge
13. Store aliquots at 4°C for no more than 2 months

Calculations:
1. Minimum Dose of Anti-CCL2 per Injection per Mouse (15 g mouse)
[

4 𝑚𝑔
1 𝑘𝑔
]∙[
] ∙ [15 𝑔] = 0.06 𝑚𝑔 = 60 𝜇𝑔
𝑘𝑔
1000 𝑔

2. Maximum Dose of Anti-CCL2 per Injection per Mouse (30 g mouse)
[

4 𝑚𝑔
1 𝑘𝑔
]∙[
] ∙ [30 𝑔] = 0.12 𝑚𝑔 = 120 𝜇𝑔
𝑘𝑔
1000 𝑔

3. Total Number of Anti-CCL2 Injections (per group)
[2 𝑔𝑟𝑜𝑢𝑝𝑠] ∙ [

5 𝑚𝑖𝑐𝑒
1 𝑖𝑛𝑗𝑒𝑐𝑡.
2 𝑖𝑛𝑗𝑒𝑐𝑡.
4 𝑖𝑛𝑗𝑒𝑐𝑡.
] ∙ [(
)+(
)+(
)]
𝑐𝑜ℎ𝑜𝑟𝑡 ∙ 𝑔𝑟𝑜𝑢𝑝
𝑐𝑜ℎ𝑜𝑟𝑡 1
𝑐𝑜ℎ𝑜𝑟𝑡 2
𝑐𝑜ℎ𝑜𝑟𝑡 3
= 70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠

4. Total Anti-CCL2 used:
[70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠] ∙ [

0.12 𝑚𝑔
] = 8.4 𝑚𝑔
𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛

5. Required Volume of anti-CCL2/Saline (not diluted) Per Mouse:
𝑉𝑎𝑛𝑡𝑖−𝐶𝐶𝐿2 (𝜇𝐿)
=[

0.7 𝑚𝐿 𝑠𝑜𝑙𝑣.
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
]∙[
]∙[
]∙[
]
5.3 𝑚𝑔 𝑎𝑛𝑡𝑖𝐶𝐶𝐿2 𝑘𝑔 𝑚𝑜𝑢𝑠𝑒 1000 𝑔 𝑚𝑜𝑢𝑠𝑒
1 𝑚𝐿 𝑠𝑜𝑙𝑣.

∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔)
6. Required Volume of Saline for 1.2 mg/mL Aliquot of anti-CCL2
𝑉𝑠𝑎𝑙𝑖𝑛𝑒 (𝜇𝐿) = ([

5.3 𝑚𝑔
1 𝑚𝐿
] ∙ [0.020 𝑚𝐿 (𝑓𝑟𝑜𝑚 𝑒𝑞. 5, 25𝑔 𝑚𝑜𝑢𝑠𝑒)] ∙ [
]) − 0.020 𝑚𝐿
0.7 𝑚𝐿
1.2 𝑚𝑔

= 106 𝜇𝐿
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7. Required Volume of anti-CCL2/Saline (diluted) Per Mouse
𝑉𝑎𝑛𝑡𝑖−𝐶𝐶𝐿2 𝑑𝑖𝑙. = [

1 𝑚𝐿 𝑠𝑜𝑙𝑣.
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
]∙[
]∙[
]∙[
]
1.2 𝑚𝑔 𝑎𝑛𝑡𝑖𝐶𝐶𝐿2 𝑘𝑔 𝑚𝑜𝑢𝑠𝑒 1000 𝑔 𝑚𝑜𝑢𝑠𝑒
1 𝑚𝐿 𝑠𝑜𝑙𝑣.

∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔)
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Preparation of Isotype Control Antibodies

Quantity per Container

5 mg

Dose Schedule

Every Other Day (0, 2, 4, 6)

Dose per Day

4 mg/kg/day

Anti-CCL2 per Injection (15 g to 30 g mouse)

60 – 120 μg

Injections (cohort 1)

1

Injections (cohort 2)

2

Injections (cohort 3)

4

Injection Method

Intraperitoneal (I.P.)

Step 1: Making Isotype Control
1. Determine number of injections you want to make
2. Obtain desired amount of 1.5 mL microcentrifuge tubes
3. Sterilize microcentrifuge tubes in autoclave
4. Prepare the biosafety cabinet
5. Obtain stock isotype control solution
6. Obtain normal sterile saline
7. Spray everything into biosafety hood
8. Label tubes with initials, date, and 150 μg isotype control/Saline
9. Aliquot 20 μL (150 μg Isotype Control) of stock isotype control into each tube
10. Aliquot 106 µL saline into each tube to create a 1.2 mg/mL isotype control/saline solution
11. Place isotype control stock solution back in 4°C fridge
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12. Place 1.2 mg/mL anti-CCL2 solutions back in 4°C fridge
13. Store aliquots at 4°C for no more than 2 months

Calculations:
1. Minimum Dose of Isotype Control per Injection per Mouse (15 g mouse)
[

4 𝑚𝑔
1 𝑘𝑔
]∙[
] ∙ [15 𝑔] = 0.06 𝑚𝑔 = 60 𝜇𝑔
𝑘𝑔
1000 𝑔

2. Maximum Dose of Isotype Control per Injection per Mouse (30 g mouse)
[

4 𝑚𝑔
1 𝑘𝑔
]∙[
] ∙ [30 𝑔] = 0.12 𝑚𝑔 = 120 𝜇𝑔
𝑘𝑔
1000 𝑔

3. Total Number of Isotype Control Injections (per group)
[2 𝑔𝑟𝑜𝑢𝑝𝑠] ∙ [

5 𝑚𝑖𝑐𝑒
1 𝑖𝑛𝑗𝑒𝑐𝑡.
2 𝑖𝑛𝑗𝑒𝑐𝑡.
4 𝑖𝑛𝑗𝑒𝑐𝑡.
] ∙ [(
)+(
)+(
)]
𝑐𝑜ℎ𝑜𝑟𝑡 ∙ 𝑔𝑟𝑜𝑢𝑝
𝑐𝑜ℎ𝑜𝑟𝑡 1
𝑐𝑜ℎ𝑜𝑟𝑡 2
𝑐𝑜ℎ𝑜𝑟𝑡 3
= 70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠

4. Total Isotype Control used:
[70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠] ∙ [

0.12 𝑚𝑔
] = 8.4 𝑚𝑔
𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛

5. Required Volume of Isotype Control/Saline (not diluted) Per Mouse:
𝑉𝑖𝑠𝑜𝑡𝑦𝑝𝑒 (𝜇𝐿) = [

0.7 𝑚𝐿 𝑠𝑜𝑙𝑣.
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
]∙[
]∙[
]∙[
]
5.3 𝑚𝑔 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑘𝑔 𝑚𝑜𝑢𝑠𝑒 1000 𝑔 𝑚𝑜𝑢𝑠𝑒
1 𝑚𝐿 𝑠𝑜𝑙𝑣.

∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔)
6. Required Volume of Saline for 1.2 mg/mL Aliquot of Isotype Control
𝑉𝑠𝑎𝑙𝑖𝑛𝑒 (𝜇𝐿) = ([

5.3 𝑚𝑔
1 𝑚𝐿
] ∙ [0.020 𝑚𝐿 (𝑓𝑟𝑜𝑚 𝑒𝑞. 5, 25𝑔 𝑚𝑜𝑢𝑠𝑒)] ∙ [
]) − 0.020 𝑚𝐿
0.7 𝑚𝐿
1.2 𝑚𝑔

= 106 𝜇𝐿
7. Required Volume of Isotype Control/Saline (diluted) Per Mouse
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𝑉𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑑𝑖𝑙. = [

1 𝑚𝐿 𝑠𝑜𝑙𝑣.
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
]∙[
]∙[
]∙[
]
1.2 𝑚𝑔 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑘𝑔 𝑚𝑜𝑢𝑠𝑒 1000 𝑔 𝑚𝑜𝑢𝑠𝑒
1 𝑚𝐿 𝑠𝑜𝑙𝑣.

∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔)
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Tissue Preparation
Equipment and Materials
Item

Distributor

Item Number

Gloves

VWR

89038-270

KimWipes

VWR

470224-038

Leica CM1860 Cryostat

Leica

CM1860

Low-Profile 819 Disposable Blades

VWR

10015-014

SuperFrost Plus Microscope Slides

VWR

48311-703

Coverslips (22 x 50)

VWR

16004-314

Microscope Slide Storage Box (Red)

VWR

89510-824

Tissue-Tek Cryomold (25x20x5)

VWR

25608-916

Razor Blades

VWR

55411-050

Artificial Tears Ointment

Walmart

305366550917

Plastic Divider Box (x2)

DigiKey

510-1030-ND

Plastic Divider Tabs (x6)

DigiKey

510-1035-ND

Steel Cooker

Amazon

B00H3377W6

Nalgene Dewar Flask (1 L)

VWR

633880-052

Dissecting Forceps (12”)

VWR

470018-958

Tissue-Tek O.C.T. Compound

VWR

25608-930

Low Temperature Organic Thermometer

VWR

89062-908

Lab Markers, Black

VWR

52877-310

Parafilm M Roll

VWR

52858-076

Nair Hair Removal Lotion

Amazon

B009ZCFSO2
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Small Animal Surgical Cordless Trimmer

Braintree Scientific

CLP-9868 14

Aluminum Foil

VWR

89107-726

Isopentane (2-Methylbutane)

VWR

AA19387-AP

Liquid Nitrogen Tank

Airgas

NI NF180LT22
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Tissue Dissection and Freezing

Step 1: Preparation of Supplies
1. Pre-cut the necessary amount of 5” x 5” aluminum foil squares (1 per tumor)
2. Label aluminum foil with the mouse identification number
3. Pre-prep 25 x 20 cryomolds (1 per tumor) with 2 mm of OCT in the base
4. Label cyromolds with initials, date, mouse number¸ either IHC and the T shape
5. Obtain plastic bag
6. Label plastic bag with initials, date, mouse number, and IACUC protocol number
7. Obtain steel cooker and Styrofoam container
8. Obtain white cutting board and ruler

Step 2: Anesthetize Mouse
1. Prep anesthesia machine
2. Place mouse in induction chamber
3. Anesthetize mouse with 1.5% isoflurane and 1 L/min O2

Step 3: Preparation of Liquid Nitrogen
1. In the chemical fume hood, dispense ~250 mL of isopentane into the steel cooker
2. Fill Styrofoam container with liquid nitrogen
3. In the chemical fume hood, place steel cooker (with isopentane) in liquid nitrogen
4. Place thermometer in steel cooker so that the tip is submerged in liquid nitrogen
5. Begin swirling around the isopentane to distribute heat
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6. Turn up mouse anesthesia to 4.0% isoflurane and 1 L/min O2
7. Continually monitor temperature of isopentane

Step 4: Preparation of Mouse
1. Once mouse is fully anesthetized, transfer to nosecone
2. Maintain mouse on 4.0% isoflurane with 1 L/min O2
3. Obtain a black lab marker
4. Draw a 5 mm line through the DRS measurement axis of each measurement location.
5. Dissect tumor with scissors
6. Set tumor on white cutting board with ruler in background and photograph
7. Continually monitor temperature of isopentane

Step 5: Flash Freezing Tumor in Liquid Nitrogen
1. Place tumor in the OCT filled cryomold
2. Fill the cyromold with more OCT to cover the tumor
3. Remove isopentane from liquid nitrogen
4. Grab the edge of cryomold with 12” dissecting forceps
5. When the temperature of isopentane is 73-78°C, dip cryomold in isopentane for 15 seconds
6. Remove cryomold from isopentane
7. Place more OCT on any exposed parts of the tumor and cryomold
8. Dip cryomold in isopentane for 15 seconds
9. Set the frozen cryomold on the aluminum foil square
10. Wrap the frozen cryomold in aluminum foil
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11. Transport the foil-wrapped tissue sample to the -80°C freezer

Step 6: Euthanizing Mouse
1. Euthanize the mouse via cervical dislocation
2. Keep euthanized mouse on 4.0% isoflurane for 60 seconds following cervical dislocation
3. Place the euthanized mouse in plastic bag
4. Place the plastic bag with the mouse in the freezer in the small animal facility for disposal

Tips for Monitoring Isopentane Temperature
1. Continually use the thermometer to stir the isopentane
2. When the isopentane reaches 65-70°C, remove from liquid nitrogen – the temperature will
continue to drop
3. Place the isopentane back in the liquid nitrogen when the temperature rises to 65°C
4. Do not let the temperature get below 90°C – this can ruin the thermometer
5. Only place the tumor/cryomold/OCT in the isopentane when the temperature is 73-78°C
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Cryotome Sectioning

Step 1: Preparing the Cryotome and Materials
1. Obtain microscope slides (x8)
2. Transfer cryotome blades from -20°C freezer to the cryotome
3. Place the frozen tissue sample(s) into the cryotome
4. Leave the frozen tissue sample(s) and blades in the cryotome (at -20°C) for 20 minutes
5. Using the pencil, label the microscope slides (on the rough side) (x8) with the following (i.e.
example shown in picture): 1) mouse identification number, 2) Balb/c, 3) CT26, 4) initials,
and 5) slide number (out of 8)

Step 2: Preparing and Mounting the Blade
1. Check to see if there is a blade in the blade holder. If there is a blade in the blade holder, look
for a small black handle on the right side of the main carrier that is located in the center of
the cryotome and pull the black handle towards you. (This releases the blade)
2. Remove the old blade
3. Obtain a new blade
4. Using the magnet on the bottom of the white brush, place the blade into the blade holder,
making sure that the sharp portion of the blade is facing up
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5. Once the blade is in place, push the small black handle back

Step 3: Adjusting Angles
1. Obtain calipers
2. Ensure that the distance between the 2 cylinders is 6mm, measured with at least 3 points

3. Ensure the angle of the blade is at ~7°

4. Ensure the glass blade cover is directly aligned over the top of the blade (i.e. cover and blade
edge are parallel)
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Step 4: Cutting Away Excess OCT
1. Obtain OCT/tumor sample
2. Obtain a razorblade
3. Cut away excess OCT surrounding the tumor so there is just 2-4 mm of OCT surrounding the
tumor. Note: this doesn’t have to be perfect; we’ve noticed cutting away some excess OCT
helps with getting good tissue sections

Step 5: Preparation of Sample on Chuck
1. Obtain the chuck
2. Place a dime-sized amount of OCT onto the chuck
3. Take the sample out of the cryomold
4. Place the non-cutting edge of sample onto the chuck making sure that the correct corner is
point up. (The cutting edge is the flat square face. Note: the tissue sample should be in a
diamond shape)
5. Place the chuck with the sample onto the blue freezing panel
6. Close the lid of the cryotome and let the chuck/sample freeze for 5 minutes
7. Set the cutting thickness to 100 µm

Step 6: Preparation of Sample for Sectioning
1. Turn the wheel until the sample is close to the blade
2. Move the sample forward using the fast and slow track buttons on the left side of the
cryotome. (The blade should not be hitting the plastic guard or the carrier)
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3. Start turning the rotating arm on the right side of the cryotome to start slicing away excess
OCT
4. Once the blade has sliced through approximately 1/3 way through the tumor, set the cutting
thickness to 10 µm

Step 7: Sample Sectioning (10 μm)
1. Turn the wheel at ~1 turn per second.
2. Lift the cover and place the rough side of the slide onto the sample
3. The OCT will melt onto the slide and the actual tissue will remain intact
4. Leave the microscope slide in the cryotome to maintain temperature
5. Use the same microscope slide for the 2nd tissue slice
6. Repeat until you have four (4) good microscope slides (8 good tissue slices)

Step 8: Sample Sectioning (5 μm)
1. Set the cutting thickness to 5 μm
2. Lift the cover and place the rough side of the slide onto the sample
3. The OCT will melt onto the slide and the actual tissue will remain intact
4. Leave the microscope slide in the cryotome to maintain temperature
5. Use the same microscope slide for the 2nd tissue slice
6. Repeat until you have four (4) good microscope slides (8 good tissue slices)

Step 10: Storing Slides
1. Once complete, place all slides into a microscope storage box
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2. Immediately places the microscope slide storage box in the -80°C freezer
3. Save the excess tumor, wrap it in foil, and place it back in the -80°C freezer
4. Clean the cryotome appropriately
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Tissue Analysis
Equipment and Materials
Item

Distributor

Item Number

Anti-CD68 (anti-mouse) Alexa Fluor 488

BioLegend

137012

Anti-CD80 (anti-mouse) Brilliant Violet 421

BioLegend

104725

Anti-CD206 (anti-mouse) Alexa Fluor 594

BioLegend

141726

NucBlueTM Fixed Cell ReadyProbe (DAPI)

Thermo Fisher

R37606

Universal Antibody Dilution Buffer

Sigma-Aldrich

U3510-100ML

Hematoxylin Solution, Mayer’s

VWR

100504-404

Eosin Y

VWR

10143-130

Bluing Reagent Solution

VWR

95057-852

Xylene

VWR

EM-XX0060-4

Cytoseal XYL

VWR

48212-196

100% Reagent Ethanol

VWR

EM-EX0276-4S

95% Reagent Ethanol

VWR

BDH1156-4LP

Microcentrifuge Tubes

VWR

20170-038

80-Place Storage System

VWR

30128-276

15 mL Conical-Bottom Centrifuge Tubes

VWR

89039-666

50 mL Conical-Bottom Centrifuge Tubes

VWR

89039-658

Gloves

VWR

89038-270

KimWipes

VWR

470224-038

Acetone

VWR

BDH1101-4LP

SuperFrost Plus Microscope Slides

VWR

48311-703
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Coverslips (22 x 50)

VWR

16004-314

EasyDipTM Kit with Rack

VWR

CA10154-052

EasyDipTM Slide Staining Jars – White

VWR

87000-126

Whatman Grade 1 Qualitative Filter Paper

VWR

10035-812

Laboratory Bench and Table Protector

VWR

89126-790

Powder Funnel (Wide Stem)

VWR

16126-912

Phosphate Buffered Saline (PBS), 1X

VWR

45000-446

Phosphate Buffered Saline (PBS) Tablet

Sigma-Aldrich

P4417-100TAB

Tween 20

Sigma-Aldrich

P9416-50ML

Triton-X100

Sigma-Aldrich

X100-100ML

Goat serum

Sigma-Aldrich

G9023-10ML

Sodium Azide

Sigma-Aldrich

S2002-5G

Bovine Serum Albumin

Sigma-Aldrich

A8806-5G

Fluoromount-G Slide Mounting Medium

VWR

100241-874

Sterile Saline (0.9% NaCl)

VWR

S5815

Pipetting Device

VWR

53498-001

5 mL Serological Pipet Tip

VWR

89130-896

Rapid-Flow Sterilization Filter Unit

VWR

28199-098

Analytical Balance

VWR

10159-998

Variable Volume Pipettors

VWR

75788-458

Universal Shelf Clip for 3 Pipettors

VWR

40000-272

Universal Shelf Clip for 3 Pipettors

VWR

40000-272

10 µL Pipette Tips (Sterile-Aerosol)

VWR

89174-520
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10 µL Pipette Tips (Sterile)

VWR

89368-970

100 µL Pipette Tips (Sterile-Aerosol)

VWR

10126-388

100 µL Pipette Tips (Sterile)

VWR

89140-162

1000 µL Pipette Tip (Sterile-Aerosol)

VWR

89174-530

1000 µL Pipette Tip (Sterile)

VWR

83007-380
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Immunohistochemistry Reagent Preparation

Step 1: Cold Acetone
1. Obtain 250 mL of acetone
2. Label with initials, date, and Acetone and store at -20° C

Step 2: Dilution Buffer for IHC: Universal Antibody Dilution Buffer
1. Purchase pre-made Universal Antibody Dilution Buffer
2. Store at room temperature
Universal Antibody Dilution Buffer Percentages
▪

1.0% BSA

▪

0.3% Tris HCl

▪

0.025% Triton-X

Step 3: Making PBS-t Washing Solution
1. Obtain a bottle that can hold at least 600 mL
2. Fill with 600 mL of MilliPore filtered water
3. Add three PBS tablets to the canister
4. Obtain Tween-20
5. Obtain 1.2 mL of Tween-20
6. Dispense 1.2 mL of Tween-20 into the canister of 600 mL PBS
7. Cap canister
8. Place magnetic stirrer in PBS-t
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9. Place PBS-t on magnetic plate at RT and 300 RPM until everything is dissolved
10. Label canister as PBS-t, mm/dd/yyyy, and initials

Step 4: Blocking Buffer for IHC (Goat Serum-Based)
1. Prepare biosafety hood
2. Obtain 50 mL centrifuge tube of sterile 1X PBS from 4°C
3. Obtain Goat Serum from -20°C
4. Place the Goat Serum in the 37.3°C water bath until liquid. Do not submerge the lid
5. Place the 1X PBS tube in the 37.3°C water bath for 15 minutes. Do not submerge the lid
6. Obtain Bovine Serum Albumin (BSA) from 4°C
7. Obtain Triton-X100 from 23°C
8. Obtain Tween-20 from 23°C
9. Obtain Sodium Azide from 23°C
10. Obtain one (1) empty 50 mL centrifuge tube
11. Label the 50 mL tube with date, initials, and Blocking Buffer: 4% Goat Serum, 0.5% BSA
12. Dispense 38.4 mL of 1X PBS into the empty 50 mL centrifuge tube
13. Obtain the analytical balance
14. Weigh 0.04 g (40 mg) of Sodium Azide (NaN3) and dispense Sodium Azide (NaN3) into 50
mL centrifuge tube
15. Weigh 0.2 g (200 mg) of BSA and dispense BSA into 50 mL centrifuge tube
16. Dispense 40 µL of Triton-X100 into the 50 mL centrifuge tube
17. Dispense 20 µL of Tween-20 into the 50 mL centrifuge tube
18. Vortex the solution for 2 minutes
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19. Prepare biosafety hood
Complete all of the following steps in the Biosafety hood in ENRC 2545
20. Spray the 50 mL centrifuge tube (with the blocking buffer) into the hood
21. Spray the Goat Serum into the hood
22. Obtain Rapid-Flow Sterilization Filter Unit and spray into the hood
23. Using a sterile 1000 µL pipette, dispense 1,600 µL of goat serum into the 50 mL centrifuge
tube
24. Mix well
25. Perform sterile vacuum filtration
26. Label the beaker with initials, date, and Blocking Buffer: 4% Goat Serum, 0.5% BSA
27. Aliquot into microcentrifuge tubes (1.6 mL) and label with B
28. Store at 4°C
29. Clean the hood
Blocking Solution Percentages (B)
▪

4% Goat Serum

▪

0.5% BSA

▪

0.1% NaN3

▪

0.1% Triton-X

▪

0.05% Tween-20
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CD68-CD80-CD206 Stain

Step 1: Preparing Blocking Solution
1. Obtain empty microcentrifuge tubes
2. Remove goat-based blocking solution from 4°C
3. Dispense 800 µL of goat-based blocking solution into microcentrifuge tubes (each tube ≈ 10
sections)
4. Label microcentrifuge tubes with B
5. Obtain necessary quantity of full microcentrifuge tubes per number of tissue sections (each
tube ≈ 10 sections)

Step 2: Preparing Slides for Staining
1. Remove slides from the -80°C freezer
2. Remove the slides you want to stain with anti-CD68/80/206
3. Label the slides appropriately with a pencil
4. Place the slides in a -20°C freezer. Start a timer
5. Bring the rest of the slides not being stained back to the -80°C freezer for permanent storage

Step 3: Preparation of Solution Boxes
1. Fill 2nd staining jar with ~90 mL of new room temperature PBS-t
2. Fill 3rd staining jar with ~90 mL of new room temperature PBS-t
3. Fill 4th staining jar with ~90 mL of new room temperature PBS-t.
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Step 4: Preparing Macrophage Antibody Cocktail (MAC)
1. Store the undiluted 0.5 mg/mL anti-CD68 solution (100 μg/200 μL total) in the 4° C fridge
2. Store the undiluted 0.5 mg/mL (lot-specific) anti-CD80 in the 4° C fridge
3. Store the undiluted 0.5 mg/mL anti-CD206 solution (100 μg/200 μL total) in the 4° C fridge
4. Determine number of tissue sections to be stained. One microcentrifuge tube can hold 10 trials
5. Multiply the number of tissue sections by 100 μL (x)
6. Multiply the number of tissue sections by 1.0 μL (a – M). (1:100)
7. Multiply the number of tissue sections by 5.0 μL (b – M1). (1:100)
8. Multiply the number of tissue sections by 0.8 μL (c – M2). (1:125)
9. Obtain microcentrifuge tubes (≤10 tissue sections = 1 tube, 11-20 tissue sections = 2 tubes,
etc.)
10. Label microcentrifuge tubes appropriately
11. Dispense x μL of the Universal Antibody Dilution Buffer into each microcentrifuge tube
12. Dispense a μL of undiluted anti-CD68 antibody into the microcentrifuge tube
13. Dispense b μL of undiluted anti-CD80 antibody into the microcentrifuge tube
14. Dispense c μL of undiluted anti-CD206 antibody into the microcentrifuge tube
15. Gently and sufficiently pipette up and down within the microcentrifuge tube to mix using 1000
µL pipette
16. Wrap microcentrifuge tubes with aluminum foil and store at 4°C for 4 hr. maximum

Step 5: Preparing Acetone
1. 17 minutes after step 2.4, remove acetone from the -20°C freezer
2. Fill 1st staining jar with ~90 mL of -20°C acetone
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3. Place Celsius thermometer in 1st staining jar with acetone

Step 6: Fixation with Acetone
1. When the acetone reaches -5°C to -3°C, remove slides from the -20°C freezer
2. Place the slides (up to 10) in the black slide holder
3. Place the slide holder in acetone (Jar 1) for 10 minutes
4. Remove from acetone (Jar 1)
5. Air dry and let drip for 5 seconds

Step 7: Wash with PBS-t (#1)
1. Place the slide holder in PBS-t (Jar 2) for 3 minutes
2. Remove slides from PBS-t (Jar 2)
3. Air dry and let drip for 5 seconds

Step 8: Adding Blocking Solution
1. Obtain one paper towel and split in half
2. Lay out one-half of the paper towel. Set the other half aside for now
3. Obtain the Eppendorf tube labeled B
4. Obtain the 10-100 μL micropipette and place an appropriate pipette tip on the end
5. Remove the slide holder from the PBS-t (Jar 2)
6. Air-dry and let drip for 5 seconds
7. Remove 3 slides from the slide holder and place on the paper towel half
8. Keep the other slides (if more than 3) in the slide holder and place back in the PBS-t
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9. Use the 2nd paper towel half and dry off the top of the slides at the areas around the tissue
10. Slowly drip ~80 μL (depends on tissue size) blocking solution onto each tissue section
11. Place the slides in the dark humidified chamber at room temperature
12. Repeat steps 5-11 for more than 3 slides. Do no more than 3 slides at a time
13. Leave slides in dark humidified chamber for 50 minutes
14. After 50 minutes, reapply ~80 µL blocking solution
15. Leave slides in dark humidified chamber for additional 40 minutes (90 minutes total)

Step 9: Adding Macrophage Antibody Cocktail
1. Obtain one paper towel and split in half
2. Lay out one of the paper towel halves. Set the other paper towel half aside for now
3. Obtain the microcentrifuge tube with the macrophage antibody cocktail
4. Remove 1 slide from the humidified chamber. Keep the others in the chamber for now
5. Drain off blocking solution onto the 1st paper towel half
6. Set slide down on the 1st paper towel half
7. Use the 2nd paper towel half and dry off the top of the slides at the areas around the tissue
8. Slowly drip ~90 μL of the macrophage antibody cocktail onto each tissue section
9. Place the slides in the dark humidified chamber at room temperature for 90 minutes
10. Immediately after step 10, finish the remaining slides. Do no more than 3 slides at a time to
avoid tissue drying

Step 10: Wash with PBS-t (#2)
1. Obtain one paper towel
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2. Remove one slide from the dark humidified chamber
3. Drain off the excess macrophage antibody cocktail onto the paper towel
4. Place the slide in the slide holder
5. Repeat steps 1-4 for up to 10 slides
6. Place the slide holder in PBS-t (Jar 3) for 3 minutes
7. Remove slides from PBS-t (Jar 3)
8. Air dry and let drip for 5 seconds
9. Dip the slide holder slowly in the PBS-t (Jar 3) 20 times. Let each “dip cycle” be 3 seconds
(60s total)
10. Gently “swirl” the black slide holder in the staining jar for 1 minute
11. Set the black slide holder stable in PBS-t (Jar 3) for 1 more minute

Step 11: Wash with PBS-t (#3)
1. Obtain one paper towel and set on the IHC table
2. Remove one slide from the dark humidified chamber
3. Drain off the excess macrophage antibody cocktail onto the paper towel.
4. Place the slide in the slide holder
5. Repeat steps 1-4 for up to 10 slides
6. Place the slide holder in PBS-t (Jar 4) for 3 minutes
7. Remove slides from PBS-t (Jar 4)
8. Air dry and let drip for 5 seconds
9. Dip the slide holder slowly in the PBS-t (Jar 4) 20 times. Let each “dip cycle” be 3 seconds
(60s total)
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10. Gently “swirl” the black slide holder in the staining jar for 1 minute
11. Set the black slide holder stable in PBS-t (Jar 4) for 1 more minute

Step 12: Mounting with Fluoromount G
1. Obtain two paper towels and split in half and split one of them in half
2. Obtain a 22x50 coverslip.
3. Obtain Fluoromount G
4. Obtain a 5 mL serological pipette and open
5. Lay out one of the paper towel halves. Set the other paper towel half aside for now
6. Remove the slide holder from the PBS-t (Jar 5)
7. Air-dry and let drip for 5 seconds
8. Remove 3 slides from the slide holder and place on the 1st paper towel half
9. Keep the other slides (if more than 3) in the slide holder and place back in the PBS-t
10. Use the 2nd paper towel half and dry off the top of the slides at the areas around the tissue
11. Place the 5 mL serological pipette tip barely in the Fluoromount G and then remove
12. Drip the Fluoromount G onto the tissue sections – only enough to cover the tissue, don’t use
too much
13. Gently place a coverslip on the slide
14. Use tweezers to gently press the coverslip onto the slide
15. Use tweezers to gently press out all air bubbles on the samples
16. Place the slides with coverslips on paper towel
17. Wipe off any excess mounting solution. Although if there is excess, you used too much
18. Repeat steps for additional slides. Do no more than 3 slides at a time
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Step 13: Attaching Coverslip to Slide with Nail Polish
1. Apply nail polish along the edges of the coverslip
2. Ensure the edges are completely covered
3. Set all completed slides in drying chamber to finish drying
4. After 1 hour, store completed slides permanently in slide rack
5. Store in the dark at room temperature
6. Clean everything appropriately
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Hematoxylin and Eosin (H&E) Staining

Step 1: Preparing Hematoxylin
1. Aliquot Hematoxylin into two (2) 50 mL centrifuge tubes (45 mL each)
2. Label 50 mL centrifuge tube lids with Hematoxylin, initials, and date
3. Cover the tubes with aluminum foil
4. Store at 23°C in the dark
5. Dispense 90 mL of hematoxylin into hematoxylin jar

Step 2: Preparing Eosin
1. Aliquot eosin into two (2) 50 mL centrifuge tubes (45 mL each)
2. Label 50 mL centrifuge tube lids with Eosin, initials, and date
3. Cover the tubes with aluminum foil
4. Store at 23°C in the dark
5. Dispense 90 mL of eosin into eosin jar

Step 3: Preparing Slides for Staining
1. Remove slides from the -80°C freezer
2. Remove the slides you want to stain with hematoxylin and eosin
3. Label the slides appropriately with a pencil
4. Place the petri dish in the -20°C freezer for 12 minutes. Start a timer
5. Bring the rest of the slides not being stained back to the -80°C freezer for permanent storage
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Step 4: Preparing Work Station
Fill all jars. All jars receive 80 mL of liquid
1. Obtain 600 mL beaker
2. Obtain 250 mL beaker
3. Jar #2: Hematoxylin
4. Jar #3: Bluing Solution
5. Jar #4: Distilled H2O
6. Jar #5: Eosin
7. Jar #6: EtOH (70%)
8. Jar #7: EtOH (95%)
9. Jar #8: EtOH (100%)
10. Jar #9: Xylene (must remain in the chemical fume hood at all times)
11. 12 minutes after step 3.4, remove acetone from the -20°C freezer
12. Fill 1st staining jar with ~90 mL of -20°C acetone
13. Place thermometer in acetone
14. Proceed to Step 6 once the acetone reaches 0°C (may need to stir to disperse heat)

Step 5: H&E Staining
Each “dip” cycle lasts one (4) seconds, such that the slides are submerged and then taken out of
solution
1. Obtain 6 µm sliced sections. There should be two sections per slide
2. Set slides in cold acetone (Jar #1) for 6 minutes
3. Gently shake off and air dry sections in your gloved hands for 5 seconds
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4. Set slides in hematoxylin (Jar #2) for 5 minutes. Drain well (i.e. let excess liquid drip off)
5. While waiting for step 5 to finish, fill a 600 mL beaker with cool tap water
6. After step 6 is complete, set slides in full 600 mL beaker
7. Run cool tap water in beaker for 7 minutes
8. Remove slides from bucket. Drain well
9. Dip slides in bluing solution (Jar #3) 15 times. Drain well
10. Dip slides in distilled H2O (Jar #4) 2 times. Drain well
11. Set slides in eosin (Jar #5) for 30 seconds. Drain well

Step 6: Ethanol Dehydration
Each “dip” cycle lasts one (4) seconds, such that the slides are submerged and then taken out of
solution
1. Dip slides in 70% EtOH (Jar #6) 15 times (slow 4-second dips). Drain well
2. Dip slides in 95% EtOH (Jar #7) 15 times (slow 4-second dips). Drain well
3. Dip slides in 100% EtOH (Jar #8) 15 times (slow 4-second dips). Drain well
4. Dip slides in 95% EtOH (Jar #7) 15 times (slow 4-second dips). Drain well
5. Dip slides in 100% EtOH (Jar #8) 15 times (slow 4-second dips). Drain well

Step 7: Xylene Clearing
1. Place black slide holder (with slides) in a 250 mL beaker
2. Transfer 250 mL beaker to the chemical fume hood near the xylene (Jar #9)
3. Set slides in xylene (Jar #9) for 4 minutes. Drain well
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Step 8: Coverslip Mounting
All steps must be completed in an approved chemical fume hood
1. Lay out paper towel in hood (avoid xylene/Cytoseal dripping on the fume hood surface)
2. Lay out three 22x50 mm coverslips on the Kimwipes
3. Remove slides from xylene. Drain well
4. Remove three slides from the black slide holder
5. Set the 3 slides on the Kimwipes near the coverslips so the rough/labeled side is facing up
6. Set slides back in xylene (Jar #9) temporarily (avoid slides drying out)
7. Place Cytoseal XYL drops (5-7 mm diameter) on the tissue sections
8. Set the 22x40 coverslips on the slides at a slow, controlled, 45° angle
9. Cytoseal XYL should spread without leaving air bubbles. Use tweezers to facilitate spread
10. Set the cover-slipped slides to the side to dry
11. Repeat steps 2-10 until all slides are finished
12. Wipe off Cytoseal container well so it doesn’t harden on the tip
13. Obtain nail polish
14. Apply nail polish along the edges of the coverslip
15. Ensure the edges are completely covered
16. Clean everything appropriately
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Tissue Analysis
Equipment and Materials
Item

Distributor

Item Number

Upright microscope

Nikon

89501-464

Monochrome digital camera

Nikon

Ds-Qi1Mc

PC-based camera control unit

Nikon

DS-U3

SOLA Light Engine® fluorescent lamp

Lumencor

SOLA SM 6-LCR-SB

DAPI filter set

Chroma

49000

FITC filter set

Chroma

SP101

Texas red filter set

Chroma

41004

Objective lens, 20X/0.50NA

Nikon

CFI Plan Fluor 20X

NIS-Elements F Ver4.60.00 for 64bit edition

Nikon

N/A
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Imaging Macrophage-Stained Slides

Step 1: Preparing Microscope
1. Close the shutter for the fluorescence lamp
2. Switch to the 20X objective
3. Turn on the Nikon camera, microscope, and Lumencor fluorescent lamp
4. Open up NIS Elements F 4.00.00
5. Select “Camera Ds-Qi iMc-U3….”
6. For the Ds-Qi1Mc Settings:
o

Change the mode to normal

o

Fast focus at “1280x1024 no binning”

o

Change the quality capture to “1280x1024 no binning”

o

Set the exposure to 100 ms (can be changed later)

o

Set the analog gain to 1.0x

o

Click commands: ROI, then select to use Current ROI

Step 2: Preparing Slide Position
1. Obtain the desired slide.
2. Set the slide on the microscope slide stage
3. Turn the filter wheel to the DAPI filter
4. Open the shutter for the fluorescence lamp
5. Adjust the translation stage so the light is hitting some part of the desired tissue section
6. Apply course focus
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7. Locate the top of the tissue either by the hair or a marking on the slide.
8. Apply fine focus to bring the M1 macrophages in-focus
9. Manually adjust the exposure (between 50-250 ms) to reduce background noise.

Step 3: Saving M1 Macrophage Images with DAPI Filter
1. Bring the M1 macrophages (DAPI filter) in-focus
2. Click “Capture” then “Save as”
3. Save as a TIFF file
4. Click “LIVE”

Step 4: Saving Non-Polarized Macrophage Images with FITC Filter
1. Do not move the slide or translation stage
2. Bring the non-polarized macrophages (FITC filter) in-focus
3. Click “Capture” then “Save as”
4. Save as a TIFF file
5. Click “LIVE”

Step 5: Saving M2 Macrophage Images with Texas Red
1. Do not move the slide or translation stage
2. Bring the M2 macrophages (Texas Red filter) in-focus
3. Click “Capture” then “Save as”
4. Save as a TIFF file
5. Click “LIVE”
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Counting Tumor-Associated Macrophages (TAMs)

Step 2: Run Code
1. Ensure there are at least three TIFF files in the appropriate folder: M1 (DAPI), non-polarized
(FITC), and M2 (Texas Red) images
Note: Ideally, there will be 12 images for each region-of-interest: 4 from each filter to account
for cells slightly out of the plane-of-focus in the 5 μm thick slide. This is how the code,
tamcount.m, is set up to run
2. Open and run tamcount.m
3. A black-and-white image will appear full screen
4. With the mouse, click the center of each mostly-in-focus TAM you see. It is very important to
click the center
a. TAMs will often appear as elongated “rings” or “C shapes” with a dark center and
white ring/C
5. Once you are done clicking the center of each TAM, hit the enter button
6. A new black-and-white image will appear full screen
7. Repeat these steps until you are finished with all 12 images
Notes:
1. Be sure the click the center of each TAM. Use your best judgement
2. There may be instances in which the same TAM appears in-focus across multiple images – it
is okay to select the same TAM twice (or more) in back-to-back images. The code will
automatically identify duplicates and only include one in the count
3. Something being in-focus or out-of-focus is slightly subjective. Use your best judgement
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Other General Procedures
Equipment and Materials
Item

Distributor

Item Number

Tabletop Animal Anesthesia System

VWR

89012-492

Mobile Cart for Anesthesia System

Amazon

OF-STC111-B

Gloves

VWR

89038-270

KimWipes

VWR

470224-038

Microcentrifuge Tubes

VWR

20170-038

Alcohol Swab

VWR

BD326859

80-Place Storage System

VWR

30128-276

Water Bath

VWR

89501-464

Warm Water Pump

Global Medical

TP700

Warm Water Pump Pad

Kent Scientific

TPZ-0510EA

Valved In-Line Hose Barb Coupling Body

Fresh Water Systems

42100

Non-Valved In-Line Hose Barb Coupling

Fresh Water Systems

40900

Analytical Balance

VWR

10159-998

Alcohol Swab

VWR

BD326859

28G U-100 BD Micro-Fine IV Syringe

VWR

BD329410

Compressed Air Cylinder, Size 200L

Airgas

AI USP200

Compressed O2 Cylinder, Size 200L

Airgas

OX USP200

Isothesia (Isoflurane) Solution

Henry Schein

1169567762

Regulator for Air Cylinder

Airgas

HCL3000762

Regulator for O2 Cylinder

Airgas

HCL3000714

480

O2 DISS Femaile Hex Nut – ¼” Hose Barb

Med. Support Products 0115

Activated Charcoal Filter VaporGuard

VWR

89012-608

Cylinder Bench Clamp

VWR

60142-003
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Anesthetizing Mice with Isoflurane

Step 1: Preparing Warm Water Pad.
1. Place the heated water pump in the hood
2. Place the heated water pad in the hood
3. Connect the water pad to the pump using the in-line hose barb coupling
4. Turn on the heated water pump
5. Place a large Kimwipe over the heated water pad (so the mouse won’t lay directly on the pad)
6. Wait 20 minutes until the water is warm

Step 2: Preparing the Anesthesia Machine
1. Place the carbon filter in the back of the hood, such that it is 2 inches from the back wall
2. Place the mouse-isoflurane chamber in the hood, such that it is 6 inches from the front of the
hood
3. Place the analytical scale in the hood
4. Place a large folded paper towel in the mouse-isoflurane chamber
5. Open both valves (tank valve and nosecone valve)
6. Tape the nosecone down on the edge of the warm water pump pad such that it is parallel to the
surface
7. Slightly loosen the top gray knob of the oxygen tank to start gas flow
8. Adjust the silver isoflurane tank knob between 1.5 and 4 (% isoflurane)
a. 1.5%: Immobility (no analgesia, use for giving shots)
b. 2%: Shallow Anesthesia

482

c. 3%: Medium Anesthesia
d. 4%: Deep Anesthesia (used for euthanasia)
e. 5%: Very Deep Anesthesia (not used in any of our studies)
9. Set the green isoflurane tank knob to 1.0 (1.0 L/min oxygen)

Step 3: Anesthetizing Mice
1. Obtain a mouse
2. Pick the mouse up by the tail
3. Place the mouse in the mouse-isoflurane chamber
4. Secure the lid by locking the black hinge
5. When mouse passes out, remove the mouse by the tail
6. Place the mouse on the nosecone such that its eyes are at the level of the cone bottom
7. Put eye drop gel in the mouse’s eyes
8. Ensure the mouse is on the nose cone for 30 seconds
9. Remove mouse from nosecone and quickly weigh the mouse
10. Put mouse back on nosecone for 20 seconds
11. Perform desired task
12. Remove mouse from nosecone
13. Place mouse in hands and wait until it wakes up (time depends on anesthesia level)
14. Place mouse back in cage
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Intraperitoneal Injection (I.P.) of Mice

Step 1: Preparation for Injection
1. Set up the isoflurane tank and chamber
2. With 28G syringe, draw up required volume to nearest 10 μL
3. Get rid of all air bubbles
4. Set the 28G needle aside
5. Remove mouse from cage
6. Put mouse in isoflurane chamber until sedated
7. Remove mouse from isoflurane chamber and weigh mouse
8. Remove mouse from scale and place under nosecone in biosafety cabinet

Step 2: Intraperitoneal (IP) Injection
1. Obtain 28G needle from the Kimwipe
2. Turn the needle so that the bevel points up and the numbers on the syringe barrel can be read
3. Bring the needle to a 35° ± 5° angle from the abdomen
4. Place the needle 2 mm off the abdominal midline (you can see where the hair parts)
5. Place the needle on the same line as the visible knee bones
6. Push needle in until ~1/2 of the needle length is inserted
7. Depress the plunger until the solution has been fully administered (2-second plunge)
8. Do not allow the needle to move around inside the abdomen
9. Pull the needle straight out and place the syringe/needle into a Sharps container without
recapping
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10. Leave mouse in hand or on warm water pad until awake
11. Place the mouse back in the cage

Potential Complications
Note: These complications were not experienced throughout the study. IACUC should be
contacted immediately if these complications are experienced
1. Aspiration of green material: bowel has been punctured
2. Aspiration of yellow liquid: bladder has been punctured
3. Aspiration of blood: abdominal blood vessel has been punctured
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Humane Endpoint Criteria

Mice will be euthanized based their appropriate endpoint per study, or on humane endpoint criteria,
whichever comes first:

Humane endpoint criteria are as follows.
1. Tumor Volume = 1500 mm3
2. Maximum Tumor Diameter = 20 mm (or 2 cm)
3. Body Condition Score < 2
4. Weight Loss ≥ 20% (~3-4 g)
5. Chronic Pain or Distress
a. Changes in Health and Well-Being (monitored by IACUC and Investigator)
b. Impaired mobility (the inability to reach food and water)
c. Inability to remain upright
d. Interference with a vital physiological function:
i. Respiration, mastication, swallowing, urination, defecation, or locomotion
e. Location of the tumor causing interference with movement
f. Hunched abnormal posture for more than 48 hours
g. Labored breathing and cyanosis [bluish pinnae (ears) or feet or mucous
membranes]
h. Clinical dehydration and/or prolonged decreased food intake
i. Muscle atrophy and signs of lethargy and lack of physical activity
j. Chronic diarrhea or constipation for more than 48 hours
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k. Hematological or biochemical values that indicate organ failure
l. Severe anemia [pale pinnae (ears) or feet or mucous membranes]
m. Bloodstained or mucopurulent discharge from any orifice
n. Lack of grooming behavior; rough/unkempt hair coat for more than 48 hours
o. Enlarged lymph nodes or spleen
p. Significant abdominal distension
q. Cranial deformity/neurological signs
r. Exophthalmos (bulging eye)
s. Ulceration or necrosis of tumor
t. Restlessness/inability to get comfortable
u. Unconsciousness with no response to external stimuli
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Institutional Review Board (IRB) Approval
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Institutional Animal Care and Use Committee (IACUC) Approval
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MATLAB Code
SiliconePhantom.m
%% Gage J. Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% Translational Biophotonics and Imaging Laboratory
% February 9, 2017
clear all; close all; clc;

% This MATLAB script will determine the following user-specified variables
% in order to construct a PDMS-based optical tissue phantom using
% titanium dioxide as the scattering agent.
%
%
%
%

1.
2.
3.
4.

Application wavelength
Desired Reduced Scattering Coefficient
Desired thickness of thin layer
Weight of PDMS elastomer base measured

[nm]
[1/cm]
[um]
[g]

% Then, this MATLAB script will output the following parameters
%
%
%
base]
%
%

1. Volume of PDMS elastomer base
2. Volume of Curing Agent
3. Concentration of TiO2

[uL]
[uL]
[g/g PDMS elastomer

4. Amount of TiO2
5. Spin Speed in Spincoater

[g]
[rpm]

%% Determine the 5 user-specified variables
fprintf('\nSilicone Phantom Design Module\n');
fprintf('by Gage J. Greening\n')
fprintf('Department of Biomedical Engineering, University of Arkansas\n');
fprintf('From the Journal of Biomedical Optics, Manuscript #115002-2, Nov.
2014\n\n');
fprintf('Substrate Material: Poly(dimethylsiloxane) (PDMS)\n');
fprintf('Scattering Agent: Titanium Dioxide\n');
fprintf('Absorbing Agent: Red Food Dye\n');
fprintf('Acceptable Wavelengths: 591, 621, 659, 691, 731, and 851 nm\n\n');
fprintf('Input Parameters\n');
wl_s
= input('Reference Wavelength for Scattering [nm]?:
Scattering wavelength
wl_a
= input('Reference Wavelength for Absorption [nm]?:
Absorption wavelength
us
= input('Desired Reduced Scattering Coefficient [1/cm]?:
Desired Reduced Scattering Coefficient
ua
= input('Desired Absorption Coefficient [1/cm]?:
Desired Absorption Coefficient
thick = input('Desired Layer Thickness [um]?:
Desired thickness of thin layer
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');

% 1.

');

% 2.

');

% 3.

');

% 4.

');

% 5.

base
= input('Weight of PDMS Elastomer Base [g]?:
Weight of PDMS elastomer base measured

');

% 6.

%% 1. Concentration of Scattering Agent
if wl_s == 591
scat_conc = (0.0003797*us) + (-0.0001878);
elseif wl_s == 621
scat_conc = (0.0004367*us) + (-0.000174);
elseif wl_s == 659
scat_conc = (0.0004904*us) + (-0.0001579);
elseif wl_s == 691
scat_conc = (0.0005377*us) + (-0.00009323);
elseif wl_s == 731
scat_conc = (0.0005852*us) + (-0.00007569);
elseif wl_s == 851
scat_conc = (0.0007266*us) + (-0.00007963);
else
disp('Tested wavelength not specified: choose from 591, 631, 659, 691,
731, or 851 nm');
end
scat_conc_new = scat_conc*1000;
%% Volume of PDMS elastomer base
vol_base = (base) * (1/1030) * (1/1000) * (100^3) * (1/1000) * (1000000/1);
%% Amount of Curing Agent
mass_ca = (base/10);
% The average experimental density of curing agent is 889 kg/m^3
vol_ca = (mass_ca)*(1/889)*(1/1000)*(1000/1)*(1000000/1);
%% Amount of Scattering Agent
scat_amt = scat_conc*(base);
%% Amount of Absorpting Agent
% Read in the Excel file of the absorption coefficient of the stock solution
mua = xlsread('abs.csv');
row = wl_a - 449;
if ua < mua(row,2)
abs_conc = (ua/(mua(row,2))) * 0.417;
else
abs_conc = (ua/(mua(row,3))) * 0.782;
end
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abs_amt = abs_conc * (base);
%% Spin Speed in Spincoater
speed = ((115900)*(thick^-0.9985))-15.09;
%% Display all the values necessary to complete construction of the PDMSbased tissue phantom
fprintf('\nOutput Parameters\n');
fprintf('Volume of PDMS Elastomer Base:\t\t\t\t\t %.1f uL\n',vol_base);
fprintf('Volume of Curing Agent:\t\t\t\t\t\t\t %.1f uL\n',vol_ca);
fprintf('Concentration of Scattering Agent:\t\t\t\t %.4f
mg/g\n',scat_conc_new);
fprintf('Amount of Scattering Agent:\t\t\t\t\t\t %.4f g\n',scat_amt);
fprintf('Concentration of Absorbing Agent:\t\t\t\t %.4f uL/g\n',abs_conc);
fprintf('Amount of Absorbing Agent:\t\t\t\t\t\t %.2f uL\n',abs_amt);
fprintf('Spin Speed:\t\t\t\t\t\t\t\t\t\t %.0f rpm\n\n',speed);

lutfunc1.m
%% Gage J. Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% March 19, 2016
% lutfunc1.m
function [lambda, Qsca, Qback, g] = lutfunc1(l_min, l_max, dl, r,
sphere_type)
%%%%%%%%%%%%%%%%%%%%%%%%% mie_lambda %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% This function calculates scattering crosssections, Qsca, and anisotropy
% parameter, g, vs. wavelength.
%
% Inputs:
%
- l_min:
minimum wavelength [um]
%
- l_max:
maximum wavelength [um]
%
- dl:
wavelength step [um]
%
- r:
radius of particle [um]
%
- bead_type:
type of sphere (bead (1) or tissue (2))
%
% Outputs:
%
- lambda:
wavelength [nm]
%
- Qsca:
Total scattering efficiency [1/um^3]
%
- Qback:
Backscattering efficiency [1/um^3]
%
- g:
Anisotropy parameter
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

for lambda = l_min:dl:l_max,
switch lower(sphere_type)
case {'tissue'}
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n_sph = 1.424;
n_med = 1.36;
m = n_sph/n_med;
case {'beads'}
n_sph = 1.5663;
%A=1.31279;
%B=0.015763;
%C=0.004382;
%D=0.0011455;
%n_med=(A+B./lambda-C./lambda.^2+D./lambda.^3);
n_med = 1.33;
%m=1.59/n_med;
m=(n_sph + .00785/(lambda.^2) + .000334/(lambda.^4))/n_med;
%m=(n_sph + .010002/(lambda^2))/n_med;
%m=(1.5663 + (0.00785/lambda^2) - (0.000334/lambda^4))/n_med;
end
k=2*pi*n_med/lambda;
x=r*k;
F = lutfunc2(m,x);
% returns [Re(m) Im(m) x Qext Qsca Qabs Qback g
Qratio]
Qsca(round((lambda-l_min)/dl+1))
= F(5);
g(round((lambda-l_min)/dl+1))
= F(8);
Qback(round((lambda-l_min)/dl+1)) = F(7);
end
lambda = l_min:dl:l_max;

lutfunc2.m
%% Gage J. Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% March 19, 2016
% lutfunc2.m
function result = lutfunc2(m, x)
% Computation of Mie Efficiencies for given
% complex refractive-index ratio m=m'+im"
% and size parameter x=k0*a, where k0= wave number in ambient
% medium, a=sphere radius, using complex Mie Coefficients
% an and bn for n=1 to nmax,
% s. Bohren and Huffman (1983) BEWI:TDD122, p. 103,119-122,477.
% Result: m', m", x, efficiencies for extinction (qext),
% scattering (qsca), absorption (qabs), backscattering (qb),
% asymmetry parameter (asy=<costeta>) and (qratio=qb/qsca).
% Uses the function "Mie_abcd" for an and bn, for n=1 to nmax.
% C. Mätzler, May 2002.
if x==0
% To avoid a singularity at x=0
result=[real(m) imag(m) 0 0 0 0 0 0 1.5];
elseif x>0
% This is the normal situation
nmax=round(2+x+4*x^(1/3));
n1=nmax-1;
n=(1:nmax);cn=2*n+1; c1n=n.*(n+2)./(n+1); c2n=cn./n./(n+1);
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x2=x*x;
f=lutfunc3(m,x);
anp=(real(f(1,:))); anpp=(imag(f(1,:)));
bnp=(real(f(2,:))); bnpp=(imag(f(2,:)));
g1(1:4,nmax)=[0; 0; 0; 0]; % displaced numbers used for
g1(1,1:n1)=anp(2:nmax);
% asymmetry parameter, p. 120
g1(2,1:n1)=anpp(2:nmax);
g1(3,1:n1)=bnp(2:nmax);
g1(4,1:n1)=bnpp(2:nmax);
dn=cn.*(anp+bnp);
q=sum(dn);
qext=2*q/x2;
en=cn.*(anp.*anp+anpp.*anpp+bnp.*bnp+bnpp.*bnpp);
q=sum(en);
qsca=2*q/x2;
qabs=qext-qsca;
fn=(f(1,:)-f(2,:)).*cn;
gn=(-1).^n;
f(3,:)=fn.*gn;
q=sum(f(3,:));
qb=q*q'/x2;
asy1=c1n.*(anp.*g1(1,:)+anpp.*g1(2,:)+bnp.*g1(3,:)+bnpp.*g1(4,:));
asy2=c2n.*(anp.*bnp+anpp.*bnpp);
asy=4/x2*sum(asy1+asy2)/qsca;
qratio=qb/qsca;
result=[real(m) imag(m) x qext qsca qabs qb asy qratio];
end;

lutfunc3.m
%% Gage J. Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% March 19, 2016
% lutfunc3.m
function result = lutfunc3(m, x)
%
%
%
%
%
%

Computes a matrix of Mie coefficients, a_n, b_n, c_n, d_n,
of orders n=1 to nmax, complex refractive index m=m'+im",
and size parameter x=k0*a, where k0= wave number
in the ambient medium, a=sphere radius;
p. 100, 477 in Bohren and Huffman (1983) BEWI:TDD122
C. Mätzler, June 2002

nmax=round(2+x+4*x^(1/3));
n=(1:nmax); nu = (n+0.5); z=m.*x; m2=m.*m;
sqx= sqrt(0.5*pi./x); sqz= sqrt(0.5*pi./z);
bx = besselj(nu, x).*sqx;
bz = besselj(nu, z).*sqz;
yx = bessely(nu, x).*sqx;
hx = bx+i*yx;
b1x=[sin(x)/x, bx(1:nmax-1)];
b1z=[sin(z)/z, bz(1:nmax-1)];
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y1x=[-cos(x)/x, yx(1:nmax-1)];
h1x= b1x+i*y1x;
ax = x.*b1x-n.*bx;
az = z.*b1z-n.*bz;
ahx= x.*h1x-n.*hx;
an = (m2.*bz.*ax-bx.*az)./(m2.*bz.*ahx-hx.*az);
bn = (bz.*ax-bx.*az)./(bz.*ahx-hx.*az);
cn = (bx.*ahx-hx.*ax)./(bz.*ahx-hx.*az);
dn = m.*(bx.*ahx-hx.*ax)./(m2.*bz.*ahx-hx.*az);
result=[an; bn; cn; dn];

step1_createPhantoms
%% Gage J. Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% May 3, 2016
% step1_createPhantoms.m
%
%
%
%
%

This program provides the amount of beads to generate each phantom and
the amount of ink needed at each step. Although this program generates
exact numbers for the volume to be added, it might not be always possible
to pipet out the exact numbers. In such cases, correct x1 and volumeDist
to represent actual volumes added.

clear all; close all; clc;
% The total volume of solution
tot_vol = input('Phantom Volume (mL): ');
% The reduced scattering coefficients (us') of the phantoms at 630 nm
redscatCoef = [3.43, 4.94, 7.14, 10.31, 14.88, 21.48] / 10;
% Diameter of the beads (um)
actBeadSize = 0.99;
% Standard deviation of the bead size (um)
stdev = 0.03;
% Percent solid of beads
perSol = 2.6;
%% Use the function 'lutfunc1.m' to determine scattering efficiency
% Input parameters for the mie2 function (also described in mie2.m)
minwave = 0.30;
% Minimum wavelength (um)
maxwave = 0.80;
% Maximum wavelength (um)
wavestep = 0.001;
% Wavelength step (um)
radius = actBeadSize/2; % Radius of beads (um)
% Output parameters for the mie2 function (also described in mie2.m)
% lambda:
Wavelength
% Qsca:
Total scattering efficiency [1/um^3]
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% Qback:
% g:

Backscattering efficiency [1/um^3]
Anisotropy coefficient

[lambda, Qsca, Qback, g] =
lutfunc1(minwave,maxwave,wavestep,radius,'beads');
% Convert lambda (um) to lambda_nm (nm) for plotting purposes
lambda_nm = lambda.*1000;
% Calculation of the scattering cross section (Tsca = scattering cross
section)
Tsca = Qsca.*pi*(radius)^2;
% [1/um^3] * [um^2] = [um^-1] ????
% Calculation of the reduced scattering cross section
redScat = Tsca.*(1-g);
%% Absorption Coefficient
% The
%
%
%
%
%

stock solution is made with the following:
2,000 uL yellow food dye
800 uL red food dye
400 uL blue food dye
16,800 uL deionized water
20,000 uL total volume

% Read in the Excel file of the absorption coefficient of the stock solution
mua_init = xlsread('Dye Combination Stock - Dilution of 10x 05192017.csv');
% Absorption coefficient of the stock solution (without 1st column of
% wavelength)
mua_init_c1 = mua_init(:,1);
mua_init_c2 = mua_init(:,2)*10;
% 10x stock solution
for i = 1:501
% absorbance data btw 300-800 nm
if mua_init_c2(i) < 0
mua_init_c2(i) = 0.001;
end
end
% Desired maxiumum absorption coefficient of calibration phantoms
max_mua = input('Maximum Absorption Coefficient (1/cm): ');
wavelength_min = input('Minimum Wavelength (nm): ');
wavelength_min_index = (wavelength_min - (mua_init_c1(1) - 1));
wavelength_max = input('Maximum Wavelength (nm): ');
wavelength_max_index = (wavelength_max - (mua_init_c1(1) - 1));
% The scale of the desired max ua and the ua of the stock solution
scale = max_mua /
max(mua_init_c2(wavelength_min_index:wavelength_max_index));
% The absorption coefficient of the calibration phantoms
mua = scale * mua_init_c2;
% The volume of the stock solution needed to yield the desired ua
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mLAbsorber = zeros(1,2*length(redscatCoef));
mLAbsorber(length(redscatCoef)+1:2*length(redscatCoef)) = (tot_vol)*scale;
%% Create the phantoms
% Density [1/um^3]
density = redscatCoef(1,:)./redScat(331)/1000;
% #part per ml of bead solution
partBeads = tot_vol.*density.*10^12;
%Total number of beads in Solution
totBeads = (6.*(perSol./100).*10^12)./(1.05*pi.*actBeadSize.^3);
%mL of beads to use to create phantom
mLBeads = partBeads./totBeads;
mLBeads = horzcat(mLBeads,mLBeads);
%mL of water used to create phantom
mLWater(1:length(redscatCoef)) = tot_vol - (mLBeads(1:length(redscatCoef)) +
mLAbsorber(1:length(redscatCoef)));
mLWater(length(redscatCoef)+1:2*length(redscatCoef)) = tot_vol (mLBeads(length(redscatCoef)+1:2*length(redscatCoef)) +
mLAbsorber(length(redscatCoef)+1:2*length(redscatCoef)));
%volumeDist is a table with mLs beads in the first column and the
%corresponding mLs of water in the second.
volumeDist = [mLBeads' mLAbsorber' mLWater' mLBeads'+mLWater'+mLAbsorber'];
% Volume distribution in uL (microliters)
volumeDist = round(volumeDist*1000);
%% Reduced Scattering Coefficient
% If less than 6 phantoms are needed to span the desired range of reduced
% scattering coefficients, comment out the extra phantoms.
redScatCS = redScat;

% Reduced scattering cross section [cm^2]

% Reduced scattering coefficients for all phantoms put in terms of cm
musp1 = redScatCS.*(density(1,1))*10000;
% Reduced scattering cross
section * volume density = musp for phantom 1 [cm^-1]
musp2 = redScatCS.*(density(1,2))*10000;
% Reduced scattering cross
section * volume density = musp for phantom 2 [cm^-1]
musp3 = redScatCS.*(density(1,3))*10000;
% Reduced scattering cross
section * volume density = musp for phantom 3 [cm^-1]
musp4 = redScatCS.*(density(1,4))*10000;
% Reduced scattering cross
section * volume density = musp for phantom 4 [cm^-1]
musp5 = redScatCS.*(density(1,5))*10000;
% Reduced scattering cross
section * volume density = musp for phantom 5 [cm^-1]
musp6 = redScatCS.*(density(1,6))*10000;
% Reduced scattering cross
section * volume density = musp for phantom 6 [cm^-1]
% Currently, the resolution of the reduced scattering coefficients is 1.
% Interpolate these values such that they correlate with the resoultion of
% the spectrometer (~0.35).
load('Wavelength.mat');
musp1 = interp1(lambda_nm,musp1,wavelength_501);
musp1 = musp1(wavelength_min_index:wavelength_max_index);
musp2 = interp1(lambda_nm,musp2,wavelength_501);
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musp2
musp3
musp3
musp4
musp4
musp5
musp5
musp6
musp6

=
=
=
=
=
=
=
=
=

musp2(wavelength_min_index:wavelength_max_index);
interp1(lambda_nm,musp3,wavelength_501);
musp3(wavelength_min_index:wavelength_max_index);
interp1(lambda_nm,musp4,wavelength_501);
musp4(wavelength_min_index:wavelength_max_index);
interp1(lambda_nm,musp5,wavelength_501);
musp5(wavelength_min_index:wavelength_max_index);
interp1(lambda_nm,musp6,wavelength_501);
musp6(wavelength_min_index:wavelength_max_index);

muspmin =
[min(musp1);min(musp2);min(musp3);min(musp4);min(musp5);min(musp6)];
muspmax =
[max(musp1);max(musp2);max(musp3);max(musp4);max(musp5);max(musp6)];
% Plot the reduced scattering and absorption coefficients
figure(1)
subplot(1,2,1);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp1,'Linewi
dth',2);
hold on;
subplot(1,2,1);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp2,'Linewi
dth',2);
hold on;
subplot(1,2,1);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp3,'Linewi
dth',2);
hold on;
subplot(1,2,1);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp4,'Linewi
dth',2);
hold on;
subplot(1,2,1);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp5,'Linewi
dth',2);
hold on;
subplot(1,2,1);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp6,'Linewi
dth',2);
[yaxis]=get(get(gca,'children'),'ydata');
legend('Phantom 1,7','Phantom 2,8','Phantom 3,9','Phantom 4,10','Phantom
5,11','Phantom 6,12');
title('\mu_s^'' vs. wavelength for LUT calibration phantoms');
xlabel('Wavelength (nm)');
ylabel('\mu_s^'' (cm^-^1)');
axis square; axis([wavelength_min wavelength_max 0 max(musp6)*1.1]);
mua_zeros = zeros(length(wavelength_501),1);
mua_zeros(:) = 0.001;
subplot(1,2,2);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),mua_zeros(wav
elength_min_index:wavelength_max_index),'Linewidth',2);
hold on;
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subplot(1,2,2);
plot(wavelength_501(wavelength_min_index:wavelength_max_index),mua(wavelengt
h_min_index:wavelength_max_index),'Linewidth',2);
legend('Phantom 1-6','Phantom 7-12');
title('\mu_a vs. wavelength for LUT calibration phantoms');
xlabel('Wavelength (nm)');
ylabel('\mu_a (cm^-^1)');
axis square; axis([wavelength_min wavelength_max 0 max(mua)*1.1]);
% Write data to table
table = {'Phantom', 'Polystyrene Beads (uL)', 'Absorber (uL)', 'Deionized
Water (uL)', 'Total Volume (mL)', 'Min. us'' (cm-1)', 'Max. us'' (cm-1)',
'Min. ua (cm-1)', 'Max. ua (cm-1)'};
for i = 2:13
table{i,1}
table{i,2}
table{i,3}
table{i,4}
table{i,5}
end

=
=
=
=
=

i-1;
volumeDist(i-1,1);
volumeDist(i-1,2);
volumeDist(i-1,3);
volumeDist(i-1,1)+volumeDist(i-1,2)+volumeDist(i-1,3);

for i = 2:7
table{i,6}
table{i,7}
table{i,8}
table{i,9}
end

=
=
=
=

muspmin(i-1,1);
muspmax(i-1,1);
0;
0;

for i = 8:13
table{i,6}
table{i,7}
table{i,8}
table{i,9}
end

=
=
=
=

muspmin(i-7,1);
muspmax(i-7,1);
0;
max_mua;

table_double = cell2mat(table(2:13,:));
total_beads = sum(table_double(:,2));
total_dye =sum(table_double(:,3));
total_water = sum(table_double(:,4));
total_volume = sum(table_double(:,5));
table{16,1}
table{16,2}
table{16,3}
table{16,4}
table{16,5}

=
=
=
=
=

'Total (mL)';
total_beads/1000;
total_dye/1000;
total_water/1000;
total_volume/1000;

filename = 'PhantomSpecifications.xlsx';
xlswrite(filename,table,'PhantomSpecifications','A1');
% Save an Excel file with absorption coefficients
table2(:,1) = wavelength_501(wavelength_min_index:wavelength_max_index);
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table2(:,2) = mua_zeros(wavelength_min_index:wavelength_max_index);
filename = 'PhantomAbsCoeffZeros.xlsx';
xlswrite(filename,table2,'PhantomAbsCoeffZeros','A1')
table3(:,1) = wavelength_501(wavelength_min_index:wavelength_max_index);
table3(:,2) = mua(wavelength_min_index:wavelength_max_index);
filename = 'PhantomAbsCoeff.xlsx';
xlswrite(filename,table3,'PhantomAbsCoeff','A1')
% Save variables
mua_P01toP06 = mua_zeros';
mua_P07toP12 = mua';
save('temp.mat','volumeDist','musp1','musp2','musp3','musp4','musp5','musp6'
,'mua_P01toP06','mua_P07toP12','table','wavelength_min','wavelength_max');
clear all;
load('Wavelength.mat');
load('temp.mat');
%
save('temp.mat','musp1','musp2','musp3','musp4','musp5','musp6','mua_P08toP1
4','mua_P01toP07','sample','wavelength_301','wavelength_857');

step2_createLUT.m
%% Gage J. Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% March 6, 2017
% step2_createLUT.m
clc; close all;
%% Load in the calibration curve taken with the reflectance standard
fprintf('Load Calibration Curve:\n\n');
filename = uigetfile;
C = csvread(filename);
wavelength_long = C(1:2228,1);
% cut off at 800 nm
calibration_curve = C(1:2228,2);
% cut off at 800 nm
%% Load in the dark noise curve taken when all lights are off
fprintf('Load Darknoise Curve:\n\n');
filename = uigetfile;
D = csvread(filename);
darknoise_curve = D(1:2228,2);
% cut off at 800 nm
%% Interpolate phantom generation data to match wavelengths of spectrometer
% Set the standard 1 nm resolution wavelength range
wavelength_range = wavelength_min:1:wavelength_max;
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% Create interpolated musp values based on spectrometer resolution
musp_interp(:,1) = interp1(wavelength_range,musp1,wavelength_long);
musp_interp(:,2) = interp1(wavelength_range,musp2,wavelength_long);
musp_interp(:,3) = interp1(wavelength_range,musp3,wavelength_long);
musp_interp(:,4) = interp1(wavelength_range,musp4,wavelength_long);
musp_interp(:,5) = interp1(wavelength_range,musp5,wavelength_long);
musp_interp(:,6) = interp1(wavelength_range,musp6,wavelength_long);
musp_interp(:,7) = interp1(wavelength_range,musp7,wavelength_long);
% Create interpolated mua values based on spectrometer resolution
mua_ranges = input('Ranges of Absorption Coefficients: ');
fprintf('Load Phantoms Absorption Curves, starting with zeros:\n\n');
fprintf('\n');
for i = 1:mua_ranges
filename = uigetfile;
A = csvread(filename);
abs_coeff(:,i) = A(:,2);
end
mua_interp(:,1) = interp1(wavelength_range,abs_coeff(:,1),wavelength_long);
mua_interp(:,2) = interp1(wavelength_range,abs_coeff(:,2),wavelength_long);
mua_interp(:,3) = interp1(wavelength_range,abs_coeff(:,3),wavelength_long);
phantom_number = input('Number of Phantoms: ');
fprintf('Load Phantom Raw Reflectance Data:\n\n');
for i = 1:phantom_number
filename = uigetfile;
P = csvread(filename);
phantom(:,i) = P(1:2228,2);
end
phantom_calibrated = zeros(length(calibration_curve),phantom_number);
for i = 1:phantom_number
phantom_calibrated(:,i) = (phantom(:,i) - darknoise_curve(:,1)) ./
((calibration_curve(:,1) - darknoise_curve(:,1)) * 5);
end
%% Create mesh
% Reduced Scattering Coefficient
musp(:,1:7) = musp_interp;
musp(:,8:14) = musp_interp;
musp(:,15:21) = musp_interp;
musp(isnan(musp)) = 0;
% Absorption Coefficient
for i = 1:7
mua(:,i) = mua_interp(:,1);
mua(:,i+7) = mua_interp(:,3);
mua(:,i+14) = mua_interp(:,2);
end
mua(isnan(mua)) = 0;
% Calibrated Reflectance
ref(:,:) = phantom_calibrated(:,:);
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% Convert matrices to vectors
vector_musp = musp(:);
vector_mua = mua(:);
vector_ref = ref(:);
% Create LResolution for Lookup Table
musp_min = min(vector_musp(vector_musp>0));
musp_max = max(vector_musp);
mua_min = min(vector_mua(vector_mua>0));
mua_max = max(vector_mua);
ref_min = min(vector_ref(vector_ref>0));
ref_max = max(vector_ref(vector_ref<1));
res_musp = linspace(musp_min,musp_max,200);
res_mua = linspace(mua_min,mua_max,200);
% Create Lookup Table
lut = griddata(vector_musp,vector_mua,vector_ref,res_musp',res_mua);
surf(res_musp',res_mua,lut); hold on;
scatter3(vector_musp,vector_mua,vector_ref,'k');
axis([5, 40, -1, 10, 0, 0.3]);
xlabel('\mu_s^'' (cm^-^1)');
ylabel('\mu_a (cm^-^1)');
zlabel('Reflectance (A.U.)');
title('Lookup Table');
box on; grid on; axis square; colormap(jet); colorbar;
% Save necessary variables
save('specLookupTable.mat','res_musp','res_mua','lut');

calcOP_hb_3000_hb.m
function R = calcOP_hb_3000_hb(InitialValues,lambda,Hb,HbO2,mel)
% The goal of this function is to determine R
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% lambda in um
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
A
B
C
cHb
alpha
S

=
=
=
=
=
=

InitialValues(1);
InitialValues(2);
InitialValues(3);
InitialValues(4);
InitialValues(5);
InitialValues(6);

if cHb<0
cHb = 0;
end
% Reduced Scattering Coefficient
mu_sp = (A*10).*(lambda./0.730).^(-B);
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% Absorption Coefficient
mu_a1 = (2.303*(150).*(alpha.*HbO2(:,2) + (1-alpha).*Hb(:,2)));
mu_a = 0.01*cHb.*mu_a1.*(1 - exp(-S.*mu_a1))./(S.*mu_a1);
% mu_a = mu_a + (2.303*0.1.*C*mel(:,2));
% Loading the appropriate LUT
load('calcOP.mat');
R = interp2(musp3000',mua3000,lut3000,mu_sp,mu_a);
end

calcOP_hb_3000_oxy.m
function R = calcOP_hb_3000_oxy(InitialValues,lambda,Hb,HbO2,mel)
% The goal of this function is to determine R
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% lambda in um
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
A
B
C
cHb
alpha
S

=
=
=
=
=
=

InitialValues(1);
InitialValues(2);
InitialValues(3);
InitialValues(4);
InitialValues(5);
InitialValues(6);

if cHb<0
cHb = 0;
end
% Reduced Scattering Coefficient
mu_sp = (A*10).*(lambda./0.590).^(-B);
% Absorption Coefficient
mu_a1 = (2.303*(150).*(alpha.*HbO2(:,2) + (1-alpha).*Hb(:,2)));
mu_a = 0.01*cHb.*mu_a1.*(1 - exp(-S.*mu_a1))./(S.*mu_a1);
% mu_a = mu_a + (2.303*0.1.*C*mel(:,2));
% Loading the appropriate LUT
load('calcOP.mat');
R = interp2(musp3000',mua3000,lut3000,mu_sp,mu_a);
end

chisqOP_hb_3000_hb.m
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%This function calculates the chi-squared error between the
%OP model and measured data (Rmeas)
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
function chisq = chisqOP_hb_3000_hb(InitialValues,Rmeas,lambda,Hb,HbO2,mel)
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R = calcOP_hb_3000_hb(InitialValues,lambda,Hb,HbO2,mel);
chisq = sum(((R - Rmeas)./R).^2);

chisqOP_hb_3000_oxy.m
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%This function calculates the chi-squared error between the
%OP model and measured data (Rmeas)
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
function chisq = chisqOP_hb_3000_oxy(InitialValues,Rmeas,lambda,Hb,HbO2,mel)
R = calcOP_hb_3000_oxy(InitialValues,lambda,Hb,HbO2,mel);
chisq = sum(((R - Rmeas)./R).^2);

PostProcess3mm.m
%% Gage Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% June 30, 2016

%% Loading in Calibration and Dark Noise Data
clear all; close all; clc;
% Load in the calibration curve
[filename, ~] = uigetfile('*.csv', 'Select the calibration dataset');
cal = load(filename);
cal = cal;
% Load in the dark noise curve
dn = csvread('3mm_75ms_DARKNOISE.csv');
data(:,1) = dn(:,1);

%% Initialize variables
samples = input('Number of Spectra: ' );
% samples = input('Number of Spectroscopy Measurements: ');
name = ['3-1';'3-2';'3-3';'3-4';'3-5';'3-6';'3-7';'3-8';'3-9'];
name2 = ['3-10';'3-11';'3-12';'3-13';'3-14';'3-15';'3-16';'3-17';'3-18';'319';'3-20';'3-21';'3-22';'3-23';'3-24';'3-25';'3-26';'3-27';'3-28';'329';'3-30';'3-31';'3-32';'3-33';'3-34';'3-35'];
temp = zeros(2048,2);
temp2 = zeros(2048,2);
specraw = zeros(2048,samples);

%% Create Matrix with Raw Spectra
% Raw spectra
for i = 1:9
temp = csvread([name(i,:),'.csv']);
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specraw(:,i) = temp(:,2);
end
for i = 10:samples
temp2 = csvread([name2(i-9,:),'.csv']);
specraw(:,i) = temp2(:,2);
end
% (Raw spectra - darknoise) / (5(calibration - darknoise))
for i = 1:samples
data(:,i+1) = (specraw(:,i)-dn(:,2))./((cal(:,2)-dn(:,2))*5);
end

%% Boundary Conditions: Wavelength
% Set the minimum and maximum wavelengths: Oxygenation
wmin_oxy = 515;
wmax_oxy = 595;
% Set the minimum and maximum wavelengths: [Hb] and scattering
wmin_hb = 475;
wmax_hb = 750;
% Load in the absorbance values for hemoglobin and melanin
load('HbO2.txt');
load('Hb.txt');
load('mel.txt');

%% Boundary Conditions: Optical Properties
% Set the initial values: Oxygenation [A B cMel cHb SaO2 S wmin wmax]
InitParams1 =
[0.400
-1.00
0.000
2.000
0.20
0.001
wmin_oxy
wmax_oxy];
InitVal1 = InitParams1(1:6);
lb1 =
[0.000
-4.00
0.000
0.0000
0.000
0.000];
ub1 =
[1.000
0.000
0.000
12.000
1.000
0.010];
% Set the initial values: Hemoglobin [A B cMel cHb
InitParams2 =
[0.400
0.500
0.000
2.000
wmax_hb];
InitVal2 = InitParams2(1:6);
lb2 =
[0.000
-1.00
0.000
0.0000
ub2 =
[1.000
1.500
0.000
12.000

SaO2 S wmin wmax]
0.20
0.001
wmin_hb
0.000
1.000

0.000];
0.010];

%% Model Fit
for i = 1:samples
% Choose wavelength range by index: Oxygenation
[~, lambdaMinIndex1] = min((data(:,1) - InitParams1(7)).^2);
[~, lambdaMaxIndex1] = min((data(:,1) - InitParams1(8)).^2);
lambda1 = data(lambdaMinIndex1:lambdaMaxIndex1,1)/1000;
% Choose wavelength range by index: Hemoglobin
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[~, lambdaMinIndex2] = min((data(:,1) - InitParams2(7)).^2);
[~, lambdaMaxIndex2] = min((data(:,1) - InitParams2(8)).^2);
lambda2 = data(lambdaMinIndex2:lambdaMaxIndex2,1)/1000;
% Scale
eHbO21
eHb1
emel1
% Scale
eHbO22
eHb2
emel2

= initParams(6): Oxygenation
= [lambda1 interp1q(HbO2(:,1)/1000,HbO2(:,2),lambda1)];
= [lambda1 interp1q(Hb(:,1)/1000,Hb(:,2),lambda1)];
= [lambda1 interp1q(mel(:,1)/1000,mel(:,2),lambda1)];
= initParams(6): Hemoglobin
= [lambda2 interp1q(HbO2(:,1)/1000,HbO2(:,2),lambda2)];
= [lambda2 interp1q(Hb(:,1)/1000,Hb(:,2),lambda2)];
= [lambda2 interp1q(mel(:,1)/1000,mel(:,2),lambda2)];

% Generate first guess at reflectance based on initial parameters:
Oxygenation
RFirstGuess1 = calcOP_hb_3000_oxy(InitVal1,lambda1,eHb1,eHbO21,emel1);
% Generate first guess at reflectance based on initial parameters:
Hemoglobin
RFirstGuess2 = calcOP_hb_3000_hb(InitVal2,lambda2,eHb2,eHbO22,emel2);
% Get measured reflectance data: Oxygenation
Rmeas1(:,i) = data(lambdaMinIndex1:lambdaMaxIndex1,i+1);
% Get measured reflectance data: Hemoglobin
Rmeas2(:,i) = data(lambdaMinIndex2:lambdaMaxIndex2,i+1);
% Adjust fit parameters
% FitOptimize =optimset('MaxFunEvals',6000,'MaxIter',6000,'TolX',5E5,'TOlFun',5E-5,'LevenbergMarquardt','on');
fitOptimize =
optimset('LargeScale','off','MaxFunEvals',6000,'MaxIter',6000,'TolX',5E5,'TOlFun',5E-5);
%[FitVals chisq] =
fminsearch('chisqOP',InitVal,fitOptimize,Rmeas,lambda,eHbO2): Oxygenation
[FitVals1(i,:), chisq1(i,:)] =
fmincon('chisqOP_hb_3000_oxy',InitVal1,[],[],[],[],lb1,ub1,[],fitOptimize,Rm
eas1(:,i),lambda1,eHb1,eHbO21,emel1);
%[FitVals chisq] =
fminsearch('chisqOP',InitVal,fitOptimize,Rmeas,lambda,eHbO2): Hemoglobin
[FitVals2(i,:), chisq2(i,:)] =
fmincon('chisqOP_hb_3000_hb',InitVal2,[],[],[],[],lb2,ub2,[],fitOptimize,Rme
as2(:,i),lambda2,eHb2,eHbO22,emel2);

Fit1(:,i) = calcOP_hb_3000_oxy(FitVals1(i,:),lambda1,eHb1,eHbO21,emel1);
Fit2(:,i) = calcOP_hb_3000_hb(FitVals2(i,:),lambda2,eHb2,eHbO22,emel2);
if exist('chisq1')==0
chisq1(i) = sum(((Fit1(:,i) - Rmeas1(:,i))./Fit1(:,i)).^2);
end
if exist('chisq2')==0
chisq2(i) = sum(((Fit2(:,i) - Rmeas2(:,i))./Fit2(:,i)).^2);
end
end
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% Multiply lambda by 1000 to get values in nm
lambda1 = lambda1 * 1000;
lambda2 = lambda2 * 1000;
clc;
% Creating optical property tables (for both wavelength ranges)
Quantify1 = zeros(samples,7); % Initializing the 1st table per number of
samples
Quantify2 = zeros(samples,7); % Initializing the 2nd table per number of
samples
for i = 1:samples
% Table for fit values: Accurate Oxygenation (515-595 nm)
Quantify1(i,1:6) = FitVals1(i,:); Quantify1(i,7) = chisq1(i);
% Table for fit values: Accurate Hemoglobin (475-750 nm)
Quantify2(i,1:6) = FitVals2(i,:); Quantify2(i,7) = chisq2(i);
end
% Creating table of relevant optical properties
% 1st column: Oxygenation
% 2nd column: Oxygenation Chi-Squared Value
% 3rd column: Hemoglobin Content
% 4th column: Hemoglobin Content Chi-Squared Value
% 5th column: Reduced Scattering Coefficient
table1 = zeros(samples,4);
table1(:,1) = Quantify1(:,5);
table1(:,2) = Quantify1(:,7);
table1(:,3) = Quantify2(:,4);
table1(:,4) = Quantify2(:,7);
table1(:,5) = Quantify2(:,1);
% Exclude samples that don't meet Chi-Squared criteria
table2 = zeros(size(table1));
for i = 1:samples
if table1(i,2) > 2 | table1(i,4) > 6 | table1(i,1) < 0.01 | table1(i,3)
< 1.2
table2(i,:) = NaN;
else
table2(i,:) = table1(i,:);
end
end
table2(isnan(table2(:,1)),:) = [];
% Create a 3rd table with the average oxygenation and hemoglobin
table3(1,1) = mean(table2(:,1));
table3(2,1) = mean(table2(:,3));
table3(3,1) = mean(table2(:,5)*10);
disp(table3);

tamcount.m
%% Gage Greening
% University of Arkansas
% College of Engineering
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% Department of Biomedical Engineering
% May 24, 2018
% tamcount.m
clear all; close all; clc;
%% Load in 12 image files
Files = dir('*.tif');
numfiles = length(Files);
mydata = cell(1, numfiles);
for k = 1:numfiles
mydata{k} = imread(Files(k).name);
end
x = mydata{1};
[height width] = size(x);
error = round(height * 0.06);
%% Mark the macrophages you see in the images; click ENTER when done for
each image
figure
a=imshow(mydata{1}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(a);
[x01,y01] = getpts;
figure
b=imshow(mydata{2}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(b);
[x02,y02] = getpts;
figure
c=imshow(mydata{3}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(c);
[x03,y03] = getpts;
figure
d=imshow(mydata{4}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(d);
[x04,y04] = getpts;
figure
e=imshow(mydata{5}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(e);
[x05,y05] = getpts;
figure
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f=imshow(mydata{6}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(f);
[x06,y06] = getpts;
figure
g=imshow(mydata{7}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(g);
[x07,y07] = getpts;
figure
h=imshow(mydata{8}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(h);
[x08,y08] = getpts;
figure
i=imshow(mydata{9}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(i);
[x09,y09] = getpts;
figure
j=imshow(mydata{10}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(j);
[x10,y10] = getpts;
figure
k=imshow(mydata{11}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(k);
[x11,y11] = getpts;
figure
l=imshow(mydata{12}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5
0.5 0.5 0.5]);
imcontrast(l);
[x12,y12] = getpts;
close all;
%% Exclude duplicate M1 TAMs
plot(x01,y01,'k*');
plot(x02,y02,'k*');
plot(x03,y03,'k*');
plot(x04,y04,'k*');
max_length_M1tams(1)
max_length_M1tams(2)
max_length_M1tams(3)
max_length_M1tams(4)

hold
hold
hold
hold
=
=
=
=

on;
on;
on;
on;

length(x01);
length(x02);
length(x03);
length(x04);
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M1tams_x =
zeros(max_length_M1tams(1)+max_length_M1tams(2)+max_length_M1tams(3)+max_len
gth_M1tams(4),1);
M1tams_y =
zeros(max_length_M1tams(1)+max_length_M1tams(2)+max_length_M1tams(3)+max_len
gth_M1tams(4),1);
M1tams_x(1:length(x01),1) = x01;
M1tams_x(1+length(x01):length(x01)+length(x02),1) = x02;
M1tams_x(1+length(x01)+length(x02):length(x01)+length(x02)+length(x03),1) =
x03;
M1tams_x(1+length(x01)+length(x02)+length(x03):length(x01)+length(x02)+lengt
h(x03)+length(x04),1) = x04;
M1tams_y(1:length(x01),1) = y01;
M1tams_y(1+length(x01):length(x01)+length(x02),1) = y02;
M1tams_y(1+length(x01)+length(x02):length(x01)+length(x02)+length(x03),1) =
y03;
M1tams_y(1+length(x01)+length(x02)+length(x03):length(x01)+length(x02)+lengt
h(x03)+length(x04),1) = y04;
M1tams = zeros(length(M1tams_x),2);
M1tams(:,1) = round(M1tams_x); M1tams(:,2) = round(M1tams_y);
M1tams(:,3) = M1tams(:,1).*M1tams(:,2);
M1tams_update = M1tams;
distance = zeros(length(M1tams(:,1)),length(M1tams(:,1)));
for i = 1:length(M1tams(:,1))
for j = 1:length(M1tams(:,1))
if i > j
distance(i,j) = sqrt(((M1tams(i,1) - M1tams(j,1))^2) +
((M1tams(i,2) - M1tams(j,2))^2));
else
distance(i,j) = 0;
end
end
end
distance(distance==0) = NaN;
distance_logic = zeros(length(M1tams(:,1)),length(M1tams(:,1)));
for i = 1:length(M1tams(:,1))
for j = 1:length(M1tams(:,1))
if distance(i,j) < error
distance_logic(i,j) = 1;
else
distance_logic(i,j) = 0;
end
end
end
for i = 1:length(M1tams(:,1))
for j = 1:length(M1tams(:,1))
if distance_logic(i,j) == 1
M1tams_update(i,1) = 0; M1tams_update(i,2) = 0;
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end
end
end
temp = find(M1tams_update(:,1) > 0);
count_M1 = length(temp);
M1tams_update = M1tams_update(temp,:);
%% Exclude duplicate TAMs
plot(x05,y05,'k*');
plot(x06,y06,'k*');
plot(x07,y07,'k*');
plot(x08,y08,'k*');

hold
hold
hold
hold

max_length_Mtams(1)
max_length_Mtams(2)
max_length_Mtams(3)
max_length_Mtams(4)

=
=
=
=

on;
on;
on;
on;

length(x05);
length(x06);
length(x07);
length(x08);

Mtams_x =
zeros(max_length_Mtams(1)+max_length_Mtams(2)+max_length_Mtams(3)+max_length
_Mtams(4),1);
Mtams_y =
zeros(max_length_Mtams(1)+max_length_Mtams(2)+max_length_Mtams(3)+max_length
_Mtams(4),1);
Mtams_x(1:length(x05),1) = x05;
Mtams_x(1+length(x05):length(x05)+length(x06),1) = x06;
Mtams_x(1+length(x05)+length(x06):length(x05)+length(x06)+length(x07),1) =
x07;
Mtams_x(1+length(x05)+length(x06)+length(x07):length(x05)+length(x06)+length
(x07)+length(x08),1) = x08;
Mtams_y(1:length(x05),1) = y05;
Mtams_y(1+length(x05):length(x05)+length(x06),1) = y06;
Mtams_y(1+length(x05)+length(x06):length(x05)+length(x06)+length(x07),1) =
y07;
Mtams_y(1+length(x05)+length(x06)+length(x07):length(x05)+length(x06)+length
(x07)+length(x08),1) = y08;
Mtams = zeros(length(Mtams_x),2);
Mtams(:,1) = round(Mtams_x); Mtams(:,2) = round(Mtams_y);
Mtams(:,3) = Mtams(:,1).*Mtams(:,2);
Mtams_update = Mtams;
distance = zeros(length(Mtams(:,1)),length(Mtams(:,1)));
for i = 1:length(Mtams(:,1))
for j = 1:length(Mtams(:,1))
if i > j
distance(i,j) = sqrt(((Mtams(i,1) - Mtams(j,1))^2) +
((Mtams(i,2) - Mtams(j,2))^2));
else
distance(i,j) = 0;
end
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end
end
distance(distance==0) = NaN;
distance_logic = zeros(length(Mtams(:,1)),length(Mtams(:,1)));
for i = 1:length(Mtams(:,1))
for j = 1:length(Mtams(:,1))
if distance(i,j) < error
distance_logic(i,j) = 1;
else
distance_logic(i,j) = 0;
end
end
end
for i = 1:length(Mtams(:,1))
for j = 1:length(Mtams(:,1))
if distance_logic(i,j) == 1
Mtams_update(i,1) = 0; Mtams_update(i,2) = 0;
end
end
end
temp = find(Mtams_update(:,1) > 0);
count_total = length(temp);
Mtams_update = Mtams_update(temp,:);
%% Exclude duplicate M2 TAMs
plot(x09,y09,'k*');
plot(x10,y10,'k*');
plot(x11,y11,'k*');
plot(x12,y12,'k*');
max_length_M2tams(1)
max_length_M2tams(2)
max_length_M2tams(3)
max_length_M2tams(4)

hold
hold
hold
hold
=
=
=
=

on;
on;
on;
on;

length(x09);
length(x10);
length(x11);
length(x12);

M2tams_x =
zeros(max_length_M2tams(1)+max_length_M2tams(2)+max_length_M2tams(3)+max_len
gth_M2tams(4),1);
M2tams_y =
zeros(max_length_M2tams(1)+max_length_M2tams(2)+max_length_M2tams(3)+max_len
gth_M2tams(4),1);
M2tams_x(1:length(x09),1) = x09;
M2tams_x(1+length(x09):length(x09)+length(x10),1) = x10;
M2tams_x(1+length(x09)+length(x10):length(x09)+length(x10)+length(x11),1) =
x11;
M2tams_x(1+length(x09)+length(x10)+length(x11):length(x09)+length(x10)+lengt
h(x11)+length(x12),1) = x12;
M2tams_y(1:length(x09),1) = y09;
M2tams_y(1+length(x09):length(x09)+length(x10),1) = y10;
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M2tams_y(1+length(x09)+length(x10):length(x09)+length(x10)+length(x11),1) =
y11;
M2tams_y(1+length(x09)+length(x10)+length(x11):length(x09)+length(x10)+lengt
h(x11)+length(x12),1) = y12;
M2tams = zeros(length(M2tams_x),2);
M2tams(:,1) = round(M2tams_x); M2tams(:,2) = round(M2tams_y);
M2tams(:,3) = M2tams(:,1).*M2tams(:,2);
M2tams_update = M2tams;
distance = zeros(length(M2tams(:,1)),length(M2tams(:,1)));
for i = 1:length(M2tams(:,1))
for j = 1:length(M2tams(:,1))
if i > j
distance(i,j) = sqrt(((M2tams(i,1) - M2tams(j,1))^2) +
((M2tams(i,2) - M2tams(j,2))^2));
else
distance(i,j) = 0;
end
end
end
distance(distance==0) = NaN;
distance_logic = zeros(length(M2tams(:,1)),length(M2tams(:,1)));
for i = 1:length(M2tams(:,1))
for j = 1:length(M2tams(:,1))
if distance(i,j) < error
distance_logic(i,j) = 1;
else
distance_logic(i,j) = 0;
end
end
end
for i = 1:length(M2tams(:,1))
for j = 1:length(M2tams(:,1))
if distance_logic(i,j) == 1
M2tams_update(i,1) = 0; M2tams_update(i,2) = 0;
end
end
end
temp = find(M2tams_update(:,1) > 0);
count_M2 = length(temp);
M2tams_update = M2tams_update(temp,:);
%% Reorder matrices from left to right
TAM_M0 = sortrows(Mtams_update);
TAM_M1 = sortrows(M1tams_update);
TAM_M2 = sortrows(M2tams_update);
figure(1)
subplot(1,3,1)
imagesc(mydata{3}); colormap gray; axis image; hold on;
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plot(M1tams_update(:,1),M1tams_update(:,2),'b*'); hold off;
title('M1 Macrophages (CD80)');
figure(1)
subplot(1,3,2)
imagesc(mydata{7}); colormap gray; axis image; hold on;
plot(Mtams_update(:,1),Mtams_update(:,2),'g*'); hold off;
title('All Macrophages (CD68)');
figure(1)
subplot(1,3,3)
imagesc(mydata{11}); colormap gray; axis image; hold on;
plot(M2tams_update(:,1),M2tams_update(:,2),'r*'); hold off;
title('M2 Macrophages (CD206)');
%% Exclude M1 TAMs without associated M0 (CD68) stain
r = cell(length(TAM_M1),1);
c = cell(length(TAM_M1),1);
s = cell(length(TAM_M1),1);
check = zeros(length(TAM_M1),1);
TAM_M1_new = TAM_M1;
newerror = 0.05;
for i = 1:length(TAM_M1)
r{i} = find(TAM_M0(:,1)>TAM_M1(i,1)-(width*newerror) &
TAM_M0(:,1)<TAM_M1(i,1)+(width*newerror));
c{i} = find(TAM_M0(:,2)>TAM_M1(i,2)-(width*newerror) &
TAM_M0(:,2)<TAM_M1(i,2)+(width*newerror));
s{i} = intersect(r{i},c{i});
check(i) = any(s{i});
if check(i) == 1
TAM_M1_new(i,1) = TAM_M1(i,1);
TAM_M1_new(i,2) = TAM_M1(i,2);
TAM_M1_new(i,3) = TAM_M1(i,3);
else
TAM_M1_new(i,1) = 0;
TAM_M1_new(i,2) = 0;
TAM_M1_new(i,3) = 0;
end
end
temp = find(TAM_M1_new(:,1) > 0);
TAM_M1_new = TAM_M1_new(temp,:);
%% Exclude M2 TAMs without associated M0 (CD68) stain
r = cell(length(TAM_M2),1);
c = cell(length(TAM_M2),1);
s = cell(length(TAM_M2),1);
check = zeros(length(TAM_M2),1);
TAM_M2_new = TAM_M2;
newerror = 0.05;
for i = 1:length(TAM_M2)
r{i} = find(TAM_M0(:,1)>TAM_M2(i,1)-(width*newerror) &
TAM_M0(:,1)<TAM_M2(i,1)+(width*newerror));
c{i} = find(TAM_M0(:,2)>TAM_M2(i,2)-(width*newerror) &
TAM_M0(:,2)<TAM_M2(i,2)+(width*newerror));
s{i} = intersect(r{i},c{i});
check(i) = any(s{i});
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if check(i) == 1
TAM_M2_new(i,1)
TAM_M2_new(i,2)
TAM_M2_new(i,3)
else
TAM_M2_new(i,1)
TAM_M2_new(i,2)
TAM_M2_new(i,3)
end

= TAM_M2(i,1);
= TAM_M2(i,2);
= TAM_M2(i,3);
= 0;
= 0;
= 0;

end
temp = find(TAM_M2_new(:,1) > 0);
TAM_M2_new = TAM_M2_new(temp,:);
%% M1/M2 Ratio
ratio = length(TAM_M1_new) / length(TAM_M2_new);
fprintf('\nM1/M2 Ratio: %.2f\n\n',ratio);
%% Final Data
close all;
figure(2)
subplot(1,3,1)
imagesc(mydata{3}); colormap gray; axis image; hold on;
plot(M1tams_update(:,1),M1tams_update(:,2),'b*'); hold off;
title('M1 Macrophages (CD80)');
figure(2)
subplot(1,3,2)
imagesc(mydata{7}); colormap gray; axis image; hold on;
plot(Mtams_update(:,1),Mtams_update(:,2),'g*'); hold off;
title('All Macrophages (CD68)');
figure(2)
subplot(1,3,3)
imagesc(mydata{11}); colormap gray; axis image; hold on;
plot(M2tams_update(:,1),M2tams_update(:,2),'r*'); hold off;
title('M2 Macrophages (CD206)');
a
b
c
d

=
=
=
=

'M1/M2 Ratio = ';
num2str(ratio*100);
'%';
strcat(a,b,c);

fig = gcf;
saveas(fig,'tamcount.jpg');

format compact;
M0_totalcount = length(Mtams_update(:,1));
M1_totalcount = length(TAM_M1_new(:,1));
M2_totalcount = length(TAM_M2_new(:,1));
fprintf('M1:\t\t %.1d\n',M1_totalcount);
fprintf('Total:\t %.1d\n',M0_totalcount);
fprintf('M2:\t\t %.1d\n',M2_totalcount);
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samplingdepth.m
%% Gage Greening
% University of Arkansas
% College of Engineering
% Department of Biomedical Engineering
% samplingdepth_3mm.m
% Initialize Variables
close all; clear all; clc;
n = input('Number of Phantoms: ');
name = ['s (01)';'s (02)';'s (03)';'s (04)';'s (05)';'s (06)';'s (07)';'s
(08)';'s (09)';'s (10)';'s (11)';'s (12)';'s (13)';'s (14)';'s (15)';'s
(16)';'s (17)';'s (18)';'s (19)';'s (20)';'s (21)';'s (22)';'s (23)';'s
(24)';'s (25)';'s (26)';'s (27)';'s (28)';'s (29)';'s (30)';'s (31)';'s
(32)';'s (33)';'s (34)';'s (35)';'s (36)';'s (37)';'s (38)';'s (39)';'s
(40)';'s (41)';'s (42)';'s (43)';'s (44)';'s (45)';'s (46)';'s (47)';'s
(48)';'s (49)';'s (50)';'s (51)';'s (52)';'s (53)';'s (54)';'s (55)';'s
(56)';'s (57)';'s (58)';'s (59)';'s (60)';'s (61)';'s (62)';'s (63)';'s
(64)';'s (65)';'s (66)';'s (67)';'s (68)';'s (69)';'s (70)';'s (71)';'s
(72)';'s (73)';'s (74)';'s (75)';'s (76)';'s (77)';'s (78)';'s (79)';'s
(80)';'s (81)';'s (82)';'s (83)';'s (84)';'s (85)';'s (86)';'s (87)';'s
(88)';'s (89)';'s (90)';'s (91)';'s (92)';'s (93)';'s (94)';'s (95)';'s
(96)';'s (97)';'s (98)';'s (99)'];
wavelength = csvread('s (01).csv'); wavelength = wavelength(:,1);
temp = zeros(2048,2);
specori = zeros(2048,n);
% Determine matrix index for getting 1 nm resolution in spectra
x = linspace(1,1050,1050);
wavelength_550to890 = round(wavelength(575:1624));
p = polyfit(wavelength_550to890,x',2);
x1 = linspace(550,890,341);
y1 = round(polyval(p,x1))';
% Create matrix with all spectra of increasing distance from abs. layer
for i = 1:n
temp = csvread([name(i,:),'.csv']);
specori(:,i) = temp(:,2);
for i = 1:2048
for j = 1:n
specori(i,j) = round(specori(i,j));
end
end
end
specori = specori - 300;
spectra_550to890 = specori(575:1624,:);
spectra = spectra_550to890([y1(1:341)],:);
wavelength = linspace(550,890,341)';
maxspec = spectra(:,n);
halfspec = round(maxspec./2);
x1 = zeros(341,1);
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x2 = zeros(341,1);
sampdepth = zeros(341,1);
for i = 1:341
x1 = find(spectra(i,:)<halfspec(i));
x2(i) = max(x1);
sampdepth = (((x2*50)/1000)-0.05);
end
scatter(wavelength,sampdepth); axis square; box on;
xlabel('Wavelength (nm)')
ylabel('Sampling depth (mm)');
title('Sampling depth of probe into optical phantom');
save('sd.mat','wavelength','sampdepth');
clc;

Input Text Files for PostProcess3mm.m
Wavelength
Hb.txt
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282

HbO2.txt

1.747845
1.747845
1.747845
1.747845
1.747845
1.756279
1.764713
1.77414
1.783566
1.793302
1.803039
1.812868
1.822698
1.832868
1.843039
1.853364
1.86369
1.874047
1.884403
1.89476
1.905116
1.906791
1.908465
1.899597
1.890729
1.88186
1.872992
1.865488
1.857985
1.850481
1.842977
1.833333
1.82369

1.645147
1.640806
1.636465
1.652806
1.669147
1.685643
1.70214
1.726605
1.75107
1.777674
1.804279
1.833829
1.86338
1.896124
1.928868
1.962078
1.995287
2.029147
2.063008
2.086295
2.109581
2.118605
2.127628
2.136744
2.14586
2.138233
2.130605
2.118171
2.105736
2.075628
2.045519
2.012837
1.980155

560

mel.txt
30.92699
30.92699
30.65722
30.52234
30.38745
30.25257
30.11768
29.9828
29.84791
29.71303
29.57814
29.44326
29.31882
29.2008
29.08278
28.96475
28.84673
28.7287
28.61068
28.49265
28.37463
28.2566
28.13858
28.02055
27.90253
27.78451
27.66648
27.54846
27.43043
27.31241
27.19049
27.06691
26.94333

283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332

1.801922
1.780155
1.758357
1.736558
1.698822
1.661085
1.593054
1.525023
1.472868
1.420713
1.375628
1.330543
1.262946
1.195349
1.136
1.076651
1.03786
0.99907
0.974729
0.950388
0.931225
0.912062
0.897178
0.882295
0.887814
0.893333
0.90524
0.917147
0.941116
0.965085
0.989085
1.013085
1.036093
1.059101
1.08155
1.104
1.129581
1.155163
1.184434
1.213705
1.242977
1.272248
1.299628
1.327008
1.349674
1.372341
1.390481
1.40862
1.426729
1.444837

1.937985
1.895814
1.85107
1.806326
1.744124
1.681922
1.652992
1.624062
1.578977
1.533891
1.450171
1.36645
1.298078
1.229705
1.164341
1.098977
1.060899
1.022822
1.001395
0.979969
0.970233
0.960496
0.963597
0.966698
0.970605
0.974512
0.978357
0.982202
1.002512
1.022822
1.046419
1.070016
1.096279
1.122543
1.146822
1.171101
1.196031
1.220961
1.248124
1.275287
1.304093
1.332899
1.362543
1.392186
1.422977
1.453767
1.482791
1.511814
1.538574
1.565333

561

26.81975
26.69617
26.57258
26.449
26.32542
26.20184
26.07826
25.95467
25.83109
25.70751
25.58393
25.46035
25.33702
25.23869
25.14036
25.04204
24.94371
24.84538
24.74706
24.64873
24.5504
24.45208
24.35375
24.25542
24.15709
24.05877
23.96044
23.86211
23.76379
23.66546
23.56745
23.47307
23.37869
23.28431
23.18993
23.09555
23.00117
22.90679
22.81241
22.71803
22.62365
22.52927
22.42292
22.31477
22.20663
22.09849
21.99034
21.8822
21.77406
21.66592

333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382

1.462977
1.481116
1.51414
1.547163
1.583473
1.619783
1.65076
1.681736
1.701302
1.720868
1.740465
1.760062
1.779659
1.799256
1.820186
1.841116
1.867008
1.892899
1.918822
1.944744
1.970636
1.996527
2.02245
2.048372
2.060093
2.071814
2.081953
2.092093
2.100651
2.109209
2.116403
2.123597
2.130791
2.137985
2.145395
2.152806
2.161426
2.170047
2.178698
2.187349
2.195969
2.204589
2.21324
2.221891
2.230512
2.239132
2.245395
2.251659
2.251659
2.251659

1.585023
1.604713
1.616062
1.627411
1.638915
1.650419
1.661519
1.67262
1.681736
1.690853
1.698853
1.706853
1.698636
1.690419
1.682295
1.674171
1.663256
1.652341
1.640434
1.628527
1.618109
1.60769
1.591194
1.574698
1.545705
1.516713
1.492806
1.468899
1.44955
1.430202
1.411504
1.392806
1.382326
1.371845
1.36431
1.356775
1.361922
1.36707
1.39355
1.420031
1.447535
1.475039
1.504465
1.533891
1.568744
1.603597
1.651132
1.698667
1.756062
1.813457
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21.55777
21.44963
21.34149
21.23335
21.1252
21.01706
20.90892
20.80077
20.69263
20.58449
20.46183
20.33825
20.21467
20.09109
19.96751
19.84392
19.72034
19.59676
19.47318
19.3496
19.22601
19.10243
18.97885
18.85527
18.73169
18.61756
18.53178
18.44601
18.36024
18.27447
18.1887
18.10292
18.01715
17.93138
17.84561
17.75984
17.67406
17.58829
17.50252
17.41675
17.33097
17.2452
17.15943
17.07366
16.98789
16.90211
16.81634
16.73057
16.6448
16.55902

383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432

2.278295
2.30493
2.34555
2.386171
2.42986
2.47355
2.537395
2.60124
2.696
2.79076
2.880186
2.969612
3.051659
3.133705
3.215783
3.29786
3.379907
3.461953
3.561891
3.661829
3.795008
3.928186
4.061364
4.194543
4.324837
4.455132
4.583814
4.712496
4.847287
4.982078
5.146822
5.311566
5.47631
5.641054
5.810295
5.979535
6.149147
6.31876
6.491783
6.664806
6.907597
7.150388
7.310388
7.470388
7.617674
7.764961
7.980155
8.195349
8.377985
8.56062

1.878977
1.944496
2.019783
2.09507
2.195597
2.296124
2.448434
2.600744
2.771225
2.941705
3.114729
3.287752
3.439318
3.590884
3.721054
3.851225
3.989426
4.127628
4.267101
4.406574
4.596434
4.786295
5.138946
5.491597
6.019597
6.547597
6.892713
7.237829
7.496434
7.755039
7.941705
8.128372
8.109767
8.091163
8.04186
7.992558
7.72
7.447442
7.071628
6.695814
6.264465
5.833116
5.443938
5.05476
4.722047
4.389333
4.102202
3.81507
3.56738
3.31969
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16.46076
16.35346
16.24616
16.13886
16.03156
15.92425
15.81695
15.70965
15.60235
15.49504
15.38774
15.28044
15.17314
15.06584
14.95853
14.85123
14.74393
14.63663
14.52932
14.42202
14.31472
14.20742
14.10012
13.99281
13.88551
13.80487
13.72623
13.64759
13.56895
13.49031
13.41168
13.33304
13.2544
13.17576
13.09712
13.01849
12.93985
12.86121
12.78257
12.70393
12.6253
12.54666
12.46802
12.38938
12.31074
12.23211
12.15347
12.07483
11.99619
11.92096

433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482

8.56062
8.56062
8.52093
8.48124
8.128682
7.776124
7.091783
6.407442
6.019535
5.631628
5.007473
4.383318
4.030605
3.677891
3.182512
2.687132
2.144279
1.601426
1.286295
0.971163
0.765969
0.560775
0.518363
0.47595
0.438645
0.40134
0.381978
0.362617
0.343256
0.323895
0.311256
0.298617
0.289947
0.281278
0.27262
0.263963
0.257225
0.250487
0.243926
0.237364
0.235336
0.233309
0.231327
0.229346
0.228295
0.227243
0.226412
0.225581
0.228149
0.230716

2.941488
2.563287
2.311256
2.059225
1.953178
1.847132
1.71876
1.590388
1.514419
1.43845
1.350574
1.262698
1.223008
1.183318
1.11138
1.039442
1.006667
0.973891
0.943256
0.91262
0.871442
0.830264
0.798822
0.76738
0.751876
0.736372
0.712992
0.689612
0.665116
0.64062
0.628893
0.617166
0.595972
0.574778
0.557705
0.540633
0.527752
0.514871
0.502552
0.490233
0.478555
0.466878
0.457088
0.447299
0.438518
0.429736
0.421296
0.412856
0.405665
0.398474
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11.85542
11.78988
11.72434
11.6588
11.59326
11.52772
11.46218
11.39664
11.3311
11.26556
11.20002
11.13448
11.06894
11.0034
10.93786
10.87231
10.80677
10.74123
10.67569
10.61015
10.54461
10.47907
10.41353
10.34799
10.28245
10.21691
10.15648
10.10642
10.05636
10.0063
9.956237
9.906176
9.856115
9.806055
9.755994
9.705933
9.655872
9.605812
9.555751
9.50569
9.455629
9.405569
9.355508
9.305447
9.255386
9.205326
9.155265
9.105204
9.055143
9.005083

483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532

0.233284
0.235851
0.238419
0.240986
0.243733
0.246481
0.252574
0.258667
0.264757
0.270847
0.27694
0.283033
0.289122
0.295212
0.301802
0.308391
0.315916
0.323442
0.330967
0.338493
0.346019
0.353544
0.36107
0.368595
0.376121
0.383647
0.391619
0.399591
0.408608
0.417625
0.426642
0.435659
0.444676
0.453693
0.46271
0.471727
0.480744
0.489761
0.499541
0.509321
0.521309
0.533296
0.545284
0.557271
0.569256
0.58124
0.593228
0.605216
0.617212
0.629209

0.394434
0.390394
0.386434
0.382474
0.378639
0.374803
0.371002
0.3672
0.362567
0.357935
0.353057
0.34818
0.343473
0.338766
0.334189
0.329612
0.327076
0.32454
0.321932
0.319324
0.317941
0.316558
0.312899
0.30924
0.309628
0.310016
0.310319
0.310623
0.311516
0.312409
0.314571
0.316732
0.321169
0.325606
0.337296
0.348986
0.362109
0.375231
0.392657
0.410084
0.431935
0.453786
0.478803
0.50382
0.530902
0.557985
0.588735
0.619485
0.649867
0.680248

565

8.955022
8.906236
8.858166
8.810097
8.762028
8.713958
8.665889
8.61782
8.569751
8.521681
8.473612
8.425543
8.377473
8.329404
8.281335
8.233265
8.185196
8.137127
8.089057
8.040988
7.992919
7.94485
7.89678
7.848711
7.800642
7.752572
7.704503
7.656434
7.608364
7.560295
7.512226
7.464156
7.416087
7.368018
7.319949
7.271879
7.22381
7.175741
7.127671
7.079602
7.031533
6.98398
6.938063
6.892146
6.846229
6.800313
6.754396
6.708479
6.662562
6.616645

533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582

0.640868
0.652527
0.664186
0.675845
0.687473
0.699101
0.710729
0.722357
0.734419
0.746481
0.758574
0.770667
0.78276
0.794853
0.804372
0.813891
0.820992
0.828093
0.833271
0.83845
0.84186
0.845271
0.845426
0.845581
0.842667
0.839752
0.836837
0.833922
0.822202
0.810481
0.797271
0.784062
0.770543
0.757023
0.74245
0.727876
0.713333
0.698791
0.685364
0.671938
0.659349
0.64676
0.634171
0.621581
0.608989
0.596397
0.585175
0.573953
0.563538
0.553122

0.703876
0.727504
0.749426
0.771349
0.786543
0.801736
0.81355
0.825364
0.825798
0.826233
0.816961
0.80769
0.790419
0.773147
0.748279
0.723411
0.695163
0.666915
0.641017
0.615119
0.592949
0.570778
0.552651
0.534524
0.526611
0.518698
0.512164
0.505631
0.505684
0.505736
0.51578
0.525823
0.54582
0.565817
0.594319
0.622822
0.656341
0.68986
0.726109
0.762357
0.794419
0.826481
0.843783
0.861085
0.854791
0.848496
0.812651
0.776806
0.724093
0.67138

566

6.570728
6.524811
6.478895
6.432978
6.387061
6.341144
6.295227
6.24931
6.203393
6.157477
6.11156
6.065643
6.019726
5.973809
5.927892
5.881976
5.836059
5.790142
5.74827
5.715836
5.683402
5.650968
5.618534
5.586101
5.553667
5.521233
5.488799
5.456365
5.423931
5.391498
5.359064
5.32663
5.294196
5.261762
5.229328
5.196894
5.164461
5.132027
5.099593
5.067159
5.034725
5.002291
4.969857
4.937424
4.90499
4.872556
4.840122
4.807688
4.775254
4.742821

583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632

0.542707
0.532291
0.520809
0.509327
0.495557
0.481786
0.460462
0.439138
0.417011
0.394884
0.37244
0.349997
0.328487
0.306977
0.285724
0.264471
0.246012
0.227553
0.219377
0.2112
0.203023
0.194847
0.186673
0.178499
0.170471
0.162443
0.154428
0.146412
0.139805
0.133197
0.126769
0.120341
0.117107
0.113873
0.110636
0.107398
0.104161
0.100924
0.098471
0.096019
0.093798
0.091578
0.089355
0.087132
0.085169
0.083206
0.081516
0.079826
0.078136
0.076447

0.604214
0.537048
0.474729
0.412409
0.359408
0.306406
0.264837
0.223268
0.192785
0.162301
0.140676
0.119051
0.103585
0.088118
0.078977
0.069836
0.059724
0.049612
0.045457
0.041302
0.037147
0.032992
0.030366
0.02774
0.026642
0.025544
0.024447
0.023349
0.022251
0.021153
0.020056
0.018958
0.018084
0.017209
0.016558
0.015907
0.015256
0.014605
0.013953
0.013302
0.012651
0.012
0.011485
0.010971
0.010592
0.010214
0.009836
0.009457
0.009079
0.008701

567

4.710387
4.677953
4.645519
4.613085
4.580651
4.548217
4.517434
4.497694
4.477953
4.458213
4.438473
4.418732
4.398992
4.379252
4.359512
4.339771
4.320031
4.300291
4.280551
4.26081
4.24107
4.22133
4.20159
4.181849
4.162109
4.142369
4.122629
4.102888
4.083148
4.063408
4.043668
4.023927
4.004187
3.983271
3.957
3.93073
3.904459
3.878188
3.851917
3.825646
3.799375
3.773104
3.746833
3.720563
3.694292
3.668021
3.64175
3.615479
3.589208
3.562937

633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682

0.074896
0.073346
0.07235
0.071355
0.070357
0.069358
0.068363
0.067367
0.066372
0.065377
0.064381
0.063386
0.06243
0.061474
0.060641
0.059808
0.058975
0.058141
0.057308
0.056475
0.055642
0.054809
0.053976
0.053142
0.052309
0.051476
0.05075
0.050024
0.049355
0.048687
0.048017
0.047348
0.046679
0.046011
0.045342
0.044673
0.044004
0.043335
0.042666
0.041998
0.041368
0.040739
0.040171
0.039603
0.039035
0.038468
0.0379
0.037332
0.036764
0.036197

0.008322
0.007944
0.007684
0.007423
0.007281
0.007138
0.006995
0.006853
0.00671
0.006567
0.006425
0.006282
0.006167
0.006053
0.005966
0.005879
0.005792
0.005705
0.005619
0.005532
0.005445
0.005358
0.005278
0.005197
0.005122
0.005048
0.005002
0.004955
0.004912
0.004868
0.004825
0.004781
0.004738
0.004695
0.004657
0.00462
0.004589
0.004558
0.004527
0.004496
0.004462
0.004428
0.0044
0.004372
0.00435
0.004329
0.004316
0.004304
0.004291
0.004279

568

3.536666
3.510396
3.484125
3.457854
3.431583
3.405312
3.379041
3.35277
3.326499
3.300229
3.276784
3.262801
3.248819
3.234836
3.220853
3.20687
3.192888
3.178905
3.164922
3.15094
3.136957
3.122974
3.108991
3.095009
3.081026
3.067043
3.05306
3.039078
3.025095
3.011112
2.99713
2.983147
2.969164
2.955181
2.941199
2.927216
2.913233
2.899251
2.885268
2.871285
2.857302
2.84332
2.829337
2.815354
2.801372
2.787389
2.773406
2.759423
2.745323
2.728408

683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732

0.035629
0.035062
0.034494
0.033926
0.033358
0.032791
0.032302
0.031813
0.031414
0.031015
0.030616
0.030218
0.029819
0.02942
0.02902
0.028621
0.02822
0.027818
0.027405
0.026992
0.02658
0.026167
0.025754
0.025341
0.024946
0.024551
0.024217
0.023883
0.023549
0.023216
0.022882
0.022548
0.022215
0.021881
0.021547
0.021214
0.020885
0.020556
0.020241
0.019925
0.019609
0.019294
0.018978
0.018662
0.018267
0.017873
0.017481
0.017088
0.017088
0.017088

0.004267
0.004254
0.004242
0.004229
0.004242
0.004254
0.004267
0.004279
0.004291
0.004304
0.004316
0.004329
0.00435
0.004372
0.004403
0.004434
0.004465
0.004496
0.004527
0.004558
0.004589
0.00462
0.004657
0.004695
0.004738
0.004781
0.004825
0.004868
0.004912
0.004955
0.004998
0.005042
0.005095
0.005147
0.005209
0.005271
0.005333
0.005395
0.005457
0.005519
0.005581
0.005643
0.005709
0.005774
0.005842
0.00591
0.005978
0.006047
0.006115
0.006183

569

2.711492
2.694576
2.67766
2.660745
2.643829
2.626913
2.609997
2.593082
2.576166
2.55925
2.542335
2.525419
2.508503
2.491587
2.474672
2.457756
2.44084
2.423924
2.407009
2.390093
2.373177
2.356261
2.339346
2.32243
2.305514
2.288598
2.271683
2.254767
2.237851
2.220935
2.209274
2.201263
2.193252
2.185242
2.177231
2.16922
2.16121
2.153199
2.145188
2.137178
2.129167
2.121156
2.113146
2.105135
2.097124
2.089113
2.081103
2.073092
2.065081
2.057071

733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782

0.017088
0.017088
0.017085
0.017082
0.017072
0.017062
0.017181
0.0173
0.017655
0.01801
0.018365
0.018719
0.019174
0.019629
0.020149
0.02067
0.021229
0.021787
0.02264
0.023493
0.023698
0.023903
0.024048
0.024193
0.024193
0.024193
0.024101
0.024008
0.023697
0.023387
0.023008
0.022629
0.022249
0.021869
0.021487
0.021106
0.020722
0.020339
0.019956
0.019573
0.019189
0.018806
0.018423
0.01804
0.017662
0.017284
0.016979
0.016673
0.016368
0.016063

0.006251
0.006319
0.006406
0.006493
0.006598
0.006704
0.006809
0.006915
0.00702
0.007126
0.007231
0.007336
0.007448
0.00756
0.007678
0.007795
0.007913
0.008031
0.008149
0.008267
0.008385
0.008502
0.008608
0.008713
0.008806
0.008899
0.008992
0.009085
0.009178
0.009271
0.009364
0.009457
0.009557
0.009656
0.009761
0.009867
0.009972
0.010078
0.010183
0.010288
0.010394
0.010499
0.010592
0.010685
0.010766
0.010847
0.010927
0.011008
0.011088
0.011169

570

2.04906
2.041049
2.033261
2.027098
2.020936
2.014774
2.008611
2.002449
1.996287
1.990125
1.983962
1.9778
1.971638
1.965476
1.959313
1.953151
1.946989
1.940826
1.934664
1.928502
1.92234
1.916177
1.910015
1.903853
1.897691
1.891528
1.885366
1.879204
1.873041
1.866879
1.860717
1.854555
1.844935
1.834974
1.825013
1.815052
1.805091
1.79513
1.785169
1.775208
1.765247
1.755286
1.745325
1.735364
1.725403
1.715442
1.705481
1.69552
1.685559
1.675598

783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832

0.015758
0.015453
0.015148
0.014843
0.014567
0.014291
0.014051
0.013811
0.013571
0.01333
0.01309
0.01285
0.012649
0.012449
0.012289
0.01213
0.01197
0.01181
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005

0.01125
0.01133
0.011402
0.011473
0.011535
0.011597
0.011659
0.011721
0.011783
0.011845
0.011907
0.011969
0.012081
0.012192
0.012353
0.012515
0.012583
0.012651
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005

571

1.667512
1.659546
1.651579
1.643613
1.635647
1.627681
1.619715
1.611749
1.603782
1.595816
1.58785
1.579884
1.571918
1.563951
1.555985
1.548019
1.540053
1.532087
1.524121
1.516154
1.508188
1.500222
1.492256
1.48429
1.476323
1.468357
1.460391
1.452425
1.444459
1.436493
1.428526
1.42056
1.412594
1.404628
1.396662
1.388696
1.380729
1.372763
1.364797
1.356831
1.348865
1.340898
1.332932
1.324966
1.317
1.309034
1.301068
1.293101
1.285135
1.277169

833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882

0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005

0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005

572

1.269203
1.261237
1.25327
1.245304
1.237338
1.229372
1.221406
1.21344
1.205473
1.197507
1.189541
1.181575
1.173609
1.165642
1.157676
1.14971
1.141744
1.133778
1.125812
1.117845
1.109879
1.101913
1.093947
1.085981
1.078014
1.070048
1.062082
1.054116
1.04615
1.038184
1.030217
1.022251
1.014285
1.006319
0.998353
0.990387
0.98242
0.974454
0.966488
0.958522
0.950556
0.942589
0.934623
0.926657
0.918691
0.910725
0.902759
0.894792
0.886826
0.87886

883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900

0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005

0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005
0.005

573

0.870894
0.862928
0.854961
0.846995
0.839029
0.831063
0.823097
0.815131
0.807164
0.799198
0.791232
0.783266
0.7753
0.767333
0.759367
0.751401
0.743435
0.735469

Engineering Sketches

574

575

576

577

578

579

